Unnamed: 0
stringlengths
3
8
Date
stringlengths
23
23
Article_title
stringlengths
1
250
Stock_symbol
stringlengths
1
5
Url
stringlengths
44
135
Publisher
stringclasses
1 value
Author
stringclasses
1 value
Article
stringlengths
1
343k
Lsa_summary
stringlengths
3
53.9k
Luhn_summary
stringlengths
1
53.9k
Textrank_summary
stringlengths
1
53.9k
Lexrank_summary
stringlengths
1
53.9k
32800.0
2020-02-05 00:00:00 UTC
Health Care Sector Update for 02/05/2020: AIMT, NVO, JNJ, PFE, ABT, MRK, AMGN
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-02-05-2020%3A-aimt-nvo-jnj-pfe-abt-mrk-amgn-2020-02-05-0
nan
nan
Top Health Care Stocks: JNJ: +0.79% PFE: +0.74% ABT: +0.87% MRK: -4.59% AMGN: +0.96% Top health care stocks were mixed pre-market Wednesday. Stocks moving on news include: (+) Aimmune Therapeutics (AIMT), which was almost 7% higher after the biopharmaceutical company said Nestle Health Science would make an additional equity investment of $200 million, bringing its total investment to $473 million. (+) Novo Nordisk (NVO) was climbing more than 3% as it booked Q4 earnings of DKK3.70 ($0.55) per share, up from DKK3.53 per share in the year-ago quarter, which was behind consensus compiled by Capital IQ for DKK3.76 a share. (-) Merck (MRK) was over 3% lower even after it reported Q4 non-GAAP EPS of $1.16, up from $1.04 per share in the same quarter last year, which was a penny higher than the consensus forecast provided by analysts surveyed by Capital IQ. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Top health care stocks were mixed pre-market Wednesday. Stocks moving on news include: (+) Aimmune Therapeutics (AIMT), which was almost 7% higher after the biopharmaceutical company said Nestle Health Science would make an additional equity investment of $200 million, bringing its total investment to $473 million. (-) Merck (MRK) was over 3% lower even after it reported Q4 non-GAAP EPS of $1.16, up from $1.04 per share in the same quarter last year, which was a penny higher than the consensus forecast provided by analysts surveyed by Capital IQ.
Top Health Care Stocks: Top health care stocks were mixed pre-market Wednesday. (+) Novo Nordisk (NVO) was climbing more than 3% as it booked Q4 earnings of DKK3.70 ($0.55) per share, up from DKK3.53 per share in the year-ago quarter, which was behind consensus compiled by Capital IQ for DKK3.76 a share.
Stocks moving on news include: (+) Aimmune Therapeutics (AIMT), which was almost 7% higher after the biopharmaceutical company said Nestle Health Science would make an additional equity investment of $200 million, bringing its total investment to $473 million. (+) Novo Nordisk (NVO) was climbing more than 3% as it booked Q4 earnings of DKK3.70 ($0.55) per share, up from DKK3.53 per share in the year-ago quarter, which was behind consensus compiled by Capital IQ for DKK3.76 a share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Top Health Care Stocks: Top health care stocks were mixed pre-market Wednesday. Stocks moving on news include: (+) Aimmune Therapeutics (AIMT), which was almost 7% higher after the biopharmaceutical company said Nestle Health Science would make an additional equity investment of $200 million, bringing its total investment to $473 million.
32801.0
2020-02-05 00:00:00 UTC
Health Care Sector Update for 02/05/2020: AIMT, NVO, JNJ, PFE, ABT, MRK, AMGN
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-02-05-2020%3A-aimt-nvo-jnj-pfe-abt-mrk-amgn-2020-02-05
nan
nan
Top Health Care Stocks: JNJ: +0.79% PFE: +0.74% ABT: +0.87% MRK: -4.59% AMGN: +0.96% Top health care stocks were mixed pre-market Wednesday. Stocks moving on news include: (+) Aimmune Therapeutics (AIMT), which was almost 7% higher after the biopharmaceutical company said Nestle Health Science would make an additional equity investment of $200 million, bringing its total investment to $473 million. (+) Novo Nordisk (NVO) was climbing more than 3% as it booked Q4 earnings of DKK3.70 ($0.55) per share, up from DKK3.53 per share in the year-ago quarter, which was behind consensus compiled by Capital IQ for DKK3.76 a share. (-) Merck (MRK) was over 3% lower even after it reported Q4 non-GAAP EPS of $1.16, up from $1.04 per share in the same quarter last year, which was a penny higher than the consensus forecast provided by analysts surveyed by Capital IQ. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Top health care stocks were mixed pre-market Wednesday. Stocks moving on news include: (+) Aimmune Therapeutics (AIMT), which was almost 7% higher after the biopharmaceutical company said Nestle Health Science would make an additional equity investment of $200 million, bringing its total investment to $473 million. (-) Merck (MRK) was over 3% lower even after it reported Q4 non-GAAP EPS of $1.16, up from $1.04 per share in the same quarter last year, which was a penny higher than the consensus forecast provided by analysts surveyed by Capital IQ.
Top Health Care Stocks: Top health care stocks were mixed pre-market Wednesday. (+) Novo Nordisk (NVO) was climbing more than 3% as it booked Q4 earnings of DKK3.70 ($0.55) per share, up from DKK3.53 per share in the year-ago quarter, which was behind consensus compiled by Capital IQ for DKK3.76 a share.
Stocks moving on news include: (+) Aimmune Therapeutics (AIMT), which was almost 7% higher after the biopharmaceutical company said Nestle Health Science would make an additional equity investment of $200 million, bringing its total investment to $473 million. (+) Novo Nordisk (NVO) was climbing more than 3% as it booked Q4 earnings of DKK3.70 ($0.55) per share, up from DKK3.53 per share in the year-ago quarter, which was behind consensus compiled by Capital IQ for DKK3.76 a share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Top Health Care Stocks: Top health care stocks were mixed pre-market Wednesday. Stocks moving on news include: (+) Aimmune Therapeutics (AIMT), which was almost 7% higher after the biopharmaceutical company said Nestle Health Science would make an additional equity investment of $200 million, bringing its total investment to $473 million.
32802.0
2020-02-03 00:00:00 UTC
Abbott Laboratories Reports Rise In Q2 Earnings
ABT
https://www.nasdaq.com/articles/abbott-laboratories-reports-rise-in-q2-earnings-2020-02-03
nan
nan
(RTTNews) - Abbott Laboratories (ABT) reported earnings for its second quarter that rose from last year. The company's profit totaled $2.7 million, or $0.06 per share. This compares with $1.8 million, or $0.04 per share, in last year's second quarter. The company's revenue for the quarter rose 5.7% to $25.8 million from $24.4 million last year. Abbott Laboratories earnings at a glance: -Earnings (Q2): $2.7 Mln. vs. $1.8 Mln. last year. -EPS (Q2): $0.06 vs. $0.04 last year. -Revenue (Q2): $25.8 Mln vs. $24.4 Mln last year. -Guidance: Full year revenue guidance: $103 - $106 Mln The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) reported earnings for its second quarter that rose from last year. Abbott Laboratories earnings at a glance: -Earnings (Q2): $2.7 Mln. -Guidance: Full year revenue guidance: $103 - $106 Mln The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) reported earnings for its second quarter that rose from last year. The company's revenue for the quarter rose 5.7% to $25.8 million from $24.4 million last year. -Guidance: Full year revenue guidance: $103 - $106 Mln The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) reported earnings for its second quarter that rose from last year. The company's revenue for the quarter rose 5.7% to $25.8 million from $24.4 million last year. -Revenue (Q2): $25.8 Mln vs. $24.4 Mln last year.
(RTTNews) - Abbott Laboratories (ABT) reported earnings for its second quarter that rose from last year. The company's revenue for the quarter rose 5.7% to $25.8 million from $24.4 million last year. Abbott Laboratories earnings at a glance: -Earnings (Q2): $2.7 Mln.
32803.0
2020-02-03 00:00:00 UTC
Abbott's Trial To Assess New Therapy Option For People At Risk Of Stroke
ABT
https://www.nasdaq.com/articles/abbotts-trial-to-assess-new-therapy-option-for-people-at-risk-of-stroke-2020-02-03
nan
nan
(RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has approved a new trial designed to assess its Amplatzer Amulet Left Atrial Appendage Occluder for people with atrial fibrillation or AF - a condition in which the normal rhythm of the heart's upper chambers is disrupted and becomes erratic - who are at risk of stroke. The CATALYST trial is the first-ever clinical trial comparing the effectiveness of a left atrial appendage (LAA) closure device to a newer class of blood thinners, known as non-vitamin K antagonist oral anticoagulant (NOAC) drugs, which are currently the standard treatment option for AF. Atrial Fibrillation is the most common sustained cardiac arrhythmia, with the prevalence in the U.S. projected to increase to 12.1 million by 2030. The global, multicenter CATALYST trial will compare the effectiveness of the Abbott Amplatzer Amulet to NOACs as an alternative treatment option in an expanded population of AF patients. Blood thinners, first warfarin and now NOACs, are commonly the first-line therapy to reduce the risk of ischemic stroke - the most common type of all stroke - in patients with AF who are at an increased risk. However, risk of bleeding events, medication expenses, narrow therapeutic window, patient lifestyle, and medication compliance often limit blood thinner effectiveness in clinical practice. The CATALYST trial will randomize up to 2,650 subjects at 150 sites worldwide to assess whether sealing off the LAA with the Amulet device may be a viable alternative to a lifetime of these newer blood thinners. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has approved a new trial designed to assess its Amplatzer Amulet Left Atrial Appendage Occluder for people with atrial fibrillation or AF - a condition in which the normal rhythm of the heart's upper chambers is disrupted and becomes erratic - who are at risk of stroke. The global, multicenter CATALYST trial will compare the effectiveness of the Abbott Amplatzer Amulet to NOACs as an alternative treatment option in an expanded population of AF patients. The CATALYST trial will randomize up to 2,650 subjects at 150 sites worldwide to assess whether sealing off the LAA with the Amulet device may be a viable alternative to a lifetime of these newer blood thinners.
(RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has approved a new trial designed to assess its Amplatzer Amulet Left Atrial Appendage Occluder for people with atrial fibrillation or AF - a condition in which the normal rhythm of the heart's upper chambers is disrupted and becomes erratic - who are at risk of stroke. The CATALYST trial is the first-ever clinical trial comparing the effectiveness of a left atrial appendage (LAA) closure device to a newer class of blood thinners, known as non-vitamin K antagonist oral anticoagulant (NOAC) drugs, which are currently the standard treatment option for AF. The global, multicenter CATALYST trial will compare the effectiveness of the Abbott Amplatzer Amulet to NOACs as an alternative treatment option in an expanded population of AF patients.
(RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has approved a new trial designed to assess its Amplatzer Amulet Left Atrial Appendage Occluder for people with atrial fibrillation or AF - a condition in which the normal rhythm of the heart's upper chambers is disrupted and becomes erratic - who are at risk of stroke. The CATALYST trial is the first-ever clinical trial comparing the effectiveness of a left atrial appendage (LAA) closure device to a newer class of blood thinners, known as non-vitamin K antagonist oral anticoagulant (NOAC) drugs, which are currently the standard treatment option for AF. Blood thinners, first warfarin and now NOACs, are commonly the first-line therapy to reduce the risk of ischemic stroke - the most common type of all stroke - in patients with AF who are at an increased risk.
(RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has approved a new trial designed to assess its Amplatzer Amulet Left Atrial Appendage Occluder for people with atrial fibrillation or AF - a condition in which the normal rhythm of the heart's upper chambers is disrupted and becomes erratic - who are at risk of stroke. The CATALYST trial is the first-ever clinical trial comparing the effectiveness of a left atrial appendage (LAA) closure device to a newer class of blood thinners, known as non-vitamin K antagonist oral anticoagulant (NOAC) drugs, which are currently the standard treatment option for AF. Atrial Fibrillation is the most common sustained cardiac arrhythmia, with the prevalence in the U.S. projected to increase to 12.1 million by 2030.
32804.0
2020-02-03 00:00:00 UTC
Why Abbott Laboratories Just Became an Even Better Buy
ABT
https://www.nasdaq.com/articles/why-abbott-laboratories-just-became-an-even-better-buy-2020-02-03
nan
nan
Abbott Laboratories (NYSE: ABT) has been a great buy for many years. The healthcare stock has made investors rich in a number of ways. While it may pay a modest dividend, the annual increases to its payouts for more than 40 years has made it an exceptionally good long-term buy. The returns shareholders have earned over the years from simply holding its shares have been very strong. In 2019, Abbott's stock was up 20%, a little better than the 18% returns investors would have earned by holding the Health Care Select Sector SPDR Fund. As good of a buy as Abbott has been, it just got even better. The company showed strong sales growth in 2019 Abbott released its fourth-quarter earnings on Jan. 22, and the numbers were very strong. Revenue of $8.31 billion was up 7.1% in Q4, which was good enough to beat analyst expectations of $8.26 billion. Meanwhile, diluted earnings per share (EPS) of $0.95 were in line with Wall Street's expectations as well. The company's overall performance was even stronger when looking at its organic growth rate, which factors out the effect of foreign exchange as well as non-core business in the nutrition segment that Abbott discontinued in 2018. Organic growth in Q4 was 8.5% and two segments were up by double-digits: Medical devices rose by 11.3% and pharmaceuticals grew by 10%. Medical device sales were also up 10.5% for the entire year when looking at its organic numbers. Image source: Getty Images. Abbott's bottom line was even more impressive Revenue was strong, but what really stood out was the jump in earnings. The company's net earnings of $1.05 billion were up 61% from the prior-year quarter when Abbott earned $654 million. Small wins along the way, such as fewer expenses related to interest and debt, saved the company $36 million, while the net effect of foreign exchange added $2 million to its bottom line compared to a loss of $26 million a year ago. That's $62 million in cost reductions; that alone would have been good enough for a 10% improvement from last year's bottom line. However, the biggest gains were in the company's operating income where Abbott was able to squeeze out more from its top line. Operating expenses, including cost of goods sold, rose at a rate of 4.9%, slightly below the 7.1% increase that the company saw in its top line. That helped Abbott's operating income rise by $224 million. It was the same story when looking at the company's full-year results, as Abbott's revenue growth of 4.3% was well above the 1.7% increase that its operating expenses rose by, leaving more of the top line to trickle through to the bottom. As a result, full-year earnings were also up an impressive 56% year over year. It's expecting another good year in 2020 With a stellar 2019 on the books, Abbott is expecting another strong showing this year. In its full-year guidance for 2020, the company is projecting that organic growth will again fall between 7% to 8%. In 2019, organic growth for the year came in at 7.7%. On the earnings side, the company is expecting diluted EPS of between $2.35 and $2.45. That would be another double-digit improvement from the company's diluted EPS of $2.06 in 2019. It's hard not to like Abbott At a forward price-to-earnings ratio of 22 and a price-to-book multiple of around five, Abbott is not a cheap stock for value investors. However, given the growth the company has demonstrated and its numbers being weighed down by foreign exchange, there's reason to be optimstic that it can build on these results not just for one year but many years down the road. It's a sign of good management that a company can grow sales and at the same time bring its costs down. But given that the company has been able to increase its dividend payments for decades, it may not be all that surprising that Abbott is such a quality stock to invest in. With good revenue diversification and multiple segments showing strong sales growth, the healthcare stock is a good option for risk-averse investors who may be concerned that a recession is around the corner and are in search of a quality dividend. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Abbott Laboratories (NYSE: ABT) has been a great buy for many years. The company's overall performance was even stronger when looking at its organic growth rate, which factors out the effect of foreign exchange as well as non-core business in the nutrition segment that Abbott discontinued in 2018. Operating expenses, including cost of goods sold, rose at a rate of 4.9%, slightly below the 7.1% increase that the company saw in its top line.
Abbott Laboratories (NYSE: ABT) has been a great buy for many years. Small wins along the way, such as fewer expenses related to interest and debt, saved the company $36 million, while the net effect of foreign exchange added $2 million to its bottom line compared to a loss of $26 million a year ago. It was the same story when looking at the company's full-year results, as Abbott's revenue growth of 4.3% was well above the 1.7% increase that its operating expenses rose by, leaving more of the top line to trickle through to the bottom.
Abbott Laboratories (NYSE: ABT) has been a great buy for many years. The company showed strong sales growth in 2019 Abbott released its fourth-quarter earnings on Jan. 22, and the numbers were very strong. It was the same story when looking at the company's full-year results, as Abbott's revenue growth of 4.3% was well above the 1.7% increase that its operating expenses rose by, leaving more of the top line to trickle through to the bottom.
Abbott Laboratories (NYSE: ABT) has been a great buy for many years. That's $62 million in cost reductions; that alone would have been good enough for a 10% improvement from last year's bottom line. It was the same story when looking at the company's full-year results, as Abbott's revenue growth of 4.3% was well above the 1.7% increase that its operating expenses rose by, leaving more of the top line to trickle through to the bottom.
32805.0
2020-01-29 00:00:00 UTC
MIT Researchers Create First Bionic Heart to Test Cardiac Devices
ABT
https://www.nasdaq.com/articles/mit-researchers-create-first-bionic-heart-to-test-cardiac-devices-2020-01-29
nan
nan
Researchers at the Massachusetts Institute of Technology (MIT) have succeeded in developing a bionic heart that fuses both organic muscle alongside artificial, biorobotic tissues. This new hybrid heart isn't meant for patients, but rather, will be used by medical engineers to test out new cardiac devices, such as prosthetic valve implants. The device first began with a real human heart which was wrapped in a set of artificial robotic muscles that simulate a human heart's contractions. While it's an impressive technical achievement to produce a heart which so accurately mimics the human heart, this device is expected to be very useful for medical device makers, that can better test new cardiac devices for potential complications without using live patients. Image source: Getty Images. Ellen Roche, an MIT assistant professor of mechanical engineering, said "regulatory testing of cardiac devices requires many fatigue tests and animal tests." She added that the device "could realistically represent what happens in a real heart, to reduce the amount of animal testing or iterate the design more quickly." The cardiac device market Theglobal marketfor cardiovascular devices is growing at a steady rate, with some estimates putting the global cardiac device market at $59.1 billion by 2022. While still at an experimental stage, this device could be useful for major medical device manufacturers, such as Abbott Laboratories (NYSE: ABT) and Medtronic (NYSE: MDT), in helping test the next generation of cardiac devices. Shares of Abbott recently jumped to an all-time high following strong quarterly sales estimates driven primarily from the sale of its heart and diabetes devices. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
While still at an experimental stage, this device could be useful for major medical device manufacturers, such as Abbott Laboratories (NYSE: ABT) and Medtronic (NYSE: MDT), in helping test the next generation of cardiac devices. Researchers at the Massachusetts Institute of Technology (MIT) have succeeded in developing a bionic heart that fuses both organic muscle alongside artificial, biorobotic tissues. This new hybrid heart isn't meant for patients, but rather, will be used by medical engineers to test out new cardiac devices, such as prosthetic valve implants.
While still at an experimental stage, this device could be useful for major medical device manufacturers, such as Abbott Laboratories (NYSE: ABT) and Medtronic (NYSE: MDT), in helping test the next generation of cardiac devices. This new hybrid heart isn't meant for patients, but rather, will be used by medical engineers to test out new cardiac devices, such as prosthetic valve implants. Ellen Roche, an MIT assistant professor of mechanical engineering, said "regulatory testing of cardiac devices requires many fatigue tests and animal tests."
While still at an experimental stage, this device could be useful for major medical device manufacturers, such as Abbott Laboratories (NYSE: ABT) and Medtronic (NYSE: MDT), in helping test the next generation of cardiac devices. While it's an impressive technical achievement to produce a heart which so accurately mimics the human heart, this device is expected to be very useful for medical device makers, that can better test new cardiac devices for potential complications without using live patients. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned.
While still at an experimental stage, this device could be useful for major medical device manufacturers, such as Abbott Laboratories (NYSE: ABT) and Medtronic (NYSE: MDT), in helping test the next generation of cardiac devices. The device first began with a real human heart which was wrapped in a set of artificial robotic muscles that simulate a human heart's contractions. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.
32806.0
2020-01-28 00:00:00 UTC
Health Care Sector Update for 01/28/2020: XLRN, PHG, JNJ, ABT, MRK, PFE, AMGN
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-01-28-2020%3A-xlrn-phg-jnj-abt-mrk-pfe-amgn-2020-01-28
nan
nan
Top Health Care Stocks: JNJ: Flat PFE: -2.02% ABT: +0.32% MRK: Flat AMGN: +0.48% Leading health care stocks were mixed pre-market Tuesday. Early movers include: (+) Acceleron Pharma (XLRN), which was surging more than 50% after saying the Pulsar phase 2 trial of its sotatercept therapy met its primary and secondary endpoints in patients with pulmonary arterial hypertension. (-) Royal Philips (PHG) was down more than 3% after posting a Q4 adjusted EPS of EUR0.83 ($0.91), up from EUR0.76 a year ago and in line with the average estimate of EUR0.83 from analysts surveyed by Capital IQ. Philips also announced a review of strategic options for the future ownership of its domestic appliances business and the start of the separation process for the segment. (-) Pfizer (PFE) was declining by nearly 2% as it posted Q4 adjusted earnings per share of $0.55, down from $0.63 in the same quarter a year ago. The drug maker's result was below the Capital IQ-compiled consensus forecast of $0.58 per share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Early movers include: (+) Acceleron Pharma (XLRN), which was surging more than 50% after saying the Pulsar phase 2 trial of its sotatercept therapy met its primary and secondary endpoints in patients with pulmonary arterial hypertension. (-) Royal Philips (PHG) was down more than 3% after posting a Q4 adjusted EPS of EUR0.83 ($0.91), up from EUR0.76 a year ago and in line with the average estimate of EUR0.83 from analysts surveyed by Capital IQ. Philips also announced a review of strategic options for the future ownership of its domestic appliances business and the start of the separation process for the segment.
Top Health Care Stocks: JNJ: Flat Leading health care stocks were mixed pre-market Tuesday. (-) Royal Philips (PHG) was down more than 3% after posting a Q4 adjusted EPS of EUR0.83 ($0.91), up from EUR0.76 a year ago and in line with the average estimate of EUR0.83 from analysts surveyed by Capital IQ.
Top Health Care Stocks: JNJ: Flat Leading health care stocks were mixed pre-market Tuesday. (-) Royal Philips (PHG) was down more than 3% after posting a Q4 adjusted EPS of EUR0.83 ($0.91), up from EUR0.76 a year ago and in line with the average estimate of EUR0.83 from analysts surveyed by Capital IQ.
Top Health Care Stocks: JNJ: Flat Early movers include: (+) Acceleron Pharma (XLRN), which was surging more than 50% after saying the Pulsar phase 2 trial of its sotatercept therapy met its primary and secondary endpoints in patients with pulmonary arterial hypertension. (-) Royal Philips (PHG) was down more than 3% after posting a Q4 adjusted EPS of EUR0.83 ($0.91), up from EUR0.76 a year ago and in line with the average estimate of EUR0.83 from analysts surveyed by Capital IQ.
32807.0
2020-01-28 00:00:00 UTC
3 Dividend Stocks Perfect for Retirees
ABT
https://www.nasdaq.com/articles/3-dividend-stocks-perfect-for-retirees-2020-01-28
nan
nan
A well-constructed dividend portfolio can help pave the way to greater financial flexibility in retirement and help you enjoy your later years in style. Many retirees rely on dividend-paying stocks for extra income, but not every stock that offers a substantial yield will wind up pulling its weight in a retirement portfolio. Retirees have to strike a balance among stocks that offer big enough yields to create a meaningful stream of income, trade at valuations that protect the principal of the investment, and have business strengths that will allow them to navigate some twists and turns and keep the dividends flowing. For investors seeking big, dependable dividends, these three stocks offer yields north of 5% and are backed by sturdy businesses that should power long-term performance. Image source: Getty Images. 1. ExxonMobil DIVIDEND YIELD ANNUAL PAYOUT GROWTH STREAK PAYOUT GROWTH OVER THE LAST 10 YEARS FCF PAYOUT RATIO 5.2% 37 years 107.1% 98% FCF = free cash flow. Sources: ExxonMobil, Yahoo! Finance. ExxonMobil (NYSE: XOM) has a top position in the oil and gas industry that's unlikely to be disrupted, along with underappreciated growth prospects and a great dividend. The company has returned a whopping $14.44 billion to shareholders through dividends over the trailing 12-month period, which is second only to AT&T in terms of the total amount of dividends paid across the period. Exxon's roughly 98% payout ratio might look concerning, but the company has been in the midst of a big spending push that has elevated expenses and pressured earnings. It is investing in new drilling and production operations that are projected to boost its 2025 earnings roughly 140% over 2017 levels (assuming an oil price of $60 per barrel). But the market has been tepid on the stock because this big investment to increase production is taking place when oil prices are already relatively low. The market's hesitance to embrace the production push has resulted in the stock trading at an opportune valuation, sporting a fantastic dividend yield. Even if renewable energy technologies see significant advances, expansion for the global population and economy will mean increased fossil-fuel demand for the foreseeable future, and retirees are getting a great dividend and a sturdy business with Exxon. 2. AT&T DIVIDEND YIELD ANNUAL PAYOUT GROWTH STREAK PAYOUT GROWTH OVER THE LAST 10 YEARS FCF PAYOUT RATIO 5.4% 36 years 23.8% 52% Sources: AT&T, Yahoo! Finance. AT&T's (NYSE: T) dividend growth has been slow over the last decade, but the company already offers a great yield, and it's generating plenty of cash flow to fund its distribution. The company's mobile wireless business is sturdy and poised to benefit from 5G tailwinds, its Time Warner has a runway for growth amid growing global demand for entertainment content, and its DirecTV satellite television subsidiary is still generating substantial free cash flow (even though it's losing subscribers due to cord-cutting). Acquiring DirecTV and Time Warner left AT&T with a big debt load, and it seems clear that the company overpaid for the former, but it's making progress paying down the debt while still investing in the business. The company is on track to generate $28 billion in free cash flow this year and reduce its debt from $166 billion to $146 billion. It has returned $14.8 billion in dividends to shareholders over the trailing 12-month period. The chances of mobile internet service seeing reduced demand are very slim. And AT&T's large existing subscriber base and network infrastructure put it in position to bridge subscribers over to faster 5G network service and new subscription packages for wearables, smart cars, and other Internet of Things (IoT) devices. The company will also have an opportunity to provide 5G services for enterprises and their IoT applications and cloud-computing needs. With a strong dividend and tailwinds on the horizon for its mobile wireless business, AT&T stands out as a great retirement stock. 3. AbbVie DIVIDEND YIELD *ANNUAL PAYOUT GROWTH STREAK PAYOUT GROWTH OVER THE LAST 10 YEARS FCF PAYOUT RATIO 5.7% 47 years 195% 54.3% *Payout growth streak includes AbbVie's time as part of Abbott Laboratories. Sources: AbbVie, Yahoo! Finance. AbbVie (NYSE: ABBV) has a great yield and looks ideally suited for a retirement portfolio. While the S&P 500 index climbed nearly 29% in 2019, AbbVie stock dipped roughly 4%, with the sell-off stemming from declining sales for its Humira arthritis drug in Europe and other international markets. The biopharmaceutical company's shares now trade at roughly 8.5 times this year's expected earnings and look attractively valued for retirees seeking high yield stocks. Humira is still the world's top-selling drug by revenue, but the launch of biosimilars have tamped down sales outside the U.S. (where the drug is still protected thanks to patents on its manufacturing and formulation), and protections on its marquee product will start to slip in 2023. Increasing competition for the drug prompted the company to make a $63 billion bid to acquire pharmaceutical company Allergan, which is mostly known for its Botox. While the market balked at the price of the Allergan acquisition, the deal will significantly boost AbbVie's cash flow and put it in even better position to continue delivering substantial payout growth over the next decade and beyond. Humira sales will likely continue to be pressured by competition, but the company has received 14 new-product and major-treatment approvals over the last five years, and it has other new treatments in the pipeline that should strengthen the business. The company has also been delivering stellar payout growth over the last decade, and that trend looks poised to continue. 10 stocks we like better than AT&T When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AT&T wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Noonan owns shares of AT&T. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Retirees have to strike a balance among stocks that offer big enough yields to create a meaningful stream of income, trade at valuations that protect the principal of the investment, and have business strengths that will allow them to navigate some twists and turns and keep the dividends flowing. Even if renewable energy technologies see significant advances, expansion for the global population and economy will mean increased fossil-fuel demand for the foreseeable future, and retirees are getting a great dividend and a sturdy business with Exxon. The company's mobile wireless business is sturdy and poised to benefit from 5G tailwinds, its Time Warner has a runway for growth amid growing global demand for entertainment content, and its DirecTV satellite television subsidiary is still generating substantial free cash flow (even though it's losing subscribers due to cord-cutting).
The company's mobile wireless business is sturdy and poised to benefit from 5G tailwinds, its Time Warner has a runway for growth amid growing global demand for entertainment content, and its DirecTV satellite television subsidiary is still generating substantial free cash flow (even though it's losing subscribers due to cord-cutting). The company is on track to generate $28 billion in free cash flow this year and reduce its debt from $166 billion to $146 billion. 5.7% 47 years 195% 54.3% *Payout growth streak includes AbbVie's time as part of Abbott Laboratories.
Retirees have to strike a balance among stocks that offer big enough yields to create a meaningful stream of income, trade at valuations that protect the principal of the investment, and have business strengths that will allow them to navigate some twists and turns and keep the dividends flowing. The company's mobile wireless business is sturdy and poised to benefit from 5G tailwinds, its Time Warner has a runway for growth amid growing global demand for entertainment content, and its DirecTV satellite television subsidiary is still generating substantial free cash flow (even though it's losing subscribers due to cord-cutting). The biopharmaceutical company's shares now trade at roughly 8.5 times this year's expected earnings and look attractively valued for retirees seeking high yield stocks.
The company's mobile wireless business is sturdy and poised to benefit from 5G tailwinds, its Time Warner has a runway for growth amid growing global demand for entertainment content, and its DirecTV satellite television subsidiary is still generating substantial free cash flow (even though it's losing subscribers due to cord-cutting). The company is on track to generate $28 billion in free cash flow this year and reduce its debt from $166 billion to $146 billion. While the market balked at the price of the Allergan acquisition, the deal will significantly boost AbbVie's cash flow and put it in even better position to continue delivering substantial payout growth over the next decade and beyond.
32808.0
2020-01-25 00:00:00 UTC
Better Buy: DexCom vs. Abbott Laboratories
ABT
https://www.nasdaq.com/articles/better-buy%3A-dexcom-vs.-abbott-laboratories-2020-01-25
nan
nan
Healthcare stocks languished during most of 2019 as the markets fretted over political risks associated with the upcoming presidential election. But the sector picked up some steam in the last three months of the year as those worries subsided and investors turned to the sector looking for opportunities that could hold up well if the economy turns down. DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two very successful healthcare companies that appeal to different sorts of investors. DexCom is a pure play in one of the hottest areas in healthcare, while Abbott Labs is a diversified, steady performer. Which one wins the nod as the better stock to own for the next few years? DexCom's business DexCom specializes in one type of medical device for people with diabetes, continuous glucose monitors (CGMs), and has been wildly successful in that space. The company's current line of monitors uses a small sensor inserted under the skin and a Bluetooth transmitter that connects to a DexCom receiver, a smartphone, or a smartwatch. The system takes blood glucose measurements every five minutes and alerts the wearer when glucose levels fall outside a safe range. Image source: Getty Images. The advantages of frequent measurements and no requirement for pricking fingers have resulted in rapid sales growth for DexCom. Through the first three quarters of 2019, revenue is up a whopping 46% to $1.01 billion, and non-GAAP (adjusted) earnings per share are $0.69, up from a loss of $0.19 in the first nine months of 2018. Abbott's business Abbott Labs also makes CGMs, but it's a broadly diversified healthcare company that's over 20 times the size of DexCom and sells more than 1,500 products. The company has four business segments: Medical devices (at 38% of revenue) is the company's biggest, along with diagnostics, nutrition, and established pharmaceuticals. All four segments are contributing to Abbott's steady but relatively unspectacular growth. Overall, the company has grown year-to-date revenue by 7.4% on an organic basis (that is, excluding currency effects and the effect of a discontinued business) to $23.6 billion. Revenue from medical devices has grown 10.2% organically over the prior year, pharmaceuticals are up 6.5%, diagnostics has grown 5.7%, and nutrition 5.2%. Earnings per share are up 10.6% to $2.29. Abbott's glucose monitor, FreeStyle Libre, actually outsells DexCom's and is growing faster. The Abbott CGM generated $496 million in revenue in Q3, compared with $396 million for DexCom's. Sales growth for the product line was 63%, beating DexCom's 49% growth in the quarter. DexCom's growth prospects DexCom's rapid growth will likely continue for at least a few more years, although perhaps at a somewhat slower pace. In a recent update, the company gave muted guidance of revenue growth between 17% and 21% in 2020, down from 42% growth in 2019, but the company regularly underpromises and then beats expectations. DexCom's G6 glucose monitoring system. Image source: DexCom. DexCom's core customers are diabetes patients on intensive insulin therapy who need to regulate blood glucose level to within a range. That market is growing with the diabetes epidemic, and DexCom has plenty of runway. Only about 15% of the type 2 diabetes patients in the U.S. on intensive therapy are using CGMs. The company is gearing up to launch an improved version of its devices in late 2020, which should boost sales and improve profits due to a lower manufacturing cost. Longer term, DexCom has plenty of room to grow outside its core market, though. The company is growing its sales team to market to hospitals for glucose monitoring in inpatient settings and is conducting studies with pregnant women for management of gestational diabetes. Ultimately, the larger population of patients with type 2 diabetes who aren't on intensive diabetes therapy and even the 84 million people in the U.S. who are pre-diabetic could be part of the company's addressable market. Monitoring blood glucose could become an important part of controlling diet and exercise to halt the progression of the disease. Abbott's growth prospects Sales of Abbott's CGM may be growing faster than Dexcom's, but they're small compared with the overall total for the company. Fortunately for Abbott's shareholders, the company has other bright spots that are driving growth. Abbott's Alinity ci-series. Image source: Abbott Laboratories. Abbott's MitraClip, an implant to repair leaky heart valves, is growing sales at over 30%. Alinity is a family of high-throughput systems for core laboratory testing such as blood chemistry analysis, and the recent rollout of the products in Europe is helping to grow that product line in double digits. Abbott's established pharmaceuticals business is focused on selling branded-generic medicines into emerging markets, where demographics and improving standards of living are tailwinds for growth. There really aren't any weak points in Abbott's highly diversified business, which makes the company's bottom line steady and very predictable. It is guiding toward non-GAAP EPS growth of about 12% for 2019, and it should be able to maintain growth at about that rate for years. Dividends and valuation DexCom doesn't pay dividends, but Abbott is a Dividend Aristocrat, having increased its payout for 48 consecutive years. Last month it raised the quarterly dividend a healthy 12.5%, and it now yields 1.6%. Shares are priced to reflect the massive growth that investors expect to see from the business. The stock sells for 122 times the analyst consensus estimate for earnings in 2020, which assumes about 33% growth from 2019. Abbott's stock sells for about 25 times expected 2020 EPS, which is much cheaper than DexCom, but doesn't exactly put the stock in value territory given a growth rate in the low teens. For growth, buy DexCom; Value investors will prefer Abbott Given DexCom's strong business momentum and wide-open avenues for long-term growth, I think investors will continue to award the stock a high multiple and the shares will likely outperform those of Abbott Labs over the next few years. But DexCom's valuation adds risk to the stock, and there is also a good chance the investors will have a bumpy ride on the way to gains, especially if the market turns down and shuns risk for a time. DexCom would be my pick for risk-tolerant growth stock investors. Abbott Laboratories is more suitable for some investors, though. The well-managed blue chip produces steady growth that's diversified across a broad portfolio. And though the yield isn't particularly high, it's a dependable dividend stock that isn't very susceptible to either the economy or the whims of the market. Conservative investors who want a stock they can buy and forget about for decades should consider Abbott Labs over DexCom. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two very successful healthcare companies that appeal to different sorts of investors. The company's current line of monitors uses a small sensor inserted under the skin and a Bluetooth transmitter that connects to a DexCom receiver, a smartphone, or a smartwatch. The company is growing its sales team to market to hospitals for glucose monitoring in inpatient settings and is conducting studies with pregnant women for management of gestational diabetes.
DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two very successful healthcare companies that appeal to different sorts of investors. DexCom's business DexCom specializes in one type of medical device for people with diabetes, continuous glucose monitors (CGMs), and has been wildly successful in that space. Abbott's business Abbott Labs also makes CGMs, but it's a broadly diversified healthcare company that's over 20 times the size of DexCom and sells more than 1,500 products.
DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two very successful healthcare companies that appeal to different sorts of investors. Abbott's growth prospects Sales of Abbott's CGM may be growing faster than Dexcom's, but they're small compared with the overall total for the company. Abbott's stock sells for about 25 times expected 2020 EPS, which is much cheaper than DexCom, but doesn't exactly put the stock in value territory given a growth rate in the low teens.
DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two very successful healthcare companies that appeal to different sorts of investors. Abbott's business Abbott Labs also makes CGMs, but it's a broadly diversified healthcare company that's over 20 times the size of DexCom and sells more than 1,500 products. Sales growth for the product line was 63%, beating DexCom's 49% growth in the quarter.
32809.0
2020-01-24 00:00:00 UTC
Abbot's Brain Stimulation System Approved to Treat Parkinson's
ABT
https://www.nasdaq.com/articles/abbots-brain-stimulation-system-approved-to-treat-parkinsons-2020-01-24
nan
nan
Abbott Laboratories (NYSE: ABT) announced on Friday that it's Infinity Deep Brain Stimulation (DPS) system had received approval from the Food and Drug Administration (FDA) to target specific areas of the brain associated with motor functions. More specifically, the expanded indication permits Abbott's DPS system to target the internal globus pallidus (GPi), a specific part of the brain that regulates voluntary movement. This specific part of the brain, when stimulated, has been associated with helping improve motor-function related Parkinson's symptoms. DPS therapy can also help Parkinson's patients who are dealing with side-effects from medications, such as involuntary muscle movements and spasms (also known as dyskinesia). Image source: Getty Images. The company noted that Infinity is the only directional DPS system that's been approved by the FDA to be used for all parts of the brain associated with movement associated disorders. In addition to being available in almost 30 countries around the world, the system can also be controlled with a nearby IOS device with Bluetooth technology, such as an iPhone. A growing market DPS systems are becoming an increasingly common type of treatment for a variety of brain-related disorders. Besides Parkinson's, depression is also another condition that's being treated with DPS technology with increasing success. Other conditions, such as schizophrenia and Alzheimer's, are also being tested at the moment as well. In addition to this piece of news, Abbott recently reported strong fourth-quarter financial results. Most notably, the healthcare company's overall sales have increased by 7% in comparison to the same time last year. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Abbott Laboratories (NYSE: ABT) announced on Friday that it's Infinity Deep Brain Stimulation (DPS) system had received approval from the Food and Drug Administration (FDA) to target specific areas of the brain associated with motor functions. DPS therapy can also help Parkinson's patients who are dealing with side-effects from medications, such as involuntary muscle movements and spasms (also known as dyskinesia). The company noted that Infinity is the only directional DPS system that's been approved by the FDA to be used for all parts of the brain associated with movement associated disorders.
Abbott Laboratories (NYSE: ABT) announced on Friday that it's Infinity Deep Brain Stimulation (DPS) system had received approval from the Food and Drug Administration (FDA) to target specific areas of the brain associated with motor functions. More specifically, the expanded indication permits Abbott's DPS system to target the internal globus pallidus (GPi), a specific part of the brain that regulates voluntary movement. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.
Abbott Laboratories (NYSE: ABT) announced on Friday that it's Infinity Deep Brain Stimulation (DPS) system had received approval from the Food and Drug Administration (FDA) to target specific areas of the brain associated with motor functions. More specifically, the expanded indication permits Abbott's DPS system to target the internal globus pallidus (GPi), a specific part of the brain that regulates voluntary movement. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned.
Abbott Laboratories (NYSE: ABT) announced on Friday that it's Infinity Deep Brain Stimulation (DPS) system had received approval from the Food and Drug Administration (FDA) to target specific areas of the brain associated with motor functions. The company noted that Infinity is the only directional DPS system that's been approved by the FDA to be used for all parts of the brain associated with movement associated disorders. That's right -- they think these 10 stocks are even better buys.
32810.0
2020-01-23 00:00:00 UTC
Abbott's Proclaim XR Neurostimulation Implant Device Said to Reduce Pain
ABT
https://www.nasdaq.com/articles/abbotts-proclaim-xr-neurostimulation-implant-device-said-to-reduce-pain-2020-01-23
nan
nan
At the 2020 North American Neuromodulation Society annual meeting, Abbott (NYSE: ABT) reported data from a clinical trial testing its Proclaim XR neurostimulation implant in patients with chronic pain. The system was able to reduce pain catastrophizing scale scores (PCS), which measures the psychological aspects of pain, by an average of 62%. Using another measure for pain, the Oswestry Disability Index (ODI), 78% of patients had a score of "severe," "crippling," or "bed bound," at the start of the study, which was reduced to just 29% of patients after six months of having the implant -- with none of the patients reported as "bed bound." At the other end of the scale, 71% of people in the clinical trial had a minimal or moderate ODI score after six months of using the Proclaim XR. Image source: Getty Images. Abbott's Proclaim XR system is adjustable, allowing doctors to increase the strength of the neurostimulation if the patient isn't satisfied with the amount of pain reduction. Abbot has developed batteries that don't need to be charged, allowing the implant to function for up to 10 years when set to the lowest stimulation. The healthcare company launched the Proclaim XR in the fourth quarter of 2019. The company doesn't breakout individual sales, but Robert Ford, Abbott's president and chief operating officer, said the launch produced a "modest improvement" in the company's neurology business, which struggled in 2019 with U.S. sales down 4.2% year over year. With an estimated 50 million Americans living with chronic pain and new clinical trial data showing the system helps patients, there would seem to be room for further improvement. 10 stocks we like better than Abbott When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
At the 2020 North American Neuromodulation Society annual meeting, Abbott (NYSE: ABT) reported data from a clinical trial testing its Proclaim XR neurostimulation implant in patients with chronic pain. Abbott's Proclaim XR system is adjustable, allowing doctors to increase the strength of the neurostimulation if the patient isn't satisfied with the amount of pain reduction. With an estimated 50 million Americans living with chronic pain and new clinical trial data showing the system helps patients, there would seem to be room for further improvement.
At the 2020 North American Neuromodulation Society annual meeting, Abbott (NYSE: ABT) reported data from a clinical trial testing its Proclaim XR neurostimulation implant in patients with chronic pain. With an estimated 50 million Americans living with chronic pain and new clinical trial data showing the system helps patients, there would seem to be room for further improvement. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.
At the 2020 North American Neuromodulation Society annual meeting, Abbott (NYSE: ABT) reported data from a clinical trial testing its Proclaim XR neurostimulation implant in patients with chronic pain. Using another measure for pain, the Oswestry Disability Index (ODI), 78% of patients had a score of "severe," "crippling," or "bed bound," at the start of the study, which was reduced to just 29% of patients after six months of having the implant -- with none of the patients reported as "bed bound." See the 10 stocks *Stock Advisor returns as of December 1, 2019 Brian Orelli and The Motley Fool have no position in any of the stocks mentioned.
At the 2020 North American Neuromodulation Society annual meeting, Abbott (NYSE: ABT) reported data from a clinical trial testing its Proclaim XR neurostimulation implant in patients with chronic pain. At the other end of the scale, 71% of people in the clinical trial had a minimal or moderate ODI score after six months of using the Proclaim XR. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Brian Orelli and The Motley Fool have no position in any of the stocks mentioned.
32811.0
2020-01-23 00:00:00 UTC
Abbott Announces Positive Results In Chronic Pain Study
ABT
https://www.nasdaq.com/articles/abbott-announces-positive-results-in-chronic-pain-study-2020-01-23
nan
nan
(RTTNews) - Abbott (ABT) announced positive results from a study, providing the scientific basis for the company's Proclaim XR recharge-free neurostimulation system for people living with chronic pain. The company said its study found that BurstDR stimulation waveform reduced the negative psychological effects associated with a person's chronic pain at six-month follow up by 62%. The company noted that its proclaim XR system allows physicians to identify the lowest effective dose of BurstDR stimulation customized to each patient, optimizing system longevity while maintaining effective pain and symptom relief, and eliminating the need for recharging (for up to 10 years at low-dose settings). The patient-centric innovation is possible because of Abbott's proprietary stimulation waveform and advanced battery technology that is integrated into Proclaim XR, the company said. It is estimated that 50 million Americans live with chronic pain, which is defined as pain that lasts longer than six months. About 30% of those living with chronic pain develop depression or psychological effects when patients develop a preoccupation with pain that makes it difficult to live a normal life. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott (ABT) announced positive results from a study, providing the scientific basis for the company's Proclaim XR recharge-free neurostimulation system for people living with chronic pain. The company said its study found that BurstDR stimulation waveform reduced the negative psychological effects associated with a person's chronic pain at six-month follow up by 62%. The patient-centric innovation is possible because of Abbott's proprietary stimulation waveform and advanced battery technology that is integrated into Proclaim XR, the company said.
(RTTNews) - Abbott (ABT) announced positive results from a study, providing the scientific basis for the company's Proclaim XR recharge-free neurostimulation system for people living with chronic pain. The company said its study found that BurstDR stimulation waveform reduced the negative psychological effects associated with a person's chronic pain at six-month follow up by 62%. About 30% of those living with chronic pain develop depression or psychological effects when patients develop a preoccupation with pain that makes it difficult to live a normal life.
(RTTNews) - Abbott (ABT) announced positive results from a study, providing the scientific basis for the company's Proclaim XR recharge-free neurostimulation system for people living with chronic pain. The company noted that its proclaim XR system allows physicians to identify the lowest effective dose of BurstDR stimulation customized to each patient, optimizing system longevity while maintaining effective pain and symptom relief, and eliminating the need for recharging (for up to 10 years at low-dose settings). About 30% of those living with chronic pain develop depression or psychological effects when patients develop a preoccupation with pain that makes it difficult to live a normal life.
(RTTNews) - Abbott (ABT) announced positive results from a study, providing the scientific basis for the company's Proclaim XR recharge-free neurostimulation system for people living with chronic pain. The company said its study found that BurstDR stimulation waveform reduced the negative psychological effects associated with a person's chronic pain at six-month follow up by 62%. The company noted that its proclaim XR system allows physicians to identify the lowest effective dose of BurstDR stimulation customized to each patient, optimizing system longevity while maintaining effective pain and symptom relief, and eliminating the need for recharging (for up to 10 years at low-dose settings).
32812.0
2020-01-22 00:00:00 UTC
Health Care Sector Update for 01/22/2020: AKCA, IONS, JNJ, PFE, ABT, MRK, AMGN
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-01-22-2020%3A-akca-ions-jnj-pfe-abt-mrk-amgn-2020-01-22
nan
nan
Top Health Care Stocks: JNJ: -1.59% PFE: +0.10% ABT: +1.13% MRK: +0.17% AMGN: +0.73% Health care majors were rallying pre-market Wednesday. Early movers include: (+) Akcea Therapeutics (AKCA), which was climbing by more than 13% after the company and Ionis Pharmaceuticals (IONS) reported positive topline results from a phase 2 study of the drug AKCEA-APOCIII-LRx to treat patients with hypertriglyceridemia who are at risk for or have established cardiovascular disease (CVD). Ionis was advancing by more than 3% amid the news. In other sector news: (-) Johnson & Johnson (JNJ) was slipping by more than 1% after booking Q4 adjusted earnings of $1.88 per share, down from $1.97 a year ago but narrowly topping the $1.87 average estimate from analysts polled by Capital IQ. (+) Abbott Laboratories (ABT) was over 1% higher as it posted Q4 adjusted earnings of $0.95 per diluted share, up from $0.81 per share a year ago but in line with the $0.95 average analyst estimate compiled by Capital IQ. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(+) Abbott Laboratories (ABT) was over 1% higher as it posted Q4 adjusted earnings of $0.95 per diluted share, up from $0.81 per share a year ago but in line with the $0.95 average analyst estimate compiled by Capital IQ. Early movers include: (+) Akcea Therapeutics (AKCA), which was climbing by more than 13% after the company and Ionis Pharmaceuticals (IONS) reported positive topline results from a phase 2 study of the drug AKCEA-APOCIII-LRx to treat patients with hypertriglyceridemia who are at risk for or have established cardiovascular disease (CVD). In other sector news: (-) Johnson & Johnson (JNJ) was slipping by more than 1% after booking Q4 adjusted earnings of $1.88 per share, down from $1.97 a year ago but narrowly topping the $1.87 average estimate from analysts polled by Capital IQ.
(+) Abbott Laboratories (ABT) was over 1% higher as it posted Q4 adjusted earnings of $0.95 per diluted share, up from $0.81 per share a year ago but in line with the $0.95 average analyst estimate compiled by Capital IQ. Top Health Care Stocks: In other sector news: (-) Johnson & Johnson (JNJ) was slipping by more than 1% after booking Q4 adjusted earnings of $1.88 per share, down from $1.97 a year ago but narrowly topping the $1.87 average estimate from analysts polled by Capital IQ.
(+) Abbott Laboratories (ABT) was over 1% higher as it posted Q4 adjusted earnings of $0.95 per diluted share, up from $0.81 per share a year ago but in line with the $0.95 average analyst estimate compiled by Capital IQ. Early movers include: (+) Akcea Therapeutics (AKCA), which was climbing by more than 13% after the company and Ionis Pharmaceuticals (IONS) reported positive topline results from a phase 2 study of the drug AKCEA-APOCIII-LRx to treat patients with hypertriglyceridemia who are at risk for or have established cardiovascular disease (CVD). In other sector news: (-) Johnson & Johnson (JNJ) was slipping by more than 1% after booking Q4 adjusted earnings of $1.88 per share, down from $1.97 a year ago but narrowly topping the $1.87 average estimate from analysts polled by Capital IQ.
(+) Abbott Laboratories (ABT) was over 1% higher as it posted Q4 adjusted earnings of $0.95 per diluted share, up from $0.81 per share a year ago but in line with the $0.95 average analyst estimate compiled by Capital IQ. Top Health Care Stocks: Health care majors were rallying pre-market Wednesday.
32813.0
2020-01-22 00:00:00 UTC
Abbott Laboratories (ABT) Q4 2019 Earnings Call Transcript
ABT
https://www.nasdaq.com/articles/abbott-laboratories-abt-q4-2019-earnings-call-transcript-2020-01-22
nan
nan
Image source: The Motley Fool. Abbott Laboratories (NYSE: ABT) Q4 2019 Earnings Call Jan 22, 2020, 9:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning and thank you for standing by, welcome to Abbott's Fourth Quarter 2019 Earnings Conference Call. [Operator Instructions] With the exception of any participants' questions asked during the question-and-answer session, the entire call, including the question-and-answer session is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations, Licensing and Acquisitions. Scott Leinenweber -- Vice President of Investor Relations, Licensing and Acquisitions Good morning and thank you for joining us. With me today are Miles White, Chairman of the Board and Chief Executive Officer; Robert Ford, President and Chief Operating Officer; and Brian Yoor, Executive Vice President, Finance and Chief Financial Officer. Miles will provide opening remarks. Brian will discuss our performance and outlook in more detail. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2020. Abbott cautions that these forward-looking statements are subject to risk and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors to our annual report on Securities and Exchange Commission Form 10-K for the year ended December 31st, 2018. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments except as required by law. Please note that financial results and guidance provided on the call today for sales, EPS and line items of the P&L will be for continuing operations only. On today's conference call as in the past non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which is defined in our earnings news release issued earlier today. With that I will now turn the call over to Miles. Miles D. White -- Chairman and Chief Executive Officer Okay. Thanks, Scott. Good morning. 2019 was another highly successful year for Abbott. Our focused execution resulted in strong financial performance, including ongoing earnings per share of $3.24 reflecting 12.5% growth on an absolute basis and even higher growth when excluding the impact of currency. All four of our businesses performed well contributing to full year organic sales growth of more than 7.5% which is above the guidance range we set at the beginning of last year. The successful year was capped off by a strong fourth quarter with organic sales growth of 8.5%, including double-digit sales growth in Medical Devices, Established Pharmaceuticals and Core Laboratory Diagnostics, along with ongoing EPS growth of more than 17%. Our consistent strong performance demonstrates that our business model is working exactly as intended. We've built the Company very deliberately through a multi-year process to deliver superior results for years to come. We've shaped our businesses to align with important trends to make sure we're in the right places with the right products and we've targeted businesses that are focused on some of the world's greatest healthcare concerns, for example, diabetes and cardiovascular disease are two of the most significant healthcare challenges of our lifetime. They are chronic, long lasting and dramatically increasing in prevalence around the world. Nearly every healthcare decision begins with a diagnostic test. And this testing not only occurs in the traditional hospital setting, but also increasingly at alternate sites such as physicians' offices, pharmacies and even at home. Proper nutrition is the foundational element of good health across every stage of life. Whether you're a newborn baby, a child striving to grow, or an aging adult working to overcome a health condition. And access to healthcare continues to expand rapidly in emerging markets were 85% of the world's population resides. We shaped our Company to achieve scale and leadership positions in all of these areas. The investments we've made and our focus on execution are working. Our product pipelines are strong, our operating culture is strong and we're well positioned to achieve sustainable strong growth for years to come. For 2020 we're forecasting another year of top tier financial performance. As we announced this morning we forecast organic sales growth of 7% to 8%, and adjusted earnings per share of $3.55 to $3.65, reflecting double-digit growth. I'll now provide a brief overview of our 2019 results and 2020 outlook for each business, and I'll start with Diagnostics, where sales grew 6.5% in the fourth quarter led by double-digit growth in core laboratory testing. The rollout of Alinity continues to go well in Europe where we're winning new business at a high rate and successfully renewing existing contracts that come up for bid. We continue to expand our rollout of Alinity systems across multiple key markets including US, where last year we obtained FDA approval of Alinity for blood and plasma screening and have made significant progress obtaining regulatory approvals for a critical mass of our immunoassay and clinical chemistry test menu. I'll turn now to Nutrition, where sales increased 6% in the quarter, led by strong growth across several countries and segments of our business, including Southeast Asia and Latin America, across both Pediatric and Adult Nutrition as well as above market growth in the US. In Pediatric Nutrition growth was driven by PediaSure, our nutrition solutions to help kids grow and thrive; and Pedialyte, our oral rehydration product which continues to see unprecedented uptick with both children and adults. In Adult Nutrition, global growth of 10% in the fourth quarter was led by Ensure, our leading complete and balanced nutrition brand and Glucerna our leading brand for people with diabetes. Moving now to Medical Devices, where sales increased nearly 11.5% in the fourth quarter led by double-digit growth in Structural Heart, Diabetes Care, Electrophysiology and Heart Failure. In Structural Heart, sales increased 17% in the fourth quarter. Over the last couple of years, our portfolio and long-term growth opportunities in this area have strengthened considerably. We've been building our position organically in this area for quite some time, when in 2017, the combination with St. Jude created what I'd now consider a best-in-class Structural Heart portfolio. MitraClip, our market leading device for the minimally invasive treatment of mitral regurgitation or a leaky heart valve is the cornerstone of our portfolio with annual sales this past year of nearly $700 million, growing 30%. Last year, we obtained an important new indication in the US that significantly expands the number of people that can be treated with MitraClip. And just last week, we announced that we are initiating a clinical trial that offers the potential to expand the treatable patient population even further. Beyond MitraClip, several exciting technologies are expected to emerge from our Structural Heart pipeline in 2020, including CE Mark approvals for TriClip, a first of its kind technology to repair leaky tricuspid heart valves and for Tendyne, which targets replacement of the mitral valve, as well as US approval of Portico for Transcatheter Aortic Valve Replacement. Turning now to Diabetes Care where sales increased nearly 35% in the quarter led by FreeStyle Libre, our revolutionary continuous glucose monitoring system. Several years back we saw an opportunity to approach continuous glucose monitoring or CGM in a fundamentally different manner compared to others in the space. We challenged ourselves to rethink existing paradigms as we sought to develop a solution that would truly benefit the mass population of people living with diabetes around the world. That aspiration influenced every aspect of Libre, highly accurate, simple to use, particularly affordable and easy for patients to access. The results of our unique approach have been remarkable by any measure. Libre has quickly become theglobal marketleading wearable CGM. Its user base has roughly doubled each year to its current level of approximately 2 million users globally, including the highest user base among CGMs in the US. Reimbursement coverage has ramped up quickly around the world as payers increasingly recognize its highly differentiated value proposition. And it's only CGM that's widely available through the pharmacy channel, which is a significant benefit for patients as it simplifies the process of acquiring the product. In 2019, Libre achieved full year sales approaching $2 billion, an increase of 70% versus the prior year. And importantly, as we plan for the substantial growth opportunity to come, we significantly expanded our manufacturing capacity to keep up with anticipated demand for this life-changing technology. Now, I'll wrap up with Established Pharmaceuticals or EPD, where sales increased 10% in the quarter led by growth across several geographies in Latin America and Asia. For the full year, sales increased 7% for the second year in a row, as this business continues to execute its unique branded generic strategy in emerging markets. These markets are growing rapidly, their populations are aging, their middle classes are expanding and healthcare spending is increasing due to improving access to healthcare. Our strategy to build a significant presence and scale in these markets is unique and continues to result in strong growth. So in summary, this was another highly successful year with strong performance across our businesses. We continue to strengthen our leadership positions in some of the largest and fastest growing areas in healthcare and we're entering 2020 with great momentum across our businesses and targeting another year of strong organic sales growth and double-digit EPS growth. I'll now turn the call over to Brian to discuss our 2019 results and 2020 outlook in more detail. Brian? Brian B. Yoor -- Executive Vice President of Finance and Chief Financial Officer Thanks, Miles. As Scott mentioned earlier, please note that all references to sales growth rates unless otherwise noted are on an organic basis which is consistent with our previous guidance. Turning to our results. Sales for the fourth quarter increased 8.5%. Exchange had an unfavorable year-over-year impact of 1.4% on fourth quarter sales. Regarding other aspects of the P&L, the adjusted gross margin ratio was 59.4% of sales, adjusted R&D investment was 6.7% of sales and adjusted SG&A expense was 28.3% of sales. The fourth quarter adjusted tax rate was 12.8% lower than our previous full year guidance of around 14.5%, due to continued implementation of and adaptation to the US tax reform regulations. Our fourth quarter tax rate reflects the aggregate adjustment to achieve our full year revised effective tax rate of 14%. Turning to our outlook for the full year 2020, today we issued guidance for adjusted earnings per share of $3.55 to $3.65. For the full year we forecast organic sales growth of 7% to 8%. And based on current rates, we would expect exchange to have a negative impact of around 0.05% on our full year reported sales. We forecast an adjusted gross margin ratio of around 59% of sales for the full year, which reflects underlying gross margin improvement across our businesses, offset by the impact of investments to support the rapid market adoption of our Alinity diagnostic systems, investments in Libre and MitraClip manufacturing capacity expansions and the impact of currency mix. We forecast adjusted R&D investment of approximately 7% of sales and adjusted SG&A expense of around 29.5% of sales. We forecast net interest expense of around $515 million and non-operating income around $200 million. Lastly, we forecast an adjusted tax rate of 13.5% to 14% for the full year 2020. Turning to our outlook for the first quarter. We forecast adjusted EPS of $0.69 to $0.71 which reflects double-digit growth. We forecast organic sales growth of around 7% and at current rates would expect exchange to have a negative impact of a little more than 1% on our first quarter reported sales. We forecast an adjusted gross margin ratio of somewhat above 58.5% of sales, adjusted R&D investment of somewhat above 7% of sales and adjusted SG&A expense of around 32% of sales. Lastly, we forecast net interest expense of around $130 million in the first quarter. Before we open the call for questions, I'll now provide a quick overview of our first quarter and full year organic sales growth outlook by business. For Established Pharmaceuticals, we forecast mid to high single-digit growth for both the first quarter and the full year. In Nutrition, we forecast growth of around 4% for the full year and growth of 3% to 4% for the first quarter. In Diagnostics, we forecast mid to high single-digit growth for both the first quarter and full year, and in Medical Devices, we forecast double-digit growth similar to last year for both the first quarter and full year. With that, we will now open the call for questions. Questions and Answers: Operator Thank you. [Operator Instructions] And our first question comes from Bob Hopkins from Bank of America. Your line is open. Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Great. Thanks for taking the question. So I guess, first, Miles congratulations on such an incredible run of 20 plus years of value creation, obviously incredibly impressive track record. And in light of that the first question, I'd love to ask, both you and Robert to comment on a topic, that I know is on the minds of most investors from a big picture perspective and that is the durability of the incredible 7% revenue growth outlook that you guys have expressed for 2020 and beyond. And the main reason I want to ask that question is that when you take a step back, there is no other company in med-tech modeling anything close to that kind of growth off of that large of a base, especially for multiple years. So Miles for you, I guess, just if you wouldn't mind providing some big picture thoughts on that durability topic. And then for Robert maybe getting a little bit more specific on the product areas that give you the confidence long term and whether or not M&A or divestitures could play a slightly bigger role going forward to help you maintain that level of growth? Thank you. Miles D. White -- Chairman and Chief Executive Officer Bob, this is Miles. There is a temptation to sort of say something that sticks my successor with just unbelievable goals for the future, etc., is overwhelming. So I'm going to speak first. Seriously, we have been building what we've got here for an extended period of time. It didn't just happen. It's not based on a single driving product or driving business. It's actually quite broad-based across all of our businesses. And while you know, a lot of people have commented to me or us that gee, you get the lot of big numbers and you know hard for a big company to grow, etc. We don't actually feel like that big a company. And we don't necessarily feel even though we've got leading positions in so many of our businesses. We don't actually feel like a lot of big numbers is working against us. We feel like the opportunity for growth, if you've got an innovative pipeline and you're in markets, where there is a natural tailwind of growth demographically or from an innovation standpoint and so on, yeah, I don't really think that this whole notion of gee, our size or big numbers applies. If we were a tech company, you wouldn't be asking us that, because we'd be too small. So, you know, I think if we look at the size of the opportunities where we place the Company and its businesses and the portfolio of products and geographies and so forth, I think there is enormous market opportunity that's untapped. And I think there is enormous penetration to be tapped, and I think there are some obvious examples out there. And fortunately in all of our businesses, I think every one of them is innovating and creating new products and innovating to replace older products in a way that's really never been true before and it's across the board. And so as we look forward to that and model it, we think our growth rates are sustainable. How far out are they sustainable? I don't know, but years anyway. And are we going to have speed bumps? We're going to have speed bumps of our own making, we're going to have speed bumps from trade, we're going to have speed bumps from exchange, we're going to have speed bumps in any number of ways, as all companies have and do and yet we -- and we have them now, and we're still growing at a very healthy strong rate. And I credit the innovation pipeline, some smart acquisitions at the right time, with the right businesses, the right strategies, the right fits, I credit the execution of our organization and the culture of execution that is here. I have super confidence in my successor, no qualms. The minute you retire everybody thinks you ought to diversify your holdings, because you're too concentrated in one thing. I only wish I had more. And I'll remind them every day that I'm a shareholder, but which he knows, but I have nothing but confidence in the pipeline, the management, the products, the strategies and the new leader, who is going to take over from me, I have tremendous confidence in Robert, and he's got all the abilities, all the skills, etc. So we can keep talking about the lot of big numbers and gee, how do you grow on this base? We don't feel slowed or anything by that. We feel like we've got tremendous opportunity to sustain our growth rates. Robert B. Ford -- President and Chief Operating Officer Yeah, Bob, this is Robert here. As you're aware, under Miles' leadership last 20 plus years, Abbott has been reshaped several times. I was close to him and to the Board when we went through this last reshaping of the Company to really position and align our businesses to kind of high growth markets, geographies, etc. And as Miles said, it wasn't just the acquisition piece of it, which was important, but it was also how we looked at our internal R&D, our internal innovation, how we thought about it. So obviously with the transition here to CEO, there's the natural question of the incoming. Do they think differently? Is there a change in strategy? Is a different way of thinking? And I can tell you, I'm very much aligned with Miles. We see things very similar, as it relates to our strategy, how we operate, the philosophy of the Company, the vision we have for Abbott. And in the last 18 months for me, in particular to be kind of close to Miles during this transition period, being closer to him with his mentorship and learning how he has been able to kind of create value as you referenced in the beginning there, that leaves me with my number 1 priority to do that is to really execute as Miles said on these organic growth opportunities we have. And we have multiple growth drivers as you know, Bob that, in my opinion they're in their very early stages, whether it's Libre, the Alinity rollout, our rejuvenated cardiovascular portfolio, I think we've got a great opportunity in our adult International Nutrition business, our branded generic pharmaceutical business in the emerging markets, which is a very unique strategy. So I look at all of that and I think your question how sustainable is this. I think all these opportunities are in the early stages here, and it's really going to be up to me and the team here to make sure that we maximize on all of these opportunities. So we've got a portfolio that's aligned to the biggest areas of medical need, attractive geographies. As Miles said about the pipeline, it's a very rich pipeline. We talk about how this pipeline has evolved, and how we haven't seen as rich as a pipeline at Abbott in a long time, and it's a nice cadence also. It's not just a kind of won and done. We've got multiple kind of rollouts here. Our operate -- the way we operate is very strong. Miles talked about our culture. We set high aspirations for ourselves, and we do have a culture of accountability, of execution, and then you layer that in with 100,000 of the colleagues around the world that are passionate, they care about what they're doing, they believe in what we're doing, they believe in our strategy. I think we've got all the elements here to be able to sustain this kind of growth rate going forward. Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Great. That's super helpful. Just one super short follow-up on Diabetes. Robert, if you wouldn't mind just giving us a quick update on Libre 2 timelines and your thoughts there. And then if you're willing to give us a sense for in your 2020 guidance, what sort of growth assumption are you making for Libre in 2020? Thank you. Robert B. Ford -- President and Chief Operating Officer Sure. So on Libre 2, specifically last October, I mentioned that we were working through a handful of issues. Quite frankly, we encounter this handful of issues in other parts of our business too, so it's nothing that's for us is terribly surprising. It's normal. I'm not going to go into any of the real specifics here. But what I will say, Bob, is that since that time in October, I'm very pleased with the progress that we've made. And I continue to be very confident in Libre 2 and its performance and the product itself and its iCGM label. So regarding the guidance on Libre 2, what I can tell you is that we've got a lot of growth. We -- our guidance contemplates [Phonetic] a lot of Libre growth. So we're not necessarily differentiating here between one and two. But if you look at our Q4, we had a great Q4 with Libre and that's without Libre 2 in the US. It was a great way to exit and to enter 2020. As Miles said, we're the market leader in CGM in revenue and in the amount of patients, and we're growing at twice the rate. Our strategy here, has always been Miles talked about challenging some of the paradigms. It has always been from the moment we launched, to look at this as a more kind of consumer, retail, kind of web shop online play here. So when you look at our Q4, you don't see that kind of big Q4 spike and then drop in Q1, which you usually see from kind of medical benefit DME products. Our growth is very kind of consistent and sequential. The US has done very well in the year. Obviously, we want to do better, but we exited the year with well over 0.5 million patients in the US. We set up some goals for 2019, as it relates to distribution, payer coverage in the US, formulary positions. And we exited 2019 exactly where we wanted to be, with all of those goals, all favorable to Libre. So, our focus in the US in 2020 here is really to take advantage of what we've established in terms of the infrastructure and drive demand. So you'll see more TV advertising, you'll see more sales force expansion, you'll see more partnerships and execution of those partnerships, you'll see more sampling. And I think that, that same momentum that you see in the US is also there in our international markets, which is obviously a much larger base for us, and we saw great momentum in Q4. So our 2020 here is really focusing on international markets as expanding Libre into geographies that we haven't yet launched. We were capacity constrained in 2019 to the several markets that we haven't launched, and we put in place now plans to roll Libre into those new geographies and rollout Libre 2 into some of those Libre 1 markets. One thing I think is important to kind of put front and center here is the clinical aspect of Libre. It is the most studied CGM right now. And if you look at the data, whether it's our data, whether it's real world evidence data, whether it's third-party government sponsored trials, they all say the same thing, which is people that use Libre have better outcomes. They live better. They have let -- their A1c drops. Their hypo drops. Their rate of hospitalization goes down. So that the value proposition that we've always envisioned for Libre not only is it intact, but we actually see it growing. It's an easy to use, intuitive, consumer-friendly product that delivers the outcomes that are real and measurable and it's priced for mass adoption, it's affordable. We always saw the therapy benefit not only for type 1s and for pumpers, we saw this therapy benefit for people that were on one shot a day insulin, oral med patients. So we always looked at this market to be 80 million to 100 million people. Now, is it going to penetrate all the 100 million people? That might be a little bit too aspirational. But what I would say, is it more than 2 million, 3 million, 5 million, 10 million people? Absolutely. And that's how we're building our strategy, investing in the product, investing in the awareness and investing in the scalability, so we can capitalize on this opportunity. Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Thank you. Operator Thank you. And our next question comes from Robbie Marcus from J.P. Morgan. Your line is open. Robert Marcus -- J.P. Morgan -- Analyst Thanks for taking the question. I'll echo Bob's sentiment. Miles, sorry to see you go, but we're very happy to have someone so confident as Robert step in. Maybe if we could turn to Structural Heart. I was wondering if you could give an update on where we are with reimbursement and MitraClip? And then also a bit more broadly, Miles, you talked about some of the new product launches we're going to see in 2020. Maybe you could just walk us through those and the expectations throughout the year? Robert B. Ford -- President and Chief Operating Officer Sure, Robbie. I'll take that. On MitraClip listen, we had a great quarter, had a great year, and as Miles said in his comments about $700 million product growing at 30%. And the interesting thing here is that the penetration of the therapy is only at about 5%, right. So we see a long opportunity. I talked about MitraClip being a multi-year, multi-billion dollar opportunity here. And there's several elements to that. CMS reimbursement is an important building block. We expect that some time in Q2. But I've always said that it was more than just the CMS reimbursement for the indication expansion we got. We know that we need to be able to penetrate the therapy. We need to open new centers, make it more available. To do that, we need to hire more reps, invest in field clinical teams to be able to get that penetration. And we've also invested in a lot of clinical evidence and building clinical evidence here, we just recently announced our study to investigate MitraClip in moderate risk surgical patients. So again, we've been investing to build this market and obviously MitraClip gets a lot of attention in the Structural Heart portfolio. But if I take a step back here, I think it's important that we look at, we've always seen valvular heart disease as a big opportunity for Abbott, whether it's the demographics, whether it's the medical need. And we saw this unique opportunity with the St. Jude acquisition to put together our MitraClip capabilities with the portfolio, St. Jude and really create a stand-alone business unit that was best-in-class for Structural Heart. And we did that and it's been about two years that we've done that. And I -- I think we're seeing really the impact of the effect of a dedicated team, R&D, clinical, and we've got a nice cadence of products coming out this year as a result of that work. We've got two new CE approvals that we expect this year, Miles mentioned them, TriClip. This is a modified version of our MitraClip to treat the leaky heart valve. We believe it's a big opportunity, because the therapy -- if mitral therapy is low, tricuspid leaky valve treatment or repair is even lower. So we know that -- we know how to build this. We did it with mitral, and we're going to go about doing it the same way, building the capability, the clinical evidence. Another big opportunity we have is with Tendyne. This will be the first minimally invasive mitral replacement valve. So if you think about our team right now, we've built a lot of competency on mitral repair, and now we're going to put in the hands of this team not only the opportunity to offer repair, but also a replacement solution that's minimally invasive. And I think there is a great opportunity for us in that space too. Both those products are enrolling here in the US. So we do plan to bring those to the US. On the aortic side, we've made investments on Portico. We knew that we needed to make some clinical and some R&D investments here to increase the competitiveness of the system, and we like the data. We think there is going to be a segment of the population, segment of the market that we will be able to compete effectively. It's under FDA review, and we expect approval shortly. And then finally on our Structural intervention, this is a part of the portfolio that doesn't get a lot of attention here, but it's about a quarter of our Structural Heart business. It's growing double-digit. We've got great products there. We've seen a great ramp up with our stroke prevention technology, with PFO, our congenital business, and Amulet, which is right now under clinical evaluation in the US for treatment of LAA. So I take a step back here, I said, yeah, MitraClip is a big growth driver, and we got a lot of things going right there. We're making the right investments from a clinical, from a commercial perspective. But I look at the portfolio that's been built here and I'm very excited, it's very complete, it's very differentiated and there is a nice cadence, Robbie, to the launches. Robert Marcus -- J.P. Morgan -- Analyst Great. I appreciate that. And maybe just a quick follow-up. Alinity still hasn't really start its launch in the US, yeah, you put up 13% growth in Core Lab in the fourth quarter. How should we be thinking about the impact in 2020 from Alinity both in the US and outside the US? Robert B. Ford -- President and Chief Operating Officer Yeah. I think that we're going to continue to see this kind of rollout of the Alinity platform. The challenge we had a little bit in the US and Miles talked about the progress we made is that, when we launched it in Europe, we had a more complete kind of assay menu. And that allowed us to more -- with more intentionality go after the market, the existing accounts, new accounts. And then the US, we've now achieved, let's say a critical mass of assay menu, test panel etc., that allows us to have that same kind of intentionality we had in Europe, have that same intentionality move into the US. Q4, we did have some capital sales, so that brings up the growth rate a little bit. But I think you're going to see the same kind of growth rate in the US, the same kind of ramp up that we saw in Europe. Robert Marcus -- J.P. Morgan -- Analyst Thanks a lot. Operator Thank you. And our next question comes from David Lewis from Morgan Stanley. Your line is open. David Lewis -- Morgan Stanley -- Analyst Good morning. I don't want to sound like a broken record, but I'll reiterate Miles, there's some fairly significant and unique value creation over these last 20 years. So congratulations again on behalf of shareholders. Robert and Miles just starting off with a couple of businesses that had lagged in 2019 that are actually showing some improvement here in the back half of '19, which were Neuromodulation and CRM, some pretty decent improvement, specifically in the fourth quarter. I mean, Robert, you can just talk through what specific changes have been made in those two businesses? And how you're thinking about the outlook or sustainability of those franchises into 2020? And then I have a quick follow-up. Robert B. Ford -- President and Chief Operating Officer Sure. So let's start over with Neuro then. I mean I think we had a tough year, full year in Neuro, when we came into the year, we talked about some of the challenges we were up against. And there are really two we had, obviously the sales force expansion and some of the disruption that, that created. But we felt it was important to do, to make that sales force expansion. And then some of the market declines that we saw. We're kind of seeing double-digit growths and beginning of the year kind of saw that go to flat and even negative growth rate. So I think the sales force expansion piece, we kind of got past that in the middle of the year. It's a unique selling model, about 30% to 35% of our sales team in the US was new, was under a year. So we spend a lot of time getting them up to speed, not only with their territories, but how to go about the selling process, etc. And I think that's -- that's largely behind us. Now obviously if you look at the sales reps, the ones that have 7 to 10 years of experience, they're much more productive than the ones that have got 12 months, but we're seeing a nice steady ramp up in terms of the productivity of those new sales reps. And the other thing we talked about was how innovation and new product launches could kind of fuel the market growth? And I think you saw that in Q4 not only with us, but even with some of the other players in the market come out with new product launches, at least what I see now from some of the pre-announcements having kind of an impact there. And so we came out with our product launch, Proclaim XR early in Q4, and I think you saw the impact of that in Q4. I think it's a modest -- it was a modest improvement, we expect more. And a lot of our focus here in 2020 is going to be to ensure that this new sales team has got innovation to sell. So we're expanding our MRI portfolio. We know we need to do. We're launching a new radio frequency ablation generator. This is an important part of our customers' practices, and we felt that we weren't as competitive with our offering there. So we developed a new system that will be rolling out this year. And we also believe that programming and connectivity -- connectivity to devices, consumer devices is an important aspect, patient adoption of the therapy. So we'll continue to work on how we integrate to implant the device into those -- those more consumer products. So we've got a nice cadence of rollouts there. And on the CRM side, we talked about this in the beginning of last year, we had -- we encountered some challenges. And we felt that one of the things that we needed to do for the CRM side was to make sure, it got more focus and more attention, not only from -- not only from me obviously, but from the management team. So we made an organizational structure change. Q1 of last year, which got finalized in Q2, where we separated the CRM business from the EP [Phonetic] business. And we didn't do it just from a field sales perspective, we did it up really across all functions. So we have a dedicated CRM business unit with a dedicated leader, R&D, etc. And I think you've seen some of the output of that focus in the second half of the year. I would like to see a couple more quarters strung together. So that's what we're aspiring here too. But I think one of the biggest impact of that focus obviously, the field has an impact, but I'm more excited about the focus on the R&D side. I think we had to kind of slowed down our R&D innovation over here and that focus, that dedicated business unit focus, I think you'll see the output of that, not only in 2020, we have a couple of product launches in the US, new ICD, and in Europe also, but we've got plans for a nice cadence of innovation in '21 and '22. So I'm excited about kind of what we've done there. Obviously, it's early innings in terms of this business unit we'll be creating, but I like what I see. David Lewis -- Morgan Stanley -- Analyst Okay. And just two quick follow-ups for me. Just Robert on MitraClip, is there a specific embedded assumption in the guidance for MitraClip? And how acutely do you think we see that recovery in the back half? And then your margin guidance about 50 basis points is a little lower than 2019 consistent with our numbers, but if you could just highlight two or three of the examples of significant reinvestment for growth in 2020 that would be super helpful? Thanks so much. Robert B. Ford -- President and Chief Operating Officer So I just -- on your question about MitraClip recovering growth, and I think we've been pretty strong in our growth rate. The US has done very well. And what we saw in the international market, if that's what you're referring to, we did see that kind of impact of the -- some of the studies that came out in Europe impact us in the first quarter, but every quarter sequentially flat. We've seen improvement, and I think we've passed -- we've passed that on. Regarding the guidance, I mean we've got a lot of growth. As I said with Libre, we've got a lot of growth here. We've contemplated, as I said, CMS approval, but I have been fairly consistent with the CMS approval is going to be an important aspect here, but it's not just that, right. It's the -- we've been showing really strong growth in the US even without the reimbursement, and that's a result of the investments that we've been making both in the field and clinical perspective. And I'm sorry what was the other question? Brian B. Yoor -- Executive Vice President of Finance and Chief Financial Officer It was on -- it was on margin expansion. I'll start off by saying this margin improvement is an ongoing focus for us David, it has been and will continue to be whether that's gross margin, whether that's the leverage we continue to get in SG&A. And yes, notably, we did see that this year. You may be off just a little bit from our modelling, the foreign currency mix, we have a little bit of a headwind next year, but we have our gross margin expansion plan underlying. But keep in mind as Robert said, with these investments that we're doing for growth, whether that's continued Libre expansion, whether that's the most recent MitraClip expansion we announced, as well as the unprecedented uptake of Alinity, that's presenting a little bit of a headwind, but that's a good news item in the short term and longer term. You'll continue to see those gross margins expand, as we look out over the years. David Lewis -- Morgan Stanley -- Analyst Great. Thanks so much. Operator Thank you. Our next question comes from Vijay Kumar from Evercore. Your line is open. Vijay Kumar -- Evercore ISI -- Analyst Thanks, guys. Congrats on a really nice springs here [Phonetic]. One may be on Nutrition, the adult side has come in really strong. I know, China has been a bit of a bother with some regulation -- regulatory changes a couple of years ago. Could you comment on what you're seeing in China, is Adult Nutrition back. Is -- has something changed in China for you guys? Robert B. Ford -- President and Chief Operating Officer Well, listen we achieved a pretty strong growth rate in Q4 and that's despite some of the softness that we did see in China. We talked a little bit about it in Q3, Vijay. We've seen some improvement, but some of those dynamics are still there, whether it's the birth rate or some of the kind of competitive intensity. We have obviously developed a plan here, as were going into Q4 and going into 2020 here, a big part of that strategy to address some of those competitive dynamics there is innovation and product launches and we put a plan together here. We got a nice steady stream of -- cadence of launches in China. But I do think that it does point out to the strength of our Nutrition business that we're able to post this kind of growth rate despite still some continued softness in China. And I think that speaks to the strength of the business, Miles talked about we had some very strong growth in South, Southeast Asia and Latin America on both sides of the business, Pediatric and Adult. And I don't think that -- I think it shows this -- China is an important market for us for sure. It has our intentions -- our attention. But we're not overly reliant on it. Vijay Kumar -- Evercore ISI -- Analyst Yeah. That's helpful, Robert. And one on Diagnostics. I know flu has been the topic du jour. Just curious what that means for Diagnostics? On the Core Lab side, Alinity, really strong trends. You spoke about continued share gains in Europe. I'm just curious where we are in, on the US side? Have you -- is the win rate on the US side comparable to Europe or is that something that we should be expecting for the back half heading into '20, '21 [Phonetic]? Robert B. Ford -- President and Chief Operating Officer Yeah. As I said, in Europe, I think we've had kind of good success in Europe. We talked about winning new businesses at that 50% rate. The renewals of our existing business, where we're trailing nearly -- nearly all of that business. And I think in the US right now, it might be a little bit too early, just because you don't we really didn't have the intentionality the launch that we had in Europe. Now that we've got a more complete menu, I think our ability to compete and our competitive fitness, let's call it that way in the US increases to the same level that we've had in Europe. Vijay Kumar -- Evercore ISI -- Analyst Great. Thank you, guys. Operator Thank you. And our next question comes from Larry Biegelsen from Wells Fargo. Your line is open. Larry Biegelsen -- Wells Fargo -- Analyst Good morning. Thanks for taking the question. Congrats on another really strong quarter. And Miles, I'll echo what the other -- the other comments and add that I'll miss interacting with you on these calls, always insightful and fun. Just two quick questions. One, maybe for Robert on capital allocation. I know I've asked this on a few calls before, but you guys have paid down a lot of debt recently. Are you, Robert maybe thinking about M&A a little bit differently? Should we expect more tuck-ins in 2020? And I just have one quick follow-up. Robert B. Ford -- President and Chief Operating Officer Sure. I think what you'll see is the same philosophy, the same framework that we've had for this year, which is a very kind of balanced approach. As you've said, a lot of our focus, the last couple of years has been to pay down debt. We paid down close to $10 billion over the last two years. Our net debt to EBITDA ratio is around 1.5 now. And we've got kind of payments that are due in the next few years and that's all kind of contemplated in our capital plan. The other thing we're always going to have a mindful eye here, Larry is ensuring that a portion of that capital goes back to our shareholders. Our dividend is a big part of our identity. We've increased our dividend for 47 consecutive years. This year we just announced a 13% increase. So -- and we announced also at the end of last year, our share repurchase about $3 billion. We do that from time to time mainly to kind of offset dilution. We'll also look at our growth opportunities, and we've talked a lot about them whether it's the rollout of Alinity, whether it's the manufacturing expansion of Libre. We just announced in Q4, a new manufacturing site, a second manufacturing site for MitraClip. Those are all great returns for our shareholders in terms of the return of that capital. And then on the M&A side, we're now looking to do any deals right now. I think the framework that Miles has always worked is true to me, which is you know it needs to meet our threshold of it being strategic or, and at the same time opportunistic. And we've been looking at a lot, but we're always studying, we're always looking, and I haven't seen anything crossing the radar here that kind of falls in -- falls into those two -- those two buckets. But we're always going to keep looking, as we've always done. Larry Biegelsen -- Wells Fargo -- Analyst Perfect. And then just one housekeeping for Brian, and Brian congratulations on your retirement and I'll miss you as well. Just FX on the -- on EPS, the impact in 2020? Thanks for taking the questions. Robert B. Ford -- President and Chief Operating Officer The impact of what, EPS FX. Brian B. Yoor -- Executive Vice President of Finance and Chief Financial Officer FX, it's around $0.05, Larry. Larry Biegelsen -- Wells Fargo -- Analyst Thanks, Brian. Brian B. Yoor -- Executive Vice President of Finance and Chief Financial Officer Based on the mix, you got it. Operator Thank you. And our next question comes from Rick Wise from Stifel. Your line is open. Rick Wise -- Stifel Nicolaus -- Analyst Good morning, everybody. Maybe I'll start off with EPD. EPD, Rob, it's always a little bit of a black box to us Medical Device and after all just said to me, I won't drag everybody else into it. You're clearly doing exceptionally well, strong fourth quarter, and you're saying mid to high-single digits for 2020. But maybe just give us a little update some of the key drivers. What could gets you to the upper end of your range? And maybe some of the challenges, just give us some perspective about what you're thinking about for 2020? Robert B. Ford -- President and Chief Operating Officer Sure. I heard this comment a couple of times now about kind of EPD or pharma business kind of being a black box or not as transparent and as not as understanding. I mean I will say here, the biggest focus of this business is taking opportunity of the geographic dynamics, right? You can either have a proprietary pharmaceutical business a little bit more higher cost versus pure generic business, which is obviously very cheap. Our branded generic business kind of sits between those two book-ins. I come from an emerging market, so I can tell you that when we buy medications, it's not reimbursed. So you pay for it out of pocket and you're willing to pay a little bit of a premium to ensure that what you're getting is high quality product. And I think that's what this business has been built on is taking advantage of that dynamic of this population in these markets growing with their disposable income and allocating some of that to their healthcare costs on brands that they trust. And that's what we've been building over these years. A key driver of this strategy here is you need to be, you need to have the breadth and the depth in your therapy classes. So we have comprehensive portfolios in the geographies that we're competing. They're deep in each therapy class. You need to be omnichannel, you need to be present in the doctor's office, you need to be present in the pharmacy, you need to be able to kind of communicate directly with the consumer and you need to be local. You need to have a local R&D or engine organization and manufacturing to be able to move fast with the opportunities that you see. And I think that's at the core of our strategy. One of the challenges in this business, as Miles has always said is the FX piece of it, but the performance growth, we expect it to be in this kind of high single-digit growth, and a big driver of that is being in the right markets, with the right infrastructure, with the right products, with the depth and the focus on execution. Rick Wise -- Stifel Nicolaus -- Analyst Great. And turning to two other areas, Heart Failure business has done a great job. How sustainable is the robust growth we've seen? And maybe talk a little bit about the implications of the less invasive surgical approach for HeartMate 3, what that might mean? And just last maybe touch a little bit on Alere. It's been a little bit of an disappointment. What are the next steps? Help us understand what's going on? And where we go from here with Alere? Thank you so much. Robert B. Ford -- President and Chief Operating Officer Sure. On Heart Failure, I mean we had a very successful 2019. We achieved the destination therapy indication for HeartMate 3 at the end of '18. So that rolled into '19. So you saw the growth rate of about 20% here, Rick, that growth is predominantly driven by share gains and specifically here in the US. So we exited 2019. Our estimation right now is through our internal data north of 80%. So as we go into 2020, we expect that to not be at that 20% rate now and to mirror more of what the market is growing, which is we expect to be in that mid-single digit range. But I do believe that we've got a lot of opportunity. I talked about cadence of innovation in our products and one product that's comped pretty quiet, but we've done a really good job there, which is CardioMEMS. CardioMEMS is now close to $100 million. It's growing 30%. We continue to enrolled in our guide HF trial that's going to be used to open an NCD, but the outcomes there are also extremely meaningful in terms of hospitalization reductions, etc. So I think that will be kind of our next driver of growth in Heart Failure, and I'm very pleased with what the team has been able to build in that business. Going to your question on Alere. It's been a little bit of a -- we'll call it like a mixed bag here. We've had some businesses that we brought into Abbott, and I think we've done very well with them. We've accelerated their performance. If I look at the infectious disease portfolio in our developed markets, that's done very well. Yeah, of course there is some opportunity there with the flu season. But I think the team has done a really good job here expanding the portfolio and looking at those that installed base beyond just a flu test. And our cardiometabolic business has done very well too, growing in the high-single digits, low-double digits. So I think those two businesses, we've done a really good job with, and I think the team has done a good job on the cost side with the synergies too. But you have pointed out that there are some parts in the business here, where we were not pleased with, we're not satisfied. Our emerging market Infectious Disease segment had a tough 2019, part of that is kind of NGO purchasing cycles and dynamics in certain markets, but we've got to do better than that. And we've implemented a strategy here to really look at other emerging markets outside of the African continent here and build the value proposition of those tests in other emerging markets. In our toxicology business too, I don't think we've been able to kind of fully maximize the value there and that one there has got a lot of attention too. So we had a good Q4, a lot of focus here, a lot of good growth in the US, and I think part of that was a little bit of the flu. But if we can get these two business here, our emerging markets and our toxicology business to execute on the plans that we put in place for them, I think you'll see that is kind of a mid-growth, a mid-single digit kind of growth business for us. But I look at the trend and the dynamics of these products for the opportunities we have, the strategy to get into these businesses is still very much intact also. Miles talked about more and more testing move into alternative channels. We continue to see that, and we're targeting steady improvement here. But I think the long-term growth opportunity because of that trend is very positive. Rick Wise -- Stifel Nicolaus -- Analyst Thanks and congratulations. Scott Leinenweber -- Vice President of Investor Relations, Licensing and Acquisitions Thanks, operator. We'll take one more question. Operator Thank you. And our final question comes from Kristen Stewart from Barclays. Your line is open. Kristen Stewart -- Barclays -- Analyst Hi, thanks so much for taking my question. Congratulations Miles on your retirement and Brian, I hope your next chapter is a positive one as well. Just I guess a couple of cleanup questions. In terms of the, I guess PHP product, I was just wondering if you can maybe update us on just the timelines there for expected launch? And then also for Amulet as well just kind of expectations for a launch just to get some timelines? And then also, I think you Robert had also mentioned just some products within the CRM business launching there. Could you just maybe update us on expectations for that franchise. I think you mentioned a new ICD platform and some other milestones to expect within the CRM portfolio? Thanks. Robert B. Ford -- President and Chief Operating Officer So sure, on PHP and Amulet, I mean those are still I'd say a couple of years away. So we're still in kind of clinical evaluation of that. We'll then kind of put the information together, submit to the FDA. So I'd say you kind of have normal timelines over there. So you can look at it about a couple -- a couple of years away. On the CRM side, like I said, I think the biggest opportunity we had when we changed the structure was to kind of get the innovation going. So we've got two product launches, we've got a new version of -- new update to our implantable cardiac monitor planned for this year. We've got a new ICD planned again for both US and Europe. And our growth expectations here are to be -- to do better than what we've been doing, steady sequential improvement. We've had some challenges, and I think that these products here will allow us to continue that sequential improvement. Yeah. So I'll -- Kristen Stewart -- Barclays -- Analyst Perfect. And then, I forgot [Phonetic]. Robert B. Ford -- President and Chief Operating Officer Go ahead. Kristen Stewart -- Barclays -- Analyst I was just going to say and do you see any opportunities, I think Bob had mentioned this, but any opportunities just in terms of divestitures within Medical Devices or elsewhere within the portfolio or some smaller tuck-in. I know you said, it didn't sound like you were going to do any larger scale M&A, but just more product lines to bring into the portfolio from a more of a tuck-in acquisition from technology earlier stage? Robert B. Ford -- President and Chief Operating Officer Yeah. Listen if I take that and just talk about our model, we have a diversified model. I fundamentally believe in our diversified model. I think you've seen sequential improvement in all four areas over the last couple of years from a big picture perspective. Now when you go into each one of them, can you find some areas that we can do better, and we should do better. Yeah, we can and we've talked about some of those today. But that doesn't mean that we don't think they're great opportunities that just means that we need to focus on doing better and executing better on that. So as I look at these four businesses, I like the businesses we have. Kristen Stewart -- Barclays -- Analyst Okay, perfect. Thank you very much. Miles D. White -- Chairman and Chief Executive Officer Okay. This is Miles again. I'll wrap up and close for us. So first of all, thank you all very much for your very kind comments. And on behalf of both Brian and I -- well, speak and tell you that it's been a great honor and a great pleasure for us to lead our Company. It's been a tremendous experience. I feel like I've had two or three careers here in the last 21 years and probably have. Brian was estimating this morning this was our 85th or 86thearnings call And therefore, I can't tell you that I know yeah, whether I'm going to miss him, but I'm sure had a lot of them. And they're always challenging, they're always interesting opportunities to converse with you about the prospects of the Company and so forth. I feel like I leave the Company in perhaps its best position ever in terms of products and growth, future opportunities, etc., as I said at the beginning. I'm very pleased with the succession and the management team that's here. It's not just the CEO that's changing, the CFO is changing and Bob Funck, who's our long time Abbott employee and he's been our Controller for a number of years and been in some of the most challenging jobs at Abbott and so forth, will be an absolutely superb successor to Brian. You know that a lot of our management team has changed over the last couple of years as we move to a next generation of leaders and managers in the Company. And I think it's a great mix of people that are homegrown and also have come to us either through St. Jude or other outside places and we're just really happy with the team, we've got, the pipelines we've got, the positions we've got. We think our success is sustainable. And I think the track record that we've laid down over the last years has been recognized that way, and we're appreciative of the recognition that all of you have given. As I commented tongue in cheek, as a significant shareholder of the Company, I'll obviously be watching closely. And especially in the -- the immediate future, as the Chairman. So with that, we'll close the call. Thank you all very much, and thanks for all your support. Scott Leinenweber -- Vice President of Investor Relations, Licensing and Acquisitions Very good. Thank you, operator, and thank you for all of your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11:00 AM Central Time today on Abbott's Investor Relation website at abbottinvestor.com. Thank you for joining us today. Operator [Operator Closing Remarks] Duration: 62 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President of Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Robert Marcus -- J.P. Morgan -- Analyst David Lewis -- Morgan Stanley -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Rick Wise -- Stifel Nicolaus -- Analyst Kristen Stewart -- Barclays -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Abbott Laboratories (NYSE: ABT) Q4 2019 Earnings Call Jan 22, 2020, 9:30 a.m. Operator [Operator Closing Remarks] Duration: 62 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President of Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Robert Marcus -- J.P. Morgan -- Analyst David Lewis -- Morgan Stanley -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Rick Wise -- Stifel Nicolaus -- Analyst Kristen Stewart -- Barclays -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. MitraClip, our market leading device for the minimally invasive treatment of mitral regurgitation or a leaky heart valve is the cornerstone of our portfolio with annual sales this past year of nearly $700 million, growing 30%.
Operator [Operator Closing Remarks] Duration: 62 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President of Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Robert Marcus -- J.P. Morgan -- Analyst David Lewis -- Morgan Stanley -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Rick Wise -- Stifel Nicolaus -- Analyst Kristen Stewart -- Barclays -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abbott Laboratories (NYSE: ABT) Q4 2019 Earnings Call Jan 22, 2020, 9:30 a.m. With me today are Miles White, Chairman of the Board and Chief Executive Officer; Robert Ford, President and Chief Operating Officer; and Brian Yoor, Executive Vice President, Finance and Chief Financial Officer.
Operator [Operator Closing Remarks] Duration: 62 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President of Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Robert Marcus -- J.P. Morgan -- Analyst David Lewis -- Morgan Stanley -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Rick Wise -- Stifel Nicolaus -- Analyst Kristen Stewart -- Barclays -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abbott Laboratories (NYSE: ABT) Q4 2019 Earnings Call Jan 22, 2020, 9:30 a.m. In Diagnostics, we forecast mid to high single-digit growth for both the first quarter and full year, and in Medical Devices, we forecast double-digit growth similar to last year for both the first quarter and full year.
Operator [Operator Closing Remarks] Duration: 62 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President of Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Robert Marcus -- J.P. Morgan -- Analyst David Lewis -- Morgan Stanley -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Rick Wise -- Stifel Nicolaus -- Analyst Kristen Stewart -- Barclays -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abbott Laboratories (NYSE: ABT) Q4 2019 Earnings Call Jan 22, 2020, 9:30 a.m. Before we open the call for questions, I'll now provide a quick overview of our first quarter and full year organic sales growth outlook by business.
32814.0
2020-01-22 00:00:00 UTC
Wednesday Sector Leaders: Healthcare, Technology & Communications
ABT
https://www.nasdaq.com/articles/wednesday-sector-leaders%3A-healthcare-technology-communications-2020-01-22
nan
nan
In afternoon trading on Wednesday, Healthcare stocks are the best performing sector, up 0.6%. Within that group, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are two large stocks leading the way, showing a gain of 2.7% and 2.4%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.4% on the day, and up 3.14% year-to-date. Abbott Laboratories, meanwhile, is up 6.49% year-to-date, and Align Technology Inc is up 0.19% year-to-date. Combined, ABT and ALGN make up approximately 4.6% of the underlying holdings of XLV. The next best performing sector is the Technology & Communications sector, higher by 0.6%. Among large Technology & Communications stocks, International Business Machines Corp (Symbol: IBM) and Intel Corp (Symbol: INTC) are the most notable, showing a gain of 3.2% and 3.0%, respectively. One ETF closely tracking Technology & Communications stocks is the Technology Select Sector SPDR ETF (XLK), which is up 0.7% in midday trading, and up 6.65% on a year-to-date basis. International Business Machines Corp, meanwhile, is up 7.20% year-to-date, and Intel Corp is up 4.17% year-to-date. Combined, IBM and INTC make up approximately 5.8% of the underlying holdings of XLK. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:
Combined, ABT and ALGN make up approximately 4.6% of the underlying holdings of XLV. Within that group, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are two large stocks leading the way, showing a gain of 2.7% and 2.4%, respectively. Combined, IBM and INTC make up approximately 5.8% of the underlying holdings of XLK.
Within that group, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are two large stocks leading the way, showing a gain of 2.7% and 2.4%, respectively. Combined, ABT and ALGN make up approximately 4.6% of the underlying holdings of XLV. Among large Technology & Communications stocks, International Business Machines Corp (Symbol: IBM) and Intel Corp (Symbol: INTC) are the most notable, showing a gain of 3.2% and 3.0%, respectively.
Within that group, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are two large stocks leading the way, showing a gain of 2.7% and 2.4%, respectively. Combined, ABT and ALGN make up approximately 4.6% of the underlying holdings of XLV. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.4% on the day, and up 3.14% year-to-date.
Within that group, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are two large stocks leading the way, showing a gain of 2.7% and 2.4%, respectively. Combined, ABT and ALGN make up approximately 4.6% of the underlying holdings of XLV. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.4% on the day, and up 3.14% year-to-date.
32815.0
2020-01-22 00:00:00 UTC
Abbott Laboratories Beats Revenue Expectations With Balanced Growth
ABT
https://www.nasdaq.com/articles/abbott-laboratories-beats-revenue-expectations-with-balanced-growth-2020-01-22
nan
nan
Abbott Laboratories (NYSE: ABT) released its fourth-quarter report Wednesday morning, beating expectations for revenue and meeting its guidance for earnings per share. Shares were up by about 3% on the news. For the quarter, revenue rose by 7.1% year over year to $8.31 billion compared to analysts' consensus estimate of $8.26 billion, and was up 8.5% after excluding foreign currency effects and a discontinued business. Adjusted earnings per share were up 17.3% to $0.95, precisely hitting the midpoint of the guidance range management provided three months ago. Abbott's largest segment, medical devices, provided its strongest sales gain -- 11.3%, excluding foreign currency impacts. Sales of the company's continuous glucose monitoring system, FreeStyle Libre, increased 62%, and sales of the MitraClip heart valve implant product grew 29%.
Abbott Laboratories (NYSE: ABT) released its fourth-quarter report Wednesday morning, beating expectations for revenue and meeting its guidance for earnings per share. Adjusted earnings per share were up 17.3% to $0.95, precisely hitting the midpoint of the guidance range management provided three months ago. Abbott's largest segment, medical devices, provided its strongest sales gain -- 11.3%, excluding foreign currency impacts.
Abbott Laboratories (NYSE: ABT) released its fourth-quarter report Wednesday morning, beating expectations for revenue and meeting its guidance for earnings per share. For the quarter, revenue rose by 7.1% year over year to $8.31 billion compared to analysts' consensus estimate of $8.26 billion, and was up 8.5% after excluding foreign currency effects and a discontinued business. Abbott's largest segment, medical devices, provided its strongest sales gain -- 11.3%, excluding foreign currency impacts.
Abbott Laboratories (NYSE: ABT) released its fourth-quarter report Wednesday morning, beating expectations for revenue and meeting its guidance for earnings per share. For the quarter, revenue rose by 7.1% year over year to $8.31 billion compared to analysts' consensus estimate of $8.26 billion, and was up 8.5% after excluding foreign currency effects and a discontinued business. Adjusted earnings per share were up 17.3% to $0.95, precisely hitting the midpoint of the guidance range management provided three months ago.
Abbott Laboratories (NYSE: ABT) released its fourth-quarter report Wednesday morning, beating expectations for revenue and meeting its guidance for earnings per share. Shares were up by about 3% on the news. For the quarter, revenue rose by 7.1% year over year to $8.31 billion compared to analysts' consensus estimate of $8.26 billion, and was up 8.5% after excluding foreign currency effects and a discontinued business.
32816.0
2020-01-22 00:00:00 UTC
Abbott Laboratories Guides FY20 Adj. EPS In Line - Quick Facts
ABT
https://www.nasdaq.com/articles/abbott-laboratories-guides-fy20-adj.-eps-in-line-quick-facts-2020-01-22
nan
nan
(RTTNews) - While reporting its financial results for the fourth quarter on Wednesday, Abbott Laboratories (ABT) initiated earnings and organic sales growth guidance for the full-year 2020. The company also provided outlook for the first quarter of fiscal 2020. For fiscal 2020, the company now expects earnings from continuing operations in a range of $2.35 to $2.45 per share and adjusted earnings from continuing operations in a range of $3.55 to $3.65 per share on organic sales growth of 7.0 to 8.0 percent, which excludes the impact of foreign exchange. On average, analysts polled by Thomson Reuters expect the company to report earnings of $3.60 per share for the year. Analysts' estimates typically exclude special items.
(RTTNews) - While reporting its financial results for the fourth quarter on Wednesday, Abbott Laboratories (ABT) initiated earnings and organic sales growth guidance for the full-year 2020. For fiscal 2020, the company now expects earnings from continuing operations in a range of $2.35 to $2.45 per share and adjusted earnings from continuing operations in a range of $3.55 to $3.65 per share on organic sales growth of 7.0 to 8.0 percent, which excludes the impact of foreign exchange. On average, analysts polled by Thomson Reuters expect the company to report earnings of $3.60 per share for the year.
(RTTNews) - While reporting its financial results for the fourth quarter on Wednesday, Abbott Laboratories (ABT) initiated earnings and organic sales growth guidance for the full-year 2020. For fiscal 2020, the company now expects earnings from continuing operations in a range of $2.35 to $2.45 per share and adjusted earnings from continuing operations in a range of $3.55 to $3.65 per share on organic sales growth of 7.0 to 8.0 percent, which excludes the impact of foreign exchange. On average, analysts polled by Thomson Reuters expect the company to report earnings of $3.60 per share for the year.
(RTTNews) - While reporting its financial results for the fourth quarter on Wednesday, Abbott Laboratories (ABT) initiated earnings and organic sales growth guidance for the full-year 2020. For fiscal 2020, the company now expects earnings from continuing operations in a range of $2.35 to $2.45 per share and adjusted earnings from continuing operations in a range of $3.55 to $3.65 per share on organic sales growth of 7.0 to 8.0 percent, which excludes the impact of foreign exchange. On average, analysts polled by Thomson Reuters expect the company to report earnings of $3.60 per share for the year.
(RTTNews) - While reporting its financial results for the fourth quarter on Wednesday, Abbott Laboratories (ABT) initiated earnings and organic sales growth guidance for the full-year 2020. The company also provided outlook for the first quarter of fiscal 2020. For fiscal 2020, the company now expects earnings from continuing operations in a range of $2.35 to $2.45 per share and adjusted earnings from continuing operations in a range of $3.55 to $3.65 per share on organic sales growth of 7.0 to 8.0 percent, which excludes the impact of foreign exchange.
32817.0
2020-01-22 00:00:00 UTC
Here's Why Investors Really Liked Abbott Labs' Q4 Earnings Results
ABT
https://www.nasdaq.com/articles/heres-why-investors-really-liked-abbott-labs-q4-earnings-results-2020-01-22
nan
nan
It's fair to say that Abbott Laboratories' (NYSE: ABT) stock performance in 2019 was good but not great. Shares jumped more than 20% last year while lagging well behind the 29% gain delivered by the S&P 500 index. But Abbott is off to a great start in 2020. The global healthcare leader announced its fourth-quarter results on Wednesday before the market opened. There was a lot for investors to like with its latest quarterly update. Image source: Getty Images. By the numbers Abbott reported Q4 revenue of $8.3 billion, a solid 7.1% year-over-year increase. This also topped the consensus analysts' estimate of $8.26 billion. The company announced Q4 diluted earnings per share from continuing operations of $0.59 based on generally accepted accounting principles (GAAP). This reflected a 59.5% jump from the $0.37 per share posted in the year-ago period. Abbott's adjusted diluted EPS for the fourth quarter came in at $0.95 per share, up from $0.81 in the prior-year period. This met the average analyst earnings estimate. Behind the numbers The Q4 sales growth looks even more impressive when adjusted for foreign exchange fluctuations. The company said that its sales increased by 8.5% year over year on a constant-currency basis and excluding the impact of discontinued operations. All three of Abbott's business segments delivered solid growth. The company's medical devices unit was the biggest winner, with revenue jumping 9.7% year over year to $3.2 billion thanks to double-digit organic sales growth in its diabetes care, electrophysiology, heart failure, and structural heart businesses. Sales for the company's established pharmaceuticals segment increased 7.8% over the prior-year period to nearly $1.2 billion. Improving performances in Asia and Latin America drove this growth. Abbott's nutrition and diagnostics segments trailed with year-over-year revenue growth of 5.2% and 5%, respectively. Total Q4 revenue for the company's diagnostics segment was nearly $2.1 billion, with the Alinity line of diagnostic instruments contributing significantly to growth. The nutrition segment raked in $1.9 billion, with stronger growth in the adult market driven largely by Abbott's Ensure and Glucerna brands. The company's bottom-line improvement was even better than its sales mainly because operating costs increased at a slower pace than sales did. In addition, Abbott's interest expense and tax expense decreased significantly from the prior-year period. Looking ahead Management anticipates full-year 2020 organic sales growth to come in between 7% and 8%, with GAAP EPS between $2.35 and $2.45. Adjusted diluted EPS is expected to be between $3.55 and $3.65. For the first quarter of 2020, the company is anticipating EPS between $0.40 and $0.42, with adjusted EPS between $0.69 and $0.71. CEO Miles White said that Abbott's focus on organic growth is "driving top-tier performance." He added that the company is "entering 2020 with very good momentum and targeting continued strong growth." Abbott remains one of the top blue chip stocks on the market with solid growth and an attractive dividend. With the potential for Food and Drug Administration clearance of the company's new version of its Freestyle Libre continuous glucose monitoring system in the near future and positive Q4 results under its belt, Abbott has a pretty good chance to deliver an even better performance in 2020 than it did last year. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
It's fair to say that Abbott Laboratories' (NYSE: ABT) stock performance in 2019 was good but not great. The company announced Q4 diluted earnings per share from continuing operations of $0.59 based on generally accepted accounting principles (GAAP). The nutrition segment raked in $1.9 billion, with stronger growth in the adult market driven largely by Abbott's Ensure and Glucerna brands.
It's fair to say that Abbott Laboratories' (NYSE: ABT) stock performance in 2019 was good but not great. The company announced Q4 diluted earnings per share from continuing operations of $0.59 based on generally accepted accounting principles (GAAP). All three of Abbott's business segments delivered solid growth.
It's fair to say that Abbott Laboratories' (NYSE: ABT) stock performance in 2019 was good but not great. The company's medical devices unit was the biggest winner, with revenue jumping 9.7% year over year to $3.2 billion thanks to double-digit organic sales growth in its diabetes care, electrophysiology, heart failure, and structural heart businesses. Abbott remains one of the top blue chip stocks on the market with solid growth and an attractive dividend.
It's fair to say that Abbott Laboratories' (NYSE: ABT) stock performance in 2019 was good but not great. All three of Abbott's business segments delivered solid growth. Sales for the company's established pharmaceuticals segment increased 7.8% over the prior-year period to nearly $1.2 billion.
32818.0
2020-01-22 00:00:00 UTC
Abbott Laboratories Q4 adjusted earnings Inline With Estimates
ABT
https://www.nasdaq.com/articles/abbott-laboratories-q4-adjusted-earnings-inline-with-estimates-2020-01-22
nan
nan
(RTTNews) - Abbott Laboratories (ABT) reported a profit for its fourth quarter that climbed from the same period last year. The company's bottom line totaled $1.05 billion, or $0.59 per share. This compares with $0.65 billion, or $0.37 per share, in last year's fourth quarter. Excluding items, Abbott Laboratories reported adjusted earnings of $1.71 billion or $0.95 per share for the period. Analysts had expected the company to earn $0.95 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items. The company's revenue for the quarter rose 6.9% to $8.31 billion from $7.77 billion last year. Abbott Laboratories earnings at a glance: -Earnings (Q4): $1.71 Bln. vs. $1.44 Bln. last year. -EPS (Q4): $0.95 vs. $0.81 last year. -Analysts Estimate: $0.95 -Revenue (Q4): $8.31 Bln vs. $7.77 Bln last year. -Guidance: Next quarter EPS guidance: $0.69 to $0.71 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) reported a profit for its fourth quarter that climbed from the same period last year. Excluding items, Abbott Laboratories reported adjusted earnings of $1.71 billion or $0.95 per share for the period. Analysts had expected the company to earn $0.95 per share, according to figures compiled by Thomson Reuters.
(RTTNews) - Abbott Laboratories (ABT) reported a profit for its fourth quarter that climbed from the same period last year. This compares with $0.65 billion, or $0.37 per share, in last year's fourth quarter. Excluding items, Abbott Laboratories reported adjusted earnings of $1.71 billion or $0.95 per share for the period.
(RTTNews) - Abbott Laboratories (ABT) reported a profit for its fourth quarter that climbed from the same period last year. This compares with $0.65 billion, or $0.37 per share, in last year's fourth quarter. The company's revenue for the quarter rose 6.9% to $8.31 billion from $7.77 billion last year.
(RTTNews) - Abbott Laboratories (ABT) reported a profit for its fourth quarter that climbed from the same period last year. This compares with $0.65 billion, or $0.37 per share, in last year's fourth quarter. Excluding items, Abbott Laboratories reported adjusted earnings of $1.71 billion or $0.95 per share for the period.
32819.0
2020-01-22 00:00:00 UTC
Abbott Laboratories Q4 19 Earnings Conference Call At 9:30 AM ET
ABT
https://www.nasdaq.com/articles/abbott-laboratories-q4-19-earnings-conference-call-at-9%3A30-am-et-2020-01-22
nan
nan
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
32820.0
2020-01-22 00:00:00 UTC
Abbott Laboratories Q4 19 Earnings Conference Call At 9:30 AM ET
ABT
https://www.nasdaq.com/articles/abbott-laboratories-q4-19-earnings-conference-call-at-9%3A30-am-et-2020-01-22-0
nan
nan
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
32821.0
2020-01-21 00:00:00 UTC
VIG, CMCSA, ABT, COST: ETF Inflow Alert
ABT
https://www.nasdaq.com/articles/vig-cmcsa-abt-cost%3A-etf-inflow-alert-2020-01-21
nan
nan
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $535.3 million dollar inflow -- that's a 1.2% increase week over week in outstanding units (from 333,554,755 to 337,717,239). Among the largest underlying components of VIG, in trading today Comcast Corp (Symbol: CMCSA) is down about 0.8%, Abbott Laboratories (Symbol: ABT) is off about 0.1%, and Costco Wholesale Corp (Symbol: COST) is up by about 2.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $101.11 per share, with $128.64 as the 52 week high point — that compares with a last trade of $128.38. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Among the largest underlying components of VIG, in trading today Comcast Corp (Symbol: CMCSA) is down about 0.8%, Abbott Laboratories (Symbol: ABT) is off about 0.1%, and Costco Wholesale Corp (Symbol: COST) is up by about 2.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $101.11 per share, with $128.64 as the 52 week high point — that compares with a last trade of $128.38. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.
Among the largest underlying components of VIG, in trading today Comcast Corp (Symbol: CMCSA) is down about 0.8%, Abbott Laboratories (Symbol: ABT) is off about 0.1%, and Costco Wholesale Corp (Symbol: COST) is up by about 2.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $101.11 per share, with $128.64 as the 52 week high point — that compares with a last trade of $128.38. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Among the largest underlying components of VIG, in trading today Comcast Corp (Symbol: CMCSA) is down about 0.8%, Abbott Laboratories (Symbol: ABT) is off about 0.1%, and Costco Wholesale Corp (Symbol: COST) is up by about 2.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $535.3 million dollar inflow -- that's a 1.2% increase week over week in outstanding units (from 333,554,755 to 337,717,239). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $101.11 per share, with $128.64 as the 52 week high point — that compares with a last trade of $128.38.
Among the largest underlying components of VIG, in trading today Comcast Corp (Symbol: CMCSA) is down about 0.8%, Abbott Laboratories (Symbol: ABT) is off about 0.1%, and Costco Wholesale Corp (Symbol: COST) is up by about 2.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $535.3 million dollar inflow -- that's a 1.2% increase week over week in outstanding units (from 333,554,755 to 337,717,239). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $101.11 per share, with $128.64 as the 52 week high point — that compares with a last trade of $128.38.
32822.0
2020-01-19 00:00:00 UTC
Better Buy: Abbott Laboratories vs. AbbVie
ABT
https://www.nasdaq.com/articles/better-buy%3A-abbott-laboratories-vs.-abbvie-2020-01-19
nan
nan
You'd have to rank Abbott Laboratories' (NYSE: ABT) spin-off of AbbVie (NYSE: ABBV) in 2013 as one of the best corporate moves of the last decade. Since the separation, Abbott's share price has soared 184%, while AbbVie stock is up 158%. Which stock is the better pick now for long-term investors? Here's how Abbott and AbbVie stack up against each other. Image source: Getty Images. The case for Abbott Labs Abbott Labs focuses on four key markets. The company makes the most money selling cardiovascular and neuromodula
You'd have to rank Abbott Laboratories' (NYSE: ABT) spin-off of AbbVie (NYSE: ABBV) in 2013 as one of the best corporate moves of the last decade. Since the separation, Abbott's share price has soared 184%, while AbbVie stock is up 158%. The company makes the most money selling cardiovascular and neuromodula
You'd have to rank Abbott Laboratories' (NYSE: ABT) spin-off of AbbVie (NYSE: ABBV) in 2013 as one of the best corporate moves of the last decade. Since the separation, Abbott's share price has soared 184%, while AbbVie stock is up 158%. The case for Abbott Labs Abbott Labs focuses on four key markets.
You'd have to rank Abbott Laboratories' (NYSE: ABT) spin-off of AbbVie (NYSE: ABBV) in 2013 as one of the best corporate moves of the last decade. Since the separation, Abbott's share price has soared 184%, while AbbVie stock is up 158%. The case for Abbott Labs Abbott Labs focuses on four key markets.
You'd have to rank Abbott Laboratories' (NYSE: ABT) spin-off of AbbVie (NYSE: ABBV) in 2013 as one of the best corporate moves of the last decade. Since the separation, Abbott's share price has soared 184%, while AbbVie stock is up 158%. Image source: Getty Images.
32823.0
2020-01-13 00:00:00 UTC
Notable ETF Inflow Detected - IHI, ABT, DHR, SYK
ABT
https://www.nasdaq.com/articles/notable-etf-inflow-detected-ihi-abt-dhr-syk-2020-01-13
nan
nan
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $80.7 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 18,400,000 to 18,700,000). Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Stryker Corp (Symbol: SYK) is lower by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $200.84 per share, with $270.7396 as the 52 week high point — that compares with a last trade of $268.73. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Stryker Corp (Symbol: SYK) is lower by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $200.84 per share, with $270.7396 as the 52 week high point — that compares with a last trade of $268.73. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.
Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Stryker Corp (Symbol: SYK) is lower by about 0.3%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $200.84 per share, with $270.7396 as the 52 week high point — that compares with a last trade of $268.73. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Stryker Corp (Symbol: SYK) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $80.7 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 18,400,000 to 18,700,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $200.84 per share, with $270.7396 as the 52 week high point — that compares with a last trade of $268.73.
Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Stryker Corp (Symbol: SYK) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $80.7 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 18,400,000 to 18,700,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $200.84 per share, with $270.7396 as the 52 week high point — that compares with a last trade of $268.73.
32824.0
2020-01-13 00:00:00 UTC
Health Care Sector Update for 01/13/2020: JNJ, PFE, ABT, MRK, AMGN, IOVA, OCX, NVTA
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-01-13-2020%3A-jnj-pfe-abt-mrk-amgn-iova-ocx-nvta-2020-01-13
nan
nan
Top Health Care Stocks: JNJ: +0.28% PFE: +0.43% ABT: flat MRK: flat AMGN: flat The majority of the biggest stocks in the health care sector were flat during pre-market trading hours on Monday. Health care stocks moving on news include: (+) OncoCyte (OCX), which gained more than 7% before markets open on Monday. The company said it has recently agreed to acquire privately-held Insight Genetics for $12 million, consisting of $7 million cash and the rest in shares. (+) InVitae (NVTA), which was up more than 6% after reporting preliminary revenue for 2019 of about $216 million, up more than 45% from a year earlier. (-) Iovance Biotherapeutics (IOVA), which was down more than 1%. The company recently agreed to an exclusive worldwide license agreement with Cellectis (CLLS) to develop tumor-infiltrating lymphocytes to create more potent cancer therapeutics. It also obtained a license from Novartis (NVS) to develop and commercialize IOV-3001, an antibody cytokine engrafted protein that helps in the treatment of certain cancers. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
ABT: flat MRK: flat AMGN: flat The majority of the biggest stocks in the health care sector were flat during pre-market trading hours on Monday. Health care stocks moving on news include: (+) OncoCyte (OCX), which gained more than 7% before markets open on Monday. The company recently agreed to an exclusive worldwide license agreement with Cellectis (CLLS) to develop tumor-infiltrating lymphocytes to create more potent cancer therapeutics.
ABT: flat MRK: flat AMGN: flat The majority of the biggest stocks in the health care sector were flat during pre-market trading hours on Monday. Top Health Care Stocks: Health care stocks moving on news include: (+) OncoCyte (OCX), which gained more than 7% before markets open on Monday.
ABT: flat MRK: flat AMGN: flat The majority of the biggest stocks in the health care sector were flat during pre-market trading hours on Monday. The company said it has recently agreed to acquire privately-held Insight Genetics for $12 million, consisting of $7 million cash and the rest in shares. The company recently agreed to an exclusive worldwide license agreement with Cellectis (CLLS) to develop tumor-infiltrating lymphocytes to create more potent cancer therapeutics.
ABT: flat MRK: flat AMGN: flat The majority of the biggest stocks in the health care sector were flat during pre-market trading hours on Monday. Top Health Care Stocks: The company said it has recently agreed to acquire privately-held Insight Genetics for $12 million, consisting of $7 million cash and the rest in shares.
32825.0
2020-01-13 00:00:00 UTC
5 Dividend Aristocrats Where Analysts See Capital Gains
ABT
https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2020-01-13
nan
nan
To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments. In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. STOCK RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET UGI Corp. (Symbol: UGI) $44.10 $53.67 21.69% New Jersey Resources Corp (Symbol: NJR) $42.82 $52.00 21.44% International Business Machines Corp (Symbol: IBM) $136.69 $154.25 12.85% Abbott Laboratories (Symbol: ABT) $85.36 $95.50 11.88% Smith (A O) Corp (Symbol: AOS) $47.62 $52.43 10.10% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: STOCK DIVIDEND YIELD % UPSIDE TO ANALYST TARGET IMPLIED TOTAL RETURN POTENTIAL UGI Corp. (Symbol: UGI) 2.95% 21.69% 24.64% New Jersey Resources Corp (Symbol: NJR) 2.92% 21.44% 24.36% International Business Machines Corp (Symbol: IBM) 4.74% 12.85% 17.59% Abbott Laboratories (Symbol: ABT) 1.69% 11.88% 13.57% Smith (A O) Corp (Symbol: AOS) 2.02% 10.10% 12.12% Another consideration with dividend growth stocks is just how much the dividend is growing. We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another. STOCK PRIOR TTM DIVIDEND TTM DIVIDEND % GROWTH UGI Corp. (Symbol: UGI) $1.03 $1.21 17.48% New Jersey Resources Corp (Symbol: NJR) $1.132 $1.212 7.07% International Business Machines Corp (Symbol: IBM) $6.21 $6.43 3.54% Abbott Laboratories (Symbol: ABT) $0.84 $1.28 52.38% Smith (A O) Corp (Symbol: AOS) $0.76 $0.9 18.42% These five stocks are part of our full Dividend Aristocrats List. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on ABT — FREE Get the latest Zacks research report on AOS — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Get the latest Zacks research report on ABT — FREE Get the latest Zacks research report on AOS — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. UGI Corp. (Symbol: UGI) $44.10 $53.67 21.69% New Jersey Resources Corp (Symbol: NJR) $42.82 $52.00 21.44% International Business Machines Corp (Symbol: IBM) $136.69 $154.25 12.85% Abbott Laboratories (Symbol: ABT) $85.36 $95.50 11.88% Smith (A O) Corp (Symbol: AOS) $47.62 $52.43 10.10% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. UGI Corp. (Symbol: UGI) 2.95% 21.69% 24.64% New Jersey Resources Corp (Symbol: NJR) 2.92% 21.44% 24.36% International Business Machines Corp (Symbol: IBM) 4.74% 12.85% 17.59% Abbott Laboratories (Symbol: ABT) 1.69% 11.88% 13.57% Smith (A O) Corp (Symbol: AOS) 2.02% 10.10% 12.12% Another consideration with dividend growth stocks is just how much the dividend is growing.
UGI Corp. (Symbol: UGI) $44.10 $53.67 21.69% New Jersey Resources Corp (Symbol: NJR) $42.82 $52.00 21.44% International Business Machines Corp (Symbol: IBM) $136.69 $154.25 12.85% Abbott Laboratories (Symbol: ABT) $85.36 $95.50 11.88% Smith (A O) Corp (Symbol: AOS) $47.62 $52.43 10.10% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. UGI Corp. (Symbol: UGI) 2.95% 21.69% 24.64% New Jersey Resources Corp (Symbol: NJR) 2.92% 21.44% 24.36% International Business Machines Corp (Symbol: IBM) 4.74% 12.85% 17.59% Abbott Laboratories (Symbol: ABT) 1.69% 11.88% 13.57% Smith (A O) Corp (Symbol: AOS) 2.02% 10.10% 12.12% Another consideration with dividend growth stocks is just how much the dividend is growing. UGI Corp. (Symbol: UGI) $1.03 $1.21 17.48% New Jersey Resources Corp (Symbol: NJR) $1.132 $1.212 7.07% International Business Machines Corp (Symbol: IBM) $6.21 $6.43 3.54% Abbott Laboratories (Symbol: ABT) $0.84 $1.28 52.38% Smith (A O) Corp (Symbol: AOS) $0.76 $0.9 18.42% These five stocks are part of our full Dividend Aristocrats List.
UGI Corp. (Symbol: UGI) $44.10 $53.67 21.69% New Jersey Resources Corp (Symbol: NJR) $42.82 $52.00 21.44% International Business Machines Corp (Symbol: IBM) $136.69 $154.25 12.85% Abbott Laboratories (Symbol: ABT) $85.36 $95.50 11.88% Smith (A O) Corp (Symbol: AOS) $47.62 $52.43 10.10% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. UGI Corp. (Symbol: UGI) 2.95% 21.69% 24.64% New Jersey Resources Corp (Symbol: NJR) 2.92% 21.44% 24.36% International Business Machines Corp (Symbol: IBM) 4.74% 12.85% 17.59% Abbott Laboratories (Symbol: ABT) 1.69% 11.88% 13.57% Smith (A O) Corp (Symbol: AOS) 2.02% 10.10% 12.12% Another consideration with dividend growth stocks is just how much the dividend is growing. UGI Corp. (Symbol: UGI) $1.03 $1.21 17.48% New Jersey Resources Corp (Symbol: NJR) $1.132 $1.212 7.07% International Business Machines Corp (Symbol: IBM) $6.21 $6.43 3.54% Abbott Laboratories (Symbol: ABT) $0.84 $1.28 52.38% Smith (A O) Corp (Symbol: AOS) $0.76 $0.9 18.42% These five stocks are part of our full Dividend Aristocrats List.
UGI Corp. (Symbol: UGI) $44.10 $53.67 21.69% New Jersey Resources Corp (Symbol: NJR) $42.82 $52.00 21.44% International Business Machines Corp (Symbol: IBM) $136.69 $154.25 12.85% Abbott Laboratories (Symbol: ABT) $85.36 $95.50 11.88% Smith (A O) Corp (Symbol: AOS) $47.62 $52.43 10.10% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. UGI Corp. (Symbol: UGI) 2.95% 21.69% 24.64% New Jersey Resources Corp (Symbol: NJR) 2.92% 21.44% 24.36% International Business Machines Corp (Symbol: IBM) 4.74% 12.85% 17.59% Abbott Laboratories (Symbol: ABT) 1.69% 11.88% 13.57% Smith (A O) Corp (Symbol: AOS) 2.02% 10.10% 12.12% Another consideration with dividend growth stocks is just how much the dividend is growing. UGI Corp. (Symbol: UGI) $1.03 $1.21 17.48% New Jersey Resources Corp (Symbol: NJR) $1.132 $1.212 7.07% International Business Machines Corp (Symbol: IBM) $6.21 $6.43 3.54% Abbott Laboratories (Symbol: ABT) $0.84 $1.28 52.38% Smith (A O) Corp (Symbol: AOS) $0.76 $0.9 18.42% These five stocks are part of our full Dividend Aristocrats List.
32826.0
2020-01-11 00:00:00 UTC
3 Top Diabetes Stocks to Watch in January
ABT
https://www.nasdaq.com/articles/3-top-diabetes-stocks-to-watch-in-january-2020-01-11
nan
nan
Diabetes is a massive market in the healthcare sector. An estimated 415 million people have diabetes worldwide, and those numbers are growing. It's also an on-going healthcare issue, one that patients have to manage, often for the rest of their lives. As such, there is a lot of recurring revenue. It's not a bad idea to find a strong company focused on this vertical to add to your portfolio. Over the last decade, one of the biggest stocks in healthcare has been diabetes specialist DexCom (NASDAQ: DXCM), a wireless health company that allows patients and doctors to track glucose levels in real-time. Another potential winner in this space is Livongo Health (NASDAQ: LVGO), an up-and-coming small-cap that sends updates, reminders, and coaching tips to all its clients with diabetes (and other health issues). And biotech company Provention Bio (NASDAQ: PRVB) is hoping to get approval from the Food and Drug Administration (FDA) for a drug that delays the onset of type 1 diabetes. Read more to see if any of these stocks are buys right now. Image source: Getty Images Dominating for a decade DexCom, a $21 billion large-cap stock, has been dominant in healthcare for a long time. Over the last 10 years, shareholders have been rewarded with a 2,563% return. DexCom achieved that impressive return with a singular focus on diabetes. Traditionally, people with diabetes had to prick their finger to check their blood in order to monitor their insulin level. DexCom introduced a wireless device inserted under their skin. This sensor, called a continuous glucose monitor (CGM), is appreciated by patients because of its ease of use and valued by doctors because of its superior data and better health outcomes. DexCom recently signed a distribution deal with Walgreens Boots Alliance to sell the CGM device. Patients insert a tiny sensor under the skin using an automatic applicator. DexCom's sensor starts automatically and continuously taking glucose readings in the patient's interstitial fluid. A micro-transmitter sends the data wirelessly to a receiver. Patients can read their own data in any connected smart device. The CGM can also be set to alert the patient if certain glucose levels are reached. In its most recent quarter, DexCom reported $396 million in revenue for the quarter, 49% higher than the previous year. Net income was $60 million for the quarter. DexCom's main competition in this space is with Abbott Laboratories (NYSE: ABT) that sells a popular CGM device called Freestyle Libre. Abbott's CEO Miles White predicted in a conference call last year that his company's device would achieve sales of $5 billion a year (which would dwarf DexCom's $1.35 billion). So far, DexCom's fantastic numbers suggest DexCom is still winning in the diabetes space. Even with competition, clearly the market opportunity is vast. Here's an upstart in diabetes Livongo Health is a fascinating company and a rising star in personalized medicine. While unprofitable, the company has phenomenal revenue growth. It brought in $46 million in sales in its most recent quarter, up 148% year over year. Over 200,000 diabetes patients are on Livongo's messaging platform, up 118% year over year, and the company has 771 enterprise clients. The company is creating additional verticals in prediabetes, hypertension, weight management, and behavioral health. Livongo specializes in helping all patients with chronic conditions, giving them advice, coaching tips, and interpretations of data readouts. The company has conducted 48 studies measuring return on investment (ROI) and found that 90% of its clients had positive ROI in the first year. Indeed, some corporate clients are so happy with Livongo's offering, the clients are offering to reduce or eliminate the co-pay for hypertension or diabetes drugs for their employees, as long as the employees subscribe to Livongo. So far, Livongo's stock has been a disappointment, down 30% from the company's initial public offering in July 2019. The company has a $2.5 billion market cap, $400 million in cash, and no debt. Its price-to-sales ratio is 17, about the same as DexCom, while Livongo is growing revenues three times as fast. Gross margins are 74%, suggesting the company can become profitable at any time. Right now though, the company is focused on escalating its top-line growth. Livongo has formed partnerships with MDLIVE and Doctor on Demand to enable virtual access to doctors for all its clients, which will roll out in 2020. The future looks bright for Livongo Health. A biotech that wants to delay the onset of diabetes Provention Bio is an interesting biotech focused on preventing diseases before they become acute. It's a tiny company right now, with a market cap of $658 million. But the stock has been running wild, up 741% last year. What caused the stock to take off? The company reported amazing results in its phase 2 study for Teplizumab, a drug designed to delay the onset of diabetes in at-risk patients. In this long-term study, the median patients on placebo developed diabetes in two years. That's in sharp contrast to the group on Provention's drug. Those median patients developed diabetes in four years. In fact, 73% of the people on placebo developed diabetes, compared to 43% of those on Teplizumab. Thus the drug not only delayed the onset of diabetes, on average, but many patients avoided diabetes altogether. The numbers were so good, the FDA decided the company can file its new drug application on the basis of its phase 2 study. Provention has no profits and no revenues, so like many biotech stocks, it has to be considered speculative. On the other hand, the risk/reward ratio is very intriguing, since the diabetes market is so large. After all, diabetes is a $45 billion market in the U.S. alone. Worldwide, the diabetes market will surpass $85 billion by 2022. It's a huge market opportunity for all three of these companies. Of the three stocks, DexCom has the largest upside. The stock has quadrupled over the last two years, so patient investors might wait for a better price. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Livongo Health Inc. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
DexCom's main competition in this space is with Abbott Laboratories (NYSE: ABT) that sells a popular CGM device called Freestyle Libre. Over the last decade, one of the biggest stocks in healthcare has been diabetes specialist DexCom (NASDAQ: DXCM), a wireless health company that allows patients and doctors to track glucose levels in real-time. This sensor, called a continuous glucose monitor (CGM), is appreciated by patients because of its ease of use and valued by doctors because of its superior data and better health outcomes.
DexCom's main competition in this space is with Abbott Laboratories (NYSE: ABT) that sells a popular CGM device called Freestyle Libre. Over the last decade, one of the biggest stocks in healthcare has been diabetes specialist DexCom (NASDAQ: DXCM), a wireless health company that allows patients and doctors to track glucose levels in real-time. Image source: Getty Images Dominating for a decade DexCom, a $21 billion large-cap stock, has been dominant in healthcare for a long time.
DexCom's main competition in this space is with Abbott Laboratories (NYSE: ABT) that sells a popular CGM device called Freestyle Libre. Over the last decade, one of the biggest stocks in healthcare has been diabetes specialist DexCom (NASDAQ: DXCM), a wireless health company that allows patients and doctors to track glucose levels in real-time. Abbott's CEO Miles White predicted in a conference call last year that his company's device would achieve sales of $5 billion a year (which would dwarf DexCom's $1.35 billion).
DexCom's main competition in this space is with Abbott Laboratories (NYSE: ABT) that sells a popular CGM device called Freestyle Libre. Over the last decade, one of the biggest stocks in healthcare has been diabetes specialist DexCom (NASDAQ: DXCM), a wireless health company that allows patients and doctors to track glucose levels in real-time. Another potential winner in this space is Livongo Health (NASDAQ: LVGO), an up-and-coming small-cap that sends updates, reminders, and coaching tips to all its clients with diabetes (and other health issues).
32827.0
2020-01-10 00:00:00 UTC
Health Care Sector Update for 01/10/2020: JNJ, PFE, ABT, MRK, AMGN, ACRS, MRNA, PTLA
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-01-10-2020%3A-jnj-pfe-abt-mrk-amgn-acrs-mrna-ptla-2020-01-10
nan
nan
Top Health Care Stocks: JNJ: +0.13% PFE: +0.31% ABT: flat MRK: +0.24% AMGN: flat Most of the leading health care stocks were trading higher before markets open on Friday. Among health care stocks moving on news: (-) Portola Pharmaceuticals (PTLA), which dipped more than 40%. The company recently announced that preliminary global net revenue of Andexxa for Q4 2019 are expected to be about $28 million and for full-year Andexxa global net revenue is projected to amount to around $111 million. (+) Aclaris Therapeutics (ACRS), which gained more than 28% after disclosing positive results from a phase 1 clinical trial of ATI-450 as a potential tr
ABT: flat AMGN: flat Most of the leading health care stocks were trading higher before markets open on Friday. Among health care stocks moving on news: (-) Portola Pharmaceuticals (PTLA), which dipped more than 40%.
ABT: flat Top Health Care Stocks: AMGN: flat Most of the leading health care stocks were trading higher before markets open on Friday.
ABT: flat AMGN: flat Most of the leading health care stocks were trading higher before markets open on Friday. Among health care stocks moving on news: (-) Portola Pharmaceuticals (PTLA), which dipped more than 40%.
ABT: flat Top Health Care Stocks: AMGN: flat Most of the leading health care stocks were trading higher before markets open on Friday.
32828.0
2020-01-07 00:00:00 UTC
Abbott : FDA Okays Less Invasive Surgical Approach To Avoid Open Heart Surgery
ABT
https://www.nasdaq.com/articles/abbott-%3A-fda-okays-less-invasive-surgical-approach-to-avoid-open-heart-surgery-2020-01-07
nan
nan
(RTTNews) - Abbott Laboratories (ABT) said that the U.S. Food and Drug Administration has approved a new alternative surgical technique for the company's HeartMate 3 heart pump that will allow more advanced heart failure patients to avoid open heart surgery. According to the company, the new, less invasive approach is designed to provide surgeons a choice in surgical method for patients receiving the HeartMate 3 Left Ventricular Assist Device (LVAD), heart pump. The company noted that Heart pumps are small, implantable mechanical devices that pump blood through the body in people whose heart is too weak to do so on its own. People living with a heart pump may be waiting for a heart transplant or may not be candidates for a transplant and will live with the device for the rest of their life. Usually, heart pumps have been implanted through open heart surgery. But, Abbott's HeartMate 3 heart pump can now be implanted via lateral thoracotomy - a surgical approach where an incision is made between a patient's ribs to access the heart. Physicians believe that for many patients the surgical technique has advantages over open heart surgery because it can result in less bleeding and a shorter recovery time for patients, the company said. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) said that the U.S. Food and Drug Administration has approved a new alternative surgical technique for the company's HeartMate 3 heart pump that will allow more advanced heart failure patients to avoid open heart surgery. According to the company, the new, less invasive approach is designed to provide surgeons a choice in surgical method for patients receiving the HeartMate 3 Left Ventricular Assist Device (LVAD), heart pump. But, Abbott's HeartMate 3 heart pump can now be implanted via lateral thoracotomy - a surgical approach where an incision is made between a patient's ribs to access the heart.
(RTTNews) - Abbott Laboratories (ABT) said that the U.S. Food and Drug Administration has approved a new alternative surgical technique for the company's HeartMate 3 heart pump that will allow more advanced heart failure patients to avoid open heart surgery. Usually, heart pumps have been implanted through open heart surgery. Physicians believe that for many patients the surgical technique has advantages over open heart surgery because it can result in less bleeding and a shorter recovery time for patients, the company said.
(RTTNews) - Abbott Laboratories (ABT) said that the U.S. Food and Drug Administration has approved a new alternative surgical technique for the company's HeartMate 3 heart pump that will allow more advanced heart failure patients to avoid open heart surgery. The company noted that Heart pumps are small, implantable mechanical devices that pump blood through the body in people whose heart is too weak to do so on its own. But, Abbott's HeartMate 3 heart pump can now be implanted via lateral thoracotomy - a surgical approach where an incision is made between a patient's ribs to access the heart.
(RTTNews) - Abbott Laboratories (ABT) said that the U.S. Food and Drug Administration has approved a new alternative surgical technique for the company's HeartMate 3 heart pump that will allow more advanced heart failure patients to avoid open heart surgery. People living with a heart pump may be waiting for a heart transplant or may not be candidates for a transplant and will live with the device for the rest of their life. Usually, heart pumps have been implanted through open heart surgery.
32829.0
2020-01-07 00:00:00 UTC
The 10 Best Healthcare Stocks of the Decade
ABT
https://www.nasdaq.com/articles/the-10-best-healthcare-stocks-of-the-decade-2020-01-07
nan
nan
This list is a snapshot of the best healthcare stocks for an entire decade, from 2010 to 2020. As such, some magnificent stocks are excluded, simply because of the measurement period. For instance, Axsome Therapeutics had an amazing 3,578% return in 2019. And yet Axsome's fantastic 2019 return was predicated on an investor buying at the bottom in January. Measured from its IPO price at $9 a share, Axsome was a 10-bagger for the decade. That's a good return, of course, but not impressive enough to make this list. Our top 10 is filled with medical device makers and companies that are providing services to the healthcare industry. Only three drug companies made it to the top. If you invested $1,000 in each of these 10 companies on Jan. 4, 2010, 10 years later your portfolio would be worth $247,607. And here are the mightiest healthcare stocks over the last decade. Image source: Getty Images 10. Jazz Pharmaceuticals (up 1,699%) Jazz Pharmaceuticals (NASDAQ: JAZZ) is an Irish biotech company that focuses on drugs for sleep disorders, as well as oncology/hematology and other unmet medical needs. Its marketed products include Xyrem for excessive daytime sleepiness, as well as Erwinaze and Vyxeos for leukemia. It also has drugs for sleep apnea and Parkinson's disease in its pipeline. The $8 billion biotech is highly profitable, with margins of 29%. 9. Abiomed (up 1,782%) Abiomed (NASDAQ: ABMD) was $8.86 a share at the open on Jan. 4, 2010. Fast forward a decade, and on Jan. 3, 2020, the stock was trading for $166.82 a share. (And it's down 47% off its highs!) So that's a fantastic return for long-term shareholders. It's almost a 19-bagger. Abiomed is a medical device company focused on creating artificial pumps for failing hearts. Its major device, the Impella, is a micro-pump that can replace heart function for six hours. 8. NeoGenomics (up 1,790%) NeoGenomics (NASDAQ: NEO) was trading for $1.55 at the beginning of the decade. Ten years later, its shares are trading hands for $29.31. The company specializes in running advanced genomics tests for hospitals and doctors in the oncology space. It's a $3 billion small-cap. In its most recent quarter, Neo grew revenues at 50% year over year. (Some of that growth was due to its acquisition of Genoptix in Dec. 2018). 7. Accelerate Diagnostics (up 1,813%) Accelerate Diagnostics (NASDAQ: AXDX) was a penny stock ten years ago, trading for $0.89 a share. Investors who put in $1,000 at the beginning of the decade (1,123 shares) are sitting on $19,124 now. (Let your winners run!) Accelerate is a medical device company that specializes in infectious diseases. Its devices help doctors quickly determine if a patient has been exposed to a deadly bacteria or fungus. The company's not profitable yet, but revenues increased 68% in the most recent quarter. 6. Simulations Plus (up 2,001%) Simulations Plus (NASDAQ: SLP) was a tiny micro-cap ten years ago. Today it's worth $500 million. The company provides simulation software and services to drug companies to help with drug discovery and development. Using the company's software, scientists can simulate in vitro experiments over many molecules at once. The software will predict various properties of molecules, including absorption rates and interactions with other drugs. Simulations Plus has 25% profit margins and revenue growth of 20% in its most recent quarter. 5. Repligen (up 2,123%) Repligen (NASDAQ: RGEN) is a bioprocess developer with a market cap of almost $5 billion. Repligen is a picks-and-shovels play on the rise of biotechnology. Instead of taking the risks of drug discovery and drug failure, you can invest in Repligen, a company that provides equipment to a multitude of companies so that biologic drugs can be manufactured. Repligen has an estimated 95% market share in producing the proteins that go into vaccines and gene therapy. 4. DexCom (up 2,563%) DexCom (NASDAQ: DXCM) is now a massive $20 billion healthcare company. But 10 years ago, it was a tiny medical device company. DexCom specializes in continuous glucose monitoring (CGM) systems for people with diabetes. Right now the company is in a hot competition with Abbott Labs in the CGM market. The company's recently achieved profitability and its top-line growth is still blistering at 49% year over year. 3. Exact Sciences (up 2,612%) Exact Sciences (NASDAQ: EXAS) is a large-cap ($14 billion) company focused on molecular diagnostics for oncology. The company's main product is Cologuard, a non-invasive DNA screening test taken from a stool sample. Profitability is still elusive but the company has fantastic top-line growth. Revenues are up 85% year over year. And profitability is definitely in the cards as the company has 80% gross margins on a pro forma basis. 2. ACADIA Pharmaceuticals (up 2,956%) ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biotech that is focused on disorders of the central nervous system. Its leading pharmaceutical is Nuplazid, which is used to treat hallucinations and delusions caused by Parkinson's. The company hopes to expand the label to include other forms of dementia. 1. Neurocrine Biosciences (up 3,863%) Neurocrine Biosciences (NASDAQ: NBIX) is the top healthcare stock over the last decade. Investors who bought 361 shares at $2.77 a share are now sitting on almost $40,000. The $10 billion biotech has two drugs on the market: Ingrezza, a drug for involuntary muscle movement, and Orilissa, a hormone therapy for women's health. COMPANY PRICE JAN. 4, 2010 PRICE JAN. 3, 2020 PERCENTAGE GAIN Neurocrine Biosciences $2.77 $109.78 3,863% ACADIA Pharmaceuticals $1.32 $40.35 2,956% Exact Sciences $3.50 $94.94 2,612% DexCom $8.21 $218.70 2,563% Repligen $4.17 $92.74 2,123% Simulations Plus $1.37 $28.79 2,001% Accelerate Diagnostics $0.89 $17.03 1,813% NeoGenomics $1.55 $29.31 1,790% Abiomed $8.86 $166.82 1,782% Jazz Pharmaceuticals $8.06 $145.10 1,700% It's been a pretty amazing decade for healthcare stocks. Many of these names came out of nowhere to give astounding returns to the investors who bought and held them. And despite these very large returns, many of these stocks are still attractive going forward. My favorite is Accelerate Diagnostics, but I think several of these names will easily defeat the S&P 500 over the next decade. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Taylor Carmichael owns shares of Axsome Therapeutics. The Motley Fool owns shares of and recommends Abiomed. The Motley Fool owns shares of NeoGenomics, Inc. The Motley Fool recommends Exact Sciences, Neurocrine Biosciences, and Repligen. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Its marketed products include Xyrem for excessive daytime sleepiness, as well as Erwinaze and Vyxeos for leukemia. The company specializes in running advanced genomics tests for hospitals and doctors in the oncology space. The company's main product is Cologuard, a non-invasive DNA screening test taken from a stool sample.
Jazz Pharmaceuticals (up 1,699%) Jazz Pharmaceuticals (NASDAQ: JAZZ) is an Irish biotech company that focuses on drugs for sleep disorders, as well as oncology/hematology and other unmet medical needs. Neurocrine Biosciences $2.77 $109.78 3,863% ACADIA Pharmaceuticals $1.32 $40.35 2,956% Exact Sciences $3.50 $94.94 2,612% DexCom $8.21 $218.70 2,563% Repligen $4.17 $92.74 2,123% Simulations Plus $1.37 $28.79 2,001% Accelerate Diagnostics $0.89 $17.03 1,813% NeoGenomics $1.55 $29.31 1,790% Abiomed $8.86 $166.82 1,782% Jazz Pharmaceuticals $8.06 $145.10 1,700% It's been a pretty amazing decade for healthcare stocks. The Motley Fool recommends Exact Sciences, Neurocrine Biosciences, and Repligen.
The company provides simulation software and services to drug companies to help with drug discovery and development. Instead of taking the risks of drug discovery and drug failure, you can invest in Repligen, a company that provides equipment to a multitude of companies so that biologic drugs can be manufactured. Neurocrine Biosciences $2.77 $109.78 3,863% ACADIA Pharmaceuticals $1.32 $40.35 2,956% Exact Sciences $3.50 $94.94 2,612% DexCom $8.21 $218.70 2,563% Repligen $4.17 $92.74 2,123% Simulations Plus $1.37 $28.79 2,001% Accelerate Diagnostics $0.89 $17.03 1,813% NeoGenomics $1.55 $29.31 1,790% Abiomed $8.86 $166.82 1,782% Jazz Pharmaceuticals $8.06 $145.10 1,700% It's been a pretty amazing decade for healthcare stocks.
Investors who bought 361 shares at $2.77 a share are now sitting on almost $40,000. Neurocrine Biosciences $2.77 $109.78 3,863% ACADIA Pharmaceuticals $1.32 $40.35 2,956% Exact Sciences $3.50 $94.94 2,612% DexCom $8.21 $218.70 2,563% Repligen $4.17 $92.74 2,123% Simulations Plus $1.37 $28.79 2,001% Accelerate Diagnostics $0.89 $17.03 1,813% NeoGenomics $1.55 $29.31 1,790% Abiomed $8.86 $166.82 1,782% Jazz Pharmaceuticals $8.06 $145.10 1,700% It's been a pretty amazing decade for healthcare stocks. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.
32830.0
2020-01-07 00:00:00 UTC
3 Top Medical Device Stocks to Buy in January
ABT
https://www.nasdaq.com/articles/3-top-medical-device-stocks-to-buy-in-january-2020-01-07
nan
nan
Medical device stocks were sizzling hot in 2019. The iShares U.S. Medical Devices ETF soared 32%, easily beating the S&P 500's performance. This medical device exchange-traded fund (ETF) also trounced the 18% gain delivered by the Health Care Select Sector SPDR ETF, which includes stocks from across the healthcare sector. Will 2020 be another great year for medical device stocks? I think so. Here are three top medical device stocks you can buy in January to profit from the booming industry. Image source: Getty Images. 1. Abbott Labs Abbott Laboratories (NYSE: ABT) ranks as one of the most attractive blue chip stocks on the market right now, in my view. While Abbott's 20% return in 2019 lagged behind the broader market indexes and many other medical device stocks, I expect 2020 will be a big year for the healthcare giant. The biggest catalyst for Abbott should be the anticipated FDA clearance for the new version of its popular Freestyle Libre continuous glucose monitoring (CGM) system. This new version of Freestyle Libre supports interoperability with other devices and will include alarms, features that will enable Abbott to compete even more effectively against DexCom's G6 CGM. But Freestyle Libre isn't the only thing Abbott has going for it. The company markets a wide range of products that generated close to $32 billion in sales last year. Among those were several new products that, along with Freestyle Libre, are important growth drivers for Abbott, including Alinity diagnostic systems and MitraClip mitral regurgitation devices. Investors should also like Abbott Labs' dividend. The company recently boosted its dividend by 12.5%, marking its 48th consecutive year of dividend increases. Abbott's dividend currently yields close to 1.7%. 2. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) is another big medical device stock that underperformed a bit last year. The robotic surgical systems maker delivered a gain of more than 23%, which isn't too shabby but wasn't quite as good as some medical device stocks. But my view is that Intuitive should remain one of the steadiest winners on the market. The key reason behind my long-term optimism about Intuitive Surgical is its 21st-century version of the old razor-and-blades business model. Intuitive derives over 70% of its total revenue from recurring sources, primarily replacement instruments and accessories for its da Vinci robotic surgical systems. This recurring revenue continues to grow as the company sells and leases more systems and as customers use robotic surgery for more procedures. Procedure volumes will almost certainly increase due to two key factors: demographic trends and product innovation. With aging populations in the U.S. and across the world, more surgeries that are ideally suited for robotic assistance will be performed. Intuitive Surgical also continues to launch new products like its Ion robotic system for lung biopsy and da Vinci SP for transoral surgery, which expands the types of procedures for which its technology can be used. I also expect that robotic surgery will gain more widespread acceptance and adoption with new rivals entering the market. Although increased competition usually isn't great news for a stock, my view is that the moves by Medtronic and others to launch new products will expand the robotic surgery market and benefit Intuitive Surgical over the long run. 3. ShockWave Medical Unlike Abbott Labs and Intuitive Surgical, ShockWave Medical (NASDAQ: SWAV) handily beat the broader market indexes last year, with the stock skyrocketing 44%. The small medical device company took investors on a roller-coaster ride, however, more than doubling by May, losing all those gains by late September, and then rebounding. I like ShockWave because I like the potential for its technology. The company uses intravascular lithotripsy (IVL) to break up calcium deposits in patients with atherosclerosis, or hardening of the arteries. It's a simple process and arguably a safer approach than traditional methods used to treat the problem, such as balloons and minimally invasive surgery. And lithotripsy has been used for decades to break up kidney stones made of calcium without harming surrounding tissues. ShockWave also has a huge potential market. Different types of atherosclerosis that the company is targeting combined represent an annual sales opportunity of more than $6 billion. ShockWave plans to launch new products in 2020 and expand into new international markets this year, both of which represent key catalysts for the stock. There are a couple of downsides for ShockWave, though. It isn't profitable yet and could have to issue more shares in the future to raise cash (as it did in November 2019), a move that would dilute the value of existing shares. Also, the stock is valued at a steep premium, with shares trading at nearly 36 times trailing-12-month sales. Any bumps in the road will likely cause ShockWave's share price to plunge. Still, my view is that the growth prospects for ShockWave make it a stock for aggressive investors to seriously consider buying. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of Health Care SPDR and Intuitive Surgical. The Motley Fool owns shares of and recommends Intuitive Surgical and ShockWave Medical. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Abbott Labs Abbott Laboratories (NYSE: ABT) ranks as one of the most attractive blue chip stocks on the market right now, in my view. This new version of Freestyle Libre supports interoperability with other devices and will include alarms, features that will enable Abbott to compete even more effectively against DexCom's G6 CGM. Intuitive Surgical also continues to launch new products like its Ion robotic system for lung biopsy and da Vinci SP for transoral surgery, which expands the types of procedures for which its technology can be used.
Abbott Labs Abbott Laboratories (NYSE: ABT) ranks as one of the most attractive blue chip stocks on the market right now, in my view. This medical device exchange-traded fund (ETF) also trounced the 18% gain delivered by the Health Care Select Sector SPDR ETF, which includes stocks from across the healthcare sector. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) is another big medical device stock that underperformed a bit last year.
Abbott Labs Abbott Laboratories (NYSE: ABT) ranks as one of the most attractive blue chip stocks on the market right now, in my view. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) is another big medical device stock that underperformed a bit last year. Although increased competition usually isn't great news for a stock, my view is that the moves by Medtronic and others to launch new products will expand the robotic surgery market and benefit Intuitive Surgical over the long run.
Abbott Labs Abbott Laboratories (NYSE: ABT) ranks as one of the most attractive blue chip stocks on the market right now, in my view. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) is another big medical device stock that underperformed a bit last year. The robotic surgical systems maker delivered a gain of more than 23%, which isn't too shabby but wasn't quite as good as some medical device stocks.
32831.0
2020-01-06 00:00:00 UTC
Health Care Sector Update for 01/06/2020: JNJ, PFE, ABT, MRK, AMGN, LIFE, LPTX, NOVN
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-01-06-2020%3A-jnj-pfe-abt-mrk-amgn-life-lptx-novn-2020-01-06
nan
nan
Top Health Care Stocks: JNJ: -0.53% PFE: -0.33% ABT: flat MRK: -0.27% AMGN: -0.35% Most top health care stocks were trading lower during pre-market hours on Monday. Among stocks moving on news: (+) aTyr Pharma (LIFE), which is up more than 67%, after the company signed a deal with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923, a drug candidate for interstitial lung disease, in Japan. (+) Novan (NOVN), which gained more than 5%. The company said Monday its subsidiary Medusa Merger Corp. completed its tender offer for all outstanding shares of The Medicines Company (MDCO) at a price of $85 per share. Late last week the company also announced it plans to begin a new late-stage trial of its SB206 drug candidate in April after the prospective treatment for molluscum contagiosum skin infections produced inconclusive top-line results during a pair of ongoing phase III trials. (-) Meanwhile, Leap Therapeutics (LPTX) fell more than 5% during pre-bell trading Monday. The company recently said it has signed an agreement with BeiGene (BGNE) for the clinical development and commercialization of its antibody in Asia, excluding Japan, Australia, and New Zealand. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
ABT: flat Among stocks moving on news: (+) aTyr Pharma (LIFE), which is up more than 67%, after the company signed a deal with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923, a drug candidate for interstitial lung disease, in Japan. Late last week the company also announced it plans to begin a new late-stage trial of its SB206 drug candidate in April after the prospective treatment for molluscum contagiosum skin infections produced inconclusive top-line results during a pair of ongoing phase III trials.
ABT: flat Top Health Care Stocks: Most top health care stocks were trading lower during pre-market hours on Monday.
ABT: flat Most top health care stocks were trading lower during pre-market hours on Monday. Among stocks moving on news: (+) aTyr Pharma (LIFE), which is up more than 67%, after the company signed a deal with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923, a drug candidate for interstitial lung disease, in Japan.
ABT: flat Most top health care stocks were trading lower during pre-market hours on Monday. Among stocks moving on news: (+) aTyr Pharma (LIFE), which is up more than 67%, after the company signed a deal with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923, a drug candidate for interstitial lung disease, in Japan.
32832.0
2020-01-02 00:00:00 UTC
SPDR Portfolio S&P 500 Growth ETF Experiences Big Outflow
ABT
https://www.nasdaq.com/articles/spdr-portfolio-sp-500-growth-etf-experiences-big-outflow-2020-01-02
nan
nan
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— Growth ETF (Symbol: SPYG) where we have detected an approximate $1.0 billion dollar outflow -- that's a 15.8% decrease week over week (from 152,050,000 to 128,000,000). Among the largest underlying components of SPYG, in trading today Salesforce.com Inc (Symbol: CRM) is up about 1.3%, Broadcom Inc (Symbol: AVGO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $31.55 per share, with $42.30 as the 52 week high point — that compares with a last trade of $42.18. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Among the largest underlying components of SPYG, in trading today Salesforce.com Inc (Symbol: CRM) is up about 1.3%, Broadcom Inc (Symbol: AVGO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $31.55 per share, with $42.30 as the 52 week high point — that compares with a last trade of $42.18. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.
Among the largest underlying components of SPYG, in trading today Salesforce.com Inc (Symbol: CRM) is up about 1.3%, Broadcom Inc (Symbol: AVGO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $31.55 per share, with $42.30 as the 52 week high point — that compares with a last trade of $42.18. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed).
Among the largest underlying components of SPYG, in trading today Salesforce.com Inc (Symbol: CRM) is up about 1.3%, Broadcom Inc (Symbol: AVGO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— Growth ETF (Symbol: SPYG) where we have detected an approximate $1.0 billion dollar outflow -- that's a 15.8% decrease week over week (from 152,050,000 to 128,000,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $31.55 per share, with $42.30 as the 52 week high point — that compares with a last trade of $42.18.
Among the largest underlying components of SPYG, in trading today Salesforce.com Inc (Symbol: CRM) is up about 1.3%, Broadcom Inc (Symbol: AVGO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $31.55 per share, with $42.30 as the 52 week high point — that compares with a last trade of $42.18. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed).
32833.0
2020-01-02 00:00:00 UTC
Health Care Sector Update for 01/02/2020: JNJ, PFE, ABT, MRK, AMGN, IPHA, ONTX, AERI
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-01-02-2020%3A-jnj-pfe-abt-mrk-amgn-ipha-ontx-aeri-2020-01-02
nan
nan
Top Health Care Stocks: JNJ: +0.25% PFE: +0.56% ABT: -0.86% MRK: +0.45% AMGN: Flat Most of the biggest stocks in the health care sector were gaining during pre-market trading hours on Thursday. Among health care stocks moving on news: (+) Innate Pharma (IPHA), which rose more than 23%, after announcing that the European Medicines Agency has accepted its marketing authorization application for Lumoxiti for the treatment of adult patients with relapsed or refractory hairy cell leukemia. (+) Onconova Therapeutics (ONTX), which was up more than 6%, after announcing plans for a $10 million private placement, selling nearly 27.7 million common shares to two healthcare-focused institutional investors at 36.15 cents apiece. In other sector news: (=) Aerie Pharmaceuticals (AERI), meanwhile, was flat during pre-bell Thursday. The company said the European Medicines Agency has accepted for review its marketing authorization application for its eye treatment Roclanda. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AMGN: Flat Most of the biggest stocks in the health care sector were gaining during pre-market trading hours on Thursday. Among health care stocks moving on news: (+) Innate Pharma (IPHA), which rose more than 23%, after announcing that the European Medicines Agency has accepted its marketing authorization application for Lumoxiti for the treatment of adult patients with relapsed or refractory hairy cell leukemia. The company said the European Medicines Agency has accepted for review its marketing authorization application for its eye treatment Roclanda.
Among health care stocks moving on news: (+) Innate Pharma (IPHA), which rose more than 23%, after announcing that the European Medicines Agency has accepted its marketing authorization application for Lumoxiti for the treatment of adult patients with relapsed or refractory hairy cell leukemia. In other sector news: (=) Aerie Pharmaceuticals (AERI), meanwhile, was flat during pre-bell Thursday. The company said the European Medicines Agency has accepted for review its marketing authorization application for its eye treatment Roclanda.
AMGN: Flat Most of the biggest stocks in the health care sector were gaining during pre-market trading hours on Thursday. Among health care stocks moving on news: (+) Innate Pharma (IPHA), which rose more than 23%, after announcing that the European Medicines Agency has accepted its marketing authorization application for Lumoxiti for the treatment of adult patients with relapsed or refractory hairy cell leukemia. (+) Onconova Therapeutics (ONTX), which was up more than 6%, after announcing plans for a $10 million private placement, selling nearly 27.7 million common shares to two healthcare-focused institutional investors at 36.15 cents apiece.
Top Health Care Stocks: AMGN: Flat Most of the biggest stocks in the health care sector were gaining during pre-market trading hours on Thursday. Among health care stocks moving on news: (+) Innate Pharma (IPHA), which rose more than 23%, after announcing that the European Medicines Agency has accepted its marketing authorization application for Lumoxiti for the treatment of adult patients with relapsed or refractory hairy cell leukemia.
32834.0
2020-01-02 00:00:00 UTC
Does Medtronic's Current P/E Ratio Offer Any Opportunity To Investors?
ABT
https://www.nasdaq.com/articles/does-medtronics-current-p-e-ratio-offer-any-opportunity-to-investors-2020-01-02
nan
nan
The market currently estimates Medtronic’s (NYSE:MDT) revenue growth to be around 3%, whereas the S&P 500’s expected revenue growth is about 7% in 2020. As we discuss below, Medtronic’s margins have been consistently higher than the S&P 500. If you think that Medtronic can grow revenues by more than 3% in 2020, beating expectations, while maintaining its expected margins, Medtronic’s stock should gain – especially versus the S&P 500, assuming no change in revenue and margin expectation for S&P500. Also, Medtronic’s P/E Ratio is lower when compared with Boston Scientific and Abbott. Medtronic’s lower P/E with respect to Boston Scientific makes sense, though when compared to Abbott, it appears to be low, as discussed in the sections below. You can look at our interactive dashboard analysis ~ Does Medtronic’s P/E Ratio Make Sense? ~ for more details. Medtronic’s P/E Ratio At About 14.7, Is Largely In Line With Historical Average Improvement in revenue growth with margins remaining relatively steady has helped. Slight improvement in the P/E ratio for fiscal 2019 was due to revenue growth as well as an uptick in margins for that fiscal, and higher expected revenues going forward, as demonstrated in the charts below. Medtronic’s jump in revenues in fiscal 2016 can be attributed to the Covidien acquisition. Look at our analysis on Medtronic’s revenues and expenses for more details. Medtronic vs. S&P 500: Higher 2020 Revenue Growth For Medtronic Could Present Opportunity Medtronic’s P/E has been consistently lower than the S&P 500, explained by Medtronic’s smaller revenue growth for the most part. However, Medtronic’s 2x higher margins versus the S&P 500 lends support to a higher multiple, especially if Medtronic shows higher revenue growth in 2020, when compared to historical years. Medtronic vs. Boston Scientific: Compared to Boston Scientific, Medtronic’s P/E Ratio is much lower This is expected given that Medtronic’s Revenue Growth has been consistently lower than Boston Scientific’s, even though margins are comparable. Boston Scientific’s P/E ratio expanded in 2018, amid upbeat revenue and margins guidance by the company for 2019. Medtronic vs. Abbott: Compared to Abbott as well, Medtronic’s P/E Ratio is much lower Medtronic’s Revenue Growth has largely been lower than Abbott’s, even though Medtronic’s margins are slightly higher. Abbott acquired St. Jude Medical in 2016, and that explains the jump in revenues in 2017, and a decline in share price in 2016 explains the lower P/E multiple, again due to the acquisition news. What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Medtronic’s lower P/E with respect to Boston Scientific makes sense, though when compared to Abbott, it appears to be low, as discussed in the sections below. Medtronic’s P/E Ratio At About 14.7, Is Largely In Line With Historical Average Improvement in revenue growth with margins remaining relatively steady has helped. Boston Scientific’s P/E ratio expanded in 2018, amid upbeat revenue and margins guidance by the company for 2019.
You can look at our interactive dashboard analysis ~ Does Medtronic’s P/E Ratio Make Sense? Medtronic vs. Boston Scientific: Compared to Boston Scientific, Medtronic’s P/E Ratio is much lower This is expected given that Medtronic’s Revenue Growth has been consistently lower than Boston Scientific’s, even though margins are comparable. Medtronic vs. Abbott: Compared to Abbott as well, Medtronic’s P/E Ratio is much lower Medtronic’s Revenue Growth has largely been lower than Abbott’s, even though Medtronic’s margins are slightly higher.
Medtronic vs. S&P 500: Higher 2020 Revenue Growth For Medtronic Could Present Opportunity Medtronic’s P/E has been consistently lower than the S&P 500, explained by Medtronic’s smaller revenue growth for the most part. Medtronic vs. Boston Scientific: Compared to Boston Scientific, Medtronic’s P/E Ratio is much lower This is expected given that Medtronic’s Revenue Growth has been consistently lower than Boston Scientific’s, even though margins are comparable. Medtronic vs. Abbott: Compared to Abbott as well, Medtronic’s P/E Ratio is much lower Medtronic’s Revenue Growth has largely been lower than Abbott’s, even though Medtronic’s margins are slightly higher.
Slight improvement in the P/E ratio for fiscal 2019 was due to revenue growth as well as an uptick in margins for that fiscal, and higher expected revenues going forward, as demonstrated in the charts below. Medtronic vs. Boston Scientific: Compared to Boston Scientific, Medtronic’s P/E Ratio is much lower This is expected given that Medtronic’s Revenue Growth has been consistently lower than Boston Scientific’s, even though margins are comparable. Medtronic vs. Abbott: Compared to Abbott as well, Medtronic’s P/E Ratio is much lower Medtronic’s Revenue Growth has largely been lower than Abbott’s, even though Medtronic’s margins are slightly higher.
32835.0
2020-01-02 00:00:00 UTC
How Does Abbott's Revenue And Other Key Metrics Compare With That of Boston Scientific?
ABT
https://www.nasdaq.com/articles/how-does-abbotts-revenue-and-other-key-metrics-compare-with-that-of-boston-scientific-2020
nan
nan
Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both engaged in the medical devices business. Abbott generates 3x the revenue when compared to Boston Scientific. For both the companies, revenue over the past few years has been impacted by acquisitions. Also, both the companies generate a significant portion of their revenues from the U.S. When it comes to profitability, Boston Scientific beats Abbott on gross profit. In this note we compare both the companies’ revenues and other key metrics. You can look at our interactive dashboard analysis ~ Abbott vs. Boston Scientific: How Have Revenues & Other Key Metrics Changed Over Recent Years? ~ for more details. Abbott’s Revenues of $31 Billion Are Much Higher Than $10 Billion For Boston Scientific Abbott and Boston Scientific are both engaged primarily in the Medical Devices business. Abbott’s revenues grew from $20.2 billion in 2014 to $30.6 billion in 2018. Look at our analysis on Abbott’s revenues for more details. Boston Scientific’s revenues have grown from $7.4 billion in 2014 to $9.8 billion in 2018, led by its MedSurg business. Look at our interactive dashboard analysis for more details on Boston Scientific’s revenues. Abbott’s Revenues Grew At A Higher Pace On Average When Compared To Boston Scientific Both Abbott and Boston Scientific saw growth in revenues in the recent years. And for both there was some impact of acquisitions in the sales growth. Boston Scientific’s revenue grew at a CAGR of 7.5% between 2014 and 2018, while the figure was 11.5% for Abbott over the same period. While Abbott’s growth in 2017 was aided by the St Jude acquisition, Boston Scientific’s growth in 2016 was bolstered by AMS portfolio and the Endochoice acquisition. U.S. Accounts For A Significant Portion of Total Sales For Both The Companies Abbott generated 35% of its total sales from the U.S. in 2018. For Boston Scientific, the figure stood at 56% in 2018. Gross Profit Margin For Boston Scientific Is Better Than That For Abbott Abbott’s Gross Profit Margin grew from 54.5% in 2014 to 58.4% in 2018. Gross Profit Margin for Boston Scientific grew from 70.1% in 2014 to 71.4% in 2018. Boston Scientific’s Adjusted Net Income Margin Has Been Trending Higher, And It Is Better Than That of Abbott Boston Scientific’s adjusted net income margin grew from 15.3% in 2014 to 21.0% in 2018. Abbott’s adjusted net income margin grew from 15.0% to 16.8% over the same period. What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both engaged in the medical devices business. You can look at our interactive dashboard analysis ~ Abbott vs. Boston Scientific: How Have Revenues & Other Key Metrics Changed Over Recent Years? Boston Scientific’s revenue grew at a CAGR of 7.5% between 2014 and 2018, while the figure was 11.5% for Abbott over the same period.
Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both engaged in the medical devices business. You can look at our interactive dashboard analysis ~ Abbott vs. Boston Scientific: How Have Revenues & Other Key Metrics Changed Over Recent Years? Abbott’s Revenues of $31 Billion Are Much Higher Than $10 Billion For Boston Scientific Abbott and Boston Scientific are both engaged primarily in the Medical Devices business.
Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both engaged in the medical devices business. Abbott’s Revenues of $31 Billion Are Much Higher Than $10 Billion For Boston Scientific Abbott and Boston Scientific are both engaged primarily in the Medical Devices business. Abbott’s Revenues Grew At A Higher Pace On Average When Compared To Boston Scientific Both Abbott and Boston Scientific saw growth in revenues in the recent years.
Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both engaged in the medical devices business. Abbott generates 3x the revenue when compared to Boston Scientific. Abbott’s Revenues of $31 Billion Are Much Higher Than $10 Billion For Boston Scientific Abbott and Boston Scientific are both engaged primarily in the Medical Devices business.
32836.0
2019-12-31 00:00:00 UTC
Health Care Sector Update for 12/31/2019: NVCN, SVRA, JNJ, PFE, ABT, MRK, AMGN
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-12-31-2019%3A-nvcn-svra-jnj-pfe-abt-mrk-amgn-2019-12-31
nan
nan
Top Health Care Stocks: JNJ: -0.03% PFE: -0.05% ABT: Flat MRK: -0.15% AMGN: Flat Health care giants were flat to lower pre-bell Tuesday. Stocks moving on news include: (+) Neovasc (NVCN), which was surging more than 107% after saying it has submitted a pre-market approval application to the US Food and Drug Administration for its Neovasc Reducer medical device for the treatment of refractory angina. (-) Savara (SVRA) was down more than 2%, reversing a portion of its gains after the US Food and Drug Administration has granted breakthrough therapy designation for Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis. In other sector news: (-) The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) said it has acquired all rights to the investigational compound bermekimab, along with certain employees, from XBiotech Inc. The transaction was valued at $750 million. Johnson & Johnson was recently declining marginally. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
ABT: Flat Stocks moving on news include: (+) Neovasc (NVCN), which was surging more than 107% after saying it has submitted a pre-market approval application to the US Food and Drug Administration for its Neovasc Reducer medical device for the treatment of refractory angina. (-) Savara (SVRA) was down more than 2%, reversing a portion of its gains after the US Food and Drug Administration has granted breakthrough therapy designation for Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis.
ABT: Flat Top Health Care Stocks: AMGN: Flat Health care giants were flat to lower pre-bell Tuesday.
ABT: Flat AMGN: Flat Health care giants were flat to lower pre-bell Tuesday. Stocks moving on news include: (+) Neovasc (NVCN), which was surging more than 107% after saying it has submitted a pre-market approval application to the US Food and Drug Administration for its Neovasc Reducer medical device for the treatment of refractory angina.
ABT: Flat AMGN: Flat Health care giants were flat to lower pre-bell Tuesday. Stocks moving on news include: (+) Neovasc (NVCN), which was surging more than 107% after saying it has submitted a pre-market approval application to the US Food and Drug Administration for its Neovasc Reducer medical device for the treatment of refractory angina.
32837.0
2019-12-31 00:00:00 UTC
How Much Revenue Does Abbott Generate From The United States?
ABT
https://www.nasdaq.com/articles/how-much-revenue-does-abbott-generate-from-the-united-states-2019-12-31
nan
nan
Abbott (NYSE:ABT) generates its revenue from sales of medical devices across the globe. The company generated $11 billion in sales in the United States, accounting for over one-third of its total revenue in 2018. This figure has been on a rise and it grew from 30% to 35% between 2014 and 2018. Abbott’s sales in the United States are much lower than that of Medtronic and Boston Scientific. Below we show region-wise breakup of Abbott’s revenues, its business model, and revenue trajectory. We also compare the United States as a market for Abbott with that for other large medical devices companies. You can look at our interactive dashboard analysis ~ How Big Is The United States Market For Abbott? ~ for more details. Abbott’s Revenue Contribution As of 2018: United States ~ 35% China ~ 8% Germany ~ 5% India ~ 4% Japan ~ 4% Switzerland ~ 3% The Netherlands ~ 3% Others ~ 38% Abbott’s Sales In the United States Are Higher Than That of Boston Scientific, But Lower Than Medtronic Abbott’s sales in the United States grew from $6.1 billion in 2014 to $10.8 billion in 2018. This compares with Boston Scientific’s US sales, which grew from $3.9 billion to $5.5 billion over the same period. Medtronic’s sales in the United States grew from $12.1 billion to $16.2 billion between fiscal 2014 and fiscal 2018. Abbott’s Business Model What Need Does It Serve? Abbott primarily serves the medical devices, pharmaceuticals, and nutritional products market. These medical devices are used primarily by various healthcare institutions in several countries. Its established pharmaceuticals business focuses primarily on emerging markets. Who Pays To Abbott? Blood banks, hospitals, commercial laboratories, and clinics Physicians Government agencies Health care facilities, specialty pharmacies, wholesalers, distributors, and independent retailers Retail consumers Who Are Abbott’s Key Competitors? Abbott competes with other medical devices companies, such as Medtronic, Johnson & Johnson, Boston Scientific, and Intuitive Surgical, among others. In Diagnostics it competes with Roche among other companies. In established pharmaceuticals business, it competes with Pfizer, and GlaxoSmithKline, among others. The Contribution of the United States To Abbott’s Total Sales Has Increased In The Recent Years Abbott’s total sales grew from $20.2 billion in 2014 to $30.6 billion in 2018. Given the sales growth in the United States from $6.1 billion to $10.8 billion over the same period, the contribution of the United States as a region grew from 30% to 35%. The Contribution of United States To Total Sales For Abbott Is Lower Than That For Its Peers Abbott’s Total Revenue Grew 51% Between 2014 And 2018, And It Can Grow Another 10% By 2020 Abbott’s sales growth in 2017 can be attributed to the St. Jude acquisition. Abbott’s revenue growth in 2018 was also higher due to the impact of the Alere acquisition. The company has been seeing higher revenue growth from emerging markets, including China, India, and Russia. Looking forward, the sales growth is expected to slow, given the year-over-year impact of acquisitions. You can look at our interactive dashboard analysis on more details on Abbott’s segment-wise revenues here. What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Abbott (NYSE:ABT) generates its revenue from sales of medical devices across the globe. The company generated $11 billion in sales in the United States, accounting for over one-third of its total revenue in 2018. Blood banks, hospitals, commercial laboratories, and clinics Physicians Government agencies Health care facilities, specialty pharmacies, wholesalers, distributors, and independent retailers Retail consumers Who Are Abbott’s Key Competitors?
Abbott (NYSE:ABT) generates its revenue from sales of medical devices across the globe. Abbott’s Revenue Contribution As of 2018: United States ~ 35% China ~ 8% Germany ~ 5% India ~ 4% Japan ~ 4% Switzerland ~ 3% The Netherlands ~ 3% Others ~ 38% Abbott’s Sales In the United States Are Higher Than That of Boston Scientific, But Lower Than Medtronic Abbott’s sales in the United States grew from $6.1 billion in 2014 to $10.8 billion in 2018. Abbott primarily serves the medical devices, pharmaceuticals, and nutritional products market.
Abbott (NYSE:ABT) generates its revenue from sales of medical devices across the globe. Abbott’s Revenue Contribution As of 2018: United States ~ 35% China ~ 8% Germany ~ 5% India ~ 4% Japan ~ 4% Switzerland ~ 3% The Netherlands ~ 3% Others ~ 38% Abbott’s Sales In the United States Are Higher Than That of Boston Scientific, But Lower Than Medtronic Abbott’s sales in the United States grew from $6.1 billion in 2014 to $10.8 billion in 2018. The Contribution of the United States To Abbott’s Total Sales Has Increased In The Recent Years Abbott’s total sales grew from $20.2 billion in 2014 to $30.6 billion in 2018.
Abbott (NYSE:ABT) generates its revenue from sales of medical devices across the globe. We also compare the United States as a market for Abbott with that for other large medical devices companies. Abbott’s Revenue Contribution As of 2018: United States ~ 35% China ~ 8% Germany ~ 5% India ~ 4% Japan ~ 4% Switzerland ~ 3% The Netherlands ~ 3% Others ~ 38% Abbott’s Sales In the United States Are Higher Than That of Boston Scientific, But Lower Than Medtronic Abbott’s sales in the United States grew from $6.1 billion in 2014 to $10.8 billion in 2018.
32838.0
2019-12-30 00:00:00 UTC
7 High-Yield Dividend Stocks for Growth and Income in the 2020s
ABT
https://www.nasdaq.com/articles/7-high-yield-dividend-stocks-for-growth-and-income-in-the-2020s-2019-12-30
nan
nan
In a year where the S&P 500 grew by nearly 30%, dividend stocks often receive less attention. Despite this, with bank depositors often struggling to earn 1% per year in interest income, they remain attractive stocks to buy. Moreover, anyone who has followed the stock market for any length of time knows that some years bring higher returns than others. In a time where stock price growth lags, dividend stocks can both mitigate losses and provide a more reliable income stream. Furthermore, because of that income stream, investors tend to sell them off less often. Also, due to the massive returns in 2019, the market could struggle to deliver equivalent returns in 2020. However, dividend stocks could rescue some investors. Furthermore, as we move forward into the 2020s, some of these equities could also produce not only high-yielding payouts, but potentially considerable stock-price gains as well. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:) is one of the dividend stocks that may have finally begun its long-awaited recovery. Investors sold it off throughout most of 2018 and 2019 as patents on Humira started to expire across the world. It fell further when the company issued more shares to finance its purchase of Allergan (NYSE:). The Allergan buy now appears to have served as the low point of ABBV stock. Since that announcement, it has steadily risen. AbbVie now trades at about $89 per share. This represents a considerable run-up from the summer low of just under $63 per share. However, it remains far below the early 2018 highs of almost $126 per share. Furthermore, new investors can still profit. Despite recent increases, ABBV trades at a forward price-to-earnings (PE) ratio of 9.1. Also, with clarity as to what will replace revenue from Humira, Wall Street predicts earnings increases of 12.9% in 2019 and 9.2% next year. Moreover, next year’s annual dividend will rise to $4.72 per share, a yield of about 5.3%. Including its time as part of Abbott Laboratories (NYSE:), it has hiked payouts for 46 consecutive years. As the company absorbs Allergan and new drugs replace the revenue from Humira, ABBV stock should continue its march higher. Altria (MO) Source: Kristi Blokhin / Shutterstock.com Despite facing challenges that may have sunk other businesses, Altria (NYSE:) continues to pay off for dividend investors. Those who bought the stock as late as 2003 and reinvested the dividend in more MO stock now earn their initial investment back in payouts alone. The current payout stands at 6.6%. Since it does not rise every year, it is not a dividend aristocrat. However, it has gone up in most years, and now maintains a ten-year streak of annual increases. Also, at a forward PE ratio of 11.4, it remains reasonably-priced for new investors. This happened partially as a result of the vaping controversy surrounding Juul, which hurt MO stock this year. However, this can also serve as a buying opportunity for new investors. Moreover, the 20s could see it diversify into a new industry. In 2018, Altria announced that it would invest $1.8 billion in Canadian marijuana producer Cronos (NASDAQ:). This bought Altria a 45% stake in the company. The cannabis industry continues its March toward legalization. Once the hype in weed stocks dies down, they will likely become slower-growth, dividend-producing equities, similar to tobacco stocks. Hence, as tobacco use continues to fall, this gives Altria a segue into a new industry that should continue to serve as one of the better-paying dividend stocks throughout the 2020s. AT&T (T) Source: Lester Balajadia / Shutterstock.com AT&T (NYSE:) has positioned itself to become one of the more notable beneficiaries of 5G. As only one of three nationwide 5G providers, it will again become one of the few providers of a needed communications service. AT&T stock suffered for years as customers dropped landlines and cable TV plans. Investors also sold off T stock as heavy debt loads and the massive costs of building a nationwide 5G network weighed on the stock. Now, with smartphone makers releasing 5G phones, the investment will start to pay off soon. Moreover, AT&T’s board just passed the 35th annual dividend increase. This means investors will earn $2.08 per share in payouts in 2020, up from $2.04 per share the previous year. Since dividend aristocrats such as T stock tend to suffer for years when they cut payouts, investors can likely expect continued increases in future years. T stock also enjoyed a prosperous 2019, with the stock rising by close to 30%. However, despite the increase, it remains one of the better-paying dividend stocks. Even with the higher stock price, the dividend still yields over 5.3%. Moreover, the forward PE has only climbed to around 10.8. While it has risen from last year, it remains well below historical averages. At these levels, buying AT&T should not only bring huge payouts but also continued stock price gains. BP p.l.c. (BP) Source: JuliusKielaitis / Shutterstock.com A stagnant stock price and a generous dividend have defined BP (NYSE:) in the 2010s. The Deepwater Horizon oil spill in 2010 hurt BP stock for years. However, with this tragedy nearly ten years behind the company, it has almost worked through the liabilities that came from this accident. Moreover, CEO Bob Dudley, whose tenure began soon after the oil spill, will step down in February. Throughout Mr. Dudley’s tenure, BP became a dividend stocks that did not see significant stock price gains. Its yields have remained generous and have seen slow growth since soon after the accident. Today, its payout of $2.46 per share offers investors a return of around 6.5%. Now with Bernard Looney taking over as CEO, the stock may finally see some gains. Admittedly, fewer regulations and massive output from the Permian Basin have helped to put a lid on oil prices. Despite the state of energy prices, analysts expect profit growth to resume next year. They also believe earnings will increase by 14.6% in 2020. Over the next five years, Wall Street forecasts profit growth to average 31.5% per year. If this holds, BP stock, and possibly the payout, could see significant increases in the 2020s. Innovative Industrial Properties (IIPR) Source: Shutterstock Innovative Industrial Properties (NYSE:) does not attract the attention of many other dividend stocks. As a real estate investment trust (REIT), payouts can vary since REITs must pay out at least 90% of their net income in dividends. Even among REITs, it stands out for its niche. IIPR specializes in properties designed for the growth of cannabis. However, since 33 states have legalized medical marijuana, it can operate in most parts of the country. Moreover, since it merely provides property and facilities, it does not have to contend with the Schedule I restrictions on cannabis. Interestingly, the drop in weed stocks has helped Innovative Industrial Properties. In some cases, struggling marijuana firms have sold their properties and leased them back to keep their doors open. In many cases, IIPR has bought that property. As a result, Wall Street expects profits to grow by 124% this year and 140.5% in fiscal 2020. Even better, the forward PE ratio is now at around 18.3. This has bolstered the dividend, which now stands at $4 per share, a yield of about 5.4%. Due to REIT rules, this dividend should continue to move substantially higher. As more jurisdictions move toward legalization and more failing cannabis companies sell out to the company, IIPR stock should continue to produce increasing dividends and gains for the foreseeable future. Omega Healthcare Investors (OHI) Source: Shutterstock Omega Healthcare’s (NYSE:) real estate holdings have and will continue to benefit from demographics. The aging of baby boomers continues to add an estimated 10,000 people per day to the Medicare rolls. Fortunately for Omega, it owns 855 skilled nursing and assisted living facilities in the U.S. (and 55 in the U.K.) that can address the needs of seniors. Like with IIPR, the dividend requirements of REITs will work in favor of investors. Wall Street forecasts earnings growth of 13.6% this year. On average, they believe these increases will remain in the double-digits over the next five years. At 25 times forward earnings, this growth will not come cheap, but demographics strongly indicate it will happen nonetheless. The current annual payout of $2.68 per share takes the yield to around 6.4%. Also, thanks to a growing Medicare population and REIT dividend requirements, payouts have increased for nine straight years. Moreover, stock price gains should add to the returns. OHI stock has risen by more than 23% in 2019, an impressive performance for an equity focused on income. As long as the Medicare population continues this massive growth, OHI should move higher along with it. Qualcomm Incorporated (QCOM) Source: Katherine Welles / Shutterstock.com Most investors know Qualcomm (NASDAQ:) stock best for its chipsets that power smartphones. The upcoming 5G upgrade cycle, as well as the settlement of their long legal battle with Apple (NASDAQ:), have solidified its dominance in this industry. However, in recent years, Qualcomm has become one of the more noteworthy dividend stocks. At $2.48 per share in payouts, its yield now stands at about 2.8%. Moreover, its streak of annual payout increases has grown to eight years. Even though the legal battle with Apple depressed QCOM stock, it continued hiking the dividend throughout this time. Now QCOM stock appears set to produce massive price and dividend gains. Thanks to 5G, analysts forecast chipset revenue to grow from $2.12 billion in 2020 to $22.93 billion by 2026. As the dominant maker of chipsets, most of the benefit should accrue to Qualcomm. This likely explains why Wall Street expects profit growth to increase from 18.4% this year to 45.8% in 2020. At a forward PE of around 14.5, the earnings increases also come at a low price. QCOM stock saw a massive run-up in 2019, rising by more than 57% on the year. Hence, investors might want to wait. However, as consumers and businesses across the world upgrade to 5G, investors should see massive benefits over the next few years. As of this writing, Will Healy is long ABBV stock. You can  at @HealyWriting. More From InvestorPlace The post appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
As the company absorbs Allergan and new drugs replace the revenue from Humira, ABBV stock should continue its march higher. Admittedly, fewer regulations and massive output from the Permian Basin have helped to put a lid on oil prices. The upcoming 5G upgrade cycle, as well as the settlement of their long legal battle with Apple (NASDAQ:), have solidified its dominance in this industry.
Innovative Industrial Properties (IIPR) Source: Shutterstock Innovative Industrial Properties (NYSE:) does not attract the attention of many other dividend stocks. As more jurisdictions move toward legalization and more failing cannabis companies sell out to the company, IIPR stock should continue to produce increasing dividends and gains for the foreseeable future. Omega Healthcare Investors (OHI) Source: Shutterstock Omega Healthcare’s (NYSE:) real estate holdings have and will continue to benefit from demographics.
Those who bought the stock as late as 2003 and reinvested the dividend in more MO stock now earn their initial investment back in payouts alone. Since dividend aristocrats such as T stock tend to suffer for years when they cut payouts, investors can likely expect continued increases in future years. Throughout Mr. Dudley’s tenure, BP became a dividend stocks that did not see significant stock price gains.
Since dividend aristocrats such as T stock tend to suffer for years when they cut payouts, investors can likely expect continued increases in future years. As more jurisdictions move toward legalization and more failing cannabis companies sell out to the company, IIPR stock should continue to produce increasing dividends and gains for the foreseeable future. Now QCOM stock appears set to produce massive price and dividend gains.
32839.0
2019-12-29 00:00:00 UTC
The 3 Best Healthcare Stocks to Buy for 2020
ABT
https://www.nasdaq.com/articles/the-3-best-healthcare-stocks-to-buy-for-2020-2019-12-29
nan
nan
You'll hear plenty of predictions about what might be in store in 2020. Here's one prediction that's almost certain to come true: More money will be spent on healthcare. And where lots of money is spent, opportunities exist for investors. Which stocks are most likely to be the biggest winners in the new year? I think three healthcare stocks appear to be especially poised to deliver nice gains for investors in 2020. They're all profitable. They're all growing. And they all have strong prospects for future growth. Here are my picks for the best healthcare stocks to buy for 2020, listed in alphabetical order. Image source: Getty Images. 1. Abbott Labs It's not easy for a healthcare giant to deliver double-digit percentage year-over-year earnings growth. But that's exactly what Abbott Labs (NYSE: ABT) routinely does. I look for more of the same in 2020. The biggest potential catalyst on the way for Abbott is the anticipated U.S. clearance for the new version of its popular Freestyle Libre continuous glucose monitoring (CGM) system. Robert Ford, Abbott's current president and COO who will soon become CEO as Miles White steps down, said in the company's third-quarter conference call that Abbott is "working through a handful of open items" with the U.S. Food and Drug Administration (FDA) but remains confident about approval for the new version. I expect Abbott will indeed win the FDA clearance for the interoperable CGM version of Freestyle Libre in 2020, setting the stage for even more impressive sales growth. I also think that Abbott's other newer products, including Alinity diagnostic systems and MitraClip mitral regurgitation devices, will fuel growth next year. Investors will also like Abbott's solid dividend. The company recently boosted its dividend payout for the 48th consecutive year. Its dividend now yields nearly 1.7%. 2. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) has been one of my favorite healthcare stocks for a while and still ranks near the top of the list. The robotic surgical systems pioneer continues to generate impressive sales and earnings growth of more than 20% year over year. What I like the most about Intuitive Surgical is its rock-solid business model. The company makes over 70% of its total revenue from recurring sources, especially sales of replacement instruments and accessories for its da Vinci robotic surgical systems. Every new system it sells paves the way for higher recurring revenue. Intuitive is also leasing increasingly more systems, which boosts recurring revenue even more. I also like Intuitive Surgical's commitment to innovation. In 2019, the company received five key FDA clearances that allowed it to market the new Ion robotic system for lung biopsy, its Iris augmented reality overlay software, da Vinci SP for the transoral surgery indication, the SureForm 45 mm stapler, and the da Vinci handheld camera. These kinds of innovations should translate to more growth in the future. But could Intuitive Surgical be in trouble with more competition on the way, including Medtronic's new robotically assisted surgery system that will compete against da Vinci? I don't think so. My view is that this competition will expand the total market and actually help Intuitive Surgical over the long run. 3. Vertex Pharmaceuticals How does the stock of a company with an expanding monopoly in a multibillion-dollar market and multiple pathways to generate future growth sound to you? Vertex Pharmaceuticals (NASDAQ: VRTX) is such a company. I think this biotech stock is poised to be a big winner in 2020 and beyond. Vertex's monopoly is in treating the underlying cause of cystic fibrosis (CF), a progressive genetic disease that impacts around 75,000 patients worldwide. The biotech had three CF drugs on the market in the U.S. until October, but then won an early FDA approval for Trikafta. Vertex fully expects to win approvals in more countries for the powerful new drug and expand its total number of patients that can be treated with its therapies by more than 50%. While Vertex looks at expanding its CF opportunity tremendously over the next few years, the biotech is also developing therapies targeting other indications. It's partnering with CRISPR Therapeutics on gene-editing therapies that hold the potential to essentially cure rare blood diseases beta-thalassemia and sickle cell disease. Vertex also is evaluating a couple of candidates in early stage clinical studies for treating rare genetic disease alpha-1 antitrypsin deficiency (AATD). Although Vertex is especially strong in developing therapies for rare genetic diseases, the company has its eyes on some conditions that aren't so rare as well. Vertex claims a promising pain program that should advance to late-stage testing in the near future. It also acquired Semma Therapeutics in 2019, a small biotech that's working to develop a cure for type 1 diabetes. All of this makes Vertex the best biotech stock on the market in my opinion and one of the top healthcare stocks to buy for 2020. 10 stocks we like better than Vertex Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of Intuitive Surgical and Vertex Pharmaceuticals. The Motley Fool owns shares of and recommends Intuitive Surgical. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
But that's exactly what Abbott Labs (NYSE: ABT) routinely does. The biggest potential catalyst on the way for Abbott is the anticipated U.S. clearance for the new version of its popular Freestyle Libre continuous glucose monitoring (CGM) system. I expect Abbott will indeed win the FDA clearance for the interoperable CGM version of Freestyle Libre in 2020, setting the stage for even more impressive sales growth.
But that's exactly what Abbott Labs (NYSE: ABT) routinely does. I expect Abbott will indeed win the FDA clearance for the interoperable CGM version of Freestyle Libre in 2020, setting the stage for even more impressive sales growth. The robotic surgical systems pioneer continues to generate impressive sales and earnings growth of more than 20% year over year.
But that's exactly what Abbott Labs (NYSE: ABT) routinely does. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) has been one of my favorite healthcare stocks for a while and still ranks near the top of the list. All of this makes Vertex the best biotech stock on the market in my opinion and one of the top healthcare stocks to buy for 2020.
But that's exactly what Abbott Labs (NYSE: ABT) routinely does. The robotic surgical systems pioneer continues to generate impressive sales and earnings growth of more than 20% year over year. The company makes over 70% of its total revenue from recurring sources, especially sales of replacement instruments and accessories for its da Vinci robotic surgical systems.
32840.0
2019-12-22 00:00:00 UTC
20 High-Yield Dividend Stocks to Buy in 2020
ABT
https://www.nasdaq.com/articles/20-high-yield-dividend-stocks-to-buy-in-2020-2019-12-22
nan
nan
A new year is on the way. With it comes plenty of excitement... and perhaps some nervousness for investors. No one knows what the stock market will do in 2020. After the longest bull run ever and the inherent uncertainty in a presidential election year, investors can't be blamed for being at least a little apprehensive -- especially investors who rely on income generated by the stocks they own. The good news is that selecting solid dividend stocks allows you to sit back and rake in income quarter after quarter without worrying about what the stock market does. But which stocks are smart picks? Here are 20 high-yield dividend stocks you can buy in 2020, listed in alphabetical order. Image source: Getty Images. 1. AbbVie AbbVie (NYSE: ABBV) offers a dividend that yields nearly 5.3%. The big drugmaker recently increased its dividend by 10.3% and has grown the dividend by a whopping 195% since being spun off from Abbott Labs in 2013. Although AbbVie faces headwinds for its top-selling drug Humira, the rest of its lineup plus its pending acquisition of Allergan should put the company in great shape to keep the dividends flowing. 2. AT&T Telecommunications giant AT&T's (NYSE: T) dividend currently yields 5.4%. The company is a Dividend Aristocrat and boasts 36 consecutive years of dividend increases. AT&T's entertainment business is still under heavy pressure, but its wireless business should remain strong. 3. Brookfield Infrastructure Partners Brookfield Infrastructure Partners (NYSE: BIP) pays a dividend with a yield just shy of 4%. The company's infrastructure assets, including cell towers, natural gas pipelines, ports, and toll roads, provide a steady revenue stream. Brookfield Infrastructure expects to grow organically by between 6% and 9% in 2020 as it adds new infrastructure assets to its portfolio. 4. Brookfield Renewable Partners Brookfield Renewable Partners (NYSE: BEP) is Brookfield Infrastructure's sibling, with both companies controlled by general partner Brookfield Asset Management. Brookfield Renewable, as its name indicates, focuses primarily on renewable energy assets including hydroelectric, wind, and solar power facilities. Its dividend currently yields close to 4.5%. 5. Chevron 2019 hasn't been a great year for the energy sector. But Chevron (NYSE: CVX) has performed better than most energy stocks. The company's strong balance sheet and relatively low cash-flow break even point of $51 per barrel of oil puts the company in a position to weather a tough oil market and to perform really well in a good market. Chevron's dividend currently yields nearly 4%. Another dividend increase in 2020 seems likely. 6. Duke Energy Duke Energy (NYSE: DUK) offers a dividend that yields nearly 4.2%. As a utility that provides must-have electric and gas power to customers, the company can count on steady earnings. And that translates to steady dividends, making Duke a dividend stock that's ideal for retirees in 2020 and beyond. 7. Enbridge Enbridge (NYSE: ENB) is another company that enjoys steady earnings thanks to its oil and gas pipelines. The company's dividend yield currently stands north of 6.3%. Enbridge seems likely to be able to boost its dividend by 10% in 2020. 8. Enterprise Products Partners Enterprise Products Partners (NYSE: EPD) ranks as one of the top players in the midstream oil and gas market. The company offers a mouthwatering dividend yield of 6.4%. Enterprise also has several new projects on the way that should boost its growth prospects over the next few years. 9. Gilead Sciences There aren't many biotechs that have dividend programs, but Gilead Sciences (NASDAQ: GILD) is a notable exception. Gilead's dividend currently yields over 3.8%. Its strong HIV franchise is the biotech's anchor, but Gilead hopes to soon expand into immunology by winning FDA approval for its rheumatoid arthritis drug filgotinib next year. 10. IBM IBM (NYSE: IBM) has been a dividend investors' favorite for a long time. It still should be, with its dividend yielding nearly 4.8%. The technology company could also enjoy rising sales in 2020 thanks to its acquisition of Red Hat earlier this year and the launch of its new z15 mainframe system. 11. Innovative Industrial Properties If you're looking for a way to profit from the cannabis boom, Innovative Industrial Properties (NYSE: IIPR) should be near the top of the list. The cannabis-focused real estate investment trust (REIT) is growing like a weed (pardon the pun). It also offers a fast-growing dividend that currently yields 5.4%. 12. Medical Properties Trust Medical Properties Trust (NYSE: MPW) is a REIT that focuses on healthcare. The company owns and leases healthcare properties, primarily acute care hospitals. Its dividend currently yields 5.2%. Medical Properties Trust has steadily increased its dividend payout over the last five years. 13. ONEOK ONEOK (NYSE: OKE), like Enterprise Products Partners, operates in the midstream energy market. Its stock has outperformed most of its peers in 2019. Despite the big run-up in its share price, ONEOK's dividend yield remains high at just under 5%. The company should fare well in 2020 also, with several projects coming online that could fuel earnings growth. 14. Pfizer Pfizer's (NYSE: PFE) dividend yields over 3.9% right now, but it's likely to drop soon. So why did the big pharma stock make the list of dividend stocks to buy for 2020? The reason Pfizer's dividend is going to decline is that the company is spinning off and merging its Upjohn unit with Mylan, forming a new entity to be named Viatris. The good news for Pfizer shareholders is that between their positions in Pfizer and Viatris, the overall dividend should be roughly the same. The deal also puts Pfizer on a stronger growth path by shedding its older drugs with declining sales. 15. Public Storage One thing isn't likely to change in 2020: Americans have too much stuff and need a place to store that stuff. Public Storage (NYSE: PSA) offers a solution to that problem as the nation's largest self-storage provider. The company also offers a solution to investors looking for reliable income with its dividend yield of 3.9%. 16. Southern Company Southern Company (NYSE: SO) ranks as one of the largest utilities in the U.S. It's also one of the most attractive high-yield dividend stocks with its dividend currently yielding nearly 3.9%. Even better, Southern Company should be able to boost its dividend modestly in 2020 and in subsequent years. 17. Store Capital Warren Buffett really likes Store Capital (NYSE: STOR), the only REIT in Buffett's Berkshire Hathaway holdings. Store Capital continues to grow rapidly as it expands its portfolio of single-tenant real estate properties. That growth could translate to even higher dividends from the company, making Store Capital's current dividend yield of nearly 3.8% even more attractive. 18. Verizon Communications Like fellow telecom leader AT&T, Verizon Communications (NYSE: VZ) faces some headwinds. However, also like AT&T, Verizon offers a terrific dividend, which currently yields 4%. The company is a Dividend Aristocrat that places a high priority on dividend hikes each year. In addition, Verizon's investments in building a high-speed 5G wireless network should pay off over the long run. 19. Wells Fargo Wells Fargo's (NYSE: WFC) stock performance has lagged behind many of its peers in the financial services sector mainly because of the aftermath of the company's scandals that made headlines beginning in 2016. But those scandals didn't impact Wells Fargo's dividend program. The financial giant's dividend currently yields nearly 3.8%, and its future appears to be brighter now that a new CEO is in place. 20. Welltower Rounding out our 20 high-yield dividend stocks to buy in 2020 is Welltower (NYSE: WELL). The healthcare REIT offers a dividend yield of 4.5%. With its focus on private-pay senior housing properties, Welltower should be able to count on a steady revenue stream that allows it to keep the dividends flowing well into the future. Great income, varying growth All 20 of these stocks should provide great income for investors in 2020 and beyond. Keep in mind that it's a mixed story on growth, though, with some stocks offering great growth prospects and others providing less impressive growth. 10 stocks we like better than IBM When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and IBM wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie, Chevron, Gilead Sciences, and Pfizer. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares), Brookfield Asset Management, Enbridge, Gilead Sciences, and STORE Capital. The Motley Fool is short shares of IBM. The Motley Fool recommends Brookfield Infrastructure Partners, Enterprise Products Partners, Innovative Industrial Properties, Mylan, ONEOK, and Verizon Communications and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), long January 2020 $200 calls on IBM, short January 2020 $200 puts on IBM, short January 2020 $155 calls on IBM, and short January 2020 $220 calls on Berkshire Hathaway (B shares). The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Although AbbVie faces headwinds for its top-selling drug Humira, the rest of its lineup plus its pending acquisition of Allergan should put the company in great shape to keep the dividends flowing. The company's infrastructure assets, including cell towers, natural gas pipelines, ports, and toll roads, provide a steady revenue stream. Its strong HIV franchise is the biotech's anchor, but Gilead hopes to soon expand into immunology by winning FDA approval for its rheumatoid arthritis drug filgotinib next year.
Brookfield Renewable Partners Brookfield Renewable Partners (NYSE: BEP) is Brookfield Infrastructure's sibling, with both companies controlled by general partner Brookfield Asset Management. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares), Brookfield Asset Management, Enbridge, Gilead Sciences, and STORE Capital. The Motley Fool recommends Brookfield Infrastructure Partners, Enterprise Products Partners, Innovative Industrial Properties, Mylan, ONEOK, and Verizon Communications and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), long January 2020 $200 calls on IBM, short January 2020 $200 puts on IBM, short January 2020 $155 calls on IBM, and short January 2020 $220 calls on Berkshire Hathaway (B shares).
It's also one of the most attractive high-yield dividend stocks with its dividend currently yielding nearly 3.9%. That growth could translate to even higher dividends from the company, making Store Capital's current dividend yield of nearly 3.8% even more attractive. The Motley Fool recommends Brookfield Infrastructure Partners, Enterprise Products Partners, Innovative Industrial Properties, Mylan, ONEOK, and Verizon Communications and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), long January 2020 $200 calls on IBM, short January 2020 $200 puts on IBM, short January 2020 $155 calls on IBM, and short January 2020 $220 calls on Berkshire Hathaway (B shares).
It still should be, with its dividend yielding nearly 4.8%. Its dividend currently yields 5.2%. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares), Brookfield Asset Management, Enbridge, Gilead Sciences, and STORE Capital.
32841.0
2019-12-20 00:00:00 UTC
Noteworthy Friday Option Activity: ABT, WNC, MS
ABT
https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-abt-wnc-ms-2019-12-20
nan
nan
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 23,433 contracts has been traded thus far today, a contract volume which is representative of approximately 2.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 54.7% of ABT's average daily trading volume over the past month, of 4.3 million shares. Particularly high volume was seen for the $92.50 strike call option expiring January 17, 2020, with 4,880 contracts trading so far today, representing approximately 488,000 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $92.50 strike highlighted in orange: Wabash National Corp (Symbol: WNC) options are showing a volume of 1,815 contracts thus far today. That number of contracts represents approximately 181,500 underlying shares, working out to a sizeable 54.7% of WNC's average daily trading volume over the past month, of 331,840 shares. Especially high volume was seen for the $15 strike call option expiring January 17, 2020, with 950 contracts trading so far today, representing approximately 95,000 underlying shares of WNC. Below is a chart showing WNC's trailing twelve month trading history, with the $15 strike highlighted in orange: And Morgan Stanley (Symbol: MS) options are showing a volume of 47,530 contracts thus far today. That number of contracts represents approximately 4.8 million underlying shares, working out to a sizeable 53.9% of MS's average daily trading volume over the past month, of 8.8 million shares. Especially high volume was seen for the $50 strike call option expiring January 17, 2020, with 5,861 contracts trading so far today, representing approximately 586,100 underlying shares of MS. Below is a chart showing MS's trailing twelve month trading history, with the $50 strike highlighted in orange: For the various different available expirations for ABT options, WNC options, or MS options, visit StockOptionsChannel.com. Today's Most Active Call & Put Options of the S&P 500 » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
That number works out to 54.7% of ABT's average daily trading volume over the past month, of 4.3 million shares. Particularly high volume was seen for the $92.50 strike call option expiring January 17, 2020, with 4,880 contracts trading so far today, representing approximately 488,000 underlying shares of ABT. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 23,433 contracts has been traded thus far today, a contract volume which is representative of approximately 2.3 million underlying shares (given that every 1 contract represents 100 underlying shares).
Below is a chart showing ABT's trailing twelve month trading history, with the $92.50 strike highlighted in orange: Wabash National Corp (Symbol: WNC) options are showing a volume of 1,815 contracts thus far today. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 23,433 contracts has been traded thus far today, a contract volume which is representative of approximately 2.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 54.7% of ABT's average daily trading volume over the past month, of 4.3 million shares.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 23,433 contracts has been traded thus far today, a contract volume which is representative of approximately 2.3 million underlying shares (given that every 1 contract represents 100 underlying shares). Especially high volume was seen for the $50 strike call option expiring January 17, 2020, with 5,861 contracts trading so far today, representing approximately 586,100 underlying shares of MS. Below is a chart showing MS's trailing twelve month trading history, with the $50 strike highlighted in orange: For the various different available expirations for ABT options, WNC options, or MS options, visit StockOptionsChannel.com. That number works out to 54.7% of ABT's average daily trading volume over the past month, of 4.3 million shares.
Especially high volume was seen for the $50 strike call option expiring January 17, 2020, with 5,861 contracts trading so far today, representing approximately 586,100 underlying shares of MS. Below is a chart showing MS's trailing twelve month trading history, with the $50 strike highlighted in orange: For the various different available expirations for ABT options, WNC options, or MS options, visit StockOptionsChannel.com. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 23,433 contracts has been traded thus far today, a contract volume which is representative of approximately 2.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 54.7% of ABT's average daily trading volume over the past month, of 4.3 million shares.
32842.0
2019-12-19 00:00:00 UTC
This Dividend Aristocrat Just Gave Shareholders a Great Gift
ABT
https://www.nasdaq.com/articles/this-dividend-aristocrat-just-gave-shareholders-a-great-gift-2019-12-19
nan
nan
Abbott Laboratories (NYSE: ABT) has a gift on the way for all of its shareholders. And it's the kind of gift that keeps on giving throughout the entire year. Last week, the company's board of directors approved a 12.5% dividend increase. The announcement came just in time for the holidays, so the higher dividend could be viewed as a Christmas gift. However, it might be better seen as a Valentine's Day present: The dividend will actually be paid on Feb. 14, 2020, to shareholders of record as of Jan. 15, 2020. Abbott's dividend increase brings the healthcare giant's dividend yield to nearly 1.7%. If that's not enough to entice you to invest in the stock, there are several other reasons you might want to consider buying Abbott. Image source: Getty Images. It's not just one dividend increase A one-time dividend hike of 12.5% is great, but by itself isn't enough to get excited about. But put into context, Abbott's recently announced dividend increase is pretty exciting. This marks Abbott's 48th consecutive year of dividend increases. That track record lands Abbott a spot among the elite group of stocks known as Dividend Aristocrats -- S&P 500 members that have raised their dividends for at least 25 years in a row. Abbott's not too far away from joining an even more prestigious group -- Dividend Kings. These stocks have increased their dividends for an impressive 50 consecutive years. I think it's a virtual certainty that Abbott will become a Dividend King in a couple of years. The dividend payable in February 2020 will also be Abbott's 384th consecutive quarterly dividend paid out. When a company has been sending dividend checks since Calvin Coolidge was president of the U.S., you can sleep peacefully knowing that the dividends are likely to keep on flowing. More good things on the way Abbott has delivered a strong return of close to 20% so far in 2019. Some might point out that this performance lags behind the S&P 500's year-to-date gain of 28%. However, over the last three years, Abbott has soared 127%, compared with only 42% for the S&P 500 index. More importantly, Abbott has several good things on the way that should enable its stock to beat the market. Put the anticipated FDA clearance of the new version of Freestyle Libre at the top of the list. The continuous glucose monitoring (CGM) system is already a big success for Abbott. It could soon become a monster success. Sales for Freestyle Libre jumped 63% year over year to $496 million in the third quarter of 2019. That puts the CGM system on a path to annual sales of around $2 billion. But the new version of Freestyle Libre should be able to rake in annual sales of $5 billion and perhaps a lot more than that. And that's just one growth driver for Abbott. Sales continue to soar for the company's MitraClip device for treating mitral regurgitation, or leaky heart valves. In the third quarter, Abbott won FDA approval for the next generation of this device. Look for even more impressive sales growth in the future. The company's Alinity family of diagnostics systems is really picking up steam in international markets. But it's still really early for Alinity in the U.S. -- the biggest market of all. Dividends and growth Abbott Labs is without question a solid dividend stock. Its latest dividend hike only adds to the company's credentials on that front. However, Abbott is also an attractive growth opportunity, too. Wall Street analysts project the company will deliver average annual earnings growth of 11% over the next five years. That's a level that many investors should like, especially with Abbott's ever-increasing dividends thrown into the mix. You can certainly find stocks that pay higher dividend yields. And you can find stocks that have stronger growth prospects. But there aren't too many stocks that provide great dividends and growth and that claim a track record like Abbott Labs. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Abbott Laboratories (NYSE: ABT) has a gift on the way for all of its shareholders. Sales continue to soar for the company's MitraClip device for treating mitral regurgitation, or leaky heart valves. Wall Street analysts project the company will deliver average annual earnings growth of 11% over the next five years.
Abbott Laboratories (NYSE: ABT) has a gift on the way for all of its shareholders. This marks Abbott's 48th consecutive year of dividend increases. The dividend payable in February 2020 will also be Abbott's 384th consecutive quarterly dividend paid out.
Abbott Laboratories (NYSE: ABT) has a gift on the way for all of its shareholders. Abbott's dividend increase brings the healthcare giant's dividend yield to nearly 1.7%. That track record lands Abbott a spot among the elite group of stocks known as Dividend Aristocrats -- S&P 500 members that have raised their dividends for at least 25 years in a row.
Abbott Laboratories (NYSE: ABT) has a gift on the way for all of its shareholders. These stocks have increased their dividends for an impressive 50 consecutive years. Sales for Freestyle Libre jumped 63% year over year to $496 million in the third quarter of 2019.
32843.0
2019-12-16 00:00:00 UTC
2 Stocks You Can Keep Forever
ABT
https://www.nasdaq.com/articles/2-stocks-you-can-keep-forever-2019-12-16
nan
nan
Buying and holding investments forever is not always a practical strategy. There can be a lot of volatility in the markets that impacts not only individual stocks but entire sectors. That's why finding a forever stock can be very challenging. However, these two stocks offer investors stability and terrific track records, making them ideal long-term investments that you can buy and forget about for years to come. 1. Coca-Cola Coca-Cola (NYSE: KO) is an iconic beverage maker that has been able to remain relevant over the years as the markets changed and consumer tastes evolved. Today, the company has a strong lineup of healthy products, including Smartwater, Dasani, Vitaminwater, and other brands that give Coca-Cola the ability to cater to consumers who are moving away from sugary products. Its strategy of offering healthier products and smaller can sizes has been working. In its most recent quarterly earnings released in October, the company's net revenue was up 8% from the prior-year quarter. A big driver of the company's growth was Coke Zero Sugar, which saw improved sales. Coca-Cola's mini-cans are proving popular as well; the 7.5-oz. cans experienced double-digit sales growth during the quarter. Image Source: Getty Images. Coca-Cola has also adapted to consumer preferences by making greener products. Last month, Coca-Cola announced that its bottles in Sweden "will be made from 100% recycled material," eliminating 3,500 tons of plastic. Initiatives such as focusing on pollution reduction and offering healthier products make Coca-Cola an ideal forever stock. The company's ability to evolve and stay current is critical to its long-term success. In five years, Coca-Cola's share price has risen by more than 29%. Its 3% dividend yield is a great added bonus, especially given that Coca-Cola is a Dividend Aristocrat, and those quarterly dividend payments are likely to rise over the years. 2. Abbott Laboratories Abbott Laboratories (NYSE: ABT) is another Dividend Aristocrat that investors can add to their list for long-term dividend income. The medical device maker's dividend yield of 1.5% is a more modest payout than what Coca-Cola offers, but the company's streak of increasing dividends for more than 40 straight years makes it a formidable income stock for investors. The company's appeal is that it sells a variety of different products for both everyday consumers and health professionals, ranging from cardiovascular devices to diabetes care and diagnostics. Its Freestyle continuous glucose monitor, Similac infant formula, and Ensure nutritional products are noteworthy products in its portfolio. Its diverse product base and well-balanced financials make the stock a forever buy. In its most recent quarter, the company's sales were up 5% from the same quarter last year. But what stands out is its terrific sales mix. Abbott's sales from cardiovascular and neuromodulation products were $2.4 billion, accounting for 30% of the company's sales during the quarter. The company's diagnostic products contributed $1.9 billion, or 24% of its top line. Abbott also earned another $1.9 million in revenue from nutritional products, with established pharmaceutical products accounting for $1.2 billion and making up the smallest chunk of revenue at 15% of sales. Having a very balanced sales mix will help Abbott expand without being overly reliant on any one business segment. The company has also had no trouble staying profitable over the years, as operating income has been at least $1.7 billion in each of the past four years. In five years, the stock has grown more than 85% in value. The healthcare stock's impressive track record for dividends and impressive mix of products makes it a good stock to buy and hold forever. Which stock is the better buy today? Coca-Cola's higher dividend yield will certainly make the stock an appealing option for income-oriented investors. However, growth may be harder to come by as consumers continue to turn away from sugar. That's why Abbott's stock might be the better choice for investors who prioritize capital appreciation over dividend income. But either stock could be a great fit for your portfolio for many years, and even forever. 10 stocks we like better than Coca-Cola When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Coca-Cola wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Abbott Laboratories Abbott Laboratories (NYSE: ABT) is another Dividend Aristocrat that investors can add to their list for long-term dividend income. However, these two stocks offer investors stability and terrific track records, making them ideal long-term investments that you can buy and forget about for years to come. Initiatives such as focusing on pollution reduction and offering healthier products make Coca-Cola an ideal forever stock.
Abbott Laboratories Abbott Laboratories (NYSE: ABT) is another Dividend Aristocrat that investors can add to their list for long-term dividend income. However, these two stocks offer investors stability and terrific track records, making them ideal long-term investments that you can buy and forget about for years to come. Initiatives such as focusing on pollution reduction and offering healthier products make Coca-Cola an ideal forever stock.
Abbott Laboratories Abbott Laboratories (NYSE: ABT) is another Dividend Aristocrat that investors can add to their list for long-term dividend income. The medical device maker's dividend yield of 1.5% is a more modest payout than what Coca-Cola offers, but the company's streak of increasing dividends for more than 40 straight years makes it a formidable income stock for investors. The healthcare stock's impressive track record for dividends and impressive mix of products makes it a good stock to buy and hold forever.
Abbott Laboratories Abbott Laboratories (NYSE: ABT) is another Dividend Aristocrat that investors can add to their list for long-term dividend income. Buying and holding investments forever is not always a practical strategy. Abbott's sales from cardiovascular and neuromodulation products were $2.4 billion, accounting for 30% of the company's sales during the quarter.
32844.0
2019-12-16 00:00:00 UTC
Is AbbVie’s Dividend Capable Of Long-Term Growth?
ABT
https://www.nasdaq.com/articles/is-abbvies-dividend-capable-of-long-term-growth-2019-12-16
nan
nan
Nearly 20 years ago on Dec. 15, 2000, medical device and pharmaceutical maker Abbott Laboratories (NYSE: ABT) announced its $6.9 billion acquisition of Knoll Pharmaceuticals, a subsidiary of chemical giant BASF. At that time, no one knew that Knoll housed a drug, still in clinical development, that would one day become the world's largest selling drug. Then in 2013, Abbott Labs split its company in two. The medical device side retained the name Abbott Labs and the pharmaceutical business was spun-off to shareholders and the new company was named AbbVie (NYSE: ABBV). The aforementioned drug was called D2E7 by Knoll, and generically known as adalimumab, but better know as Humira, generated $19.9 billion in global sales last year and was the world's best-selling drug. Humira is a subcutaneous injection used to treat a variety of diseases including rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis among others. Humira's sales accounted for 60% of AbbVie's revenue in 2018. Humira's days of market exclusivity are numbered Humira was approved in the U.S. in 2002. Last year, U.S. sales of Humira were $13.7 billion, or roughly 42% of AbbVie's total global sales. Humira is set to lose U.S. patent protection in 2023, which will likely precipitate a significant drop in profits. Another $6.3 billion of Humira sales (19% of total sales) was generated outside the U.S. Late last year, biosimilars of Humira (generic biologics) were approved in Europe. The impact of these generics entering the market can be seen in AbbVie's third-quarter earnings release which showed international sales of Humira declining by 32%. AbbVie realized it would have a significant problem in 2023 when U.S. Humira biosimilars are scheduled to launch. Getty Images Will an $86 billion diversification strategy work? AbbVie's solution to this impending patent cliff was to acquire Allergan (NYSE: AGN) for $86 billion including the assumption of Allergan's debt. Allergan will bring over $15 billion in revenues to AbbVie and in the process reduce overall Humira exposure to less than 40% of total sales, still significant, but better. Further, over the next few years international competition from generics should cause international sales of Humira to continue declining. In fact, at the current rate of decline, international sales of Humira will likely be less than $1 billion by 2023. With Allergan, AbbVie now has two main components of its business, Humira and a diversified $30 billion pharmaceutical business it forecasts to grow at a high-single-digit rate for the next decade. The problem is domestic Humira should post similar growth rates. Thus, even if AbbVie's long-range forecast is correct, by 2023 Humira could still account for roughly 35% of sales. The Allergan acquisition should lift the trough earnings of AbbVie in 2024. According to AbbVie CEO Rick Gonzalez: You can take this $15 billion set of assets that are durable and growing and highly profitable (referring to Allergan), and the cash flows from HUMIRA prior to or shortly into the LOE (loss of exclusivity) in 2023 will have paid down the incremental debt that was necessary to be able to buy these assets. So, essentially, HUMIRA is buying the assets that replace it over the long-term. So in other words, AbbVie is viewing Allergan as a similar-sized asset that will replace the lost sales from Humira; and Humira will pay for it. The approaching 2023 patent cliff looms for investors While investors wait for more clarity surrounding AbbVie's earnings power post the Humira 2023 loss of exclusivity, a dividend yield of 5.5%, which was increased by 10% on Nov. 1, should help reduce investors' concerns. When asked about the recent dividend increase Gonzalez said, We certainly would not have increased our dividend double-digits now if we had any concerns about that going forward. So, I can tell you we are committed to a strong and growing dividend and we are committed to paying down debt and we have the ability to be able to do both. And I think the dividend increase that we are announcing today is a reflection of our confidence in that cash flow generation. One way to think about AbbVie today is that it is over-earning, or that AbbVie's normalized earnings power is less than what it is reporting today. After all, the substantial bulk of Humira's profits are going away in the not-so-distant future. But investors aren't paying much today for Humira's profits. AbbVie trades at less than 10x forward earnings. Further, Allergan will be highly accretive to AbbVie's earnings with over 20% accretion at peak. And AbbVie's other assets could also provide upside, such as its successors to Humira called Skyrizi and Rinvoq, both of which have shown superiority to Humira in head-to-head clinical trials for several indications. Given the low valuation, accretive acquisition, robust pipeline, and strong new drug launches, AbbVie is well-positioned for its impending patent cliff. While earnings will no doubt take a dip in 2023 and 2024, investors should expect dividend growth to continue. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Jon Younkman owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Nearly 20 years ago on Dec. 15, 2000, medical device and pharmaceutical maker Abbott Laboratories (NYSE: ABT) announced its $6.9 billion acquisition of Knoll Pharmaceuticals, a subsidiary of chemical giant BASF. The impact of these generics entering the market can be seen in AbbVie's third-quarter earnings release which showed international sales of Humira declining by 32%. Allergan will bring over $15 billion in revenues to AbbVie and in the process reduce overall Humira exposure to less than 40% of total sales, still significant, but better.
Nearly 20 years ago on Dec. 15, 2000, medical device and pharmaceutical maker Abbott Laboratories (NYSE: ABT) announced its $6.9 billion acquisition of Knoll Pharmaceuticals, a subsidiary of chemical giant BASF. Last year, U.S. sales of Humira were $13.7 billion, or roughly 42% of AbbVie's total global sales. The approaching 2023 patent cliff looms for investors While investors wait for more clarity surrounding AbbVie's earnings power post the Humira 2023 loss of exclusivity, a dividend yield of 5.5%, which was increased by 10% on Nov. 1, should help reduce investors' concerns.
Nearly 20 years ago on Dec. 15, 2000, medical device and pharmaceutical maker Abbott Laboratories (NYSE: ABT) announced its $6.9 billion acquisition of Knoll Pharmaceuticals, a subsidiary of chemical giant BASF. Another $6.3 billion of Humira sales (19% of total sales) was generated outside the U.S. Late last year, biosimilars of Humira (generic biologics) were approved in Europe. So in other words, AbbVie is viewing Allergan as a similar-sized asset that will replace the lost sales from Humira; and Humira will pay for it.
Nearly 20 years ago on Dec. 15, 2000, medical device and pharmaceutical maker Abbott Laboratories (NYSE: ABT) announced its $6.9 billion acquisition of Knoll Pharmaceuticals, a subsidiary of chemical giant BASF. Another $6.3 billion of Humira sales (19% of total sales) was generated outside the U.S. Late last year, biosimilars of Humira (generic biologics) were approved in Europe. So in other words, AbbVie is viewing Allergan as a similar-sized asset that will replace the lost sales from Humira; and Humira will pay for it.
32845.0
2019-12-15 00:00:00 UTC
Better Buy: AbbVie vs. Merck
ABT
https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-merck-2019-12-15
nan
nan
AbbVie (NYSE: ABBV) ranks as one of the biggest pharmaceutical stocks on the market. But it's still a lot smaller than Merck (NYSE: MRK). Bigger has proven to be better this year, with AbbVie's stock performance trailing well behind Merck's. But which of these pharma stocks is the better pick for long-term investors looking ahead? Here's how AbbVie and Merck compare on several key fronts. Image source: Getty Images. Growth prospects Wall Street thinks that Merck's growth prospects look better than AbbVie's over the next five years. Analysts project that Merck will grow its earnings by an average of nearly 10% annually while AbbVie's earnings will increase by less than 4% annually. How accurate those estimates will actually be remains to be seen, but there are certainly some good reasons to believe that Wall Street is right in going with Merck instead of AbbVie when it comes to growth. AbbVie's top-selling drug, Humira, already faces biosimilar competition in Europe that's quickly eroding revenue. Humira will battle biosimilars in the much larger U.S. market starting in 2023. That's when the blockbuster drug's sales declines will really become ugly. The good news is that AbbVie has several products that should help offset the sinking sales for Humira. Cancer drugs Imbruvica and Venclexta should continue to pick up momentum. AbbVie's new immunology drugs Rinvoq and Skyrizi are likely to be huge winners. The company should also reduce its dependence on Humira with its pending acquisition of Allergan. However, analysts think Allergan's growth prospects are even lower than AbbVie's, so the deal probably won't work miracles for AbbVie's growth story. Meanwhile, Merck claims the cancer immunotherapy that's likely to knock Humira out of the No. 1 spot among the world's biggest blockbuster drugs -- Keytruda. This one drug should drive most of Merck's growth over the next several years. However, Merck also has other products with rising sales, including its Gardasil HPV vaccine and neuromuscular block reversal drug Bridion. Dividends Merck claims a solid dividend that currently yields more than 2.7%. The drugmaker has increased its dividend each year since 2011 for a total boost of nearly 61%. With rising revenue and earnings, Merck should be in great shape to provide additional dividend hikes in the future. But it's hard to beat AbbVie when it comes to dividends. The company's dividend yield stands at 5.4%. AbbVie has increased its dividend for a remarkable 47 years in a row including the time that it was part of Abbott Labs. Since being spun off from Abbott in 2013, AbbVie's dividend payout has soared by 195%. Could the Allergan acquisition jeopardize AbbVie's terrific dividend? Probably not. Allergan currently pays a dividend of its own that yields around 1.6%. AbbVie CEO Rick Gonzalez stated in the company's third-quarter conference call that AbbVie is "committed to a strong and growing dividend" after the Allergan deal closes. Valuation Determining which of these two big pharma stocks claims the more attractive valuation isn't as easy as it might seem. Merck's price-to-earnings (P/E) ratio of 25 is a lot lower than AbbVie's P/E ratio of 40. But using multiples based on previous earnings doesn't tell the full story. If we look at near-term earnings growth, AbbVie is a lot cheaper than Merck. AbbVie's shares trade at only nine times expected earnings compared to Merck's forward earnings multiple of 16. So is AbbVie the better bargain? Not necessarily. Remember that Wall Street thinks that Merck will deliver much stronger earnings growth over the next five years than AbbVie will -- and that view is probably right. Factoring longer-term growth into the picture, Merck's valuation is more attractive than AbbVie's is. Better buy Which of these stocks is the better pick? I think it depends on your priorities. If you're an income-seeking investor looking mainly for juicy dividends, my view is to go with AbbVie. I expect AbbVie's dividend will continue to grow for a long time to come. On the other hand, if your focus is on total return, Merck is probably the better stock to buy right now. Keytruda is on a roll that isn't likely to slow anytime soon. Merck's growth won't necessarily be awe-inspiring, but it should be solid. And combined with its dividend, Merck should be able to outperform the broader market. 10 stocks we like better than Merck When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Merck & Co. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AbbVie's top-selling drug, Humira, already faces biosimilar competition in Europe that's quickly eroding revenue. However, Merck also has other products with rising sales, including its Gardasil HPV vaccine and neuromuscular block reversal drug Bridion. Remember that Wall Street thinks that Merck will deliver much stronger earnings growth over the next five years than AbbVie will -- and that view is probably right.
Growth prospects Wall Street thinks that Merck's growth prospects look better than AbbVie's over the next five years. However, analysts think Allergan's growth prospects are even lower than AbbVie's, so the deal probably won't work miracles for AbbVie's growth story. AbbVie's shares trade at only nine times expected earnings compared to Merck's forward earnings multiple of 16.
Growth prospects Wall Street thinks that Merck's growth prospects look better than AbbVie's over the next five years. However, analysts think Allergan's growth prospects are even lower than AbbVie's, so the deal probably won't work miracles for AbbVie's growth story. Remember that Wall Street thinks that Merck will deliver much stronger earnings growth over the next five years than AbbVie will -- and that view is probably right.
This one drug should drive most of Merck's growth over the next several years. Dividends Merck claims a solid dividend that currently yields more than 2.7%. AbbVie's shares trade at only nine times expected earnings compared to Merck's forward earnings multiple of 16.
32846.0
2019-12-15 00:00:00 UTC
5 High-Yield Dividend Stocks to Watch
ABT
https://www.nasdaq.com/articles/5-high-yield-dividend-stocks-to-watch-2019-12-15
nan
nan
If you're an income-oriented investor, you probably like dividend stocks for their steady payouts. But no investor minds profiting from solid growth on top of nice dividends. Can you get both high dividend yields and meaningful share appreciation in the market today? I think so. Here are five high-yield dividend stocks to watch over the next year that just might deliver on both counts. Image source: Getty Images. 1. AbbVie AbbVie's (NYSE: ABBV) dividend current yields nearly 5.5%. What's even better is that the big drugmaker has a fantastic track record of dividend hikes. AbbVie has increased its dividend for 48 consecutive years including its time as part of Abbott Labs (NYSE: ABT). Although AbbVie's year-to-date performance has been dismal, I look for 2020 to be a better year for the stock. Humira will remain the top concern for the company because of challenges from biosimilars in Europe. However, AbbVie's year-over-year comparisons for the drug should be much better next year than they were in 2019. In addition, the company has two new immunology drugs on the market -- Rinvoq and Skyrizi -- that ranked in the top five new drugs launched this year. Expect sales for both drugs to pick up considerably in 2020. 2. Brookfield Infrastructure Partners 2019 has been a great year for Brookfield Infrastructure Partners (NYSE: BIP), with its shares soaring close to 50%. Investors also have to love the infrastructure company's dividend yield of 3.9%, which was a lot higher before the stock's tremendous gains. Brookfield Infrastructure's management team thinks that 2020 will be yet another great year. The company is investing in several projects that will expand its operations. It expects to soon close on key acquisitions, including communication towers in India and a global railroad operator, that hold the opportunity to generate strong returns. Brookfield has also initiated efforts to boost profitability. With all of this combined with the steady revenue stream from the company's existing infrastructure assets across the world, I look for this dividend stock to continue its winning ways next year. 3. Chevron Chevron (NYSE: CVX) has provided positive gains for investors so far in 2019, but its stock has trailed well behind the S&P 500. However, the big oil company continued to distribute the dividends that investors like, with its dividend yield standing at a little over 4%. And its share price has held up relatively well despite Chevron's announcement that it will write down $11 billion in assets in the fourth quarter. You'll definitely want to keep your eyes on Chevron in the year ahead. The company has a strong balance sheet and isn't spending as aggressively as most of its peers. That puts Chevron in a great position to profit if oil prices rise -- and gives it a solid foundation to take on more debt if oil prices fall. There's no way to know what will happen with global oil markets in 2020, but Chevron is arguably among the best-positioned oil companies to handle whatever comes its way. 4. IBM IBM (NYSE: IBM) has lagged well behind the broader market in recent years but is performing pretty well so far in 2019. Big Blue's mouth-watering dividend yield of nearly 4.9% makes the stock's gains even more appealing. And there are a couple of reasons IBM could deliver an even better performance in 2020. The huge tech company's acquisition of Red Hat earlier this year should really begin to pay off in the coming year. IBM's revenue is likely to increase by at least 5% in 2020 from the addition of the open-source software company. Also, IBM's new z15 mainframe should fuel higher sales beginning in 2019 Q4 and going through most of next year. 5. Verizon Communications Verizon Communication's (NYSE: VZ) year-to-date performance has been so-so. But its dividend yield of a little over 4% remains spectacular. The telecommunications giant has increased its dividend payout for 13 consecutive years. That strong dividend might not be the primary attraction for Verizon in the future, though. Verizon's investments in high-speed 5G networks could transform its business. CEO Hans Vestberg predicts that half of the U.S. population will have access to 5G by the end of 2020, although it will probably take another four years for all of those individuals to have 5G phones and fully benefit from 5G. Verizon appears to be a high-yield dividend stock that long-term investors will want to keep on their radar screens. 10 stocks we like better than Verizon Communications When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Verizon Communications wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Chevron. The Motley Fool is short shares of IBM. The Motley Fool recommends Brookfield Infrastructure Partners and Verizon Communications and recommends the following options: long January 2020 $200 calls on IBM, short January 2020 $200 puts on IBM, and short January 2020 $155 calls on IBM. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AbbVie has increased its dividend for 48 consecutive years including its time as part of Abbott Labs (NYSE: ABT). It expects to soon close on key acquisitions, including communication towers in India and a global railroad operator, that hold the opportunity to generate strong returns. With all of this combined with the steady revenue stream from the company's existing infrastructure assets across the world, I look for this dividend stock to continue its winning ways next year.
AbbVie has increased its dividend for 48 consecutive years including its time as part of Abbott Labs (NYSE: ABT). Brookfield Infrastructure Partners 2019 has been a great year for Brookfield Infrastructure Partners (NYSE: BIP), with its shares soaring close to 50%. Verizon Communications Verizon Communication's (NYSE: VZ) year-to-date performance has been so-so.
AbbVie has increased its dividend for 48 consecutive years including its time as part of Abbott Labs (NYSE: ABT). With all of this combined with the steady revenue stream from the company's existing infrastructure assets across the world, I look for this dividend stock to continue its winning ways next year. However, the big oil company continued to distribute the dividends that investors like, with its dividend yield standing at a little over 4%.
AbbVie has increased its dividend for 48 consecutive years including its time as part of Abbott Labs (NYSE: ABT). Chevron Chevron (NYSE: CVX) has provided positive gains for investors so far in 2019, but its stock has trailed well behind the S&P 500. However, the big oil company continued to distribute the dividends that investors like, with its dividend yield standing at a little over 4%.
32847.0
2019-12-13 00:00:00 UTC
Daily Dividend Report: T, ABT, AMT, EIX, ORCL
ABT
https://www.nasdaq.com/articles/daily-dividend-report%3A-t-abt-amt-eix-orcl-2019-12-13
nan
nan
AT&T's board of directors approved a 2% increase in the company's quarterly dividend. The dividend is payable on Feb. 3, 2020, to stockholders of record at the close of business on Jan. 10, 2020. AT&T's quarterly dividend will increase from $0.51 per share to $0.52 per share. Abbott (ABT) increased the company's quarterly common dividend to 36 cents per share - a 12.5% increase. The cash dividend is payable Feb. 14, 2020, to shareholders of record at the close of business on Jan. 15, 2020. American Tower Corporation (AMT) has declared its quarterly cash distribution of $1.01 per share on shares of the Company's common stock. The distribution is payable on January 14, 2020 to such stockholders of record at the close of business on December 27, 2019. Edison International (EIX) declared a quarterly common stock dividend of $0.6375 per share, payable on Jan. 31, 2020, to shareholders of record on Dec. 31, 2019. Oracle declared a quarterly cash dividend of $0.24 per share of outstanding common stock. This dividend will be paid to stockholders of record as of the close of business on January 9, 2020, with a payment date of January 23, 2020. VIDEO: Daily Dividend Report: T, ABT, AMT, EIX, ORCL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Abbott (ABT) increased the company's quarterly common dividend to 36 cents per share - a 12.5% increase. VIDEO: Daily Dividend Report: T, ABT, AMT, EIX, ORCL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The distribution is payable on January 14, 2020 to such stockholders of record at the close of business on December 27, 2019.
Abbott (ABT) increased the company's quarterly common dividend to 36 cents per share - a 12.5% increase. VIDEO: Daily Dividend Report: T, ABT, AMT, EIX, ORCL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. American Tower Corporation (AMT) has declared its quarterly cash distribution of $1.01 per share on shares of the Company's common stock.
Abbott (ABT) increased the company's quarterly common dividend to 36 cents per share - a 12.5% increase. VIDEO: Daily Dividend Report: T, ABT, AMT, EIX, ORCL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AT&T's quarterly dividend will increase from $0.51 per share to $0.52 per share.
Abbott (ABT) increased the company's quarterly common dividend to 36 cents per share - a 12.5% increase. VIDEO: Daily Dividend Report: T, ABT, AMT, EIX, ORCL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AT&T's quarterly dividend will increase from $0.51 per share to $0.52 per share.
32848.0
2019-12-12 00:00:00 UTC
5 Dividend Aristocrats Where Analysts See Capital Gains
ABT
https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2019-12-12
nan
nan
To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments. In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing. We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another. These five stocks are part of our full Dividend Aristocrats List. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing.
Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect.
Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect.
Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
32849.0
2019-12-11 00:00:00 UTC
Best ETFs for 2020: The AdvisorShares Vice ETF Is a Long-Term Winner
ABT
https://www.nasdaq.com/articles/best-etfs-for-2020%3A-the-advisorshares-vice-etf-is-a-long-term-winner-2019-12-11
nan
nan
This article is a part of InvestorPlace.com’s Best ETFs for 2020 contest. The InvestorPlace Staff’s pick for the contest is the AdvisorShares Vice ETF (NASDAQ:). This year was a peculiar one for marijuana stocks. Early on, hopes (and stocks) ran high on the idea that major growth was guaranteed in the cannabis space. But numerous factors have since put a dent in that thesis … at least in the short term. In 2019, marijuana stocks and other substance-based vice stocks faced issues of oversupply, quality control and , which led many investors to question their investment viability this year. But, despite the disappointment in 2019, I am cautiously optimistic about a comeback in some vice stocks in 2020. This is why I have picked the AdvisorShares Vice ETF (NASDAQ:) for this year’s Best ETFs contest. The core idea behind this exchange-traded fund is that in good times or bad, people will always seek “sinful” indulgences like pot, alcohol and tobacco. Its “recession-resistant” areas makes it particularly promising for those who might be concerned that we’re headed for more dreary times. But it doesn’t need a recession to be successful, as the vices it promotes will always be appealing. When looking for the best ETFs to buy it’s always important to consider the expenses associated with the investment. Although ACT’s design as an actively managed fund adds to its overall expenses — it has a net expense ratio of 0.99%, or $99 annually per $10,000 invested — I see this as a justified cost. It allows its management team to closely monitor the space and adjust its holdings according to shifts within the various industries it embodies. And right now, the marijuana space is particularly volatile. Furthermore, the success of ACT’s management team is reflected in the fact that despite the general pain in many marijuana and tobacco stocks this year, the ETF is up almost 16% year to date. It has been slowly marching back into the green this year. And I think the outlook on marijuana/tobacco stocks will brighten as investors’ expectations come back down to Earth. This more realistic perspective should give it room to run higher next year. ACT’s Holdings Are Packed With Potential My optimism for ACT’s success is also backed by a few other perks. The U.S. House Judiciary Committee just passed the to decriminalize marijuana at the federal level. If the MORE Act becomes law, it will be a crucial first step toward the U.S. taking Canada’s lead on marijuana legalization. Although it doesn’t stand a very good chance of moving forward under the current Senate majority leadership, it’s certainly a promising move that will help drive ACT in the right direction. Luckily for investors who are concerned about too much direct exposure to marijuana stocks, ACT’s top three holdings are bio-pharmaceutical healthcare and research companies that aren’t strictly based in pot. These holdings include: Thermo Fisher Scientific (NYSE:), Abbott Laboratories (NYSE:) and Abbvie (NYSE:). Each falls under the ETF’s “cannabis-related” sector allocation, which makes up 32.7% of its vice pie. As mentioned earlier, in addition to cannabis-related holdings, ACT recognizes the staying power of alcohol and tobacco stocks. I like this diversification because it doesn’t solely rely on the success of cannabis stocks alone. Still, the bulk of its tobacco stocks are tobacco companies with cannabis exposure, which make up 17.8% of the ETF’s sector allocation. Among ACT’s other top holdings are Boston Beer Company (NYSE:), LVMH Moet Hennessy (OTCMKTS:) and Philip Morris International (NYSE:). For investors interested in an ETF that is solely focused on marijuana stocks there are other options like the AdvisorShares Pure Cannabis ETF (NYSEARCA:). But this is a much riskier play given its much less diverse holdings. Given these unpredictable times, I’d rather take a bet on an ETF with significant growth prospects and a decent degree of safety. As an added bonus, it also has a much less cringey ticker than “YOLO.” Bottom Line on ACT All in all, the ACT ETF has long-term durability with concentrated exposure to select companies related to alcohol, cannabis and tobacco. The evolving landscape of cannabis in particular has the potential to lead to real growth opportunities in 2020 and beyond. As such, the ACT ETF is one of the best ETFs to consider now regardless of whether it ends up winning InvestorPlace.com’s ETF contest. Anna Jacoby is a web editor for . As of this writing, she did not hold a position in any of the aforementioned securities. InvestorPlace Web Editor Robert Waldo also contributed to this article. More From InvestorPlace The post appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The core idea behind this exchange-traded fund is that in good times or bad, people will always seek “sinful” indulgences like pot, alcohol and tobacco. Luckily for investors who are concerned about too much direct exposure to marijuana stocks, ACT’s top three holdings are bio-pharmaceutical healthcare and research companies that aren’t strictly based in pot. As mentioned earlier, in addition to cannabis-related holdings, ACT recognizes the staying power of alcohol and tobacco stocks.
This is why I have picked the AdvisorShares Vice ETF (NASDAQ:) for this year’s Best ETFs contest. Luckily for investors who are concerned about too much direct exposure to marijuana stocks, ACT’s top three holdings are bio-pharmaceutical healthcare and research companies that aren’t strictly based in pot. Still, the bulk of its tobacco stocks are tobacco companies with cannabis exposure, which make up 17.8% of the ETF’s sector allocation.
Furthermore, the success of ACT’s management team is reflected in the fact that despite the general pain in many marijuana and tobacco stocks this year, the ETF is up almost 16% year to date. For investors interested in an ETF that is solely focused on marijuana stocks there are other options like the AdvisorShares Pure Cannabis ETF (NYSEARCA:). As such, the ACT ETF is one of the best ETFs to consider now regardless of whether it ends up winning InvestorPlace.com’s ETF contest.
This year was a peculiar one for marijuana stocks. Furthermore, the success of ACT’s management team is reflected in the fact that despite the general pain in many marijuana and tobacco stocks this year, the ETF is up almost 16% year to date. As such, the ACT ETF is one of the best ETFs to consider now regardless of whether it ends up winning InvestorPlace.com’s ETF contest.
32850.0
2019-12-11 00:00:00 UTC
Health Care Sector Update for 12/11/2019: JNJ, PFE, ABT, MRK, AMGN, AQST, RCKT, MRNS
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-12-11-2019%3A-jnj-pfe-abt-mrk-amgn-aqst-rckt-mrns-2019-12-11
nan
nan
Top Health Care Stocks: JNJ: +0.16% PFE: +0.08% ABT: flat MRK: +0.45% AMGN: flat The top health care stocks were mostly gaining during pre-market trading Wednesday. Stocks moving on news include: (-) Aquestive Therapeutics (AQST), which fell more than 10% after announcing that it is planning to offer $35 million of common shares. (-) Rocket Pharmaceuticals (RCKT), which dropped 2% after pricing its underwritten public offering of 3.82 million common shares at $22.25 per share for gross proceeds of approximately $85 million. (+) Marinus Pharmaceuticals (MRNS), which gained more than 2%. The company said it plans to launch an underwritten public offering to sell shares of its common stock. The company also expects to concurrently commence a private placement to sell some shares of its convertible preferred stock worth not more than about $30 million to certain investors. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
ABT: flat AMGN: flat The top health care stocks were mostly gaining during pre-market trading Wednesday. Stocks moving on news include: (-) Aquestive Therapeutics (AQST), which fell more than 10% after announcing that it is planning to offer $35 million of common shares.
ABT: flat Top Health Care Stocks: (-) Rocket Pharmaceuticals (RCKT), which dropped 2% after pricing its underwritten public offering of 3.82 million common shares at $22.25 per share for gross proceeds of approximately $85 million.
ABT: flat AMGN: flat The top health care stocks were mostly gaining during pre-market trading Wednesday. Stocks moving on news include: (-) Aquestive Therapeutics (AQST), which fell more than 10% after announcing that it is planning to offer $35 million of common shares.
ABT: flat AMGN: flat The top health care stocks were mostly gaining during pre-market trading Wednesday. The company said it plans to launch an underwritten public offering to sell shares of its common stock.
32851.0
2019-12-11 00:00:00 UTC
How Does Boston Scientific’s Revenue And Other Key Metrics Compare With That of Medtronic?
ABT
https://www.nasdaq.com/articles/how-does-boston-scientifics-revenue-and-other-key-metrics-compare-with-that-of-medtronic
nan
nan
Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) are both engaged in the medical devices business. Medtronic generates 3x the revenue when compared to Boston Scientific. For both the companies, revenue over the past few years has been impacted by acquisitions. Also, both the companies generate over half of their revenues from the U.S. When it comes to profitability, Boston Scientific beats Medtronic on gross profit. In this note we compare both the companies’ revenues and other key metrics. You can look at our interactive dashboard analysis ~ Boston Scientific vs. Medtronic: How Have Revenues & Other Key Metrics Changed Over Recent Years? ~ for more details. Medtronic’s Revenues of $30 Billion Are Much Higher Than $10 Billion For Boston Scientific. Boston Scientific and Medtronic are both engaged primarily in the Medical Devices business. Boston Scientific’s revenues have grown from $7.4 billion in 2014 to $9.8 billion in 2018, led by its MedSurg business. Look at our interactive dashboard analysis for more details on Boston Scientific’s revenues. Medtronic’s revenues grew from $20.3 billion in fiscal 2015 to $30.6 billion in fiscal 2019. Look at our analysis on Medtronic’s revenues for more details. Medtronic’s Revenues Grew At A Higher Pace On Average When Compared To Boston Scientific. Both Boston Scientific and Medtronic saw growth in revenues in the recent years. And for both there was some impact of acquisitions in the sales growth. Boston Scientific’s revenue grew at a CAGR of 7.5% between 2014 and 2018, while the figure was 12.0% for Medtronic between fiscal 2015 and fiscal 2019. While Medtronic’s growth in fiscal 2016 was aided by the Covidien acquisition, Boston Scientific’s growth in 2016 was bolstered by AMS portfolio and Endochoice acquisition. US Accounts For Over Half of The Total Sales For Both The Companies. US accounted for 56% of total sales for Boston Scientific in 2018. For Medtronic, the figure stood at 53% in fiscal 2019. Gross Profit Margin For Boston Scientific Is Slightly Better Than That For Medtronic. Gross Profit Margin for Boston Scientific grew from 70.1% in 2014 to 71.4% in 2018. Medtronic’s Gross Profit Margin grew from 68.9% in fiscal 2015 to 70.0% in fiscal 2019. While Boston Scientific’s Adjusted Net Income Margin Has Been Trending Higher, It Is Slightly Below That of Medtronic. What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
You can look at our interactive dashboard analysis ~ Boston Scientific vs. Medtronic: How Have Revenues & Other Key Metrics Changed Over Recent Years? Medtronic’s Revenues Grew At A Higher Pace On Average When Compared To Boston Scientific. While Boston Scientific’s Adjusted Net Income Margin Has Been Trending Higher, It Is Slightly Below That of Medtronic.
Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) are both engaged in the medical devices business. You can look at our interactive dashboard analysis ~ Boston Scientific vs. Medtronic: How Have Revenues & Other Key Metrics Changed Over Recent Years? Gross Profit Margin for Boston Scientific grew from 70.1% in 2014 to 71.4% in 2018.
You can look at our interactive dashboard analysis ~ Boston Scientific vs. Medtronic: How Have Revenues & Other Key Metrics Changed Over Recent Years? Medtronic’s Revenues of $30 Billion Are Much Higher Than $10 Billion For Boston Scientific. Boston Scientific’s revenue grew at a CAGR of 7.5% between 2014 and 2018, while the figure was 12.0% for Medtronic between fiscal 2015 and fiscal 2019.
You can look at our interactive dashboard analysis ~ Boston Scientific vs. Medtronic: How Have Revenues & Other Key Metrics Changed Over Recent Years? Medtronic’s revenues grew from $20.3 billion in fiscal 2015 to $30.6 billion in fiscal 2019. Medtronic’s Gross Profit Margin grew from 68.9% in fiscal 2015 to 70.0% in fiscal 2019.
32852.0
2019-12-10 00:00:00 UTC
Health Care Sector Update for 12/10/2019: EQ, SUPN, SNY, JNJ, ABT, PFE, MRK, AMGN
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-12-10-2019%3A-eq-supn-sny-jnj-abt-pfe-mrk-amgn-2019-12-10
nan
nan
Top Health Care Stocks: JNJ: -0.19% PFE: -0.08% ABT: Flat MRK: -0.10% AMGN: Flat Health care majors were flat to lower pre-market Tuesday. Stocks moving on news include: (+) Equillium (EQ), which was up more than 18% after its investigational drug itolizumab for the treatment of lupus nephritis was given a Fast Track Designation by the US Food and Drug Administration. (+) Supernus Pharmaceuticals (SUPN) was gaining over 9% in value after saying it is currently in the process of preparing for the second phase 3 study it plans to conduct on SPN-810, a potential treatment for impulsive aggression in patients with attention deficit hyperactivity disorder. (+) Sanofi (SNY) was climbing by more than 4% after saying it will discontinue its diabetes and cardiovascular disease research programs as part of its efficiency initiative which aims to generate EUR2 billion ($2.21 billion) in savings by 2022. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
ABT: Flat Stocks moving on news include: (+) Equillium (EQ), which was up more than 18% after its investigational drug itolizumab for the treatment of lupus nephritis was given a Fast Track Designation by the US Food and Drug Administration. (+) Supernus Pharmaceuticals (SUPN) was gaining over 9% in value after saying it is currently in the process of preparing for the second phase 3 study it plans to conduct on SPN-810, a potential treatment for impulsive aggression in patients with attention deficit hyperactivity disorder.
ABT: Flat Top Health Care Stocks: AMGN: Flat Health care majors were flat to lower pre-market Tuesday.
ABT: Flat AMGN: Flat Health care majors were flat to lower pre-market Tuesday. Stocks moving on news include: (+) Equillium (EQ), which was up more than 18% after its investigational drug itolizumab for the treatment of lupus nephritis was given a Fast Track Designation by the US Food and Drug Administration.
ABT: Flat AMGN: Flat Health care majors were flat to lower pre-market Tuesday. Stocks moving on news include: (+) Equillium (EQ), which was up more than 18% after its investigational drug itolizumab for the treatment of lupus nephritis was given a Fast Track Designation by the US Food and Drug Administration.
32853.0
2019-12-10 00:00:00 UTC
Analysts See 11% Gains Ahead For FTXH
ABT
https://www.nasdaq.com/articles/analysts-see-11-gains-ahead-for-ftxh-2019-12-10
nan
nan
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $25.34 per unit. With FTXH trading at a recent price near $22.74 per unit, that means that analysts see 11.44% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Pacira BioSciences Inc (Symbol: PCRX), Alkermes plc (Symbol: ALKS), and Abbott Laboratories (Symbol: ABT). Although PCRX has traded at a recent price of $45.55/share, the average analyst target is 14.50% higher at $52.15/share. Similarly, ALKS has 14.08% upside from the recent share price of $21.74 if the average analyst target price of $24.80/share is reached, and analysts on average are expecting ABT to reach a target price of $93.80/share, which is 11.84% above the recent price of $83.87. Below is a twelve month price history chart comparing the stock performance of PCRX, ALKS, and ABT: Combined, PCRX, ALKS, and ABT represent 9.28% of the First Trust Nasdaq Pharmaceuticals ETF. Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Below is a twelve month price history chart comparing the stock performance of PCRX, ALKS, and ABT: Combined, PCRX, ALKS, and ABT represent 9.28% of the First Trust Nasdaq Pharmaceuticals ETF. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Pacira BioSciences Inc (Symbol: PCRX), Alkermes plc (Symbol: ALKS), and Abbott Laboratories (Symbol: ABT). Similarly, ALKS has 14.08% upside from the recent share price of $21.74 if the average analyst target price of $24.80/share is reached, and analysts on average are expecting ABT to reach a target price of $93.80/share, which is 11.84% above the recent price of $83.87.
Similarly, ALKS has 14.08% upside from the recent share price of $21.74 if the average analyst target price of $24.80/share is reached, and analysts on average are expecting ABT to reach a target price of $93.80/share, which is 11.84% above the recent price of $83.87. Below is a twelve month price history chart comparing the stock performance of PCRX, ALKS, and ABT: Combined, PCRX, ALKS, and ABT represent 9.28% of the First Trust Nasdaq Pharmaceuticals ETF. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Pacira BioSciences Inc (Symbol: PCRX), Alkermes plc (Symbol: ALKS), and Abbott Laboratories (Symbol: ABT).
Similarly, ALKS has 14.08% upside from the recent share price of $21.74 if the average analyst target price of $24.80/share is reached, and analysts on average are expecting ABT to reach a target price of $93.80/share, which is 11.84% above the recent price of $83.87. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Pacira BioSciences Inc (Symbol: PCRX), Alkermes plc (Symbol: ALKS), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of PCRX, ALKS, and ABT: Combined, PCRX, ALKS, and ABT represent 9.28% of the First Trust Nasdaq Pharmaceuticals ETF.
Below is a twelve month price history chart comparing the stock performance of PCRX, ALKS, and ABT: Combined, PCRX, ALKS, and ABT represent 9.28% of the First Trust Nasdaq Pharmaceuticals ETF. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Pacira BioSciences Inc (Symbol: PCRX), Alkermes plc (Symbol: ALKS), and Abbott Laboratories (Symbol: ABT). Similarly, ALKS has 14.08% upside from the recent share price of $21.74 if the average analyst target price of $24.80/share is reached, and analysts on average are expecting ABT to reach a target price of $93.80/share, which is 11.84% above the recent price of $83.87.
32854.0
2019-12-09 00:00:00 UTC
Health Care Sector Update for 12/09/2019: JNJ, PFE, ABT, MRK, AMGN, ARQL, THOR, MBIO, XBIT
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-12-09-2019%3A-jnj-pfe-abt-mrk-amgn-arql-thor-mbio-xbit-2019-12
nan
nan
Top Health Care Stocks: JNJ: -0.1% PFE: +0.1% ABT: -1.4% MRK: -0.3% AMGN: -0.4% Health care stocks were weaker broadly in midday trade, with the NYSE Health Care Index declining over 0.3% while the shares of health care companies in the S&P 500 also were down over 0.4% as a group. The Nasdaq Biotechnology index was a touch lower. Among health care stocks moving on news: (+) ArQule (ARQL) more than doubled after the biopharmaceutical company agreed to be acquired by Merck (MRK) for $20 per share in cash, implying a total equity value of about $2.7 billion. Merck was 0.3% softer. (+) Synthorx (THOR) was surging 170% after French drug giant Sanofi (SNY) said it has agreed to acquire all of the outstanding Synthorx shares for $68 per share in cash or approximately $2.5 billion. Sanofi was 1.7% lower. (+) XBiotech (XBIT) was gaining almost 80% amid an agreement to sell to Johnson & Johnson's (JNJ) Janssen Pharmaceutical subsidiary all the rights to bermekimab, which is being developed as a potential treatment for bowel cancer, for $750 million. (-) Mustang Bio (MBIO) was sliding almost 17% after an updated phase 1/2 trial data for MB-107 lentiviral gene therapy for X-linked severe combined immunodeficiency showing the drug was well tolerated by newly diagnosed infants but had a hematologic adverse event related to busulfan. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Among health care stocks moving on news: (+) ArQule (ARQL) more than doubled after the biopharmaceutical company agreed to be acquired by Merck (MRK) for $20 per share in cash, implying a total equity value of about $2.7 billion. (+) XBiotech (XBIT) was gaining almost 80% amid an agreement to sell to Johnson & Johnson's (JNJ) Janssen Pharmaceutical subsidiary all the rights to bermekimab, which is being developed as a potential treatment for bowel cancer, for $750 million. (-) Mustang Bio (MBIO) was sliding almost 17% after an updated phase 1/2 trial data for MB-107 lentiviral gene therapy for X-linked severe combined immunodeficiency showing the drug was well tolerated by newly diagnosed infants but had a hematologic adverse event related to busulfan.
Top Health Care Stocks: Health care stocks were weaker broadly in midday trade, with the NYSE Health Care Index declining over 0.3% while the shares of health care companies in the S&P 500 also were down over 0.4% as a group. Among health care stocks moving on news: (+) ArQule (ARQL) more than doubled after the biopharmaceutical company agreed to be acquired by Merck (MRK) for $20 per share in cash, implying a total equity value of about $2.7 billion.
Health care stocks were weaker broadly in midday trade, with the NYSE Health Care Index declining over 0.3% while the shares of health care companies in the S&P 500 also were down over 0.4% as a group. Among health care stocks moving on news: (+) ArQule (ARQL) more than doubled after the biopharmaceutical company agreed to be acquired by Merck (MRK) for $20 per share in cash, implying a total equity value of about $2.7 billion. (+) Synthorx (THOR) was surging 170% after French drug giant Sanofi (SNY) said it has agreed to acquire all of the outstanding Synthorx shares for $68 per share in cash or approximately $2.5 billion.
Among health care stocks moving on news: (+) ArQule (ARQL) more than doubled after the biopharmaceutical company agreed to be acquired by Merck (MRK) for $20 per share in cash, implying a total equity value of about $2.7 billion. Sanofi was 1.7% lower. (+) XBiotech (XBIT) was gaining almost 80% amid an agreement to sell to Johnson & Johnson's (JNJ) Janssen Pharmaceutical subsidiary all the rights to bermekimab, which is being developed as a potential treatment for bowel cancer, for $750 million.
32855.0
2019-12-08 00:00:00 UTC
Is Abbott Laboratories Stock a Buy?
ABT
https://www.nasdaq.com/articles/is-abbott-laboratories-stock-a-buy-2019-12-08
nan
nan
Some might look at Abbott Laboratories' (NYSE: ABT) year-to-date gain of 18% and rightly point out that it's well below the performance for the S&P 500 index. Others might note that Abbott has absolutely trounced the S&P over the past three years, soaring over 120% while the broader index is up a little over 40%. The main thing for investors to know, however, is that how well Abbott has performed in the past -- whether so far in 2019 or in recent years -- doesn't matter when trying to determine how the stock will do in the future. Is Abbott Labs stock a buy now? Here's how the healthcare giant grades in three key areas important to investors. Image source: Getty Images. Growth Two things primarily drive share price appreciation over the long run: revenue growth and earnings growth. Abbott Labs has consistently delivered both in recent years. The company posted year-over-year revenue growth of 5.5% in the third quarter of 2019. Abbott's Q3 adjusted earnings per share (EPS) jumped 12% over the prior-year period result. While neither of these numbers would be impressive for a small growth stock, they're pretty good for a company with a market cap topping $150 billion. More important, though, Abbott's growth prospects for the future look very good. Several products should fuel significant growth over the next few years, including Abbott's Alinity diagnostic systems, its HeartMate 3 left ventrical assist device, and its MitraClip device for treating mitral regurgitation. The biggest catalyst is likely to be the company's new version of its already-popular Freestyle Libre continuous glucose monitoring (CGM) system, which awaits FDA clearance. Abbott CEO Miles White said in the company's Q3 conference call that Abbott is "actively working through a handful of open items" with the FDA to obtain that highly anticipated clearance. Wall Street analysts project that Abbott Labs will increase its earnings by more than 11% on average annually over the next five years. Over the last five years, the company's earnings increased by an annual average of a little over 8%. Grade: B+. Dividend Abbott Labs' dividend currently yields north of 1.5%. That's not a bad yield, but some income-oriented investors could be looking for more. The good news with Abbott is that more is exactly what's probably in store. The company has paid a dividend every quarter without skipping a beat since 1924. Even more impressive, Abbott has increased its dividend 47 consecutive years, ranking it among the elite group of stocks known as Dividend Aristocrats. There's no reason whatsoever to think that Abbott's fantastic streak of hiking its dividend will come to a halt. As we've already seen, the company appears to be poised for solid earnings growth over the next few years. Even if earnings didn't increase as much as expected, Abbott's payout ratio of 67% gives the company flexibility to boost its dividend. Grade: A. Valuation Investors looking for value stocks won't find Abbott to be an ideal pick. Its shares currently trade at 46 times trailing 12-month earnings -- not exactly bargain territory. Abbott's growth prospects make its valuation look more attractive, though. The stock trades at a more palatable 24 times expected earnings. Perhaps the best way of assessing Abbott's valuation is to compare it against other big healthcare stocks with market caps of $100 billion or more. Abbott's shares trade at a higher forward earnings multiple than all of them. However, factoring in expected earnings growth over the next five years, Abbott's valuation ranks in the middle of the pack of the biggest healthcare stocks on the market. Grade: C. Overall score Your investing style will dictate how much weight each of these individual grades should receive in determining a composite score for Abbott Labs. I tend to focus first on growth, followed by dividend and, to a lesser extent, valuation. My overall score for Abbott Labs is a strong B that could easily be a B+. I think Abbott is an ideal stock for retired investors and others seeking to buy shares of a solid, well-run company that will keep the dividend checks flowing. For aggressive growth investors and big-time bargain hunters, there are other stocks to buy that will be a better fit than Abbott Labs. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Some might look at Abbott Laboratories' (NYSE: ABT) year-to-date gain of 18% and rightly point out that it's well below the performance for the S&P 500 index. The biggest catalyst is likely to be the company's new version of its already-popular Freestyle Libre continuous glucose monitoring (CGM) system, which awaits FDA clearance. However, factoring in expected earnings growth over the next five years, Abbott's valuation ranks in the middle of the pack of the biggest healthcare stocks on the market.
Some might look at Abbott Laboratories' (NYSE: ABT) year-to-date gain of 18% and rightly point out that it's well below the performance for the S&P 500 index. Growth Two things primarily drive share price appreciation over the long run: revenue growth and earnings growth. Over the last five years, the company's earnings increased by an annual average of a little over 8%.
Some might look at Abbott Laboratories' (NYSE: ABT) year-to-date gain of 18% and rightly point out that it's well below the performance for the S&P 500 index. However, factoring in expected earnings growth over the next five years, Abbott's valuation ranks in the middle of the pack of the biggest healthcare stocks on the market. I think Abbott is an ideal stock for retired investors and others seeking to buy shares of a solid, well-run company that will keep the dividend checks flowing.
Some might look at Abbott Laboratories' (NYSE: ABT) year-to-date gain of 18% and rightly point out that it's well below the performance for the S&P 500 index. Is Abbott Labs stock a buy now? Dividend Abbott Labs' dividend currently yields north of 1.5%.
32856.0
2019-12-06 00:00:00 UTC
Health Care Sector Update for 12/06/2019: JNJ, PFE, ABT, MRK, AMGN, CYAD, SAVA, CRIS
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-12-06-2019%3A-jnj-pfe-abt-mrk-amgn-cyad-sava-cris-2019-12-06
nan
nan
Top Health Care Stocks: JNJ: +0.64% PFE: +0.58% ABT: +0.43% MRK: +0.06% AMGN: +0.14% Health care stocks pared early gains but remained in positive territory in late Friday trade, with the NYSE Health Care Index advancing over 0.4% while the shares of health care companies in the S&P 500 also were up almost 0.7% as a group. The Nasdaq Biotechnology index was rising more than 1%. Among health care stocks moving on news: (+) Celyad (CYAD) was rising over 3% after the CAR-T cell therapies company secured EUR2.5 million ($2.8 million) in non-dilutive funding, taking the total from two donors to EUR11 million for this year. (+) Amgen (AMGN) was up 0.2% after receiving US Food and Drug Administration's approval for Avsola, a treatment for autoimmune diseases such as Crohn's disease and psoriatic arthritis to help stop inflammation. (+) Cassava Sciences (SAVA) was gaining 3% after additional data from a phase 2a study of PTI-125 showing its ability to slow down both neurodegen eration and neuroinflammation in patients. Separately, H.C. Wainwright raised its price target on Cassava to $6 from $3 and reaffirmed its buy rating. (-) Curis (CRIS) was over 13% weaker, even after reporting encouraging data from two drug trials. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(+) Cassava Sciences (SAVA) was gaining 3% after additional data from a phase 2a study of PTI-125 showing its ability to slow down both neurodegen eration and neuroinflammation in patients. Separately, H.C. Wainwright raised its price target on Cassava to $6 from $3 and reaffirmed its buy rating. (-) Curis (CRIS) was over 13% weaker, even after reporting encouraging data from two drug trials.
Top Health Care Stocks: Health care stocks pared early gains but remained in positive territory in late Friday trade, with the NYSE Health Care Index advancing over 0.4% while the shares of health care companies in the S&P 500 also were up almost 0.7% as a group. Among health care stocks moving on news: (+) Celyad (CYAD) was rising over 3% after the CAR-T cell therapies company secured EUR2.5 million ($2.8 million) in non-dilutive funding, taking the total from two donors to EUR11 million for this year.
Health care stocks pared early gains but remained in positive territory in late Friday trade, with the NYSE Health Care Index advancing over 0.4% while the shares of health care companies in the S&P 500 also were up almost 0.7% as a group. Among health care stocks moving on news: (+) Celyad (CYAD) was rising over 3% after the CAR-T cell therapies company secured EUR2.5 million ($2.8 million) in non-dilutive funding, taking the total from two donors to EUR11 million for this year. (+) Amgen (AMGN) was up 0.2% after receiving US Food and Drug Administration's approval for Avsola, a treatment for autoimmune diseases such as Crohn's disease and psoriatic arthritis to help stop inflammation.
Top Health Care Stocks: Health care stocks pared early gains but remained in positive territory in late Friday trade, with the NYSE Health Care Index advancing over 0.4% while the shares of health care companies in the S&P 500 also were up almost 0.7% as a group. The Nasdaq Biotechnology index was rising more than 1%.
32857.0
2019-12-06 00:00:00 UTC
Health Care Sector Update for 12/06/2019: JNJ, PFE, ABT, MRK, AMGN, CYAD, ONCY, RCKT, SAVA
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-12-06-2019%3A-jnj-pfe-abt-mrk-amgn-cyad-oncy-rckt-sava-2019-12
nan
nan
Top Health Care Stocks: JNJ: +1.00% PFE: +1.04% ABT: +0.60% MRK: +0.28% AMGN: +0.67% Health care stocks were gaining broadly, with the NYSE Health Care Index advancing over 0.7% while the shares of health care companies in the S&P 500 also were up almost 1% as a group. The Nasdaq Biotechnology index was rising more than 1%. Among health care stocks moving on news: (+) Celyad (CYAD) was rising 5% after the CAR-T cell therapies company secured EUR2.5 million ($2.8 million) in non-dilutive funding, taking the total from two donors to EUR11 million for this year. (+) Amgen (AMGN) was gaining 0.7% after receiving US Food and Drug Administration's approval for Avsola, a treatment for autoimmune diseases such as Crohn's disease and psoriatic arthritis to help stop inflammation. (+) Cassava Sciences (SAVA) was gaining 18% after additional data from a phase 2a study of PTI-125 showing its ability to slow down both neurodegeneration and neuroinflammation in patients. (+) Rocket Pharmaceuticals (RCKT) was surging more than 13% after saying it has treated the first patient in the phase 2 trial of RP-L102, a gene therapy for the treatment of Fanconi Anemia, a rare genetic disorder that affects the bone marrow The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(+) Amgen (AMGN) was gaining 0.7% after receiving US Food and Drug Administration's approval for Avsola, a treatment for autoimmune diseases such as Crohn's disease and psoriatic arthritis to help stop inflammation. (+) Cassava Sciences (SAVA) was gaining 18% after additional data from a phase 2a study of PTI-125 showing its ability to slow down both neurodegeneration and neuroinflammation in patients. (+) Rocket Pharmaceuticals (RCKT) was surging more than 13% after saying it has treated the first patient in the phase 2 trial of RP-L102, a gene therapy for the treatment of Fanconi Anemia, a rare genetic disorder that affects the bone marrow The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Top Health Care Stocks: Health care stocks were gaining broadly, with the NYSE Health Care Index advancing over 0.7% while the shares of health care companies in the S&P 500 also were up almost 1% as a group. Among health care stocks moving on news: (+) Celyad (CYAD) was rising 5% after the CAR-T cell therapies company secured EUR2.5 million ($2.8 million) in non-dilutive funding, taking the total from two donors to EUR11 million for this year.
Health care stocks were gaining broadly, with the NYSE Health Care Index advancing over 0.7% while the shares of health care companies in the S&P 500 also were up almost 1% as a group. Among health care stocks moving on news: (+) Celyad (CYAD) was rising 5% after the CAR-T cell therapies company secured EUR2.5 million ($2.8 million) in non-dilutive funding, taking the total from two donors to EUR11 million for this year. (+) Rocket Pharmaceuticals (RCKT) was surging more than 13% after saying it has treated the first patient in the phase 2 trial of RP-L102, a gene therapy for the treatment of Fanconi Anemia, a rare genetic disorder that affects the bone marrow The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Health care stocks were gaining broadly, with the NYSE Health Care Index advancing over 0.7% while the shares of health care companies in the S&P 500 also were up almost 1% as a group. The Nasdaq Biotechnology index was rising more than 1%. (+) Amgen (AMGN) was gaining 0.7% after receiving US Food and Drug Administration's approval for Avsola, a treatment for autoimmune diseases such as Crohn's disease and psoriatic arthritis to help stop inflammation.
32858.0
2019-12-05 00:00:00 UTC
Strong Q3 Results Drive Guardant's Stock 15% Higher In 20 Days
ABT
https://www.nasdaq.com/articles/strong-q3-results-drive-guardants-stock-15-higher-in-20-days-2019-12-05-0
nan
nan
Guardant Health (GH) offers non-invasive cancer diagnosis tests and is based out of the U.S. The company has seen its stock rally 15% since its Q3 results were announced. The company reported strong results in Q3 with sales growth coming in at $61 Mil – a 181% jump year-on-year. Earnings loss for the company also narrowed to -$0.14 per share – much better than the consensus estimate of -$0.37. Additionally, the company raised its revenue guidance for full-year 2019 to the $202-$207 Mil range from $180-$190 Mil. We step back from these recent swings to review Guardant Health’s performance over the last few years, as a context for what might come next. Our Interactive dashboard – Why has Guardant Health rallied by 15% in the last 20 days?, reviews the near term reasons and the big picture. The context for the last few years: A closer look At Guardant Health’s Total Revenues over the last few years and the outlook. Total Revenues for Guardant Health substantially increased from $49.8 Mil in 2017 to $90.6 Mil in 2018; an increase of 81.9%. (Increase is on account of higher volumes of Guardant360 Oncology Test) This compares with Total Revenues growth of 97.4% in 2017. (Increase is on account of higher volumes of Guardant360 Oncology Test) We expect Total Revenues growth to be 127.3% in 2019 (on account of approval for Liquid Biopsy Testing). A closer look At Guardant Health’s Total Expenses over the last few years and the outlook Total Expense for Guardant Health substantially increased from $133 Mil in 2017 to $175 Mil in 2018; an increase of 31.4%. This compares with Total Expense growth of 86.4% in 2017. We expect Total Expense growth to be 66.2% in 2019. How does Guardant Health’s Revenue Growth compare with rivals? For more information on how Guardant Health’s revenue growth compares with Alnylam Pharmaceuticals, Alkermes and Agios Pharmaceuticals, view our interactive dashboard analysis. How has Guardant Health’s EBT trended? LBT for Guardant Health increased marginally by 1.21% from $83.2 Mil in 2017 to $84.2 Mil in 2018. We expect LBT to increase by 0.5% to $84.2 Mil in 2019. How has Guardant Health’s Net Income and EPS trended? For more details about Guardant Health’s Net Income and EPS, view our interactive dashboard analysis. What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
We step back from these recent swings to review Guardant Health’s performance over the last few years, as a context for what might come next. Our Interactive dashboard – Why has Guardant Health rallied by 15% in the last 20 days?, reviews the near term reasons and the big picture. For more details about Guardant Health’s Net Income and EPS, view our interactive dashboard analysis.
(Increase is on account of higher volumes of Guardant360 Oncology Test) We expect Total Revenues growth to be 127.3% in 2019 (on account of approval for Liquid Biopsy Testing). For more information on how Guardant Health’s revenue growth compares with Alnylam Pharmaceuticals, Alkermes and Agios Pharmaceuticals, view our interactive dashboard analysis. For more details about Guardant Health’s Net Income and EPS, view our interactive dashboard analysis.
Total Revenues for Guardant Health substantially increased from $49.8 Mil in 2017 to $90.6 Mil in 2018; an increase of 81.9%. A closer look At Guardant Health’s Total Expenses over the last few years and the outlook Total Expense for Guardant Health substantially increased from $133 Mil in 2017 to $175 Mil in 2018; an increase of 31.4%. For more information on how Guardant Health’s revenue growth compares with Alnylam Pharmaceuticals, Alkermes and Agios Pharmaceuticals, view our interactive dashboard analysis.
Total Revenues for Guardant Health substantially increased from $49.8 Mil in 2017 to $90.6 Mil in 2018; an increase of 81.9%. A closer look At Guardant Health’s Total Expenses over the last few years and the outlook Total Expense for Guardant Health substantially increased from $133 Mil in 2017 to $175 Mil in 2018; an increase of 31.4%. For more details about Guardant Health’s Net Income and EPS, view our interactive dashboard analysis.
32859.0
2019-12-05 00:00:00 UTC
Noteworthy ETF Outflows: IUSG, BA, ABT, MDT
ABT
https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-iusg-ba-abt-mdt-2019-12-05
nan
nan
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $23.0 million dollar outflow -- that's a 0.3% decrease week over week (from 111,900,000 to 111,550,000). Among the largest underlying components of IUSG, in trading today Boeing Co. (Symbol: BA) is off about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.4%, and Medtronic PLC (Symbol: MDT) is lower by about 0.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $49.14 per share, with $66.45 as the 52 week high point — that compares with a last trade of $65.50. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Among the largest underlying components of IUSG, in trading today Boeing Co. (Symbol: BA) is off about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.4%, and Medtronic PLC (Symbol: MDT) is lower by about 0.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $49.14 per share, with $66.45 as the 52 week high point — that compares with a last trade of $65.50. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.
Among the largest underlying components of IUSG, in trading today Boeing Co. (Symbol: BA) is off about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.4%, and Medtronic PLC (Symbol: MDT) is lower by about 0.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $49.14 per share, with $66.45 as the 52 week high point — that compares with a last trade of $65.50. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed).
Among the largest underlying components of IUSG, in trading today Boeing Co. (Symbol: BA) is off about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.4%, and Medtronic PLC (Symbol: MDT) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $23.0 million dollar outflow -- that's a 0.3% decrease week over week (from 111,900,000 to 111,550,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $49.14 per share, with $66.45 as the 52 week high point — that compares with a last trade of $65.50.
Among the largest underlying components of IUSG, in trading today Boeing Co. (Symbol: BA) is off about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.4%, and Medtronic PLC (Symbol: MDT) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $23.0 million dollar outflow -- that's a 0.3% decrease week over week (from 111,900,000 to 111,550,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $49.14 per share, with $66.45 as the 52 week high point — that compares with a last trade of $65.50.
32860.0
2019-12-05 00:00:00 UTC
Strong Q3 Results Drive Guardant's Stock 15% Higher In 20 Days
ABT
https://www.nasdaq.com/articles/strong-q3-results-drive-guardants-stock-15-higher-in-20-days-2019-12-05
nan
nan
Guardant Health (GH) offers non-invasive cancer diagnosis tests and is based out of the U.S. The company has seen its stock rally 15% since its Q3 results were announced. The company reported strong results in Q3 with sales growth coming in at $61 Mil – a 181% jump year-on-year. Earnings loss for the company also narrowed to -$0.14 per share – much better than the consensus estimate of -$0.37. Additionally, the company raised its revenue guidance for full-year 2019 to the $202-$207 Mil range from $180-$190 Mil. We step back from these recent swings to review Guardant Health’s performance over the last few years, as a context for what might come next. Our Interactive dashboard – Why has Guardant Health rallied by 15% in the last 20 days?, reviews the near term reasons and the big picture. The context for the last few years: A closer look At Guardant Health’s Total Revenues over the last few years and the outlook. Total Revenues for Guardant Health substantially increased from $49.8 Mil in 2017 to $90.6 Mil in 2018; an increase of 81.9%. (Increase is on account of higher volumes of Guardant360 Oncology Test) This compares with Total Revenues growth of 97.4% in 2017. (Increase is on account of higher volumes of Guardant360 Oncology Test) We expect Total Revenues growth to be 127.3% in 2019 (on account of approval for Liquid Biopsy Testing). A closer look At Guardant Health’s Total Expenses over the last few years and the outlook Total Expense for Guardant Health substantially increased from $133 Mil in 2017 to $175 Mil in 2018; an increase of 31.4%. This compares with Total Expense growth of 86.4% in 2017. We expect Total Expense growth to be 66.2% in 2019. How does Guardant Health’s Revenue Growth compare with rivals? For more information on how Guardant Health’s revenue growth compares with Alnylam Pharmaceuticals, Alkermes and Agios Pharmaceuticals, view our interactive dashboard analysis. How has  Guardant Health’s EBT trended? LBT for Guardant Health increased marginally by 1.21% from $83.2 Mil in 2017 to $84.2 Mil in 2018. We expect LBT to increase by 0.5% to $84.2 Mil in 2019. How has Guardant Health’s Net Income and EPS trended? For more details about Guardant Health’s Net Income and EPS, view our interactive dashboard analysis. What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Our Interactive dashboard – Why has Guardant Health rallied by 15% in the last 20 days?, reviews the near term reasons and the big picture. For more details about Guardant Health’s Net Income and EPS, view our interactive dashboard analysis. See How it’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts?
(Increase is on account of higher volumes of Guardant360 Oncology Test) We expect Total Revenues growth to be 127.3% in 2019 (on account of approval for Liquid Biopsy Testing). For more information on how Guardant Health’s revenue growth compares with Alnylam Pharmaceuticals, Alkermes and Agios Pharmaceuticals, view our interactive dashboard analysis. For more details about Guardant Health’s Net Income and EPS, view our interactive dashboard analysis.
Total Revenues for Guardant Health substantially increased from $49.8 Mil in 2017 to $90.6 Mil in 2018; an increase of 81.9%. A closer look At Guardant Health’s Total Expenses over the last few years and the outlook Total Expense for Guardant Health substantially increased from $133 Mil in 2017 to $175 Mil in 2018; an increase of 31.4%. For more information on how Guardant Health’s revenue growth compares with Alnylam Pharmaceuticals, Alkermes and Agios Pharmaceuticals, view our interactive dashboard analysis.
Total Revenues for Guardant Health substantially increased from $49.8 Mil in 2017 to $90.6 Mil in 2018; an increase of 81.9%. A closer look At Guardant Health’s Total Expenses over the last few years and the outlook Total Expense for Guardant Health substantially increased from $133 Mil in 2017 to $175 Mil in 2018; an increase of 31.4%. For more details about Guardant Health’s Net Income and EPS, view our interactive dashboard analysis.
32861.0
2019-12-03 00:00:00 UTC
Medtronic Spending Less On Building, And More On Selling?
ABT
https://www.nasdaq.com/articles/medtronic-spending-less-on-building-and-more-on-selling-2019-12-04
nan
nan
Medtronic (NYSE:MDT) spends more money on selling, and less on building. In fact, the company’s selling, general & administrative expenses (SG&A) were 40% of its total expenditure in 2018. This compares with 35% of total expenses on cost of goods sold (COGS), and a mere 9% on research & development. This can be attributed to new product launches in recent years, for which the company incurred higher promotional expenses. Over the recent years, Medtronic has seen steady revenue and expenses growth. However, its total expenses as a percentage of revenue has largely declined. The jump in fiscal 2018 seen can be attributed to the tax reforms. In this note we discuss the key drivers of Medtronic’s total expenses. You can look at our interactive dashboard analysis ~ How Does Medtronic Spend Its Money? ~ for more details. Medtronic’s Total Expenses As Percentage of Revenue Has Declined In Recent Years Breaking Down Medtronic’s Total Expenses SG&A SG&A, or selling, general & administrative expenses, includes salary, benefit costs, professional and marketing fees, shipping and handling costs, advertising and product promotions, among others. It accounted for 40% of the company’s total expense in fiscal 2019. SG&A as % of revenue grew from 32.8% in fiscal 2016 to 34.1% in fiscal 2019. Trefis estimates the metric to grow further to 34.8% in fiscal 2021. The growth in the recent years can be attributed to higher spending on the company’s new products. COGS COGS or cost of goods sold accounted for 35% of the company’s total expense in fiscal 2019. COGS as % of revenue declined from 31.7% in fiscal 2016 to 30.0% in fiscal 2019. Trefis estimates the metric to hover around the 30% mark in the near term. R&D R&D, or research & development expenses, includes the costs of research on healthcare products, and their development, among other related expenses. It accounted for 9% of the company’s total expense in fiscal 2019. R&D as % of revenue have remained in the tight range of 7.4% to 7.7% in recent years. Trefis estimates the metric to see modest growth in the near term. Other Operating Expenses Other Operating Expenses accounted for 9% of the company’s total expenses in fiscal 2016. Other operating expenses as % of revenue have fluctuated in the recent years, and the figure stood at 7.8% in fiscal 2019. We expect the figure to see slight growth in the near term. Interest & Other Expenses Interest & Other Expense, which includes interest expense and investment income, among others, accounted for 4% of the company’s total expenses in fiscal 2019. Interest & Other Expense as % of revenue grew slightly from 3.3% in fiscal 2016 to 3.5% in fiscal 2019, and we estimate it to be around 3.9% in fiscal 2021. Income Taxes Income Taxes saw a sharp increase in fiscal 2018, due to the impact of the tax reform. The effective tax rate for Medtronic stood at 10.5% in fiscal 2019, and we estimate it to grow toward the 18% mark by fiscal 2021. What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In fact, the company’s selling, general & administrative expenses (SG&A) were 40% of its total expenditure in 2018. This compares with 35% of total expenses on cost of goods sold (COGS), and a mere 9% on research & development. This can be attributed to new product launches in recent years, for which the company incurred higher promotional expenses.
Medtronic’s Total Expenses As Percentage of Revenue Has Declined In Recent Years Breaking Down Medtronic’s Total Expenses Other Operating Expenses Other Operating Expenses accounted for 9% of the company’s total expenses in fiscal 2016. Interest & Other Expenses Interest & Other Expense, which includes interest expense and investment income, among others, accounted for 4% of the company’s total expenses in fiscal 2019.
Medtronic’s Total Expenses As Percentage of Revenue Has Declined In Recent Years Breaking Down Medtronic’s Total Expenses Other Operating Expenses Other Operating Expenses accounted for 9% of the company’s total expenses in fiscal 2016. Interest & Other Expenses Interest & Other Expense, which includes interest expense and investment income, among others, accounted for 4% of the company’s total expenses in fiscal 2019.
Medtronic’s Total Expenses As Percentage of Revenue Has Declined In Recent Years Breaking Down Medtronic’s Total Expenses It accounted for 40% of the company’s total expense in fiscal 2019. The growth in the recent years can be attributed to higher spending on the company’s new products.
32862.0
2019-12-03 00:00:00 UTC
Despite the Naysayers, AbbVie Keeps Marching On
ABT
https://www.nasdaq.com/articles/despite-the-naysayers-abbvie-keeps-marching-on-2019-12-03
nan
nan
AbbVie's (NYSE: ABBV) story in recent years is familiar to those who follow the pharmaceutical industry. The company's top-selling product (and the world's best-selling drug), Humira, helped catapult its shares upward after it split from Abbott Laboratories. However, with cheap biosimilars being introduced in Europe in late 2018, international sales of Humira are set to decline in the coming years. Further, since biosimilars will also be introduced in the U.S. market (Humira's largest market) by 2023, the future doesn't look particularly bright for this drug. These factors prompted AbbVie's shares to plunge by as much as 30% during the first half (or so) of the year. But the company has rebounded nicely since August, and its shares are almost at the same level they were at the beginning of the year. In short, despite many predicting the demise of AbbVie, the company is still alive and well. Here's why. AbbVie's third-quarter results AbbVie released its third-quarter earnings report on Nov. 1, and the company's results were solid. AbbVie's revenue of $8.4 billion improved 3% year over year and came in ahead of the consensus analyst estimates. The company's bottom line, too, was better than expected; its adjusted earnings per share (EPS) was $2.33, slightly higher than the $2.30 Wall Street was gearing up for. Sales of Humira declined slightly -- by 3.7% -- compared to the year-ago period, but that was despite the fact that revenue from AbbVie's top-selling product dropped by 33.5% internationally. In the U.S., Humira is maintaining its upward trajectory, increasing its sales by 9.7% year-over-year during the quarter. For now, the continued dominance of Humira in the U.S. is almost offsetting the decline of its sales in Europe, which is obviously good news for the company. Image Source: Getty Images. The Allergan deal isn't looking so bad AbbVie's acquisition of Allergan (NYSE: AGN) in June was criticized for two major reasons. First, the price AbbVie paid seemed steep: The $63 billion price tag was a 45% premium over Allergan's share price at the time of the deal. Second, Allergan had been suffering from an overreliance on one product line, namely its Botox business. But now that the dust has largely settled, it seems that AbbVie stands to benefit from this acquisition. In addition to its strong position in the immunology department thanks to Humira and newcomers Skyrizi and Rinvoq -- which have already racked up more than $100 million in sales after hitting the market earlier this year -- the company will inherit Allergan's products, including offerings in medical aesthetics, eye care, central nervous system (CNS), and gastroenterology. The days of AbbVie's reliance on Humira will be long gone, which at least partly explains the company's confidence in its decision to acquire Allergan. AbbVie CEO Richard Gonzalez said, "With the planned acquisition of Allergan, we will be adding highly valuable on-market assets with leadership positions across additional and attractive growth segments including significant new growth platforms in medical aesthetics and CNS." Better days ahead With the continued dominance of Humira in the U.S. and AbbVie's acquisition of Allergan -- which will give it access to a much wider portfolio of products -- the company will likely see much better days ahead. AbbVie's reputation as a strong dividend growth stock only sweetens the deal for investors. That is why, despite its struggles this year, it would be a mistake to ignore the big pharma company. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The company's top-selling product (and the world's best-selling drug), Humira, helped catapult its shares upward after it split from Abbott Laboratories. Sales of Humira declined slightly -- by 3.7% -- compared to the year-ago period, but that was despite the fact that revenue from AbbVie's top-selling product dropped by 33.5% internationally. In addition to its strong position in the immunology department thanks to Humira and newcomers Skyrizi and Rinvoq -- which have already racked up more than $100 million in sales after hitting the market earlier this year -- the company will inherit Allergan's products, including offerings in medical aesthetics, eye care, central nervous system (CNS), and gastroenterology.
AbbVie's third-quarter results AbbVie released its third-quarter earnings report on Nov. 1, and the company's results were solid. The Allergan deal isn't looking so bad AbbVie's acquisition of Allergan (NYSE: AGN) in June was criticized for two major reasons. Better days ahead With the continued dominance of Humira in the U.S. and AbbVie's acquisition of Allergan -- which will give it access to a much wider portfolio of products -- the company will likely see much better days ahead.
AbbVie's third-quarter results AbbVie released its third-quarter earnings report on Nov. 1, and the company's results were solid. In addition to its strong position in the immunology department thanks to Humira and newcomers Skyrizi and Rinvoq -- which have already racked up more than $100 million in sales after hitting the market earlier this year -- the company will inherit Allergan's products, including offerings in medical aesthetics, eye care, central nervous system (CNS), and gastroenterology. Better days ahead With the continued dominance of Humira in the U.S. and AbbVie's acquisition of Allergan -- which will give it access to a much wider portfolio of products -- the company will likely see much better days ahead.
Better days ahead With the continued dominance of Humira in the U.S. and AbbVie's acquisition of Allergan -- which will give it access to a much wider portfolio of products -- the company will likely see much better days ahead. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.
32863.0
2019-12-01 00:00:00 UTC
3 Stocks to Buy Ahead of the Next Market Crash
ABT
https://www.nasdaq.com/articles/3-stocks-to-buy-ahead-of-the-next-market-crash-2019-12-01
nan
nan
No one knows when the next market crash is coming. But pretty much everyone knows that another crash is bound to happen at some point. While we can't know the timing of a major market downturn, we can know the kinds of stocks that are best to own when one comes. Three great stocks to buy ahead of the next market crash are Abbott Laboratories (NYSE: ABT), Bristol-Myers Squibb (NYSE: BMY), and Dollar General (NYSE: DG). Here's what makes these stocks more crash-proof than most. Image source: Getty Images. 1. Abbott Labs Abbott Labs handled the big market crash of 2008 quite well with shares falling only a fraction of the overall market decline before quickly bouncing back. There's a good reason why that was the case: It's a blue-chip stock that doesn't have to worry about demand falling off for its products during rough patches. Investors also had confidence that Abbott would continue paying its attractive dividend just as it had done since 1924. It's been over 10 years since then, but while Abbott has changed during that time it's still in a great position to weather any storms that might come. The company has several strong businesses that sell products that are in demand regardless of what happens with the market or the overall economy. Abbott's biggest moneymaker is its medical devices segment. Sales are rising steadily for the business thanks in part to increased market adoption of its HeartMate 3 left ventricular assist device and MitraClip device for treating mitral regurgitation. The company's established pharmaceuticals and diagnostics business segments also continue to deliver solid growth. But Abbott's growth should soon kick into an even higher gear. The company awaits U.S. Food and Drug Administration (FDA) clearance of a new version of the Freestyle Libre continuous glucose monitoring (CGM) system. Longtime CEO Miles White, who plans to transition into the executive chairman role in March 2020, said in July that he thinks sales of $5 billion or more should be achievable with the new version of the company's popular CGM system. 2. Bristol-Myers Squibb Bristol-Myers Squibb (BMS) is another healthcare stock that navigated the last big market crash relatively well. Patients need prescription drugs whether the stock market is rising or falling. The company doesn't just have run-of-the-mill prescription drugs, though. Market researcher EvaluatePharma projects that two of Bristol-Myers Squibb's products, Eliquis and Opdivo, will rank No. 3 and No. 4, respectively, among the world's best-selling drugs by 2024. BMS now claims additional blockbuster drugs thanks to its acquisition of Celgene. The deal also provides BMS a pipeline that's full of potential winners, including multiple sclerosis drug ozanimod and cell therapies liso-cel and ide-cel. Ozanimod is expected to win FDA approval early next year with approvals for liso-cel and ide-cel not too far behind. While the Celgene acquisition should boost Bristol-Myers Squibb's growth prospects, its dividend program shouldn't be impacted by the deal. BMS' dividend currently yields a little under 3% and provides a bit of a cushion even if the stock should slip a little in the wake of a massive market downturn. 3. Dollar General Discount retail stocks also tend to perform well during a major market decline caused by an economic recession. Dollar General wasn't publicly traded during the big market crash of 2008, but it definitely appears to be a top stock to ride out a recession relatively unscathed. There are two big advantages for discount retailers during tough economic times. First, the companies market consumer staples that customers need in good times and bad times. Second, because of their bargain prices, customers are more likely to shop at discount retailers during economic downturns than they are during periods when the economy is strong. Dollar General ranks among the strongest discount retailers in the U.S. While many retailers have been shutting down stores, Dollar General continues to add new stores. It's also remodeling many of its existing stores in an effort to boost sales. The company has several key initiatives underway that could put it in an even stronger position. Dollar General is transitioning to an internal distribution of frozen and refrigerated goods, a move that will improve its profit margin. It has also launched customer self-checkout as well as improved the stocking process in its stores. I expect Dollar General to be a winner even if the stock market tanks. 10 stocks we like better than Bristol-Myers Squibb When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Bristol-Myers Squibb wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of Bristol-Myers Squibb and Dollar General. The Motley Fool owns shares of and recommends Bristol-Myers Squibb. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Three great stocks to buy ahead of the next market crash are Abbott Laboratories (NYSE: ABT), Bristol-Myers Squibb (NYSE: BMY), and Dollar General (NYSE: DG). The company awaits U.S. Food and Drug Administration (FDA) clearance of a new version of the Freestyle Libre continuous glucose monitoring (CGM) system. Longtime CEO Miles White, who plans to transition into the executive chairman role in March 2020, said in July that he thinks sales of $5 billion or more should be achievable with the new version of the company's popular CGM system.
Three great stocks to buy ahead of the next market crash are Abbott Laboratories (NYSE: ABT), Bristol-Myers Squibb (NYSE: BMY), and Dollar General (NYSE: DG). Abbott Labs Abbott Labs handled the big market crash of 2008 quite well with shares falling only a fraction of the overall market decline before quickly bouncing back. Dollar General Discount retail stocks also tend to perform well during a major market decline caused by an economic recession.
Three great stocks to buy ahead of the next market crash are Abbott Laboratories (NYSE: ABT), Bristol-Myers Squibb (NYSE: BMY), and Dollar General (NYSE: DG). Bristol-Myers Squibb Bristol-Myers Squibb (BMS) is another healthcare stock that navigated the last big market crash relatively well. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of Bristol-Myers Squibb and Dollar General.
Three great stocks to buy ahead of the next market crash are Abbott Laboratories (NYSE: ABT), Bristol-Myers Squibb (NYSE: BMY), and Dollar General (NYSE: DG). Bristol-Myers Squibb Bristol-Myers Squibb (BMS) is another healthcare stock that navigated the last big market crash relatively well. I expect Dollar General to be a winner even if the stock market tanks.
32864.0
2019-11-30 00:00:00 UTC
Better Buy: Abbott Laboratories vs. Johnson & Johnson
ABT
https://www.nasdaq.com/articles/better-buy%3A-abbott-laboratories-vs.-johnson-johnson-2019-11-30
nan
nan
Healthcare giants. Blue chip stocks. Long-time winners for investors. All of these are true for both Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ). In recent years, Abbott Labs has delivered significantly greater returns for investors than Johnson & Johnson has. But which of these stocks is the best pick for the future? Here's how Abbott and J&J stack up against each other. Image source: Getty Images. The case for Abbott Labs Abbott Labs has been a healthcare leader for more than 130 years. The company currently ranks No. 1 in multiple healthcare markets, including adult nutrition, blood and plasma screening, glucose monitoring, and point-of-care testing. Innovation has been the key to Abbott's impressive record of success.
All of these are true for both Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ). In recent years, Abbott Labs has delivered significantly greater returns for investors than Johnson & Johnson has. 1 in multiple healthcare markets, including adult nutrition, blood and plasma screening, glucose monitoring, and point-of-care testing.
All of these are true for both Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ). In recent years, Abbott Labs has delivered significantly greater returns for investors than Johnson & Johnson has. The case for Abbott Labs Abbott Labs has been a healthcare leader for more than 130 years.
All of these are true for both Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ). In recent years, Abbott Labs has delivered significantly greater returns for investors than Johnson & Johnson has. The case for Abbott Labs Abbott Labs has been a healthcare leader for more than 130 years.
All of these are true for both Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ). Blue chip stocks. In recent years, Abbott Labs has delivered significantly greater returns for investors than Johnson & Johnson has.
32865.0
2019-11-29 00:00:00 UTC
Health Care Sector Update for 11/29/2019: JNJ, PFE, ABT, MRK, AMGN, CANF, REGN, AZN
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-11-29-2019%3A-jnj-pfe-abt-mrk-amgn-canf-regn-azn-2019-11-29
nan
nan
Top Health Care Stocks: JNJ: +0.36% PFE: -0.05% ABT: Flat MRK: -0.62% AMGN: Flat The leading health care stocks were mixed during pre-market trading hours on Friday. Health care stocks moving on news include: (+) Can-Fite Biopharma Ltd (CANF), which rose more than 47% after reporting a net loss of $0.11 per share in the first nine months of 2019 compared with a loss of $0.08 per share a year ago. Revenue declined to $1.84 million from $3.53 million in the 2018 period. (-) AstraZeneca (AZN), which declined less than 1%. The company said the US Food and Drug Administration has accepted its supplemental biologics license application and granted priority review for Imfinzi, a lung cancer drug. In other sector news: (=) Regeneron (REGN) was flat after announcing that its Ebola virus drug REGN-EB3 has achieved among the highest survival rates among four treatments tested in a recent clinical study. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
ABT: Flat AMGN: Flat The leading health care stocks were mixed during pre-market trading hours on Friday. Health care stocks moving on news include: (+) Can-Fite Biopharma Ltd (CANF), which rose more than 47% after reporting a net loss of $0.11 per share in the first nine months of 2019 compared with a loss of $0.08 per share a year ago.
ABT: Flat Top Health Care Stocks: AMGN: Flat The leading health care stocks were mixed during pre-market trading hours on Friday.
ABT: Flat Health care stocks moving on news include: (+) Can-Fite Biopharma Ltd (CANF), which rose more than 47% after reporting a net loss of $0.11 per share in the first nine months of 2019 compared with a loss of $0.08 per share a year ago. Revenue declined to $1.84 million from $3.53 million in the 2018 period.
ABT: Flat Top Health Care Stocks: Revenue declined to $1.84 million from $3.53 million in the 2018 period.
32866.0
2019-11-27 00:00:00 UTC
Exclusive Interview: Livongo Health CEO on Chronic Illness, the U.S. Healthcare System, and Its Opportunity
ABT
https://www.nasdaq.com/articles/exclusive-interview%3A-livongo-health-ceo-on-chronic-illness-the-u.s.-healthcare-system-and
nan
nan
More than 147 million Americans have at least one chronic medical condition. Unfortunately, the U.S. healthcare system is not designed to provide these patients with the continual care that they need. This forces many of them to manage their condition on their own with limited guidance. Livongo Health (NASDAQ: LVGO) says it's on a mission "to empower people with chronic conditions to live better and healthier lives." The company created a platform that uses data science and technology to provide personalized coaching to patients in real-time. Livongo calls these interactions "health nudges," and it has the data to prove that they lead patients to make smarter health choices that drive behavior changes, improve clinical outcomes, and lower healthcare costs. Image source: Livongo Health. The company's revenues are growing at a triple-digit rate, and it's starting to attract the attention of growth investors. I was recently afforded the opportunity to interview Livongo's CEO Zane Burke to learn more about the company and the opportunity ahead. Below is a transcript from our conversation (which has been lightly edited for clarity). Brian Feroldi: I think I have a pretty good understanding of the company's founding. Your founder is named Glen Tullman and his son was diagnosed with diabetes years ago. Tullman was a very successful businessman who created Livongo to make it easier for people with chronic conditions to live a healthier life. Is that the gist? Zane Burke: The whole idea is, how do you help people live their healthiest life? How do we keep people out of the system? How do we create a platform that provides a great experience and helps our members stay healthy? And how do we create a great return on investment for our clients overall? Feroldi: Can you talk a little bit about your business model, your go-to market strategy. Are you guys focused on employers, payers, or do you go direct to consumers? CEO Zane Burke. Image source: Livongo Health. Burke: Our go-to market strategy is focused on Fortune 500 companies, large organizations that are self-funded and take on all of the risks without any regard to quality, what the experience is going to be like, or return on investment. That's really where we started. We have a number of very large clients already, over 20% of the Fortune 500 today. That has allowed us to move into the health plan market. Four of the seven largest health plans are resellers of our solutions. The two largest pharmacy benefits managers (PBMs) in the country are resellers of our solutions. And then we also sell to labor unions, governments, and health systems. That's the lineage of how we started. Today, we're exclusively in the U.S. Feroldi: Is your sales force focused on the employers, the payers, or the PBMs? And once they sign, how do you go get members on board? Burke: We sell to the client first, so whoever has the risk, and then we come back and enroll the members. Our clients only pay for members who we enroll and [who] stay engaged. So we are absolutely aligned with whoever has that financial risk, whether it's the employers or the health plan. We benefit when we get people enrolled and keep them engaged. And we do that by using data science at the core to enroll people in a personalized manner so we can learn about who they are and we can tailor our messages to them. We're pretty unique in our core solution of diabetes, where we get 34% enrollment across our book of business today. And that number continues to grow over time. And we only get paid on a per-participant/per-month model as we keep them engaged. Feroldi: It sounds like there is no financial risk for clients to sign up since they only pay if their members enroll. And then you have the data to prove that your model leads to better health and cost savings -- is that right? Burke: That's right. We're seeing in excess of 3x return on investment in our core diabetes solution in year one. And we've been able to validate that in multiple medical journals and third-party groups. You can really tell that the model is working because we're getting into the self-insured business. So, we've sold to big, self-insured employers. Now, the health plans are seeing the great clinical outcomes and the financial ROI, and they're putting it into their core product. That's really a huge win for us because my cost of sales goes down and my sales team could not effectively market to those members, but the health plans can. Feroldi: Can you just walk me through the consumer experience? When a new member says "yes," do they just download an app? Do you guys send them a free blood glucose meter? Are there any fees? Burke: We are very consumer-focused, starting with enrollment. We personalize the enrollment experience to encourage people to sign up and then once they sign up we send them a two-way cellular glucometer [and] strips for them to take their glucose readings. When they open the box, it's pre-configured; when they put the strip in, the machine automatically turns on, it already knows who they are, and they can immediately begin to utilize the solution. The consumer has no costs on their side from a device perspective or from a strip perspective, nor do they have those on an ongoing basis. Oftentimes, one of the big elements is that persons with diabetes have to pay for the strips that are necessary to manage their condition. We send the strips for free because we know when they're using the strips electronically through the two-way cellular connection. They can reorder directly off of the device. It creates a great consumer experience. There's a lot of thought that's gone into the design of all the pieces. We know that people will stick their finger and then wipe their blood on the neoprene. That may not be sound important, but it is super-important as it relates to a person with diabetes. Then we can help them make sure they have those strips with no co-pays. And in those moments when a member is outside the bounds, either too high or too low, we coach them every single time electronically. So every time they interact with us, we're using our data science to say "try this" to help nudge them electronically. At those moments when they need somebody on the other end, we have certified diabetes coaches monitoring what's going on. And for the first time in healthcare, there's somebody that's there when the consumer wants them to be there. That's what is so cool about our model. When that member has decided to prick their finger, or step on a weight scale, or put the blood pressure cuff on, at the moment of that health signal when the member is actually taking their health into their own hands, there's a real live human on the other end. They're electronically coached every time. And that's just totally different than the rest of healthcare, and that's what makes us really unique from a consumer-experience [standpoint]. I like to say, we meet the member in their life flow. The members also choose if it's a call or a text from a health coach. They get to choose and opt into that. It also depends on whatever their reading is, whether it's in the high range or low range. So with all the members, it's all in their hands. If they choose, they can use our app, cause sometimes people prefer that. Feroldi: But there is communication directly on the meter itself? The "health nudge" comes up on their glucometer screen? Burke: Yes, it's a two-way cellular [connection]. So they're getting the nudge in that moment when they're waiting for the reading to go to the cloud and get trended data. We've found that people are the most susceptible to coaching when they want to be coached. We use those two or three seconds while they are waiting for the reading to give them a little piece of advice, a little bit of knowledge. Feroldi: I worked for Insulet Corporation for 10 years as a field rep, so I know all about certified diabetes educators (CDEs) and I have a huge respect for them. I've also dealt with plenty of patients who have had co-pay problems with strips, so this model is intriguing. So you're saying that if I had diabetes and had a copay on my strips, if I become a Livongo member then my copay disappears because it's built into the per-member/per-month cost? Burke: Yes. It disappears. So that's an easy sell. It's a huge satisfier right out of the gate for members. And then we automatically ship the strips to the member because we know how many they've used because we're connected to the cloud. And those are free to them. It creates a better experience overall. Feroldi: That makes total sense. Do you have tie-in with doctors and healthcare providers to allow them to access that data? Burke: We do. We have relationships with the big electronic medical record providers if that's what the member wants to happen. They control it for themselves. The member can send it to their endocrinologist, or they could send a fax, or use the app. Feroldi: Got it. Making that process as simple as possible for providers is a big deal. Burke: What's fascinating is that we have a handful of clients where the experience and the outcomes are so good that they're paying for the insulin if the member uses Livongo. Feroldi: Wow. Burke: Because again, the clinical outcomes are so strong and the return is so good and people just love it. So we were actually seeing a number of clients who are going that route, and we're seeing the same thing on hypertension. Hypertension is really about medicine compliance. We have companies that say if the members are doing the test, if they'll take their blood pressure reading three times a month, then the company will cover the co-pay on their hypertension medications. Feroldi: And there's no cheating! Burke: That's right. There's no cheating. We know how they're doing. It's been really fun to just think about how this problem in a different way. Our return on investment comes from fewer emergency room visits and fewer outpatient visits. Over time, it turns into the really big ROI from fewer surgeries and fewer complications. But there's also an immediate return on investment. Feroldi: Can you explain your relationship with the Food and Drug Administration? Burke: We do have a relationship with the FDA. The devices are all certified and HIPAA compliant. We do have a responsibility from an FDA perspective to abide by their rules and regulations, and we do that. Feroldi: But as long as your CDEs are practicing within the guideline, that's alright? Burke: They're providing advice within their licensure. What I'm not doing is changing the medication or medication orders. We do hot referrals to providers in those instances. We have relationships with the two largest PBMs in the country -- one of those is CVS Health. If a member comes into a CVS pharmacy, we're so integrated at CVS that if that person is eligible, but hasn't yet received a kit, they can automatically receive a kit. We can also do a hot transfer to the pharmacist as part of our solution set. And that's kind of what we're doing with telehealth too. We made an announcement around behavioral health where we are actually integrating with partners at the behavioral health level. So from our electronic coaching piece, we're able to hand off those patients to a telehealth visit with a doctor. Feroldi: For outside investors, what are the metrics that we should pay attention to the most? Burke: We're a subscription model, so growth in our members is a really important metric. We just announced our revenues were up 148% year over year, and we're over 207,000 members, which was up 118% year over year. And our number of clients is up 121%. I'm really pleased with the short-term results. But more important is the long-term progress we're making. It's really about becoming a true platform for chronic condition management. That's the long-term piece for investors to watch. Our strategic march into other marketplaces such as government, and other conditions like hypertension and weight management. Those are just a handful of things that I think are really important future growth drivers for us. Feroldi: Your net loss was just $0.05 per share, or about $3 million, so peanuts in the grand scheme of things. Burke: Peanuts. Yup. We've been on a march to profitability. We've made a huge leap if you go from last year to this year. Our EBITDA margins were negative 40% last year and our guidance would take you to kind of the negative high teens this year. Even if you just even rounded to 20%, you're talking about a 20 [percentage] point increase in our march to profitability. I feel really good about that. Feroldi: I'm a fan of fast revenue growth and high margins, and you guys have both. Burke: Me too! That's what I love about healthcare. You can really root for companies, because if they're successful, they're usually doing something great. Feroldi: Can you talk briefly about the international opportunity? It doesn't exist right now, but is it on the horizon? Burke: Chronic conditions are not just a U.S.-specific challenge. We do not have any announced or definitive plans on going outside the U.S., but we'll continue to evaluate the timing for that. We're certainly not opportunity constrained. If you look at the rest of the executive team, it's a really deep team, kind of beyond the size of our company at this point. And that's on purpose since it will allow us to be more aggressive as we tackle additional conditions and additional geographies. That's something we're actively thinking about. Nothing to formally announce at this point in time. Feroldi: We are big believers in looking at corporate cultures since we believe that great places to work attract great employees. What makes you guys special? Burke: I'll tell you what makes us special: It's the mission. It's about our members. Almost every corporate interaction that we have is with one of our members. It reminds us why we're doing what we do. We're also reflective of the rest of the U.S. population, where one out of two adults has a chronic condition. Our associate base is very much a mirror of our membership. Two-thirds of our associate base will identify that they either personally have a chronic condition or that they have a loved one who has one of those conditions. It is really about that mission and vision. On the recruiting side, people will talk about how hard it is to recruit in Silicon Valley and other places, and yet we have not used any external hiring agencies. None. So we've grown over 50% on headcount, and we use zero outside agencies. And the reason for that is because the mission and the culture are so strong, and its a very accountable and self-policing culture. So people don't hire other people who are not going to be dedicated to the mission. It's incredibly diverse and inclusive. And I'll just say that I've never been associated with or known a company that's been like this. I'd love to say this was all made by me, but it's not. The culture was here before I got here. I certainly applaud it and love it. It just allows people to be who they are and bring their best self to work every day. It creates a really fun and energetic environment. Feroldi: Well, you guys get good ratings on Glassdoor.com, so it seems to be working. Burke: It's funny, I read negative reviews on Glassdoor because there's a kernel of truth in all those. I actually do read the comment box. Feroldi: I personally never invest in a company without checking out Glassdoor.com. I realize that it's not a perfect metric by any means and that it's a biased sample size, but it's usually directionally accurate. Burke: I agree. You've got to look at the good and the bad. Just like when you're checking out something on Amazon. You throw away the good, you throw away the bad, you kind of take the average. Feroldi: Is continuous glucose monitoring (CGM) a threat to you guys? I know that Dexcom and Abbott Laboratories are just crushing it right now. Burke: We love CGM because we love the data. What we do differently is we aggregate that data and use it to coach. And in fact, we have a relationship with Abbott, which makes the Freestyle Libre, and then informally, we take that data. We're big believers in the value of that data. Our president is a person with type 1 diabetes. She actually wears both devices. So she's a self-described nerdy doc who loves data. She would tell you that it's the coaching, it's the data science, and the fact that sometimes the darn thing falls off, or she just has an issue if she wants to wear a dress that night and she doesn't want something sticking out. She'll take a night off. She can use her glucometer instead. And when she's not using her Libre, she's using the Livongo app and still getting the coaching. So we love CGM. We think it's great. It's probably going to continue to be used by just a portion of people with diabetes who are able to utilize that technology. So even though they're doing really well and we want them to do better, the vast majority of people with diabetes will never be CGM users. 87% of people with diabetes are type 2 and 13% type 1. Feroldi: Can you comment on your customer concentration? Two of your partners accounted for 51% of revenue in Q2 2019. Burke: I talked about how we've co-opted the rest of the health ecosystem to become a force multiplier for Livongo. These partners and health plans that are resellers of our solutions have helped us grow in the marketplace significantly. We create relationships with each one of those clients, but it's not as if we're subject to being exclusive through any one channel. And what's really important is that even with that 51% with those two very large partners, there are multiple ways we could go to market if we had to, because we have relationships with almost all of the employee benefit planning consultants and many of the health plans as well. So there are multiple ways we can go to market if we had to, and we have a very good direct sales force. The two biggest partners we have are with the pharmacy benefit managers like CVS Health, where we are expanding our relationship. So if I look at it as the breadth of what we're doing, we're more and more of a strategic partner for them all the time. If you listen to their conference calls, they talked a lot about chronic condition management, and we're at the core of what they're doing in that space today. So I feel really good about the strategic value of that. But we do think about the case of having multiple entry points to a client such that we're not beholden to any one partner. Feroldi: Do you guys have any direct competition? Is there anybody that's doing what you're doing? Burke: Well, the biggest competitor we have today is inertia. When you think about it from a competitive standpoint, it's not as if hypertension or diabetes management or behavioral health are new challenges. But the problem is that disease management programs just haven't been effective enough. What we do is really bridge a gap between the healthcare system and the me-as-a-person programs. Today I have not seen anybody that has taken a whole-person approach to the problem. What we do have are a number of niche players in each market space, but on a platform basis, we don't have a direct competitor. Feroldi: One of the things that attracted me to you guys is that your ROI for new clients is very strong. You're also unique in the space with the idea of the real-time intervention. I know that diabetes is the main focus, but can you talk a little bit about hypertension, behavioral health, and...what's the third one? Burke: Weight management and prediabetes. If you think about it, diabetes is at the core, because if you have type 2 diabetes, you're 70% likely to have hypertension. You're also highly likely to have weight management challenges. If you have more than one of those conditions, the percentage odds that you actually have behavioral health [issues], anxiety, or depression goes up dramatically. Strategically, we're continuing to build our condition set for the whole person, but really starting with that diabetes at the core. You can almost pick the next couple of things that we'll go do because there are places where persons with diabetes have higher preponderance rates to those chronic conditions. The cool part is that it's architected to be at the person level, so we don't think about it as disease states. We were very purposeful about that in our language. If you hear me say the term "diabetic," it is a slip of my tongue. Because it's a person with diabetes, a person with hypertension, a person who has weight management challenges, or behavioral health challenges. We don't want to identify people as their disease. That is dehumanizing. And so we really do fundamentally believe in that whole-person strategy. So we're continuing to build out. We've had great success. We built hypertension from the ground up because there wasn't anything else that made sense. We built that into our platform stack. We do Amazon Alexa integration. So we're using the whole ecosystem to engage patients. We said in our recent investor call that 20% of our bookings in the third quarter of 2019 came from solutions outside of diabetes management. That was 500% growth year over year. So we've really built up a lot of trust from our existing clients because we've delivered great results. We're going to continue to build out those on a single platform that we call "AI AI" -- we call it our artificial intelligence engine. And that helps clients who want to buy. The marketplace doesn't want to have all these contracts that manage sleep deprivation, anxiety, and depression. I mean, behavioral health alone is in the teens and twenties of conditions, let alone diabetes management and hypertension and weight management. So our clients want one place to go. We want to offer that and our members want a single experience. And that's really the strategy and logic that we're using as we move forward. But we're seeing really good success, especially for the age of those solutions. Feroldi: I saw that your average prediabetes and weight management user sheds 7% of their body weight in the first year. That's impressive. Burke: It's pretty cool. I'm having so much fun. I was previously the president at Cerner, the big EMR (electronic medical record) company, and I had gotten to know Livongo early in the company's history. In 2014, I brought Livongo into Cerner so we could resell it to our clients and use it for our own associate population, mostly because I could just see this was the right mousetrap if you will. It's where I always thought the healthcare system would go, but it never did. I couldn't be having any more fun in terms of thinking about how to make this a very large-scale business with a huge addressable market. So we're talking billions upon billions of dollars market for our solution set. Burke: Makes complete sense. This has been incredibly informative. You have a very interesting business here. I'll probably be buying shares myself soon, even though you're trading at 19 times sales. That's pricing in a heck of a lot of growth! 10 stocks we like better than Livongo Health Inc When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Livongo Health Inc wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Brian Feroldi owns shares of Amazon. The Motley Fool owns shares of and recommends Amazon and Livongo Health Inc. The Motley Fool recommends Cerner, CVS Health, and Insulet. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Tullman was a very successful businessman who created Livongo to make it easier for people with chronic conditions to live a healthier life. Burke: Our go-to market strategy is focused on Fortune 500 companies, large organizations that are self-funded and take on all of the risks without any regard to quality, what the experience is going to be like, or return on investment. She would tell you that it's the coaching, it's the data science, and the fact that sometimes the darn thing falls off, or she just has an issue if she wants to wear a dress that night and she doesn't want something sticking out.
The company created a platform that uses data science and technology to provide personalized coaching to patients in real-time. Feroldi: We are big believers in looking at corporate cultures since we believe that great places to work attract great employees. Because it's a person with diabetes, a person with hypertension, a person who has weight management challenges, or behavioral health challenges.
Livongo calls these interactions "health nudges," and it has the data to prove that they lead patients to make smarter health choices that drive behavior changes, improve clinical outcomes, and lower healthcare costs. When that member has decided to prick their finger, or step on a weight scale, or put the blood pressure cuff on, at the moment of that health signal when the member is actually taking their health into their own hands, there's a real live human on the other end. Because it's a person with diabetes, a person with hypertension, a person who has weight management challenges, or behavioral health challenges.
The company created a platform that uses data science and technology to provide personalized coaching to patients in real-time. Strategically, we're continuing to build our condition set for the whole person, but really starting with that diabetes at the core. I couldn't be having any more fun in terms of thinking about how to make this a very large-scale business with a huge addressable market.
32867.0
2019-11-27 00:00:00 UTC
Health Care Sector Update for 11/27/2019: JNJ, PFE, ABT, MRK, AMGN, ARAV, TNXP, VRCA
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-11-27-2019%3A-jnj-pfe-abt-mrk-amgn-arav-tnxp-vrca-2019-11-27
nan
nan
Top Health Care Stocks: JNJ: -0.47% PFE: +0.21% ABT: flat MRK: +0.06% AMGN: flat Most of the biggest stocks in the health care sector were trading higher during pre-market hours on Wednesday. Among health care stocks moving on news: (-) Aravive (ARAV) retreated more than 19% after the biopharmaceutical company priced an underwritten public offering of its common shares at a discount. (+) Tonix Pharmaceuticals Holding (TNXP) rose more than 12% after announcing that the official minutes it received following a meeting with the US Food and Drug Administration for Tonmya for the treatment of posttraumatic stress disorder (PTSD) were consistent with the guidance from the meeting. (-) Verrica Pharmaceuticals Inc. (VRCA) was down 2% after reporting that the US Food and Drug Administration has accepted its New Drug Application for VP-102, a drug intended to treat molluscum contagiosum. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
ABT: flat AMGN: flat Most of the biggest stocks in the health care sector were trading higher during pre-market hours on Wednesday. Among health care stocks moving on news: (-) Aravive (ARAV) retreated more than 19% after the biopharmaceutical company priced an underwritten public offering of its common shares at a discount.
ABT: flat Top Health Care Stocks: Among health care stocks moving on news: (-) Aravive (ARAV) retreated more than 19% after the biopharmaceutical company priced an underwritten public offering of its common shares at a discount.
ABT: flat AMGN: flat Most of the biggest stocks in the health care sector were trading higher during pre-market hours on Wednesday. Among health care stocks moving on news: (-) Aravive (ARAV) retreated more than 19% after the biopharmaceutical company priced an underwritten public offering of its common shares at a discount.
ABT: flat Top Health Care Stocks: AMGN: flat Most of the biggest stocks in the health care sector were trading higher during pre-market hours on Wednesday.
32868.0
2019-11-26 00:00:00 UTC
Health Care Sector Update for 11/26/2019: JNJ, PFE, ABT, MRK, AMGN, CCXI, XFOR, SNOA
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-11-26-2019%3A-jnj-pfe-abt-mrk-amgn-ccxi-xfor-snoa-2019-11-26
nan
nan
Top Health Care Stocks JNJ: -0.45% PFE: -0.21% ABT: flat MRK: +0.35% AMGN: flat Leading health care stocks were mixed during pre-bell trading on Tuesday. Health care stocks moving on news include: (+) ChemoCentryx (CCXI), which gained more than 324%. The company, along with Vifor Fresenius Medical Care Renal Pharma, reported positive topline data from its phase III advocate trial of avacopan for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA vasculitis). (-) Sonoma Pharmaceuticals (SNOA), which fell more than 18% after launching a public offering of common shares on a best-efforts basis. (-) X4 Pharmaceuticals (XFOR), which retreated more than 9% after commencing an underwritten public offering of shares and Class B warrants to purchase its shares. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
ABT: flat AMGN: flat Leading health care stocks were mixed during pre-bell trading on Tuesday. The company, along with Vifor Fresenius Medical Care Renal Pharma, reported positive topline data from its phase III advocate trial of avacopan for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA vasculitis).
ABT: flat Top Health Care Stocks AMGN: flat Leading health care stocks were mixed during pre-bell trading on Tuesday.
ABT: flat AMGN: flat Leading health care stocks were mixed during pre-bell trading on Tuesday. The company, along with Vifor Fresenius Medical Care Renal Pharma, reported positive topline data from its phase III advocate trial of avacopan for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA vasculitis).
ABT: flat Top Health Care Stocks AMGN: flat Leading health care stocks were mixed during pre-bell trading on Tuesday.
32869.0
2019-11-25 00:00:00 UTC
Health Care Sector Update for 11/25/2019: JNJ, PFE, ABT, MRK, AMGN, SRNE, MDCO, NVS, ZIOP
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-11-25-2019%3A-jnj-pfe-abt-mrk-amgn-srne-mdco-nvs-ziop-2019-11
nan
nan
Top Health Care Stocks JNJ: -0.55% PFE: +0.37% ABT: +0.20% MRK: +0.18% AMGN: +0.33% The majority of the biggest stocks in the health care sector were trading higher during pre-market hours on Monday. Among health care stocks moving on news: (+) Medicines Company (MDCO), was up more than 22%, after it signed an agreement under which Swiss drug giant Novartis (NVS) will acquire the firm in a $9.7 billion deal. Novartis retreated 0.7% during pre-bell hours. (+) Sorrento Therapeutics (SRNE), which rose over 39% after it reported it received and rejected an unsolicited, all-cash acquisition proposal for between $3.00 and $5.00 per share. (+) Ziopharm Oncology (ZIOP) gained more than 4%. The company released new data from two ongoing trials of its Controlled IL-12 platform that show a decrease in tumors in adults with recurrent or progressive glioblastoma multiforme. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Among health care stocks moving on news: (+) Medicines Company (MDCO), was up more than 22%, after it signed an agreement under which Swiss drug giant Novartis (NVS) will acquire the firm in a $9.7 billion deal. (+) Sorrento Therapeutics (SRNE), which rose over 39% after it reported it received and rejected an unsolicited, all-cash acquisition proposal for between $3.00 and $5.00 per share. The company released new data from two ongoing trials of its Controlled IL-12 platform that show a decrease in tumors in adults with recurrent or progressive glioblastoma multiforme.
Top Health Care Stocks The majority of the biggest stocks in the health care sector were trading higher during pre-market hours on Monday. Among health care stocks moving on news: (+) Medicines Company (MDCO), was up more than 22%, after it signed an agreement under which Swiss drug giant Novartis (NVS) will acquire the firm in a $9.7 billion deal.
The majority of the biggest stocks in the health care sector were trading higher during pre-market hours on Monday. Among health care stocks moving on news: (+) Medicines Company (MDCO), was up more than 22%, after it signed an agreement under which Swiss drug giant Novartis (NVS) will acquire the firm in a $9.7 billion deal. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Top Health Care Stocks The majority of the biggest stocks in the health care sector were trading higher during pre-market hours on Monday. (+) Sorrento Therapeutics (SRNE), which rose over 39% after it reported it received and rejected an unsolicited, all-cash acquisition proposal for between $3.00 and $5.00 per share.
32870.0
2019-11-25 00:00:00 UTC
What’s Boston Scientific’s Fair Stock Price Estimate Based On Expected 2020 Earnings?
ABT
https://www.nasdaq.com/articles/whats-boston-scientifics-fair-stock-price-estimate-based-on-expected-2020-earnings-2019-11
nan
nan
Boston Scientific’s (NYSE:BSX) fair price estimate based on expected fiscal 2020 earnings is $44, according to Trefis estimates. This is slightly above the current market price of around $42. Boston Scientific is a healthcare company, which manufactures medical devices that are used primarily by various healthcare institutions in over 125 countries. Various hospitals, clinics, outpatient facilities, medical offices in around 100 countries in the U.S., Europe, Japan, and Asia Pacific use Boston Scientific’s devices. It competes with other medical devices companies, including Abbott Labs and Medtronic. In this note we discuss our stock price valuation for Boston Scientific. You can look at our interactive dashboard analysis ~ Boston Scientific Valuation: Expensive Or Cheap? ~ for more details. We Can Break Down Boston Scientific’s Stock Price Estimate Into 4 Factors: 1. Total Revenue, 2. Net Income Margin, 3. No. of Shares, And 4. P/E Multiple 1. Boston Scientific’s Total Revenues Could Grow In Low Double-Digits To $11.9 Billion In 2020. Look At Our Interactive Dashboard Analysis ~ BSX Revenues: How Does Boston Scientific Make Money? ~ For A More In Depth View On The Company’s Revenues. 1.1. Comparing Boston Scientific’s Revenue Growth With That of Its Peers. Boston Scientific’s revenues grew sharply in 2016, due to the AMS Portfolio and EndoChoice acquisition. Post 2016, the growth rate has been in high single-digits, trending upward. Abbott’s revenue growth jumped from low single-digits in 2015 and 2016 to 31% in 2017, due to St. Jude’s acquisition. It grew in double-digits in 2018, due to the Alere acquisition, and it is now expected to be in mid-single-digits going forward. See more on Abbott’s revenues. Medtronic’s revenue growth of 42% in fiscal 2016 reflects the impact of the Covidien acquisition. Post fiscal 2016, the growth rate has been expanding in low single-digits. See more on Medtronic’s revenues. 2. Boston Scientific’s Adjusted Net Income Has Seen Steady Growth Over The Past Few Years, And This Trend Could Continue In The Near Term. 3. Boston Scientific’s Adjusted EPS Grew 56% Between 2015 And 2018, And It Can Grow By 28% Between 2018-2020, According To Our Estimates. Boston Scientific’s Adjusted EPS grew from $0.94 in 2015 to $1.47 in 2018. We estimate it to be around $1.88 in 2020. This growth can largely be attributed to higher adjusted net income, as discussed in the previous section. 4. Our Price Estimate of $44 For Boston Scientific’s Stock Based On Our Detailed Valuation Model Implies A 23x Earnings Multiple On Expected 2020 Adjusted Earnings of $1.88 Per Share. 4.1 Comparing Boston Scientific’s Historical P/E With That of Its Peers P/E Multiples shown are based on the stock prices at the end of September of each year, and adjusted earnings for that full year (fiscal). Boston Scientific’s P/E multiple has historically been slightly higher than that of its peers. All three healthcare companies have seen multiple expansion in the recent years. Boston Scientific’s P/E multiple expanded from 19.4x in 2015 to 26.6x in 2019. This compares with Abbott, where the P/E expanded from 19.0x to 25.7x during the same period. And Medtronic’s P/E multiple expanded from 15.9x to 20.9x during the same period. What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Various hospitals, clinics, outpatient facilities, medical offices in around 100 countries in the U.S., Europe, Japan, and Asia Pacific use Boston Scientific’s devices. Boston Scientific’s Adjusted Net Income Has Seen Steady Growth Over The Past Few Years, And This Trend Could Continue In The Near Term. See How it’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts?
Boston Scientific’s (NYSE:BSX) fair price estimate based on expected fiscal 2020 earnings is $44, according to Trefis estimates. You can look at our interactive dashboard analysis ~ Boston Scientific Valuation: Expensive Or Cheap? Our Price Estimate of $44 For Boston Scientific’s Stock Based On Our Detailed Valuation Model Implies A 23x Earnings Multiple On Expected 2020 Adjusted Earnings of $1.88 Per Share.
Boston Scientific’s (NYSE:BSX) fair price estimate based on expected fiscal 2020 earnings is $44, according to Trefis estimates. Our Price Estimate of $44 For Boston Scientific’s Stock Based On Our Detailed Valuation Model Implies A 23x Earnings Multiple On Expected 2020 Adjusted Earnings of $1.88 Per Share. 4.1 Comparing Boston Scientific’s Historical P/E With That of Its Peers P/E Multiples shown are based on the stock prices at the end of September of each year, and adjusted earnings for that full year (fiscal).
Comparing Boston Scientific’s Revenue Growth With That of Its Peers. Our Price Estimate of $44 For Boston Scientific’s Stock Based On Our Detailed Valuation Model Implies A 23x Earnings Multiple On Expected 2020 Adjusted Earnings of $1.88 Per Share. 4.1 Comparing Boston Scientific’s Historical P/E With That of Its Peers P/E Multiples shown are based on the stock prices at the end of September of each year, and adjusted earnings for that full year (fiscal).
32871.0
2019-11-24 00:00:00 UTC
Better Buy: AbbVie vs. GlaxoSmithKline
ABT
https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-glaxosmithkline-2019-11-24
nan
nan
Big pharma stocks are a prized commodity among growth and income investors alike. The core reasons boil down to the fact that pharmaceuticals are an essential staple for millions of people, and the industry has been a hotbed of innovation over the past decade. Nonetheless, pharmaceutical stocks do have a serious dark side. Patent expirations for top-selling products, unexpected competition, clinical and regulatory setbacks, and political headwinds are just a few of the reasons behind the absolutely hair-raising level of volatility within this group of equities. Pharmaceutical stocks, in fact, have consistently been one of the most volatile cohorts within the entire market since the early 2000s. Image source: Getty Images. Which big pharma stocks are worth this gut-wrenching roller coaster ride? AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) are two of the industry's most trusted names among value, growth, and income investors, thanks to their top-flight product portfolios and generous dividend programs. Which of these pharma giants is the better buy right now? Let's dig deeper to find out. The case for AbbVie Illinois-based AbbVie began life in 2013. The drugmaker was originally spun off from healthcare giant Abbott Laboratories (NYSE: ABT) in a move designed to unlock the latent value in both underlying businesses. Post-split, Abbott became a medical products specialist, while AbbVie inherited the company's immunology-heavy pharmaceutical portfolio and pipeline. This strategic decision has proved to be a stroke of genius in many ways. Abbott and AbbVie have both gone on to produce market-crushing returns for shareholders over this period, as well as two of the most highly coveted dividend programs. Both companies, in fact, are included in the esteemed list of S&P 500 Dividend Aristocrats. Nonetheless, AbbVie was born with a hefty burden to bear -- namely, the eventual loss of exclusivity for top-selling immunology medicine Humira. Since 2013, Humira has gone on to become the world's best-selling medicine, raking in approximately $20 billion in global sales in 2018. The downside is that Humira's rapid growth has kept AbbVie from truly diversifying its revenue stream. Despite spending $21 billion to acquire the megablockbuster blood cancer drug Imbruvica in 2015 and organically developing multiple high-value drugs of its own over the years, Humira still makes up nearly 60% of the drugmaker's annual revenue stream. This year, AbbVie's management decided it was high-time to go all out to deal with its overreliance on Humira. To do so, the drugmaker joined forces with Botox maker Allergan (NYSE: AGN) in one of the largest mergers in biopharma history. Before this merger announcement, Allergan was in a tailspin because of a host of managerial missteps, combined with the negative impacts stemming from the battle over the patent expiration for eye medication Restasis. AbbVie, in turn, apparently saw Allergan's misfortunes as the perfect opportunity to deal with the Humira problem. The two companies are now set to consummate their merger in the first quarter of 2020. What's in store for this pharmaceutical supergiant in 2020 and beyond? The combined entity will sport best-in-class product portfolios in CNS, immunology, medical aesthetics, and women's health products. The flip side is that the new AbbVie will also happen to be one of the most highly leveraged biopharma companies in the world. To deal with this debt issue, AbbVie plans on using Humira's sizable revenue stream to delever as fast as possible. Fortunately, the drugmaker does have a solid three years before Humira loses exclusivity in the states, giving it a nice cushion to iron out the kinks. AbbVie also scored two major regulatory approvals in immunology this year with Skyrizi and Rinvoq, which should further this deleveraging effort in a big way. The case for Glaxo Glaxo, in its current iteration, is about to turn 19 years old next month. The British multinational pharmaceutical giant, however, is about to undergo a radical transformation that will see it split into a consumer healthcare business and a standalone pharmaceutical/vaccines company in the not-so-distant future. This forthcoming split is the result of Glaxo's consumer healthcare joint-venture with fellow pharma giant Pfizer (NYSE: PFE). What can investors expect from Glaxo's growth-oriented pharma and vaccines business in the next decade? Glaxo has had amazing success in the vaccine space of late, fueled by the skyrocketing sales of shingles vaccine Shingrix. However, Glaxo is still attempting to regain a foothold in the high-growth oncology arena. After selling off its oncology assets in 2014, Glaxo stormed back into the space with the $5.1 billion acquisition of Tesaro for the PARP inhibitor Zejula last year, and the company has also tacked on several high-value clinical candidates in oncology as well. Oncology, in turn, should prove to be a key component of the company's overall growth profile in the coming decade. Apart from vaccines and cancer meds, Glaxo's core respiratory franchise has also returned to its winning ways of late. Newer respiratory meds like Trelegy and Nucala have quickly come into their own as strong growth products, which has helped to offset the declines emanating from the former star asthma medication Advair. Glaxo's HIV joint venture ViiV Healthcare has been a surprising bright spot as well, even though it has had to compete against the 800-pound gorilla that is Gilead Sciences. Which stock the better buy? Although Glaxo has absolutely trounced AbbVie in terms of share price performance in 2019, this trend should flip in 2020, perhaps dramatically so. That's not to say Glaxo won't turn out to be a winning play next year, but AbbVie simply has more momentum heading into the new year. The back-to-back approvals of Skyrizi and Rinvoq -- in conjunction with this game-changing Allergan merger -- have markedly changed the sentiment around AbbVie's stock. Moreover, AbbVie's management has made a clear commitment to the company's dividend program, despite its junk bond-like yield of 5.46%. Glaxo's brain trust, on the other hand, hasn't made any long-term commitments in regard to maintaining -- much less growing -- the biopharma's enormous annualized yield of 4.4%. AbbVie, in kind, stands out as the more attractive income and growth play than Glaxo, although both stocks could easily end up beating the broader markets in 2020. 10 stocks we like better than GlaxoSmithKline When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and GlaxoSmithKline wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The drugmaker was originally spun off from healthcare giant Abbott Laboratories (NYSE: ABT) in a move designed to unlock the latent value in both underlying businesses. Patent expirations for top-selling products, unexpected competition, clinical and regulatory setbacks, and political headwinds are just a few of the reasons behind the absolutely hair-raising level of volatility within this group of equities. Before this merger announcement, Allergan was in a tailspin because of a host of managerial missteps, combined with the negative impacts stemming from the battle over the patent expiration for eye medication Restasis.
The drugmaker was originally spun off from healthcare giant Abbott Laboratories (NYSE: ABT) in a move designed to unlock the latent value in both underlying businesses. Nonetheless, AbbVie was born with a hefty burden to bear -- namely, the eventual loss of exclusivity for top-selling immunology medicine Humira. Apart from vaccines and cancer meds, Glaxo's core respiratory franchise has also returned to its winning ways of late.
The drugmaker was originally spun off from healthcare giant Abbott Laboratories (NYSE: ABT) in a move designed to unlock the latent value in both underlying businesses. AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) are two of the industry's most trusted names among value, growth, and income investors, thanks to their top-flight product portfolios and generous dividend programs. AbbVie, in kind, stands out as the more attractive income and growth play than Glaxo, although both stocks could easily end up beating the broader markets in 2020.
The drugmaker was originally spun off from healthcare giant Abbott Laboratories (NYSE: ABT) in a move designed to unlock the latent value in both underlying businesses. Nonetheless, pharmaceutical stocks do have a serious dark side. Which of these pharma giants is the better buy right now?
32872.0
2019-11-24 00:00:00 UTC
3 Dividend Stocks to Buy on Sale
ABT
https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-on-sale-2019-11-24
nan
nan
Major stock market indexes are hitting all-time highs. The current bull market is the longest one ever and is now in its 11th year. You might think it would be hard to find bargain stocks. And you probably think that it's even harder to find bargain dividend stocks. While most dividend stocks are relatively pricey, there are still some bargains to be found. Three dividend stocks that you can buy on sale right now are AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Verizon Communications (NYSE: VZ). Image source: Getty Images. 1. AbbVie If you're looking for a dividend stock with a fantastic pedigree, you'll love AbbVie. The company is a Dividend Aristocrat with 48 consecutive years of dividend increases, including its time as part of Abbott Labs. Since being spun off from Abbott in 2013, AbbVie has boosted its dividend payout by a whopping 168%. Its dividend yield now stands at 5.5%. AbbVie shares trade at a little over nine times expected earnings, well below the valuation of most big pharma stocks. It's cheap for a reason: Investors are worried about the company's prospects with its top-selling drug, Humira, facing biosimilar competition in Europe and biosimilars in the U.S. on the way in 2023. There's no question that declining sales for Humira present a problem to AbbVie. After all, the drug currently generates 58% of the company's total revenue. But I don't think AbbVie's dividend will be in jeopardy at all because of the company's strategy to reduce its dependence on Humira. A key part of that strategy is the launch of new drugs. AbbVie rolled out two immunology drugs this year, Rinvoq and Skyrizi, that should be huge blockbusters in the near future. The company also already has two cancer drugs with fast-growing sales, Imbruvica and Venclexta. In addition, AbbVie's pending acquisition of Allergan will make it significantly less reliant on Humira. While AbbVie will almost certainly face some bumps in the road over the next few years, its dividend payout should keep giving income-seeking investors a smooth ride. 2. Gilead Sciences Gilead Sciences admittedly doesn't have the impressive dividend track record of AbbVie. The big biotech didn't even initiate a dividend program until 2015. But Gilead has shown a solid commitment to paying dividends since then, increasing its payout by nearly 47% in just four years. Its dividend now yields nearly 3.9%. While many biotech stocks command premium valuations, Gilead's shares trade at close to 9 times expected earnings. The stock has been hammered over the last few years as sales for the company's hepatitis C virus (HCV) franchise declined. Gilead's HCV drugs cured so many patients that the market shrank. At the same time, competition increased, mainly from AbbVie. But Gilead continues to dominate the HIV market. Biktarvy appears to be on track to become the best-selling HIV drug of all time. The biotech is also achieving significant clinical progress with potential long-acting HIV therapy GS-6207, a drug that RBC Capital Markets analyst Brian Abrahams views as the future of Gilead's HIV franchise. Gilead is also expanding into new therapeutic areas. It hopes to win U.S. and European regulatory approval for filgotinib in treating rheumatoid arthritis. The biotech's pipeline includes drugs targeting nonalcoholic steatohepatitis, a liver disease with no approved treatments yet. Gilead remains the leader in cancer cell therapy as well with Yescarta picking up momentum. The company appears to be in a solid position to keep its attractive dividends flowing. 3. Verizon Communications Not every bargain dividend stock is in the healthcare space. Telecommunications giant Verizon has increased its dividend for 13 years in a row. Its dividend yield currently stands at 4.1%. Verizon isn't quite as cheap as AbbVie and Gilead, but its valuation still appears to be quite attractive. Shares trade at 12 times expected earnings. On another popular valuation metric, enterprise value-to-EBITDA (earnings before interest, taxes, depreciation, and amortization), Verizon is even cheaper than the two healthcare stocks and its chief rival, AT&T. The primary reason Verizon is priced at such a discount is the intense competition in the telecom industry. Verizon and its rivals are cutting prices to retain and attract customers. They're also competing by offering bundling deals with TV streaming services. For example, Verizon is bundling a one-year subscription to Disney's new Disney+ streaming service with its own unlimited wireless plans and certain other products. Despite the stiff competition, though, Verizon's dividend program shouldn't be fazed at all. The company also should have a new growth driver with the rollout of high-speed 5G networks. 10 stocks we like better than Verizon Communications When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Verizon Communications wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie, Gilead Sciences, and Walt Disney. The Motley Fool owns shares of and recommends Gilead Sciences and Walt Disney. The Motley Fool recommends Verizon Communications and recommends the following options: long January 2021 $60 calls on Walt Disney and short January 2020 $130 calls on Walt Disney. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
While many biotech stocks command premium valuations, Gilead's shares trade at close to 9 times expected earnings. On another popular valuation metric, enterprise value-to-EBITDA (earnings before interest, taxes, depreciation, and amortization), Verizon is even cheaper than the two healthcare stocks and its chief rival, AT&T. For example, Verizon is bundling a one-year subscription to Disney's new Disney+ streaming service with its own unlimited wireless plans and certain other products.
Three dividend stocks that you can buy on sale right now are AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Verizon Communications (NYSE: VZ). While many biotech stocks command premium valuations, Gilead's shares trade at close to 9 times expected earnings. The Motley Fool owns shares of and recommends Gilead Sciences and Walt Disney.
Three dividend stocks that you can buy on sale right now are AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Verizon Communications (NYSE: VZ). Gilead Sciences Gilead Sciences admittedly doesn't have the impressive dividend track record of AbbVie. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie, Gilead Sciences, and Walt Disney.
But I don't think AbbVie's dividend will be in jeopardy at all because of the company's strategy to reduce its dependence on Humira. At the same time, competition increased, mainly from AbbVie. Verizon isn't quite as cheap as AbbVie and Gilead, but its valuation still appears to be quite attractive.
32873.0
2019-11-22 00:00:00 UTC
Health Care Sector Update for 11/22/2019: JNJ, PFE, ABT, MRK, AMGN, SENS, ORGO, HSDT
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-11-22-2019%3A-jnj-pfe-abt-mrk-amgn-sens-orgo-hsdt-2019-11-22
nan
nan
Top Health Care Stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Leading health care stocks were flat during pre-market trading Friday. Among health care stocks moving on news: (-) Helius Medical Technologies (HSDT), which was down more than 32% after announcing an underwritten public offering of its class A common shares. (-) Organogenesis Holdings (ORGO), retreated more than 15% after pricing a public offering of 9 million class A common shares at $5.00 per share. (+) Senseonics Holdings (SENS), which gained more than 12%, after releasing positive data showing that the performance of its Eversense sensor over four sensor cycles is stable and does not decrease over time and there was no degradation of patient glucose outcomes over the four sensor cycles. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Top Health Care Stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Leading health care stocks were flat during pre-market trading Friday. Among health care stocks moving on news: (-) Helius Medical Technologies (HSDT), which was down more than 32% after announcing an underwritten public offering of its class A common shares. (-) Organogenesis Holdings (ORGO), retreated more than 15% after pricing a public offering of 9 million class A common shares at $5.00 per share.
Top Health Care Stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Leading health care stocks were flat during pre-market trading Friday. Among health care stocks moving on news: (-) Helius Medical Technologies (HSDT), which was down more than 32% after announcing an underwritten public offering of its class A common shares. (-) Organogenesis Holdings (ORGO), retreated more than 15% after pricing a public offering of 9 million class A common shares at $5.00 per share.
Top Health Care Stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Leading health care stocks were flat during pre-market trading Friday. (+) Senseonics Holdings (SENS), which gained more than 12%, after releasing positive data showing that the performance of its Eversense sensor over four sensor cycles is stable and does not decrease over time and there was no degradation of patient glucose outcomes over the four sensor cycles. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Top Health Care Stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Leading health care stocks were flat during pre-market trading Friday. Among health care stocks moving on news: (-) Helius Medical Technologies (HSDT), which was down more than 32% after announcing an underwritten public offering of its class A common shares. (-) Organogenesis Holdings (ORGO), retreated more than 15% after pricing a public offering of 9 million class A common shares at $5.00 per share.
32874.0
2019-11-21 00:00:00 UTC
January 2020 Options Now Available For Abbott Laboratories (ABT)
ABT
https://www.nasdaq.com/articles/january-2020-options-now-available-for-abbott-laboratories-abt-2019-11-21
nan
nan
Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the January 2020 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new January 2020 contracts and identified one put and one call contract of particular interest. The put contract at the $79.00 strike price has a current bid of 13 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $79.00, but will also collect the premium, putting the cost basis of the shares at $78.87 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $82.54/share today. Because the $79.00 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 73%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.16% return on the cash commitment, or 1.40% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $79.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $83.50 strike price has a current bid of 25 cents. If an investor was to purchase shares of ABT stock at the current price level of $82.54/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $83.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 1.47% if the stock gets called away at the January 2020 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $83.50 strike highlighted in red: Considering the fact that the $83.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 54%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.30% boost of extra return to the investor, or 2.57% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example is 40%, while the implied volatility in the call contract example is 34%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $82.54) to be 22%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com. Top YieldBoost Calls of Stocks Analysts Like » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $83.50 strike highlighted in red: Considering the fact that the $83.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the January 2020 expiration.
Below is a chart showing ABT's trailing twelve month trading history, with the $83.50 strike highlighted in red: Considering the fact that the $83.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the January 2020 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new January 2020 contracts and identified one put and one call contract of particular interest.
Below is a chart showing ABT's trailing twelve month trading history, with the $83.50 strike highlighted in red: Considering the fact that the $83.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the January 2020 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new January 2020 contracts and identified one put and one call contract of particular interest.
At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new January 2020 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABT's trailing twelve month trading history, with the $83.50 strike highlighted in red: Considering the fact that the $83.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the January 2020 expiration.
32875.0
2019-11-20 00:00:00 UTC
Why Is Insulet Stock Up More Than 15% Over The Last Month?
ABT
https://www.nasdaq.com/articles/why-is-insulet-stock-up-more-than-15-over-the-last-month-2019-11-21
nan
nan
Insulet (NASDAQ:PODD), a company best known for selling the Omnipod continuous insulin delivery system that caters to people with diabetes, has seen its stock price rally by close to 17% over the last month. There have been multiple factors driving the rally. Firstly, the company posted stronger than expected Q3 results earlier this month, with revenues growing by ~27% year-over-year to $192 million, beating estimates by almost $13 million, driven by strong sales of the Omnipod system. The company has had some favorable news on the regulatory front, gaining FDA approval for the use of Novo Nordisk’s Fiasp -a fast-acting mealtime insulin – with the Omnipod insulin management platform. Separately, in September, the FDA cleared the company’s ACE pump. This could help the company drive revenue growth. We ‘step back’ from these recent swings to review Insulet’s performance over the last few years, as a context for what might come next. Our Interactive dashboard, Why Has Insulet Stock Rallied Over The Last Month?, reviews the near term reasons and the big picture. The context for the last few years: A closer look At Insulet’s Total Revenues over the last few years and the outlook Total Revenues for Insulet significantly increased from $464 Mil in 2017 to $564 Mil in 2018; an increase of 21.6%. This compares with Total Revenues growth of: 14.1% in 2015 39.1% in 2016 26.4% in 2017 We expect Total Revenues growth to be 29.5% in 2019. A closer look At Insulet’s Total Expenses over the last few years and the outlook Total Expense for Insulet increased from $490 Mil in 2017 to $559 Mil in 2018; an increase of 13.9%. This compares with Total Expense growth of: 16.5% in 2015 21.1% in 2016 24.5% in 2017 We expect Total Expense growth to stand at 28% in 2019. How does Insulet’s Revenue Growth compare with Abbott and Tandem Diabetes Care? For more information on how Insulet’s revenue growth compares with rivals, view our interactive dashboard analysis. How has Insulet’s EBT trended? EBT for Insulet increased dramatically by -120% from -$26.6 Mil in 2017 to $5.23 Mil in 2018. We expect EBT to increase to $16.6 million in 2019. How has Insulet’s Net Income and EPS trended? For more information on Insulet’s Net Income and EPS, view our interactive dashboard analysis. What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Insulet (NASDAQ:PODD), a company best known for selling the Omnipod continuous insulin delivery system that caters to people with diabetes, has seen its stock price rally by close to 17% over the last month. Our Interactive dashboard, Why Has Insulet Stock Rallied Over The Last Month?, reviews the near term reasons and the big picture. See How it’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams More Trefis Data Like our charts?
A closer look At Insulet’s Total Expenses over the last few years and the outlook Total Expense for Insulet increased from $490 Mil in 2017 to $559 Mil in 2018; an increase of 13.9%. For more information on how Insulet’s revenue growth compares with rivals, view our interactive dashboard analysis. For more information on Insulet’s Net Income and EPS, view our interactive dashboard analysis.
The context for the last few years: A closer look At Insulet’s Total Revenues over the last few years and the outlook Total Revenues for Insulet significantly increased from $464 Mil in 2017 to $564 Mil in 2018; an increase of 21.6%. This compares with Total Revenues growth of: 14.1% in 2015 39.1% in 2016 26.4% in 2017 We expect Total Revenues growth to be 29.5% in 2019. A closer look At Insulet’s Total Expenses over the last few years and the outlook Total Expense for Insulet increased from $490 Mil in 2017 to $559 Mil in 2018; an increase of 13.9%.
This could help the company drive revenue growth. For more information on how Insulet’s revenue growth compares with rivals, view our interactive dashboard analysis. We expect EBT to increase to $16.6 million in 2019.
32876.0
2019-11-20 00:00:00 UTC
Health Care Sector Update for 11/20/2019: JNJ, PFE, ABT, MRK, AMGN, ALC, BCRX, CRSP
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-11-20-2019%3A-jnj-pfe-abt-mrk-amgn-alc-bcrx-crsp-2019-11-20
nan
nan
JNJ: +0.03% PFE: -0.29% ABT: -0.12% MRK: +0.28% AMGN: flat The majority of the leading health care stocks were higher during pre-market trading Wednesday. Among health care stocks moving on news: (-) CRISPR Therapeutics AG (CRSP) was down by more than 3% after it announced that it is commencing a public offering of 4.25 million common shares. (-) BioCryst Pharmaceuticals (BCRX) was down more than 1% after its shareholder Point72 Asset Management disclosed in a Schedule 13G filing with the Securities and Exchange Commission a 6% interest in the drug developer. (-) Alcon (ALC), which slid by about 3%. The company earlier reported revenue of $1.84 billion in the three months ended Sept. 30, up 4% year over year. This was also ahead of the consensus estimate of analysts polled by Capital IQ for $1.83 billion. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AMGN: flat The majority of the leading health care stocks were higher during pre-market trading Wednesday. Among health care stocks moving on news: (-) CRISPR Therapeutics AG (CRSP) was down by more than 3% after it announced that it is commencing a public offering of 4.25 million common shares. (-) BioCryst Pharmaceuticals (BCRX) was down more than 1% after its shareholder Point72 Asset Management disclosed in a Schedule 13G filing with the Securities and Exchange Commission a 6% interest in the drug developer.
AMGN: flat The majority of the leading health care stocks were higher during pre-market trading Wednesday. Among health care stocks moving on news: (-) CRISPR Therapeutics AG (CRSP) was down by more than 3% after it announced that it is commencing a public offering of 4.25 million common shares. The company earlier reported revenue of $1.84 billion in the three months ended Sept. 30, up 4% year over year.
Among health care stocks moving on news: (-) CRISPR Therapeutics AG (CRSP) was down by more than 3% after it announced that it is commencing a public offering of 4.25 million common shares. The company earlier reported revenue of $1.84 billion in the three months ended Sept. 30, up 4% year over year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AMGN: flat The majority of the leading health care stocks were higher during pre-market trading Wednesday. Among health care stocks moving on news: (-) CRISPR Therapeutics AG (CRSP) was down by more than 3% after it announced that it is commencing a public offering of 4.25 million common shares. (-) BioCryst Pharmaceuticals (BCRX) was down more than 1% after its shareholder Point72 Asset Management disclosed in a Schedule 13G filing with the Securities and Exchange Commission a 6% interest in the drug developer.
32877.0
2019-11-19 00:00:00 UTC
VTI, ABT, MDT, COST: ETF Inflow Alert
ABT
https://www.nasdaq.com/articles/vti-abt-mdt-cost%3A-etf-inflow-alert-2019-11-19
nan
nan
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.7 billion dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 809,865,889 to 827,190,339). Among the largest underlying components of VTI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Medtronic PLC (Symbol: MDT) is trading flat, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.6%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $119.35 per share, with $159.15 as the 52 week high point — that compares with a last trade of $158.62. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Among the largest underlying components of VTI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Medtronic PLC (Symbol: MDT) is trading flat, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.6%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $119.35 per share, with $159.15 as the 52 week high point — that compares with a last trade of $158.62. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.
Among the largest underlying components of VTI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Medtronic PLC (Symbol: MDT) is trading flat, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.6%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $119.35 per share, with $159.15 as the 52 week high point — that compares with a last trade of $158.62. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Among the largest underlying components of VTI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Medtronic PLC (Symbol: MDT) is trading flat, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.7 billion dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 809,865,889 to 827,190,339). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $119.35 per share, with $159.15 as the 52 week high point — that compares with a last trade of $158.62.
Among the largest underlying components of VTI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Medtronic PLC (Symbol: MDT) is trading flat, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.7 billion dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 809,865,889 to 827,190,339). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $119.35 per share, with $159.15 as the 52 week high point — that compares with a last trade of $158.62.
32878.0
2019-11-17 00:00:00 UTC
3 Dividend Aristocrats to Buy and Hold Forever
ABT
https://www.nasdaq.com/articles/3-dividend-aristocrats-to-buy-and-hold-forever-2019-11-17
nan
nan
You don't search for dividend stocks that require high maintenance. Investors prefer to buy set-and-forget kinds of stocks that pay solid dividends quarter after quarter. The less drama, the better. Dividend Aristocrats tend to meet these criteria. These are stocks that have not only paid out dividends regularly but also increased their dividends for at least 25 consecutive years. Here are three great Dividend Aristocrats that you can buy and hold forever. Image source: Getty Images. 1. Abbott Labs Abbott Labs (NYSE: ABT) has several healthcare irons in the fire. The company ranks as a top medical-device maker. It runs a huge diagnostics business. Abbott markets established pharmaceutical products, particularly in emerging markets. And it has a global nutrition products business. These varied businesses provide a consistent revenue stream for Abbott. That's enabled the company to boost its dividend for 47 years in a row. While you might not think Abbott's current dividend yield of a little over 1.5% is impressive, consistent annual dividend increases add up over time. What's especially appealing about buying Abbott Labs stock right now is that it's poised for tremendous growth. The company awaits U.S. Food and Drug Administration (FDA) clearance for a new version of its super-popular Freestyle Libre continuous glucose monitoring system. The new device is expected to be a massive commercial success for Abbott. The company also should enjoy strong sales growth from its Alinity line of diagnostics systems and its MitraClip mitral valve clip. Long-time Abbott CEO Miles White plans to transition to the role of Executive Chairman in March 2020. This shouldn't be a concern at all for investors, though. White will hand the reins over to Abbott's current president and COO Robert Ford, who has been with the company for 23 years and led the launch of Freestyle Libre. 2. Air Products and Chemicals If you're looking for a dividend stock that's on a roll, you'll probably love Air Products and Chemicals (NYSE: APD). Shares of the industrial giant have soared close to 50% so far in 2019. Air Products and Chemicals focuses primarily on marketing atmospheric gases used in industrial processes and equipment used for separation, storage, and transport of these gases. It's the world's largest supplier of hydrogen and ranks as a leader in supplying helium and in natural gas liquification. The company has increased its dividend for 37 consecutive years. Its dividend yield currently stands at just under 2%. Keeping the dividends flowing shouldn't be a problem, with Air Products' payout ratio at close to 58%. Perhaps the best reason to like Air Products is the management team's focus on generating long-term shareholder value. The company continually looks for ways to deploy capital more effectively and more profitably. Its performance this year reflects this shareholder-friendly strategy. 3. Chubb There's a great reason Warren Buffett likes the insurance business: It generates steady cash flow. While Buffett doesn't own Chubb (NYSE: CB), it's the kind of stock he'd probably love. Chubb is the largest publicly traded property and casual insurer in the world. It takes pride in its underwriting expertise and solid financial strength. The company's operations span across the globe, with nearly 40% of premiums coming from outside the United States. The company joined the Dividend Aristocrats club last year and notched its 26th consecutive year of dividend increases in 2019. Chubb's dividend yields nearly 2%. The company also boasts a low payout ratio of 37%. Is Chubb likely to deliver the kind of growth that some dividend stocks like Abbott Labs will? Probably not. But while property and casualty insurance isn't the most exciting business in the world, it's delivers a reliable stream of cash, especially when a company has the extensive industry track record Chubb has. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of Air Products and Chemicals and Chubb. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Abbott Labs Abbott Labs (NYSE: ABT) has several healthcare irons in the fire. The company awaits U.S. Food and Drug Administration (FDA) clearance for a new version of its super-popular Freestyle Libre continuous glucose monitoring system. White will hand the reins over to Abbott's current president and COO Robert Ford, who has been with the company for 23 years and led the launch of Freestyle Libre.
Abbott Labs Abbott Labs (NYSE: ABT) has several healthcare irons in the fire. Investors prefer to buy set-and-forget kinds of stocks that pay solid dividends quarter after quarter. Chubb There's a great reason Warren Buffett likes the insurance business: It generates steady cash flow.
Abbott Labs Abbott Labs (NYSE: ABT) has several healthcare irons in the fire. These are stocks that have not only paid out dividends regularly but also increased their dividends for at least 25 consecutive years. Air Products and Chemicals If you're looking for a dividend stock that's on a roll, you'll probably love Air Products and Chemicals (NYSE: APD).
Abbott Labs Abbott Labs (NYSE: ABT) has several healthcare irons in the fire. Keeping the dividends flowing shouldn't be a problem, with Air Products' payout ratio at close to 58%. The company joined the Dividend Aristocrats club last year and notched its 26th consecutive year of dividend increases in 2019.
32879.0
2019-11-17 00:00:00 UTC
Better Buy: Eli Lilly vs. AbbVie
ABT
https://www.nasdaq.com/articles/better-buy%3A-eli-lilly-vs.-abbvie-2019-11-17
nan
nan
Neither Eli Lilly (NYSE: LLY) nor AbbVie (NYSE: ABBV) has provided much for investors to get excited about so far in 2019. Both big pharma stocks are down by single-digit percentages year to date. But Lilly and AbbVie each hold the potential to deliver more attractive returns down the stretch. Which of these two stocks is the better pick for long-term investors? Here's how Lilly and AbbVie compare in several key areas. Image source: Getty Images. Current products Eli Lilly claims eight products with fast-growing sales. The company's top-selling drug, Trulicity, generated revenue of a little over $1 billion in the third quarter, up 24% year over year. Another diabetes drug, Jardiance, raked in nearly $241 million in Q3, a 44% jump from the prior-year period. Cancer drugs Cyramza and Verzenio saw sales soar 21% and 86%, respectively. A couple of newer products are also stepping up to the plate for Lilly. Third-quarter sales for rheumatoid arthritis drug Olumiant more than doubled from the prior-year period to nearly $115 million. Migraine drug Emgality, which the FDA approved in September 2018, delivered sales of close to $48 million in Q3. Lilly also has recently won FDA approval for another promising migraine drug, Reyvow. Lilly's immunology drug Taltz is another big winner, with sales jumping 29% year over year to $340 million in the third quarter. That increase disappointed some investors, though, who were expecting even stronger growth. Lilly's real problem areas, however, are with several of its older drugs. Sales continue to plunge for Cialis, while revenue from Humulin, Alimta, and Forteo slid by single-digit percentages in Q3. AbbVie continues to rely heavily on its powerhouse immunology drug Humira. Sales for the top-selling drug totaled over $4.9 billion in Q3, down 3.7% year over year because of biosimilar competition in Europe. Humira's sales will really plummet beginning in 2023, when biosimilars reach the U.S. market. But AbbVie has several other drugs that it thinks can more than offset the coming declines. Sales for cancer drug Imbruvica continue to soar, up 29% to a little over $1 billion in Q3. Another cancer drug, Venclexta, is generating even faster growth, with Q3 sales more than doubling year over year to $221 million. Market researcher EvaluatePharma ranked AbbVie's new immunology drugs, Rinvoq and Skyrizi, among the top five new drug launches of 2019. The drugs could together deliver peak annual sales topping $10 billion. AbbVie's pending acquisition of Allergan (NYSE: AGN) will bring several other major products into its lineup. The most important of these drugs is Botox, which saw sales rise 6% year over year in Q3 to nearly $929 million. AbbVie will also pick up fast-growing antipsychotic drug Vraylar and birth control pill Lo Loestrin in addition to several other Allergan products with significant sales. Pipeline Eli Lilly claims seven programs awaiting regulatory approval and 15 programs in late-stage clinical studies. The company also has 12 programs in phase 2 testing, with 25 programs in phase 1 studies. Several of Lilly's programs awaiting approval and in late-stage testing are seeking new indications for already-approved drugs. Two new drugs, though, especially stand out. Mirikizumab targets treatment of Crohn's disease, psoriasis, and ulcerative colitis. Tanezumab, which Lilly is developing with Pfizer, targets cancer pain, osteoarthritic pain, and chronic lower back pain. AbbVie has 16 late-stage programs. The company's pipeline also includes 12 phase 2 programs plus 22 phase 1 programs. The acquisition of Allergan would add another 12 late-stage programs and 15 phase 2 programs, along with at least five early stage programs. Like Eli Lilly, several of AbbVie's late-stage programs feature already-approved drugs that could pick up new indications, notably including Rinvoq, Skyrizi, and Venclexta. The company also has a promising new Parkinson's disease drug, ABBV-951, in late-stage testing. Dividend Lilly's dividend yield currently stands at nearly 2.3%. The company has increased its dividend payout in each of the last five years. AbbVie ranks as one of the most attractive dividend stocks on the market, with its dividend yielding nearly 5.5%. It has boosted its dividend for an impressive 47 years in a row, including the time it was part of Abbott Labs. Since being spun off from Abbott in 2013, AbbVie has increased its dividend by 195%. Valuation Eli Lilly stock currently trades at 17 times forward earnings. This is a significantly higher valuation than that of AbbVie, which trades at only nine times forward earnings. Better buy Growth investors can find better alternatives than either of these two pharma stocks. Most investors considering Lilly or AbbVie will probably primarily focus on the dividends. Based on this criterion, AbbVie is definitely the better pick. It's also the more attractive choice for value investors. I expect that Eli Lilly will deliver stronger growth over the next several years than AbbVie will, though. Lilly is already dealing with the impact of slumping sales for Cialis, while AbbVie has yet to face the toughest challenges for Humira. Over the longer term, however, I fully expect AbbVie will return to solid growth. The company's early and mid-stage pipeline looks very promising. I also suspect that the Allergan acquisition could prove to be a smarter move than many think. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AbbVie will also pick up fast-growing antipsychotic drug Vraylar and birth control pill Lo Loestrin in addition to several other Allergan products with significant sales. Like Eli Lilly, several of AbbVie's late-stage programs feature already-approved drugs that could pick up new indications, notably including Rinvoq, Skyrizi, and Venclexta. Lilly is already dealing with the impact of slumping sales for Cialis, while AbbVie has yet to face the toughest challenges for Humira.
Pipeline Eli Lilly claims seven programs awaiting regulatory approval and 15 programs in late-stage clinical studies. Like Eli Lilly, several of AbbVie's late-stage programs feature already-approved drugs that could pick up new indications, notably including Rinvoq, Skyrizi, and Venclexta. Valuation Eli Lilly stock currently trades at 17 times forward earnings.
Lilly's immunology drug Taltz is another big winner, with sales jumping 29% year over year to $340 million in the third quarter. Another cancer drug, Venclexta, is generating even faster growth, with Q3 sales more than doubling year over year to $221 million. Like Eli Lilly, several of AbbVie's late-stage programs feature already-approved drugs that could pick up new indications, notably including Rinvoq, Skyrizi, and Venclexta.
The company has increased its dividend payout in each of the last five years. AbbVie ranks as one of the most attractive dividend stocks on the market, with its dividend yielding nearly 5.5%. I expect that Eli Lilly will deliver stronger growth over the next several years than AbbVie will, though.
32880.0
2019-11-13 00:00:00 UTC
Abbott CEO Miles White To Step Down After Two Decades
ABT
https://www.nasdaq.com/articles/abbott-ceo-miles-white-to-step-down-after-two-decades-2019-11-13
nan
nan
(RTTNews) - Abbott Laboratories' (ABT) chief executive officer Miles White will step down on March 31, 2020, after 21 years at the helm of the diversified healthcare company. But, he will remain Executive Chairman of the Board. The company said it appointed Robert Ford, who currently serves as president and chief operating officer of the company, to succeed White as chief executive officer. Mr. Ford has been elected to the Abbott Board. The company stated that Mr. Ford will become the 13th CEO of Abbott in its 131-year history, all having been appointed from within the Company. Ford originally joined Abbott in the Company's Diabetes Care business in 1996. He was appointed President and Chief Operating Officer in October 2018. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories' (ABT) chief executive officer Miles White will step down on March 31, 2020, after 21 years at the helm of the diversified healthcare company. The company said it appointed Robert Ford, who currently serves as president and chief operating officer of the company, to succeed White as chief executive officer. Ford originally joined Abbott in the Company's Diabetes Care business in 1996.
(RTTNews) - Abbott Laboratories' (ABT) chief executive officer Miles White will step down on March 31, 2020, after 21 years at the helm of the diversified healthcare company. The company said it appointed Robert Ford, who currently serves as president and chief operating officer of the company, to succeed White as chief executive officer. He was appointed President and Chief Operating Officer in October 2018.
(RTTNews) - Abbott Laboratories' (ABT) chief executive officer Miles White will step down on March 31, 2020, after 21 years at the helm of the diversified healthcare company. The company said it appointed Robert Ford, who currently serves as president and chief operating officer of the company, to succeed White as chief executive officer. The company stated that Mr. Ford will become the 13th CEO of Abbott in its 131-year history, all having been appointed from within the Company.
(RTTNews) - Abbott Laboratories' (ABT) chief executive officer Miles White will step down on March 31, 2020, after 21 years at the helm of the diversified healthcare company. But, he will remain Executive Chairman of the Board. The company said it appointed Robert Ford, who currently serves as president and chief operating officer of the company, to succeed White as chief executive officer.
32881.0
2019-11-13 00:00:00 UTC
Why Does AbbVie Pay a Much Higher Dividend Than Its Peers?
ABT
https://www.nasdaq.com/articles/why-does-abbvie-pay-a-much-higher-dividend-than-its-peers-2019-11-13
nan
nan
AbbVie (NYSE: ABBV) is a major drug manufacturer best known for its product, Humira, which treats arthritis, Crohn's disease, and plaque psoriasis. At 5.02%, the company's dividend yield is by far the highest among its branded drug peers, with GlaxoSmithKline being the next highest at 4.19%, followed by Pfizer at 3.89%. While high dividend yields are great for investors who need income with minimal volatility, suspiciously high yields indicate that the market expects the dividend to fall or the stock to depreciate in the future. Is this a dividend stock to buy today? AbbVie will have to figure out how to replace Humira AbbVie holds patents in several countries for numerous applications for Humira, some of which have already begun to expire outside of the U.S. and will begin to expire domestically in 2023. Such a time frame is worrisome for investors because Humira provided 58% of the company's total revenue in the most recent quarter. Image Source: Getty Images Competition from generics is causing Humira's international revenue to decline year over year. This trend will continue as the patents expire over the next 15 years, with revenues dropping while legal and research and development expenses remain high. There are some prospective candidates in AbbVie's pipeline, such as Rinvoq, Imbruvica, Skyrizi, and Venclexta that may become blockbuster drugs. But it is always going to be difficult to replicate the financial success of a monster like Humira. A major acquisition is the other big piece of this story In June 2019, AbbVie announced an agreement to acquire Allergan (NYSE: AGN), maker of well-known Botox, for $63 billion. In the immediate aftermath, Allergan shares jumped 31%, while AbbVie fell 16%. The company cited scale, synergy, and a strong combined pipeline as the major motivating factors for the massive deal, with return on invested capital (ROIC) expected to exceed the cost of capital in the very first year following combination. Theoretically, those are attractive economics that should lead to profit accretion in the medium or long term, and the company is forecasting between 7% and 10% revenue growth in the years following the merger, which would be double or triple the industry average. Nonetheless, the market had some reservations with the merger at that price. AbbVie is paying a price-to-earnings multiple of nearly 50 to widen its pipeline, but it isn't acquiring any late-stage drugs that could approach the Humira level of financial returns. Some investors considered it a desperate move with substandard fundamentals. Moreover, AbbVie carries around $38 billion in debt and lease obligations and has negative net shareholder equity. AbbVie announced that it would issue $28 billion to fund the cash portion of the Allergan acquisition, which would be one of the largest corporate bond deals in history. Increasing financial leverage, along with fixed debt servicing obligations with an impending patent cliff approaching, is going to scare some investors. The combined entity will generate substantial free cash flow for the next few years, but the deal only makes sense if the new combined pipeline yields growth down the road and current forecasts don't instill much confidence that the company can replace Humira effectively in the near future. How long can the dividend be maintained? Management has been explicit about maintaining and growing the dividend, which has a strong history of increasing. However, since AbbVie's 2013 spinoff from Abbott Labs, the company has had Humira's incredible success to support that dividend growth. Growth from a more diversified base of drugs will be welcome, but several successful rollouts will be required to maintain the pace at the new scale. The dividend could be in jeopardy if revenue falters with this new capital structure. AbbVie could be a very interesting story for investors who are seeking a high dividend yield to offset anticipated market weakness in the next two to three years. If a recession and market decline are indeed imminent, reduced exposure to equity volatility will be a goal for many, with stable dividend payers becoming more attractive. This dividend is likely to remain strong until 2023, after which there are plenty of question marks. That could be a compelling timeline, depending on an investor's macro outlook. 10 stocks we like better than Allergan When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Allergan wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Ryan Patrick has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
A major acquisition is the other big piece of this story In June 2019, AbbVie announced an agreement to acquire Allergan (NYSE: AGN), maker of well-known Botox, for $63 billion. Theoretically, those are attractive economics that should lead to profit accretion in the medium or long term, and the company is forecasting between 7% and 10% revenue growth in the years following the merger, which would be double or triple the industry average. AbbVie is paying a price-to-earnings multiple of nearly 50 to widen its pipeline, but it isn't acquiring any late-stage drugs that could approach the Humira level of financial returns.
A major acquisition is the other big piece of this story In June 2019, AbbVie announced an agreement to acquire Allergan (NYSE: AGN), maker of well-known Botox, for $63 billion. The combined entity will generate substantial free cash flow for the next few years, but the deal only makes sense if the new combined pipeline yields growth down the road and current forecasts don't instill much confidence that the company can replace Humira effectively in the near future. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Ryan Patrick has no position in any of the stocks mentioned.
While high dividend yields are great for investors who need income with minimal volatility, suspiciously high yields indicate that the market expects the dividend to fall or the stock to depreciate in the future. AbbVie will have to figure out how to replace Humira AbbVie holds patents in several countries for numerous applications for Humira, some of which have already begun to expire outside of the U.S. and will begin to expire domestically in 2023. AbbVie could be a very interesting story for investors who are seeking a high dividend yield to offset anticipated market weakness in the next two to three years.
While high dividend yields are great for investors who need income with minimal volatility, suspiciously high yields indicate that the market expects the dividend to fall or the stock to depreciate in the future. AbbVie is paying a price-to-earnings multiple of nearly 50 to widen its pipeline, but it isn't acquiring any late-stage drugs that could approach the Humira level of financial returns. How long can the dividend be maintained?
32882.0
2019-11-11 00:00:00 UTC
3 Top Healthcare Stocks to Buy Right Now
ABT
https://www.nasdaq.com/articles/3-top-healthcare-stocks-to-buy-right-now-2019-11-11
nan
nan
As healthcare costs outpace the rise in inflation, the U.S. will soon spend about 20% of the gross domestic product on healthcare. Smart investors are eyeing key healthcare stocks set to outperform in the next year. Veeva Systems (NYSE: VEEV), AbbVie (NYSE: ABBV), and Novartis (NYSE: NVS) are three healthcare stocks worth considering for your stock portfolio. 1. Veeva Systems Veeva Systems makes cloud-based software for traditional drug companies and biotech companies. It helps pharma companies manage operations, sales, and comply with industry regulations. Its industry-specific application, Vault, has an addressable market of $5 billion. Revenue from Vault is expected to grow 40% annually and its 2019 estimated revenue is $550 million. The company reached profitability within three years, which speaks a lot about its fundamentals. Veeva has exceeded earnings expectations for the last five years, boasting an average revenue growth of 33%. It expects the annual revenue from Vault to surpass $1 billion at the end of January 2020. Source: Getty Images The sales are increasing fast and the gross profit margin on services sold is also improving. Total revenue for the second quarter increased 27% year over year to reach $266.9 million. The subscription services showed an increase of 28% year over year, hitting $217.3 million up from $169.6 million a year ago. Second-quarter net income showed a 58% increase year over year to $79.2 million. It is expected that global spending on digital transformation will grow into double digits for the future. Veeva's focus on the life sciences industry has helped it expand the relationships with customers despite competition in the industry. It's safe to say the company will have a high customer base in five years' time and the sales will continue to convert to high profits over time. Its forward P/E is 66.23 compared to the industry average P/E of 58.91. It carries a PEG ratio of 3.48, while the industry PEG ratio is more fairly valued at 2.85. These metrics clearly show the stock is trading at a premium, but investors who are willing to pay up for the price will be rewarded in the long-term. 2. AbbVie Abbvie was spun-off from Abbott Labs (NYSE: ABT) in 2013 and it has heavily relied on its legacy Humira drug, which treats arthritis, Crohn's disease, and psoriasis. AbbVie's stock fell nearly 50% from $123.21 in January 2018, reaching a new low of $62.98 in August 2019. However, the stock jumped after the company topped the third-quarter estimates and announced a hike in dividend, now trading at $82.01. Its dividend yield is 6.44% and it declared a $1.18 dividend for the quarter, a 10.3% increase from the prior dividend. AbbVie is diversifying away from Humira and is expected to launch about 20 new products by 2020. The company's immunology drugs, Skyrizi and Rinvoq recently received U.S. Food and Drug Administration approval. These drugs are being evaluated for Crohn's disease, ulcerative colitis, psoriatic arthritis, and atopic dermatitis. The company thinks Skyrizi could reach annual sales of $5 billion and Rinvoq could achieve yearly sales of $6.5 billion. If these revenues are achieved, the company should be able to offset the expected sales decline for Humira when it begins facing biosimilar competition. Humira sales fell by 3.7% to $4.94 billion. In June, the company announced its plan to acquire Allergan for $63 billion. Allergan specializes in Botox and this deal will give the company a product with high sales in aesthetics, which doesn't depend on insurance reimbursement. The company is confident that Botox will continue to drive sales in the coming quarters. AbbVie's total revenue rose to $8.48 billion, exceeding estimates of $8.38 billion. The company expects 2019 revenues to grow 2.5%, exceeding analyst estimates of $33.16 billion. The trailing P/E ratio of the company is 37.71 and forward P/E is 8.61. The company has strong growth prospects and its stock is selling at an attractive price. 3. Novartis Novartis is an impressive name in the healthcare industry. Considering its drug lineup, it's not surprising that investors are attracted to the stock. Its 10 revenue-producing drugs have seen a significant rise in the past quarter. Zolgensma offers a breakthrough treatment for a muscle disorder with a price tag of $2.1 million. It recorded sales of $160 million in the quarter, exceeding analysts' estimates. Another top-selling drug, Cosentyx, hit $937 million in quarterly revenue. The sales of Lucentis increased by 5% to reach $500 million. Further, the company released impressive clinical trial results for Kisqali, a breast cancer drug. When taken with another drug, Fulvestrant, the survival rates for patients shot up 58%. This drug could significantly increase the company's revenue over the next few years. Novartis' third-quarter results show a net income of $2 billion, with its sales hitting $12.2 billion driven by five drugs: Cosentyx generated sales of $937 million with high demand across several regions. Entresto generated sales of $430 million with a high demand in hospitals. Zolgensma generated sales of $160 million. Lutathera sales grew to $119 million. Piqray sales were $43 million. The company's free cash flow is $4 billion, compared to $3.2 billion in the previous year. The company has a strong future outlook considering the top drug lineup. The stock is currently trading at $86.46. It's not cheap, at a P/E of 17.17, but investors who are optimistic about its deal with Allergan would do well to buy today. Now is the time to buy Veeva Systems, AbbVie, and Novartis are three health stocks that can generate lucrative returns for investors in the long-run. 10 stocks we like better than Novartis When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Novartis wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Vandita Jadeja has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Veeva Systems. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AbbVie Abbvie was spun-off from Abbott Labs (NYSE: ABT) in 2013 and it has heavily relied on its legacy Humira drug, which treats arthritis, Crohn's disease, and psoriasis. Source: Getty Images The sales are increasing fast and the gross profit margin on services sold is also improving. Allergan specializes in Botox and this deal will give the company a product with high sales in aesthetics, which doesn't depend on insurance reimbursement.
AbbVie Abbvie was spun-off from Abbott Labs (NYSE: ABT) in 2013 and it has heavily relied on its legacy Humira drug, which treats arthritis, Crohn's disease, and psoriasis. The company thinks Skyrizi could reach annual sales of $5 billion and Rinvoq could achieve yearly sales of $6.5 billion. The company expects 2019 revenues to grow 2.5%, exceeding analyst estimates of $33.16 billion.
AbbVie Abbvie was spun-off from Abbott Labs (NYSE: ABT) in 2013 and it has heavily relied on its legacy Humira drug, which treats arthritis, Crohn's disease, and psoriasis. The subscription services showed an increase of 28% year over year, hitting $217.3 million up from $169.6 million a year ago. The company thinks Skyrizi could reach annual sales of $5 billion and Rinvoq could achieve yearly sales of $6.5 billion.
AbbVie Abbvie was spun-off from Abbott Labs (NYSE: ABT) in 2013 and it has heavily relied on its legacy Humira drug, which treats arthritis, Crohn's disease, and psoriasis. Total revenue for the second quarter increased 27% year over year to reach $266.9 million. This drug could significantly increase the company's revenue over the next few years.
32883.0
2019-11-11 00:00:00 UTC
5 Dividend Aristocrats Where Analysts See Capital Gains
ABT
https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2019-11-11
nan
nan
To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments. In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing. We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another. These five stocks are part of our full Dividend Aristocrats List. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing.
Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect.
Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect.
Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
32884.0
2019-11-08 00:00:00 UTC
IWV, WMT, ABT, COST: ETF Outflow Alert
ABT
https://www.nasdaq.com/articles/iwv-wmt-abt-cost%3A-etf-outflow-alert-2019-11-08
nan
nan
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $126.3 million dollar outflow -- that's a 1.3% decrease week over week (from 55,500,000 to 54,800,000). Among the largest underlying components of IWV, in trading today Walmart Inc (Symbol: WMT) is off about 0.4%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.8%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $137.4493 per share, with $181.11 as the 52 week high point — that compares with a last trade of $180.26. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Among the largest underlying components of IWV, in trading today Walmart Inc (Symbol: WMT) is off about 0.4%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.8%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $137.4493 per share, with $181.11 as the 52 week high point — that compares with a last trade of $180.26. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.
Among the largest underlying components of IWV, in trading today Walmart Inc (Symbol: WMT) is off about 0.4%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.8%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $137.4493 per share, with $181.11 as the 52 week high point — that compares with a last trade of $180.26. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed).
Among the largest underlying components of IWV, in trading today Walmart Inc (Symbol: WMT) is off about 0.4%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $126.3 million dollar outflow -- that's a 1.3% decrease week over week (from 55,500,000 to 54,800,000). For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $137.4493 per share, with $181.11 as the 52 week high point — that compares with a last trade of $180.26.
Among the largest underlying components of IWV, in trading today Walmart Inc (Symbol: WMT) is off about 0.4%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $126.3 million dollar outflow -- that's a 1.3% decrease week over week (from 55,500,000 to 54,800,000). For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $137.4493 per share, with $181.11 as the 52 week high point — that compares with a last trade of $180.26.
32885.0
2019-11-06 00:00:00 UTC
Abbott Identifies New Subtype Of HIV
ABT
https://www.nasdaq.com/articles/abbott-identifies-new-subtype-of-hiv-2019-11-06
nan
nan
(RTTNews) - Abbott (ABT) said that its scientists identified a new subtype of the human immunodeficiency virus or HIV, called HIV-1 Group M, subtype L. The discovery marked the first time a new subtype of HIV-1 has been identified since 2000. Abbott stated that the new findings show the role next-generation genome sequencing is playing in helping researchers stay one step ahead of mutating viruses and avoiding new pandemics. Group M viruses are responsible for the global pandemic, which can be traced back to the Democratic Republic of Congo (DRC) in Sub-Saharan Africa. Three cases must be discovered independently to determine whether an unusual virus is in fact a new HIV subtype. The first two samples of this subtype were discovered in DRC in the 1980s and the 1990s. The third, collected in 2001, was difficult to sequence at that time because of the amount of virus in the sample and the existing technology. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott (ABT) said that its scientists identified a new subtype of the human immunodeficiency virus or HIV, called HIV-1 Group M, subtype L. The discovery marked the first time a new subtype of HIV-1 has been identified since 2000. Abbott stated that the new findings show the role next-generation genome sequencing is playing in helping researchers stay one step ahead of mutating viruses and avoiding new pandemics. Group M viruses are responsible for the global pandemic, which can be traced back to the Democratic Republic of Congo (DRC) in Sub-Saharan Africa.
(RTTNews) - Abbott (ABT) said that its scientists identified a new subtype of the human immunodeficiency virus or HIV, called HIV-1 Group M, subtype L. The discovery marked the first time a new subtype of HIV-1 has been identified since 2000. Three cases must be discovered independently to determine whether an unusual virus is in fact a new HIV subtype. The first two samples of this subtype were discovered in DRC in the 1980s and the 1990s.
(RTTNews) - Abbott (ABT) said that its scientists identified a new subtype of the human immunodeficiency virus or HIV, called HIV-1 Group M, subtype L. The discovery marked the first time a new subtype of HIV-1 has been identified since 2000. Abbott stated that the new findings show the role next-generation genome sequencing is playing in helping researchers stay one step ahead of mutating viruses and avoiding new pandemics. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott (ABT) said that its scientists identified a new subtype of the human immunodeficiency virus or HIV, called HIV-1 Group M, subtype L. The discovery marked the first time a new subtype of HIV-1 has been identified since 2000. Abbott stated that the new findings show the role next-generation genome sequencing is playing in helping researchers stay one step ahead of mutating viruses and avoiding new pandemics. The first two samples of this subtype were discovered in DRC in the 1980s and the 1990s.
32886.0
2019-11-02 00:00:00 UTC
3 Most Important Takeaways From AbbVie's Q3 Results
ABT
https://www.nasdaq.com/articles/3-most-important-takeaways-from-abbvies-q3-results-2019-11-02
nan
nan
AbbVie (NYSE: ABBV) has kind of been the Rodney Dangerfield of big pharma stocks. To paraphrase the late comedian's famous punch line: It don't get no respect. But AbbVie just might be getting some grudging respect from investors after the company announced its third-quarter results on Friday. While those results weren't what anyone would call spectacular, there was plenty to like. Here are the three most important takeaways from AbbVie's Q3 results. Image source: Getty Images. 1. Better than expected The three words that investors like to hear the most when a company reports quarterly results are "better than expected." And AbbVie delivered this welcome phrase in three different ways with its Q3 update. Wall Street analysts projected that the drugmaker would report Q3 revenue of $8.38 billion. AbbVie's actual revenue figure came in at $8.48 billion. Analysts thought the company's adjusted earnings per share (EPS) would be close to $2.30. Again, AbbVie announced better-than-expected results, with Q3 adjusted EPS of $2.33. In addition to posting upside surprises on its top and bottom lines, AbbVie upped its full-year 2019 guidance. The company now expects adjusted EPS to be between $8.90 and $8.92, narrowing the previous outlook of between $8.82 and $8.92. The midpoint of this revised range is a little higher than the consensus analysts' full-year EPS estimate of $8.90 -- again, better than expected. 2. Humira is still a key growth driver Investors have been especially worried about AbbVie's prospects now that Humira faces biosimilar competition in Europe. Sales for the company's top-selling drug have fallen as a result of the new dynamics for Humira. The trend continued in the third quarter. But while Humira is struggling in European markets, it's performing quite well in the U.S. AbbVie announced U.S. sales for Humira increased by 9.6% in the third quarter from the prior-year period. Overall sales for Humira slipped 3.7% year over year, to $4.9 billion. But the sustained momentum for Humira in the U.S. means that the drug is still a key growth driver for AbbVie. The higher sales for the drug in the U.S. market translated to more than $370 million added to AbbVie's top line. AbbVie's overall year-over-year revenue gain was $243 million. Without Humira's U.S. performance, AbbVie's overall revenue would have declined. 3. Multiple big winners stepping up Perhaps the best news for AbbVie in Q3 was that several drugs are generating impressive growth. Unsurprisingly, Imbruvica was one of the top stars, with sales soaring 29.3% year over year to nearly $1.3 billion. Sales for AbbVie's other blood cancer drug, Venclexta, more than doubled, to $221 million. The company's new immunology drug Skyrizi picked up momentum, with sales rising to $91 million from $48 million in the previous quarter. Rinvoq, which won Food and Drug Administration (FDA) approval in August, achieved sales of $14 million in its first few weeks on the market. The two drugs are both expected to be huge blockbusters in the near future. AbbVie also received some help from several of its other drugs that don't usually get as much attention these days. Sales for pancreatic enzyme replacement therapy Creon jumped 11.2% year over year, to $265 million. Respiratory syncytial virus (RSV) drug Synagis raked in $132 million in Q3, up 36.2% over the prior-year period. AbbVie announced that Q3 sales for Parkinson's disease drug Duodopa rose 11.3%, to $117 million. However, the company had some not-so-bright spots with its lineup. In particular, combined sales for its hepatitis C virus (HCV) drugs Mavyret and Viekira dropped 19% from the prior-year period, to $698 million. More good news In addition to its solid third-quarter results, AbbVie also announced more good news on Friday. The company's board approved a dividend increase of 10.3%. This latest increase brings the company's cumulative dividend hikes since being spun off in 2013 to 195%. AbbVie already ranked as one of the most attractive dividend stocks on the market; now it will be even more attractive. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In addition to posting upside surprises on its top and bottom lines, AbbVie upped its full-year 2019 guidance. Rinvoq, which won Food and Drug Administration (FDA) approval in August, achieved sales of $14 million in its first few weeks on the market. In particular, combined sales for its hepatitis C virus (HCV) drugs Mavyret and Viekira dropped 19% from the prior-year period, to $698 million.
But AbbVie just might be getting some grudging respect from investors after the company announced its third-quarter results on Friday. But while Humira is struggling in European markets, it's performing quite well in the U.S. AbbVie announced U.S. sales for Humira increased by 9.6% in the third quarter from the prior-year period. More good news In addition to its solid third-quarter results, AbbVie also announced more good news on Friday.
But while Humira is struggling in European markets, it's performing quite well in the U.S. AbbVie announced U.S. sales for Humira increased by 9.6% in the third quarter from the prior-year period. The higher sales for the drug in the U.S. market translated to more than $370 million added to AbbVie's top line. AbbVie announced that Q3 sales for Parkinson's disease drug Duodopa rose 11.3%, to $117 million.
But while Humira is struggling in European markets, it's performing quite well in the U.S. AbbVie announced U.S. sales for Humira increased by 9.6% in the third quarter from the prior-year period. The higher sales for the drug in the U.S. market translated to more than $370 million added to AbbVie's top line. The company's new immunology drug Skyrizi picked up momentum, with sales rising to $91 million from $48 million in the previous quarter.
32887.0
2019-10-31 00:00:00 UTC
IVW, ABT, MDT, PYPL: ETF Outflow Alert
ABT
https://www.nasdaq.com/articles/ivw-abt-mdt-pypl%3A-etf-outflow-alert-2019-10-31
nan
nan
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $55.1 million dollar outflow -- that's a 0.2% decrease week over week (from 129,250,000 to 128,950,000). Among the largest underlying components of IVW, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 1.9%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.49 per share, with $185.23 as the 52 week high point — that compares with a last trade of $182.94. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. Click here to find out which 9 other ETFs experienced notable outflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Among the largest underlying components of IVW, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 1.9%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.49 per share, with $185.23 as the 52 week high point — that compares with a last trade of $182.94. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.
Among the largest underlying components of IVW, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 1.9%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.49 per share, with $185.23 as the 52 week high point — that compares with a last trade of $182.94. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed).
Among the largest underlying components of IVW, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 1.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $55.1 million dollar outflow -- that's a 0.2% decrease week over week (from 129,250,000 to 128,950,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.49 per share, with $185.23 as the 52 week high point — that compares with a last trade of $182.94.
Among the largest underlying components of IVW, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 1.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $55.1 million dollar outflow -- that's a 0.2% decrease week over week (from 129,250,000 to 128,950,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.49 per share, with $185.23 as the 52 week high point — that compares with a last trade of $182.94.
32888.0
2019-10-28 00:00:00 UTC
We Did The Math VOOG Can Go To $181
ABT
https://www.nasdaq.com/articles/we-did-the-math-voog-can-go-to-%24181-2019-10-28
nan
nan
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard S&P 500 Growth ETF (Symbol: VOOG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $180.95 per unit. With VOOG trading at a recent price near $163.02 per unit, that means that analysts see 11.00% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of VOOG's underlying holdings with notable upside to their analyst target prices are Universal Health Services, Inc. (Symbol: UHS), Abbott Laboratories (Symbol: ABT), and American Express Co. (Symbol: AXP). Although UHS has traded at a recent price of $137.93/share, the average analyst target is 14.95% higher at $158.56/share. Similarly, ABT has 13.68% upside from the recent share price of $81.65 if the average analyst target price of $92.82/share is reached, and analysts on average are expecting AXP to reach a target price of $133.27/share, which is 12.69% above the recent price of $118.26. Below is a twelve month price history chart comparing the stock performance of UHS, ABT, and AXP: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Below is a twelve month price history chart comparing the stock performance of UHS, ABT, and AXP: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VOOG's underlying holdings with notable upside to their analyst target prices are Universal Health Services, Inc. (Symbol: UHS), Abbott Laboratories (Symbol: ABT), and American Express Co. (Symbol: AXP). Similarly, ABT has 13.68% upside from the recent share price of $81.65 if the average analyst target price of $92.82/share is reached, and analysts on average are expecting AXP to reach a target price of $133.27/share, which is 12.69% above the recent price of $118.26.
Three of VOOG's underlying holdings with notable upside to their analyst target prices are Universal Health Services, Inc. (Symbol: UHS), Abbott Laboratories (Symbol: ABT), and American Express Co. (Symbol: AXP). Similarly, ABT has 13.68% upside from the recent share price of $81.65 if the average analyst target price of $92.82/share is reached, and analysts on average are expecting AXP to reach a target price of $133.27/share, which is 12.69% above the recent price of $118.26. Below is a twelve month price history chart comparing the stock performance of UHS, ABT, and AXP: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now?
Similarly, ABT has 13.68% upside from the recent share price of $81.65 if the average analyst target price of $92.82/share is reached, and analysts on average are expecting AXP to reach a target price of $133.27/share, which is 12.69% above the recent price of $118.26. Below is a twelve month price history chart comparing the stock performance of UHS, ABT, and AXP: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VOOG's underlying holdings with notable upside to their analyst target prices are Universal Health Services, Inc. (Symbol: UHS), Abbott Laboratories (Symbol: ABT), and American Express Co. (Symbol: AXP).
Below is a twelve month price history chart comparing the stock performance of UHS, ABT, and AXP: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VOOG's underlying holdings with notable upside to their analyst target prices are Universal Health Services, Inc. (Symbol: UHS), Abbott Laboratories (Symbol: ABT), and American Express Co. (Symbol: AXP). Similarly, ABT has 13.68% upside from the recent share price of $81.65 if the average analyst target price of $92.82/share is reached, and analysts on average are expecting AXP to reach a target price of $133.27/share, which is 12.69% above the recent price of $118.26.
32889.0
2019-10-26 00:00:00 UTC
5 Top Healthcare ETFs
ABT
https://www.nasdaq.com/articles/5-top-healthcare-etfs-2019-10-26
nan
nan
Healthcare is huge. In 2017, healthcare spending in the U.S. totaled $3.5 trillion -- nearly 18% of the country's gross domestic product (GDP), which is the total market value of all products and services produced. Worldwide healthcare spending topped $7.7 billion. By 2022, global healthcare spending will reach at least $10 trillion, according to professional services firm Deloitte. Where there's a lot of money being spent, there are opportunities for investors. While one option is to buy individual healthcare stocks, many investors might prefer going with healthcare-focused exchange-traded funds (ETFs), which let you buy a basket of stocks with one transaction. But you don't want to buy just any healthcare ETF. Here's what you need to know about the top healthcare ETFs and why investing in them is something you should consider. Image source: Getty Images. Why healthcare is hot Probably the most important trend fueling growth in healthcare is the aging of populations across the world. In the U.S., around 10,000 baby boomers turn 65 every day. By 2030, all of the 61 million American baby boomers will be at least 65 years old. By 2034, Americans 65 and older will outnumber those under 18 for the first time in U.S. history, according to projections from the U.S. Census Bureau. In Europe, 1 out of every 4 residents already is at least 60 years old. Lower birth rates in Europe mean that populations will age even more rapidly than in the U.S. It's a similar story in Asia, with a United Nations report finding that "all countries in Asia and the Pacific are in the process of aging at an unprecedented pace." As people age, they're more likely to require healthcare services. And as demand rises, companies that provide products and services to address healthcare issues for aging populations should benefit. In addition, significant advances are being made in healthcare and new technology is likely to generate tremendous growth for pioneering companies. For example, drugmakers are developing new approaches that could revolutionize how diseases are treated. The use of personalized medicine, where individuals' genetic information is used to determine the appropriate therapy, is picking up momentum. This is especially true in cancer treatment, where hundreds of immunotherapies that harness the body's immune system to fight cancer are in clinical testing, with several immunotherapies already on the market. Biotechs and pharmaceutical companies are even using gene editing to cure rare genetic diseases that in the past had no effective treatment available. Diagnostics companies are developing ways to detect cancer at early stages using liquid biopsies that identify fragments of DNA that have broken off from tumors and made their way into patients' blood. Medical device companies are launching new devices that use artificial intelligence, robotics, and other advanced technology to improve the delivery of healthcare services. There's also a major focus among healthcare companies to provide products and services that help control the rising costs that are associated with higher demand. The use of telehealth -- the delivery of healthcare services remotely using technology, especially the internet -- is being adopted more widely. Surgical robots are being used to perform minimally invasive surgeries that in the past required much more complicated and risky procedures. Technology to monitor patients with chronic conditions and alert healthcare professionals when issues arise is helping reduce expensive hospital visits. Rapidly growing demand fueled by aging populations across the world. Amazing new innovations that are revolutionizing patient care. It's no wonder that healthcare is a hot area for investors. Why use ETFs to invest in healthcare There's one big reason why using an ETF to invest in healthcare is a great idea: It provides diversification across lots of individual healthcare stocks. Each of the top five healthcare ETFs holds positions in at least 57 stocks, with three of the ETFs holding more than 100 stocks. This diversification across multiple stocks lowers the amount of risk taken by investors. If only a small number of individual stocks drop significantly, the rest of the stocks owned by the ETF can offset those declines. Because the healthcare sector is so broad in scope, all healthcare stocks don't necessarily move in the same direction all of the time. For example, regulations specific to medical device makers could hurt medical device stocks but not impact pharmaceutical stocks at all. Using ETFs also enables investors to target specific industries within healthcare. For example, some healthcare ETFs focus only on biotech stocks or medical device stocks rather than the entire healthcare sector. Of course, you do lose some of the benefits of diversification by investing in these industry-specific ETFs. So now that you know that ETFs offer the advantage of investing in a wide range of stocks in one fell swoop, let's look at which healthcare ETFs are especially popular. Five top healthcare ETFs An important metric for healthcare ETFs is their assets under management. This refers to the total market value (how much a stock or other holding can be sold for) of all the financial assets that the ETF manages on behalf of its clients. The larger the assets under management, the more money investors have poured into the ETF, which reflects a broad level of confidence in the ETF. The five top healthcare ETFs -- as measured by assets under management -- are: Data sources: Fund companies. All data as of Oct. 17, 2019. Health Care Select Sector SPDR Fund The Health Care Select Sector SPDR Fund is managed by State Street Global Advisors. This ETF attempts to track the performance of the Health Care Select Sector Index, which includes all of the stocks in the healthcare sector that are listed in the broader S&P 500 index. The ETF provides exposure for investors to stocks in multiple healthcare industries, including biotechnology, healthcare equipment and supplies, healthcare providers and services, healthcare technology, life sciences tools and services, and pharmaceuticals. The top holdings of the Health Care Select Sector SPDR Fund in terms of market value as of October 2019 include Johnson & Johnson, UnitedHealth Group, Merck, Pfizer, Abbott Laboratories, Medtronic, Amgen, Thermo Fischer Scientific, AbbVie, and Eli Lilly. Since its inception in 1998, the Health Care Select SPDR Fund has delivered an average annual return of 8.07%. Over the last three years and five years, the ETF has provided average annual returns of 9.44% and 8.92%, respectively. Many of the stocks held by the Health Care Select SPDR Fund pay dividends. As a result, the ETF offers an attractive dividend yield (annual dividend payments expressed as a percentage of the ETF's net asset value per share over the last 12 months) of 1.62%. This dividend yield more than offsets the ETF's low expense ratio (the fund's operating expenses divided by the average total dollar value of its managed assets) of 0.13%. ETFs deduct these expense ratios from investors' accounts. Vanguard Health Care Index Fund ETF Vanguard pioneered the use of ETFs. The company's biggest healthcare ETF in terms of assets under management is the Vanguard Health Care Index Fund ETF, which tracks the performance of the MSCI U.S. Investable Market Index (IMI)/Health Care 25/50. This benchmark index consists of stocks of large, midsize, and small U.S. healthcare companies based on market cap (the total dollar value of a company's shares). The Vanguard Health Care Index Fund ETF primarily holds positions in the stocks of companies that provide medical or healthcare products, services, technology, or equipment. Like the Health Care Select SPDR Fund, the ETF's largest holdings as of October 2019 are Johnson & Johnson, UnitedHealth Group, Merck, Pfizer, Abbott Labs, Medtronic, Amgen, Thermo Fisher Scientific, AbbVie, and Eli Lilly. This healthcare ETF has generated an average annual return of 9.47% since its launch in 2004. It has delivered average annual returns of 9.78% and 9.2% over the last three years and five years, respectively. The Vanguard Health Care Index Fund ETF currently offers a dividend yield of 2.1%. Its expense ratio of 0.10% ranks as one of the lowest among all ETFs. iShares Nasdaq Biotechnology ETF The iShares Nasdaq Biotechnology ETF is managed by BlackRock. This ETF attempts to track the performance of the Nasdaq Biotechnology Index, which consists of U.S. biotechnology and pharmaceutical stocks that are listed on the Nasdaq stock exchange. As its name indicates, the ETF focuses mainly on biotech stocks. Its largest holdings as of October 2019 include Amgen, Gilead Sciences, Celgene, Vertex Pharmaceuticals, Illumina, Biogen, Regeneron Pharmaceuticals, Alexion Pharmaceuticals, Incyte, and Seattle Genetics. Since its launch in 2001, the iShares Nasdaq Biotechnology ETF has provided investors an average annual return of 6.2%. Over the last three years, the ETF has delivered an average annual return of 1.29%. The average annual return over the last five years was 1.97%. Most biotech stocks don't pay dividends. It's not surprising, therefore, that the iShares Nasdaq Biotechnology ETF's dividend yield of 0.27% is much lower than the yields offered by ETFs that target the broader healthcare sector. The ETF's expense ratio of 0.47% is also higher than the ETFs that own holdings in more stocks across the healthcare spectrum. iShares U.S. Medical Devices ETF BlackRock also manages the iShares U.S. Medical Devices ETF. This ETF attempts to track the performance of the Dow Jones U.S. Select Medical Equipment Index, which includes selected medical equipment stocks. The iShares U.S. Medical Devices ETF focuses only on stocks of companies that derive all or a significant portion of their total revenue by selling medical devices. The ETF's largest holdings as of October 2019 include Abbott Labs, Medtronic, Thermo Fisher Scientific, Danaher, Edwards Lifesciences, Stryker, Becton Dickinson and Co., Baxter International, Intuitive Surgical, and Boston Scientific. BlackRock launched the iShares U.S. Medical Devices ETF in 2006. Since then, the ETF has delivered an average annual return of 13.17%. Over the last three years and five years, it has provided annual average returns of 19.83% and 20.71%, respectively. This ETF's dividend yield currently stands at 0.3%. That level is nearly enough to cover the ETF's expense ratio of 0.43%. SPDR S&P Biotech ETF State Street's SPDR S&P Biotech ETF attempts to track the performance of the biotechnology segment of the S&P Total Market Index, which tracks the broader U.S. equity market. While the iShares Nasdaq Biotechnology ETF and the SPDR S&P Biotech ETF both focus on biotech stocks, their top holdings are very different. The SPDR S&P Biotech ETF includes larger positions in small and midsize biotechs than the iShares ETF does. The largest holdings of the SPDR S&P Biotech ETF as of October 2019 are Seattle Genetics, Arrowhead Pharmaceuticals, The Medicines Company, Ligand Pharmaceuticals, Regeneron, AbbVie, Amgen, Celgene, Incyte, and United Therapeutics. Since the inception of the SPDR S&P Biotech ETF in 2006, the ETF has generated an average annual return of 12.21%. Over the last three years, the ETF's average annual return was 4.96%. It delivered an average annual return of 8.33% over the last five years. You might think that an ETF with a lot of relatively smaller biotech stocks among its holdings would have a low dividend yield -- and you'd be right. The SPDR S&P Biotech ETF's dividend yield of 0.02% is the lowest of these five top healthcare ETFs. The ETF's expense ratio of 0.35% is in the middle of the pack for the top healthcare ETFs. Why consider these healthcare ETFs? One key reason to consider investing in these five healthcare ETFs is that they claim strong average trading volumes (the average of how many shares are bought and sold over a given period). This means that there is plenty of liquidity, a term that refers to how quickly an asset can be bought or sold without affecting its price. You want high-liquidity investments in case you need to sell in a hurry. And while your eyes might have glossed over reading about the expense ratios, they're important. The lower expense ratios for these ETFs boost investment returns over time. Should you just buy the healthcare ETF with the highest lifetime return? Nope. For one thing, future returns might not correlate with past returns. Also, these ETFs have different approaches. If you don't want to focus only on medical device stocks, you wouldn't want to go with the iShares U.S. Medical Devices ETF even though it claims the highest lifetime return. Risks Although buying a healthcare ETF reduces the risks for investors by diversifying across multiple stocks, there are still a number of key risks for these ETFs. Several, for example, have relatively large positions in certain stocks. If these stocks decline, they could cause the ETF to fall as well. Abbott Labs makes up 13.53% of the total holdings of the iShares U.S. Medical Devices ETF. Johnson & Johnson makes up 10.14% and 8.6% of the Health Care Select Sector SPDR Fund and the Vanguard Health Care ETF, respectively. Over 9% of the iShares Nasdaq Biotechnology ETF is held in Amgen stock. These heavy weightings make these ETFs especially susceptible to risks that could impact these stocks. Abbott Labs' growth prospects could be hurt if it fails to win U.S. Food and Drug Administration (FDA) approval for its next version of the Freestyle Libre continuous glucose monitoring (CGM) system. Johnson & Johnson and Amgen face competition from biosimilar and generic rivals, which could negatively affect the companies' growth prospects. The good news, though, is that ETFs adjust their holdings as they see the need to do so. An ETF that suffers over the short term due to a large position in a stock that doesn't perform well can still be a winner over the long term. All of the top five healthcare ETFs could also experience significant declines as a result of major changes to the U.S. healthcare system. Biotechs and pharmaceutical stocks could feel the brunt of potential reforms to how drug prices are set, which could pull down all of the ETFs except the iShares U.S. Medical Devices ETF. But this ETF isn't immune from the negative effects of potential U.S. healthcare system changes. There is significant political support for a single-payer healthcare system in the U.S. It's possible that nearly every healthcare stock could experience declines -- and weigh on healthcare ETFs as well -- if considerable progress is made toward implementing such a system. Healthcare ETFs can withstand overall economic downturns better than many stocks since healthcare products and services usually are needed regardless of what's going on with the economy, however, that doesn't mean that they can't fall during a recession or broader market pullback. In 2008, for example, each of these five healthcare ETFs dropped by double-digit percentages at one point during the toughest part of the financial crisis. Two of these ETFs -- the iShares Nasdaq Biotechnology ETF and the SPDR S&P Biotech ETF -- ended down for the year and underperformed the broader S&P 500. Positives outweigh the negatives Despite these risks, the positives should outweigh the negatives for healthcare ETFs. The aging demographic trends discussed earlier will almost certainly drive higher demand for healthcare products and services over the long run. While some companies might not fare as well as others, the indexes tracked by these ETFs follow the rules of survival of the fittest. If individual stocks underperform too much, they'll be replaced in the indexes (and in the ETFs' holdings) by better-performing stocks. It's not a bad idea to invest in healthcare stocks that appear to be in the best position to succeed over the long run. But for investors who either don't want to do the research required to pick individual stocks or who prefer the lower risk resulting from diversification, healthcare ETFs are a great option. 10 stocks we like better than SPDR S&P Biotech When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and SPDR S&P Biotech wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie, Celgene, Gilead Sciences, Health Care SPDR, Illumina, Intuitive Surgical, Pfizer, SPDR S&P Biotech, and Vertex Pharmaceuticals. The Motley Fool owns shares of and recommends Biogen, Celgene, Gilead Sciences, Illumina, Intuitive Surgical, and Seattle Genetics. The Motley Fool recommends Amgen, Becton, Dickinson, Incyte, Johnson & Johnson, Nasdaq, UnitedHealth Group, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The Vanguard Health Care Index Fund ETF primarily holds positions in the stocks of companies that provide medical or healthcare products, services, technology, or equipment. Abbott Labs' growth prospects could be hurt if it fails to win U.S. Food and Drug Administration (FDA) approval for its next version of the Freestyle Libre continuous glucose monitoring (CGM) system. But for investors who either don't want to do the research required to pick individual stocks or who prefer the lower risk resulting from diversification, healthcare ETFs are a great option.
The top holdings of the Health Care Select Sector SPDR Fund in terms of market value as of October 2019 include Johnson & Johnson, UnitedHealth Group, Merck, Pfizer, Abbott Laboratories, Medtronic, Amgen, Thermo Fischer Scientific, AbbVie, and Eli Lilly. Like the Health Care Select SPDR Fund, the ETF's largest holdings as of October 2019 are Johnson & Johnson, UnitedHealth Group, Merck, Pfizer, Abbott Labs, Medtronic, Amgen, Thermo Fisher Scientific, AbbVie, and Eli Lilly. Its largest holdings as of October 2019 include Amgen, Gilead Sciences, Celgene, Vertex Pharmaceuticals, Illumina, Biogen, Regeneron Pharmaceuticals, Alexion Pharmaceuticals, Incyte, and Seattle Genetics.
Why use ETFs to invest in healthcare There's one big reason why using an ETF to invest in healthcare is a great idea: It provides diversification across lots of individual healthcare stocks. Each of the top five healthcare ETFs holds positions in at least 57 stocks, with three of the ETFs holding more than 100 stocks. The ETF provides exposure for investors to stocks in multiple healthcare industries, including biotechnology, healthcare equipment and supplies, healthcare providers and services, healthcare technology, life sciences tools and services, and pharmaceuticals.
Each of the top five healthcare ETFs holds positions in at least 57 stocks, with three of the ETFs holding more than 100 stocks. The Vanguard Health Care Index Fund ETF primarily holds positions in the stocks of companies that provide medical or healthcare products, services, technology, or equipment. Why consider these healthcare ETFs?
32890.0
2019-10-20 00:00:00 UTC
3 Stocks With Fast-Growing Dividends That Retirees Will Love
ABT
https://www.nasdaq.com/articles/3-stocks-with-fast-growing-dividends-that-retirees-will-love-2019-10-20
nan
nan
I wouldn't normally hit you with a cliche right out of the gate, but here goes: "Skate to where the puck is going to be, not where it is." Hockey great Wayne Gretzky first spoke those words. Since then, the statement been repeated so many times that it has become a cliche. But cliches don't become cliches by being untrue. The reality is that Gretzky's approach is still applicable in many arenas beyond hockey, including investing in dividend stocks. If you're a retiree, this idea is especially important. You don't want to buy dividend stocks that have had strong dividends in the past but are likely to cut payouts in the future. You're much better off buying the stocks of solid companies that have demonstrated they like to boost their dividends. Three stocks with especially fast-growing dividends are AbbVie (NYSE: ABBV), Bank of America (NYSE: BAC), and The Home Depot (NYSE: HD). Here's why retirees will love these three stocks. Image source: Getty Images. 1. AbbVie With apologies to Wayne Gretzky, sometimes looking at where the puck has been can be helpful. At least the metaphor works with a stock like AbbVie. Including the years that AbbVie was part of its parent, Abbott Labs, before being spun off as a separate entity in 2013, the company has increased its dividend for 47 consecutive years. Over the past three years, AbbVie has boosted its dividend by 67%, with its yield now standing at a mouthwatering 5.8%. But should you be worried about AbbVie's dividend in light of declining sales for its top drug Humira and the company's increased debt load resulting from its planned acquisition of Allergan? I don't think so. For one thing, the Allergan deal will reduce AbbVie's reliance on Humira. Also, the company expects to quickly lower its debt levels. Most importantly, AbbVie will continue to be in great shape to deliver ongoing dividend payments. The company claims other blockbuster drugs with strong momentum. AbbVie's two newly approved immunology drugs, Rinvoq and Skyrizi, could combine for more than $10 billion in peak annual sales. Allergan brings huge winners Botox, Juvederm, and Vraylar to the table. My prediction is that AbbVie's dividend will grow, but its dividend yield could fall as the stock rises, with investors realizing they've been too pessimistic about the big drugmaker. 2. Bank of America Bank of America's long streak of dividend increases came to a screeching halt during the economic crisis of 2008 and 2009. But the financial-services giant soon returned to its dividend-growing ways, increasing its dividend in each of the past six years and boosting the payout by an impressive 140% over the past three years. Bank of America's dividend now yields a healthy 2.5%. When Warren Buffett significantly increases Berkshire Hathaway's position in a stock, it's worth taking a look at that stock. That's exactly what has happened this year with Bank of America, with the stock now Berkshire's second largest holding. What's especially notable about Buffett's move is that it increased Berkshire's stake in Bank of America above the magic 10% threshold where additional regulatory requirements kick in. Why does Buffett like Bank of America? Probably because the company has delivered industry-leading growth but its stock is still a bargain with shares trading at only 10 times expected earnings. Those reasons, along with its strong dividend growth, are good ones why retirees who aren't billionaires and investing legends should like Bank of America, too. 3. Home Depot Home Depot didn't increase its dividend for a few years at the end of the last decade. But the home-improvement leader subsequently put the pedal to the metal, boosting its dividend payout by 444% since 2011 and nearly doubling its dividend in just the last three years. Home Depot's dividend yield currently stands at 2.3%. You might look at Home Depot's second-quarter performance and have some qualms about buying the stock. The company reported sluggish growth and lowered its full-year 2019 outlook. But the reasons behind this weakness -- low lumber prices, tariffs, and wet weather -- aren't permanent issues that fundamentally change Home Depot's long-term prospects. Home Depot basically enjoys a duopoly in the U.S. home improvement market along with its rival, Lowe's. The company remains financially strong. And while the home improvement market can be cyclical in nature, over the long run you can count on the fact that consumers and contractors will need supplies to complete their projects. I think that Home Depot, like AbbVie and Bank of America, will provide retirees reliable and growing dividends for years to come. 10 stocks we like better than Home Depot When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Home Depot wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares). The Motley Fool has the following options: short February 2020 $205 calls on Home Depot, long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and long January 2021 $120 calls on Home Depot. The Motley Fool recommends Home Depot and Lowe's. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
But should you be worried about AbbVie's dividend in light of declining sales for its top drug Humira and the company's increased debt load resulting from its planned acquisition of Allergan? But the reasons behind this weakness -- low lumber prices, tariffs, and wet weather -- aren't permanent issues that fundamentally change Home Depot's long-term prospects. And while the home improvement market can be cyclical in nature, over the long run you can count on the fact that consumers and contractors will need supplies to complete their projects.
Three stocks with especially fast-growing dividends are AbbVie (NYSE: ABBV), Bank of America (NYSE: BAC), and The Home Depot (NYSE: HD). The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares). The Motley Fool has the following options: short February 2020 $205 calls on Home Depot, long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and long January 2021 $120 calls on Home Depot.
Three stocks with especially fast-growing dividends are AbbVie (NYSE: ABBV), Bank of America (NYSE: BAC), and The Home Depot (NYSE: HD). Home Depot Home Depot didn't increase its dividend for a few years at the end of the last decade. The Motley Fool has the following options: short February 2020 $205 calls on Home Depot, long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and long January 2021 $120 calls on Home Depot.
Those reasons, along with its strong dividend growth, are good ones why retirees who aren't billionaires and investing legends should like Bank of America, too. Home Depot Home Depot didn't increase its dividend for a few years at the end of the last decade. I think that Home Depot, like AbbVie and Bank of America, will provide retirees reliable and growing dividends for years to come.
32891.0
2019-10-18 00:00:00 UTC
Health Care Sector Update for 10/18/2019: RDHL, TRXC, ISRG, JNJ, ABT, PFE, MRK, AMGN
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-10-18-2019%3A-rdhl-trxc-isrg-jnj-abt-pfe-mrk-amgn-2019-10-18
nan
nan
Top Health Care Stocks: JNJ: -2.9% PFE: Flat ABT: Flat MRK: +0.01% AMGN: Flat Leading health care stocks were mostly flat pre-market Friday. Early movers include: (+) Redhill Biopharma (RDHL), which was more than 5% higher after the company announced a strategic collaboration with Cosmo Pharmaceuticals. (+) TransEnterix (TRXC) was advancing by more than 5% after saying it is restructuring the company to cut costs and is also considering strategic alternatives, including a sale, for the company, as it expects revenue of $1.9 million to $2.1 million in Q3, sharply lower than market expectations. (+) Intuitive Surgical (ISRG) was gaining more than 3% amid third-quarter results that handily beat the Street's guidance as a strong performance from the systems and instrument divisions powered a surge in earnings. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
PFE: Flat ABT: Flat Early movers include: (+) Redhill Biopharma (RDHL), which was more than 5% higher after the company announced a strategic collaboration with Cosmo Pharmaceuticals. (+) TransEnterix (TRXC) was advancing by more than 5% after saying it is restructuring the company to cut costs and is also considering strategic alternatives, including a sale, for the company, as it expects revenue of $1.9 million to $2.1 million in Q3, sharply lower than market expectations.
PFE: Flat ABT: Flat Top Health Care Stocks: AMGN: Flat Leading health care stocks were mostly flat pre-market Friday.
PFE: Flat ABT: Flat AMGN: Flat Leading health care stocks were mostly flat pre-market Friday. (+) TransEnterix (TRXC) was advancing by more than 5% after saying it is restructuring the company to cut costs and is also considering strategic alternatives, including a sale, for the company, as it expects revenue of $1.9 million to $2.1 million in Q3, sharply lower than market expectations.
PFE: Flat ABT: Flat AMGN: Flat Leading health care stocks were mostly flat pre-market Friday. Early movers include: (+) Redhill Biopharma (RDHL), which was more than 5% higher after the company announced a strategic collaboration with Cosmo Pharmaceuticals.
32892.0
2019-10-16 00:00:00 UTC
Health Care Sector Update for 10/16/2019: TXG,CRMD,ABT,NTRA
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-10-16-2019%3A-txgcrmdabtntra-2019-10-16
nan
nan
Top Health Care Stocks JNJ +1.76% PFE -0.18% ABT -0.15% MRK -0.42% AMGN -0.79% Health care stocks were closing little changed on Wednesday, with the NYSE Health Care Index falling slightly more than 0.1% while the shares of health care companies in the S&P 500 were down almost 0.1% as a group. The Nasdaq Biotechnology index was dropping nearly 0.2% this afternoon. Among health care stocks moving on news: (+) 10x Genomics (TXG) climbed almost 5% after a new regulatory filing late Tuesday showed CEO Serge Saxonov Monday exercised options to buy 22,829 shares of the biological diagnostics company's stock priced between $1.07 to $11.48 apiece. Following the combined $80,424 purchase, Saxonov now owns 938,014 10x Genomics shares. In other sector news: (+) CorMedix (CRMD) raced 7% higher on Wednesday after the specialty drugmaker said it has successfully completed talks with the US Food and Drug Administration over the chemistry, manufacturing and controls for its Neutrolin drug candidate ahead of the company submitting the new drug application for the prospective medication to prevent infections in adult patients during hemodialysis. The agency and CorMedix have now scheduled a pre-NDA meeting to expedite review of the application, including a potential priority review designation. (-) Abbott Laboratories (ABT) was ending fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean. (-) Natera (NTRA) dropped nearly 7% after the genetic testing company late Tuesday announced plans for a $175 million follow-on public offering of its common stock. The company also plans to provide underwriters with a 30-day option to buy up to $26.3 million more of its shares to cover potential overallotments. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(-) Abbott Laboratories (ABT) was ending fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean. Among health care stocks moving on news: (+) 10x Genomics (TXG) climbed almost 5% after a new regulatory filing late Tuesday showed CEO Serge Saxonov Monday exercised options to buy 22,829 shares of the biological diagnostics company's stock priced between $1.07 to $11.48 apiece. (-) Natera (NTRA) dropped nearly 7% after the genetic testing company late Tuesday announced plans for a $175 million follow-on public offering of its common stock.
(-) Abbott Laboratories (ABT) was ending fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean. Health care stocks were closing little changed on Wednesday, with the NYSE Health Care Index falling slightly more than 0.1% while the shares of health care companies in the S&P 500 were down almost 0.1% as a group. Among health care stocks moving on news: (+) 10x Genomics (TXG) climbed almost 5% after a new regulatory filing late Tuesday showed CEO Serge Saxonov Monday exercised options to buy 22,829 shares of the biological diagnostics company's stock priced between $1.07 to $11.48 apiece.
(-) Abbott Laboratories (ABT) was ending fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean. Health care stocks were closing little changed on Wednesday, with the NYSE Health Care Index falling slightly more than 0.1% while the shares of health care companies in the S&P 500 were down almost 0.1% as a group. Among health care stocks moving on news: (+) 10x Genomics (TXG) climbed almost 5% after a new regulatory filing late Tuesday showed CEO Serge Saxonov Monday exercised options to buy 22,829 shares of the biological diagnostics company's stock priced between $1.07 to $11.48 apiece.
(-) Abbott Laboratories (ABT) was ending fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean. The Nasdaq Biotechnology index was dropping nearly 0.2% this afternoon. Among health care stocks moving on news: (+) 10x Genomics (TXG) climbed almost 5% after a new regulatory filing late Tuesday showed CEO Serge Saxonov Monday exercised options to buy 22,829 shares of the biological diagnostics company's stock priced between $1.07 to $11.48 apiece.
32893.0
2019-10-16 00:00:00 UTC
5 Top Stock Trades for Thursday: ADBE, NFLX, ABT
ABT
https://www.nasdaq.com/articles/5-top-stock-trades-for-thursday%3A-adbe-nflx-abt-2019-10-16
nan
nan
The indices did not move too much on Wednesday, but a handful of tech stocks were hit hard on the day. Let’s look at a few of the top stock trades going into the latter half of the week. Top Stock Trades for Tomorrow No. 1: Adobe (ADBE) Adobe Systems (NASDAQ:) came under pressure Wednesday following a downgrade from Citi analysts. Shares have been trying to break out over downtrend resistance (blue line) and were actually succeeding before Wednesday. However, the tepid bullish action was not enough to withstand today’s selling. Nor were the 20-day and 200-day moving averages, as ADBE stock gapped below both metrics. However, it’s finding some reprieve from the 38.2% retracement. Now investors want to know, can ADBE reclaim the 200-day and downtrend resistance or are lower prices in store? If it’s the latter, look for a decline down into the $258 to $260 area. There it will find a notable level of support as well as the 50% retracement. If that fails to hold, ADBE stock may be in trouble. On the upside, the charts are pretty cluttered until Adobe can clear the 50-day moving average. Top Stock Trades for Tomorrow No. 2: Netflix (NFLX) Netflix (NASDAQ:) is very much a mixed picture ahead of the company’s earnings report on Wednesday after the close. On the plus side, shares have broken out over downtrend resistance (blue line) and are maintaining above the 20-day moving average. On the downside, they are stuck below the 50-day moving average and the 38.2% retracement. So what now? Should shares decline, look to see if the 23.6% retracement at $267.75 can support the name. If not, $260 could be on deck, with the September low of $252.28 below that. Below the September low and the December low is possible. On the upside, see that NFLX reclaims and holds the 50-day moving average and 38.2% retracement. Above that opens the door to the 50% and 61.8% retracements at $308.61 and $326.81, respectively. Top Stock Trades for Tomorrow No. 3: Abbott Labs (ABT) Abbott Labs (NYSE:) was mixed on Wednesday after it reported earnings. However, with clear-cut support nearby and breakout potential, it’s worth watching. Look at the past year of action. Shares have a consolidation period, then tend to break out to new highs and consolidate again. The old highs also tend to become support. Luckily, the prior highs near $79 to $80 also intersect with the 200-day moving average and 61.8% retracement. That makes it a pretty solid risk/reward area for investors. Below $79 and traders may consider stopping out. On the upside, see if ABT stock can break out over downtrend resistance and the 50-day moving average. Over it and a move back to $86-plus could be in the cards. Top Stock Trades for Tomorrow No. 4: ServiceNow (NOW) ServiceNow (NYSE:) was hammered on Wednesday and it leaves the stock clinging to support. Shares are just above the 200-day moving average and range support near $250. Below $250 and the October low of $243.54 is on the table. Below that and the stock could struggle a bit. If support holds, look for NOW to reclaim the 50-day moving average and rally back up to range resistance near $275. Over $275 and perhaps ServiceNow could retest the backside of its prior uptrend (blue line). Top Stock Trades for Tomorrow No. 5: Workday (WDAY) Thought ServiceNow investors were having a bad day? Just look at Workday (NASDAQ:), which was hit even harder on the day. The 61.8% retracement held WDAY in check on Tuesday, and on Wednesday the 38.2% retracement is acting as bulls’ saving grace. Below the 38.2% and Wednesday’s low, and the $145 mark could be on the table. If current support at the 38.2% retracement holds, look for WDAY to reclaim the $165 to $166 area. Above that and it will also have to reclaim downtrend resistance. Bret Kenwell is the manager and author of and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. The post appeared first on InvestorPlace. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
3: Abbott Labs (ABT) Abbott Labs (NYSE:) was mixed on Wednesday after it reported earnings. On the upside, see if ABT stock can break out over downtrend resistance and the 50-day moving average. The indices did not move too much on Wednesday, but a handful of tech stocks were hit hard on the day.
3: Abbott Labs (ABT) Abbott Labs (NYSE:) was mixed on Wednesday after it reported earnings. On the upside, see if ABT stock can break out over downtrend resistance and the 50-day moving average. On the upside, see that NFLX reclaims and holds the 50-day moving average and 38.2% retracement.
On the upside, see if ABT stock can break out over downtrend resistance and the 50-day moving average. 3: Abbott Labs (ABT) Abbott Labs (NYSE:) was mixed on Wednesday after it reported earnings. On the upside, see that NFLX reclaims and holds the 50-day moving average and 38.2% retracement.
3: Abbott Labs (ABT) Abbott Labs (NYSE:) was mixed on Wednesday after it reported earnings. On the upside, see if ABT stock can break out over downtrend resistance and the 50-day moving average. Should shares decline, look to see if the 23.6% retracement at $267.75 can support the name.
32894.0
2019-10-16 00:00:00 UTC
Abbott Laboratories (ABT) Q3 2019 Earnings Call Transcript
ABT
https://www.nasdaq.com/articles/abbott-laboratories-abt-q3-2019-earnings-call-transcript-2019-10-16
nan
nan
Image source: The Motley Fool. Abbott Laboratories (NYSE: ABT) Q3 2019 Earnings Call Oct 16, 2019, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, and thank you for standing by. Welcome to Abbott's Third Quarter 2019 Earnings Conference Call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any participants' questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations, Licensing and Acquisitions. Scott Leinenweber -- Vice President-Investor Relations, Licensing, and Acquisitions Good morning, and thank you for joining us. With me today are Miles White, Chairman of the Board and Chief Executive Officer; Robert Ford, President and Chief Operating Officer; and Brian Yoor, Executive Vice President, Finance and Chief Financial Officer. Miles will provide opening remarks, and Brian will discuss our performance and outlook in more detail. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2019. Abbott cautions that these forward-looking statements are subject to the risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, risk factors, to our annual report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Please note that second quarter financial results and guidance provided on the call today for sales, EPS and line items of the P&L will be for continuing operations only. On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which is defined in our earnings news release issued earlier today. With that, I will now turn the call over to Miles. Miles D. White -- Chairman and Chief Executive Officer Okay. Thanks, Scott. Good morning. Today we reported results of another strong quarter with ongoing earnings per share of $0.84 reflecting 12% growth on an absolute basis and even higher growth when excluding the impact of currency. Sales increased more than 7.5% on an organic basis in the quarter led by double-digit growth in Medical Devices and sequential improvements in Established Pharmaceuticals and diagnostics. We also narrowed our full year adjusted earnings per share guidance range to $3.23 to $3.25, which at current rates would reflect high-teens growth excluding the impact of currency and is at the upper end of the range we set at the beginning of the year. As we've discussed previously, following our recent strategic shaping and acquisitions, we've been completely focused on running the company we built. This focus on organic execution is delivering strong performance on a remarkably consistent basis. Over the last eight quarters, we've averaged 7.5% organic sales growth worldwide with very little variation. We've also continued to strengthen our portfolio with new products, expanded access and reimbursement coverage and generated new clinical data that further enhances the sustainability of our strong growth outlook going forward. I'm particularly pleased with the continued exceptional performance across several of our key growth platforms, including FreeStyle Libre, MitraClip and Alinity which I'll highlight as I summarize our third quarter results in more detail. And I'll start in our Medical Devices business where sales increased double digits for the second quarter in a row. In Structural Heart, we achieved 16% sales growth led by MitraClip our market leading device for the treatment of mitral regurgitation or leaking heart valve. MitraClip sales increased more than 30% in the quarter, including U.S. growth of nearly 50%. During the quarter we received U.S. FDA approval for our next generation MitraClip device and we initiated the first ever U.S. pivotal trial for the minimally invasive treatment of tricuspid regurgitation, which will evaluate the safety and efficacy of our TriClip repair system. Turning now to FreeStyle Libre, our market leading continuous glucose monitoring system that eliminates the need for routine finger sticks. We achieved sales of $0.5 billion in the quarter and continue to add significantly to our global user base, as reflected by our organic sales growth of nearly 70%. During the quarter FreeStyle Libre obtained public reimbursement coverage in Ontario and Quebec becoming the first and only sensor-based glucose monitoring system to be listed by any provincial health plan in Canada. We also continue to advance our strategy to develop integrated solutions where people with diabetes can seamlessly manage their condition across devices, including recent announcements that we're seeking to integrate Libre with the insulin delivery technologies of Sanofi and Tandem as well as the digital care platform of Omada Health. This easy-to-use, affordable device is changing the way millions of people manage their diabetes and our ongoing efforts to expand awareness adoption and excess for Libre around the world will drive tremendous growth for years to come. Turning now to diagnostics, where sales grew 6.5% in the quarter led by double-digit growth in Core Laboratory Diagnostics the rollout of Alinity in Europe and other international markets continues to drive strong growth in our core laboratory business outside the U.S. In the U.S. where we continue to outperform the market with our legacy architect system. We've made good progress, achieving regulatory approvals of immunoassay in clinical chemistry tests for Alinity and are beginning to ramp up our launch efforts in these areas. With highly differentiated instruments and a matrix rollout across multiple geographies and diagnostic testing areas over time Alinity is well positioned to be a multi-year growth platform for our Diagnostics business. In Nutrition sales increased nearly 4% in the quarter led by double-digit growth in international Adult Nutrition for the third quarter in a row. In pediatric nutrition above market growth in the U.S. and several other countries was partially offset by challenging market dynamics in Greater China which comprises a little less than 10% of our overall Nutrition sales. While consumers continue to trade up the premium brands, which is the segment where we compete we've seen volume in the market declined due to historically low birth rates. We remain focused on strengthening our portfolio and competitiveness across the various segments and purchasing channels in China and given our broad portfolio and global footprint anticipate continued strong performance across other geographies and long-term growth opportunities such as adult Nutrition. I'll wrap up with Established Pharmaceuticals or EPD, where sales increased 8% in the quarter led by strong growth in several geographies, including India, China and Brazil. Sales growth in EPD has now improved sequentially for each of the last three quarters. With leading market positions in several international growth geographies EPD is well positioned for sustained above market growth in some of the largest and fastest growing pharmaceutical markets in the world. So in summary, we're performing [Technical Issues] well across several areas of the portfolio resulting in another quarter of strong sales and earnings growth. We continue to strengthen our product portfolios and key product platforms with a steady cadence of new product approvals reimbursement coverage and clinical data. And we're well on track to deliver ongoing EPS and organic sales growth at the upper ends of the range, as we set at the beginning of the year. I'll now turn the call over to Brian to discuss our results and outlook for the year in more detail. Brain? Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Thanks, Miles. As Scott mentioned earlier, please note that all references to sales growth rates unless otherwise noted for on an organic basis, which is consistent with our previous guidance. Turning to our results. Sales for the third quarter increased 7.6% on an organic basis. During the quarter, we saw the U.S. dollar strengthened modestly resulting in an unfavorable impact on sales of 1.9% from exchange or 50 basis points higher than if rates held steady, since the time of our call in July. Reported sales increased 5.5% in the quarter. Regarding other aspects of the P&L, the adjusted gross margin ratio was 59.2% of sales. Adjusted R&D investment was 7% of sales and adjusted SG&A expense was 29.1% of sales. Turning to our outlook for the fourth quarter. We forecast adjusted EPS of $0.94 to $0.96 which reflects nearly 17.5% growth at the midpoint. We forecast organic sales growth of around 8% and a current rates would expect exchange to have a negative impact of somewhat above 1.5% on fourth quarter reported sales. We forecast an adjusted gross margin ratio of approximately 59.5% of sales. Adjusted R&D investment of around 7% of sales and adjusted SG&A expense approaching 27.5% of sales. Before we open the call for questions. I'll now provide a quick overview of our fourth quarter organic sales growth outlook by business. For Established Pharmaceuticals, we forecast high single-digit growth. In Nutrition, we forecast low to-mid single digit growth. In Diagnostics, we forecast mid to high single-digit growth. And in Medical Devices we forecast growth similar to the third quarter which reflects continued double-digit growth in several areas of this business. With that, we will now open the call for questions. Questions and Answers: Operator Thank you. [Operator Instructions] And our first question comes from David Lewis from Morgan Stanley. Your line is open. David Lewis -- Morgan Stanley -- Analyst Good morning. Just a couple of questions for me. Miles, just want to start off on growth. So, I mean, this time of year Investors are very focused on sustainability and you obviously said you've been averaging 7.5% for seven to eight quarters. So a couple of questions, one, guidance for the fourth quarter implies a little bit of momentum deceleration in the business anything specific to call out there? And then more specifically, as you think about 2020. What are those drivers to get you confident that you can deliver growth in that 7%, 7.5% range that you've been doing in the last couple of years? And then one quick follow-up. Miles D. White -- Chairman and Chief Executive Officer Okay. David. Well, I'll start with what you said. We have had eight straight quarters averaging 7.5%. Going into the fourth quarter, we actually, we're going to be close to 8%. And -- then going into next year, I think where we are in the range we've given, I think we gave a range of the beginning of this last quarter of 7% to 8% somewhere in that range. And frankly, I see no change to that, right. I don't see any change to momentum at all here. If anything, we've got pretty strong momentum across the board. We've got sequential growth in a number of areas that we expected improvement in and we're seeing that EPD comes to mind. Obviously, our growth drivers Libre and MitraClip and the Alinity systems, et cetera, are all very strong Structural Heart is very strong. So -- you know that, as I said in the past many times this is sustainable and strong going forward, I see no change in momentum, no changes to progress, no change to growth rates. If anything, you could get a touch better. So and it clearly well in the fourth quarter. So it's pretty strong and the earnings flows with it and we're not going to make any guidance forecast or anything, but I think directionally here all fundamentals are strong for us. David Lewis -- Morgan Stanley -- Analyst Okay. Very helpful. And then just one quick product question Miles. Just there has been Libre 2, obviously an important driver for next year. I just want to get your commentary the longer this product has not been approved it's led to kind of concern about the product, the regulatory time line. Your view, your Tandem partnership yesterday suggests to us that you're still confident in Libre 2 iCGM. Are you still confident in Libre 2 iCGM? And how are you thinking about the timing of potential for that product? Thanks so much. Miles D. White -- Chairman and Chief Executive Officer I'd say, I going to comment myself and then I'm going to hand it to Robert Ford here to comment as well. But first, are we confident? Absolutely. The product is performing wonderfully -- the growth is strong, the expansion is strong. There is a lot to be pretty encouraged about. And while I recognize a lot of people, including us are feeling in patients -- in patients doesn't translate the concern. We're all inpatient and we'd all like everything yesterday. But it's not quite working out as yesterday. And Robert can comment on that here, but there is nothing but good here looking forward with Libre. And we anticipate a lot of expansion with this product including with some of these partnerships that we've announced and working with the interoperability with various partners for what I think will be the future of glucose monitoring and diabetes management. I think all of this is not just on plan, but spectacular particularly for diabetes patients and I have nothing, but confidence in it. So let me turn it over to Robert to expand on that. Robert B. Ford -- President and Chief Operating Officer Yeah, David, let's admittedly it's taking longer than we had expected. We obviously misjudged that we're currently working through a handful of open items with the agency and what I can tell you on -- I've got the same confidence level that Miles does, I'm confident in the data, I'm confident in the product, right. In the meantime, if you look at Libre in Q3, we had an exceptional Q3, sales of just under $0.5 billion, that puts us on a $2 billion run rate here with growth rate over 70%. Our international business grew 50% and that's -- that's on a large base. And in the U.S. sales sales nearly tripled. So, and it's triple because we're adding new patients at a strong and steady rate. And it's a high rate. And you could see that progression in our total Rxs. So -- and one of the challenges we've had over -- like the nine months here has really been about how to pulse our demand generation activities with aligning to our supply and we talked a little bit about kind of some of those supply constraints. So we've now released in the third quarter toward the end of the third quarter, our next tranche of manufacturing capacity on plan, on schedule. And I can tell you, the commercial team right now is really feeling excited about not being able to have that constraint over and really start to intensify the commercial efforts, whether that advertising, whether that sampling, et cetera, both in the U.S. and international. I think that's, that gives us a lot of excitement as we exit the year going into next year. The value proposition is still continues to be very strong to patients and physicians and to payers and as Miles mentioned in his opening comments, we achieved reimbursement in Canada public reimbursement the only sensor, system reimbursed in Canada. And it's important because it's one of the top five largest glucose monitoring markets in the world and similar to what we saw in some of these large markets when we obtained national reimburse when we see a pretty accelerated kind of explosive growth we saw that in Germany, we saw that in France and UK. So we expect to see that same trajectory in Canada, and early indications suggest that kind of same curve. So that will be also exciting for the team as we move into Q4. And as Miles has also said, we're pleased with the partnership strategy that we've adopted. We've gone through it at a very intentional phased approach first with Bigfoot, as you know. We then moved into announcing our agreements with insulin manufacturers, like Novo and Sanofi, that connect Libre to their pen systems. And the next phase here, we'll start to move into insulin pumps and that was the agreement that we announced yesterday with tenant to co-develop an integrated system because we know this is an important segment also connecting to pumps and we're now at a phase where we feel that we can start to kind of roll that out as we thought about our partnership strategy. So I think momentum here on Libre is exceptional, it is very strong as we go into Q4, I think we've got a lot of stuff going right, firing all cylinders, whether it's commercial, whether it's commercial, whether it's operation, whether it's our R&D program. So I'm very confident on the sustainability of Libre and Libre going forward. David Lewis -- Morgan Stanley -- Analyst Great. Thanks so much. Operator Thank you. Our next question comes from Larry Biegelsen from Wells Fargo. Your line is open. Larry Biegelsen -- Wells Fargo -- Analyst Good morning. Thanks for taking the question. So two for me, one on capital allocation, one on MitraClip. Let me start Miles with the capital allocation. Now that you have more financial flexibility. How are you thinking about capital allocation in the importance of reloading the pipeline? I think on the Q2 call, you seem to de-prioritize buybacks, but yesterday you announced a $3 billion share repurchase authorization. So has your view changed? And I just had one follow-up on MitraClip. Miles D. White -- Chairman and Chief Executive Officer Well, I'd say, look, we've come through a period where we paid down a lot of debt. And I think we find ourselves in a good capital balance. I think where we've got -- gotten to the place where our net debt to EBITDA ratio is well ahead of what we targeted probably a year earlier than we expected and that was with an aggressive paydowns strategy, et cetera. Our business is performing strong. Our cash flows are strong. Can we still continue to pay down debt? We can. Can we refinanced debt? We can. Can we do things that are prudent, good balance sheet management? Yes. And we're also generating cash. We are generating sufficient cash, more than sufficient cash to invest in a lot of manufacturing expansion for all the new products we've talked about. Robert just mentioned, one of the biggest and that's fully funded and obviously coming online and good. So you say, alright, well, then about the dividend. Why we raised the dividend 14% last December, and we have a targeted range where we like to keep that dividend as a percent of our EPS, et cetera. So as we go across all the things you can do with your cash returning cash to shareholders is also positive thing to do, if the conditions are right and if the return is good, et cetera. And we want to be prepared to have that flexibility on the table as well. We have not gone significant share repurchase as you know for several years. While we focused on the pay down of debt, but now we wanted to add back the flexibility to do that as well. So I'd say in general we find ourselves in a strong cash position, strong performance position, good strong balance sheet position we can continue to pay down some debt, but we've got the flexibility to do just about whatever makes sense for us on a return basis or return to shareholder basis. We don't have any active M&A on the radar screen to the extent that we track or follow anything. I'd say it's your typical bolt-ons and tuck-ins and so forth that are additions to already strong businesses. We're pretty happy with our pipeline. We're pretty happy with our R&D pipeline. So our standards are pretty high right now about what's attractive and what may not be. But I'm not forecasting anything significant at all in the M&A area. So obviously we want to keep our options open here with how we manage cash for our shareholder. Larry Biegelsen -- Wells Fargo -- Analyst Very helpful. And then on MitraClip. You have -- U.S. reimbursement goes up in October. You hopefully will have coverage for the functional MR indication next spring. So you're thinking about 2020 is an inflection year for MitraClip and in Europe, it looks like sales improved growth, improved this quarter. And how are you feeling about MitraClip outside the U.S? Thanks for taking the question. Miles D. White -- Chairman and Chief Executive Officer Larry, I'm going to toss that one to Robert Ford. Robert B. Ford -- President and Chief Operating Officer Hi, Larry. Thanks for the question. So you know, we filed our MitraClip NCD it was kind of opened in August. So that timeline there is usually takes about nine months, I mean that's a statutory maximum as we'll say, when we did FMR in MitraClip that's take about seven months. So I think we'll be in the December, January time frame -- kind of -- trying to kind of get exactly what quarter that's going to land in. But in the meantime, you see kind of our growth rate. The reimbursement is going to be important, but our Structural Heart was up mid-teens. And the big driver of that was MitraClip up 30%, up 50% in the U.S. So reimbursement is going to be important, there definitely be an inflection point, when we get it, but as I said in the previous call, that is a component, it's a building block here that we're focusing on. So, opening new centers is another kind of key building block. We have about 400 today, and I don't want to get to about 550 over time. And we've been supporting that with investments, investments in our sales force, our clinical specialists, our therapy development specialists so that we can not only train the centers, train the implanters to keep up with that demand that we see, but also to support the demand generation through the development of these patient referral network. So that investment is ongoing on target, on plan in terms of how we're ramping up the field team and as Miles said in his opening comments, we continue to invest also in the innovation side, on the product development side. So in July, we obtained approval for our fourth generation MitraClip which has independent graspers, more sizes, et cetera that space goods more options to the physician. So I think that, MitraClip here is and it's really early innings Alere, I think this is a multi-year, multi-billion dollar growth opportunity that we've got. And it is going to continue to ramp over time and we're making the investments to make sure we are going to lead in that. So as I looked -- Larry Biegelsen -- Wells Fargo -- Analyst Thank you very much. Robert B. Ford -- President and Chief Operating Officer 2020 I think we've got the right momentum. And once we have NCD coverage, yes, I think there'll be an inflection to growth. Larry Biegelsen -- Wells Fargo -- Analyst Thank you very much. Operator Thank you. Our next question comes from Bob Hopkins from Bank of America. Your line is open. Bob Hopkins -- Bank of America -- Analyst Hi, thanks and good morning. Just two quick product related questions first a follow-up on the Libre 2 commentary just to kind of set expectations. Just curious, is there been any new data request from the agency and is approval of Libre 2 in the U.S. you think possible next couple of months or credit take a little longer? Miles D. White -- Chairman and Chief Executive Officer Listen, we've -- what I'll say is that, probably, we've obviously misjudged that. So I'm not going to sit here and try and pinpoint the exact timeline of the approval. As I said, also we're actively working through a handful of open items with the agency and that's where we're at. Bob Hopkins -- Bank of America -- Analyst Okay. Fair enough. And then I also want to ask on pediatric nutritionals in China. And it's just curious if you could elaborate a little bit more on the slowdown there. And then just wonder if you could comment on China, more broadly and your confidence in growth continuing in China. So just comment on pediatric nutritionals in China, please. Miles D. White -- Chairman and Chief Executive Officer Sure. Let me start off with the -- with the nutritional question here, then. So you saw our Nutrition business was just under 4% we had really good growth in the U.S. in pediatrics up 4% double-digit growth in international adult for the second quarter in a row. So our challenge here really was the international pediatric performance, which was really driven by Greater China. And I would say there were some challenging market dynamics here. As Miles mentioned, we're seeing the consumer trade up into the premium brand segment, but the volume has been declining, partly because of these low birth rate. So this is led to what I would say a much more competitive environment, competitive in terms of pricing, competitive in terms of promotional activities. And this is now got our full attention, a full attention from the management team here. And our key thing is really focusing and you know the market dynamics of the market dynamics, but we've got to really focus on improving our competitive fitness, our competitive position here in the pediatric segment we're launching a series of new strategies here in the coming weeks regarding our media campaigns, strengthening our consumer relationship platforms. We've got some plans to launch some new products over the next several quarters. So I'd say that the key focus of us right now in Nutrition really has been at this point here to focus on improving our competitive fitness in China. Robert B. Ford -- President and Chief Operating Officer And I'll follow up on the rest of the -- other businesses in China, I'll give you a little bit of context. I think, you know I'll speak as a CEO, we are the multinational CEOs of the world are we? If we do business in China, are we nervous about trade, are we nervous about China, are we nervous about all this. I think you can't help but we nervous about it, but I'll tell you what's interesting, while it's affecting some segments of the U.S. economy and U.S. businesses pretty directly, it doesn't seem to be affecting us or our business. The nutrition challenge we have is completely separate from any kind of trade or economic or autonomy issues, other than birth rates. And on -- the performance in our device businesses, our Diagnostics businesses and so forth are double-digits and strong. You know there is all kinds of ways that people can hypothesized that maybe the Chinese government would intervene and make things more difficult and so forth for U.S. multinationals. But in our business we actually don't see that and you know the product approvals are coming in a timely manner, the China FDA is doing everything that they're supposed to do -- and for our products. We haven't seen any of that kind of friction at all and the demand for our products in the performance of our businesses in China has been strong other than the challenge we've got with a pediatric nutrition all our other businesses are doing well. Showing no signs of any kinds of issues. So while I know that there are industries and segments that are tied to whether it's automobiles, oil, big industries, et cetera that may have challenges particularly agriculture we're not seeing that. And our China business is good. Bob Hopkins -- Bank of America -- Analyst Thank you very much. Helpful. Operator Thank you. Our next question comes from Vijay Kumar from Evercore ISI. Your line is open. Vijay Kumar -- Evercore ISI -- Analyst Thanks for taking my question guys. Two from me. Maybe Miles starting off with that last question at the macro, China. I know there are a number of moving parts, China 4/7 on the drug side, some questions from maybe a CapEx slowdown, Diagnostics slowdown. Just to be clear, what is your exposure either on the drug or Diagnostics side to China, I maybe broadly comment on emerging markets in general it looks like some of those markets are slowing down and how is Abbott position to handle some of the macro slowdown, if you will? Miles D. White -- Chairman and Chief Executive Officer We're looking at each other trying to figure out who answers what part of that question. I'd say this underlying growth in emerging markets is still good, has it slowed some. Yeah, it has slowed some. But it's still good, it's a relative thing. So the underlying growth we see in India, Latin America, China, et cetera. It's all good, you can say there is the occasional Argentina. Okay. That's not good. Argentina is its own thing. But there are -- the advancement of the healthcare systems advancement in demand for health products Pharmaceuticals, et cetera strong. China in particular for us, for our pharmaceutical business strong, we're doing well. I don't think we have a lot of exposure. I'll let Robert expand on that in a minute. But overall, I think the conditions for us in those markets remain strong as we've said many, many times single most difficult thing we deal with this the volatile currency if it's volatile and sometimes it is, sometimes it isn't. And right now, currency isn't exactly working in our favor in those markets. So, while we grow at a pretty healthy rate on an underlying basis. And typically, faster than the market -- the currency races some of that. Robert? Robert B. Ford -- President and Chief Operating Officer Yeah, I'll just, Vijay, on the generic pharma in China, I think you're referring to the four plus -- four plus seven tendering process there. We haven't seen an impact and we don't anticipate a significant impact going forward. We have a fairly kind of concentrated portfolio here at products just about 15 products, most of these products are more specialized kind of segments in areas where there is kind of difficult to manufacturer. So on the generic side of the pharma business we're less susceptible to this. Obviously, we're going to monitor we're part of this process, we understand how the tendering process is going to work. But if I think about kind of bigger impact we have less of an impact to given the portfolio of products we have in China. Vijay Kumar -- Evercore ISI -- Analyst Yeah. That's helpful guys. And just one quick one on that guidance maybe for Brian. Brian, it looks like the Q4 guidance is implying really strong margin expansion 200 basis points plus. Just given some of the comments on FX maybe clarify the FX -- ahead to Q4 in the margin side? And in general, when you look at 2020, what kind of headwinds that we're looking at from an FX perspective. Thank you, guys. Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Yes. From a top line next year, I'm not prepared to talk about next year. But I think there would be natural some flow-through on the top line next year, Vijay. Perhaps, Scott can [Indecipherable] back to you on that. Then let me circle back. If you look at Q3 you saw we had gross margins of 59.2%. You are absolutely correct. Foreign exchange has an impact on us of about 50 basis points, otherwise you be at 59.7%. So, I feel good about where we're guiding Q4. Q4 tends to be that quarter, we get a little bit more natural leverage as well. And you'll see that play out through the bottom line, pretty consistent with how we thought about this at the beginning of the year. As you know, I mean, gross margin improvement is just part of our DNA. It's part of what we do and how we think about in addition to cash flow and it's something we're going to continue to improve upon across all of our businesses. And I think you could expect that to continue in the next year. That's how we get the double-digit growth than we usually start with and continue to invest back into our SG&A and R&D for our growth. Vijay Kumar -- Evercore ISI -- Analyst Thanks guys. Operator Thank you. Our next question comes from Robbie Marcus from JP Morgan. Your line is open. Robbie Marcus -- JP Morgan -- Analyst Great. Thanks for taking my question. Miles, I was hoping you could touch on the Diagnostics business. This is one you've called out for many quarters now is a durable multi-year growth driver for the company. We saw fantastic growth in Core Lab this quarter even without really benefit from Alinity hitting U.S. Maybe you could just update us on the status of where you are in Europe in terms of rollout. What you're seeing in terms of competition, because we're seeing some negative results from competitors. And then the latest and thoughts on the U.S. launch and how we think that uptick there? Miles D. White -- Chairman and Chief Executive Officer Okay. Thanks, Rob. I'm going to have Robert do that. Robert B. Ford -- President and Chief Operating Officer So, Robbie, we've talked about how this is a multiyear opportunity and we've been executing on this very, very focused year. If you think about the core labs and the rollout of the Alinity program, it's doing very well and you can see that -- you can see that in our top line. The rollout has been particularly strong in Europe we're winning over 50% of the businesses where we targeted an entrenched competitor. And if you think about kind of the renewal process we're retaining nearly all of our current business that comes up for contract. So we placed over 3,700 instruments and when we give out that number, we're talking about instruments that are actually placed in the market, placed in the account, running test and generating revenue. So that's gone very well. In the quarter that you saw that we also got an approval in the U.S. for the Alinity blood and plasma screening. So this fourth quarter here, the team's already kind of rolling out that commercial launch. We had a lot of success in rolling out the blood plasma systems in Europe and in Asia last year or so. It's great to see that a little bit ahead of schedule here in the U.S. and the teams are jump in on the opportunity. As it relates to the immunoassay side, a lot of our focus here is really kind of ramping up on the R&D side, ramping up the menu and the assay menu. I'd say that assay completion rate of what we need to be kind of fully competitive in Europe is getting close to that 100% mark that we need. And in the U.S., it's a little bit behind, but a lot of our focus here is to get those systems those assays approved and in place and we'll start to see that kind of play effect in our growth rate in the U.S. as we move into next year. So I think internationally, we're doing really well U.S., we've got the opportunity here as the assays come on board to be able to accelerate our growth rate. So I'm really pleased with the momentum that the team has done here. Of course, we can, we feel that we can always do better and that's what we're going to keep on pushing too. Robbie Marcus -- JP Morgan -- Analyst Great. Thanks. And maybe just one quick follow-up in neuromodulation numbers came in a little softer than the Street was looking for. I'm assuming a big chunk of that was in the spinal cord stim market. Maybe you could just update us as to what exactly you're seeing on the ground with Abbott and what do you think is driving that deceleration in the market here in the U.S. Thanks. Miles D. White -- Chairman and Chief Executive Officer Yeah, sure. So obviously still work in progress here. It's a little bit longer than we had initially hope when we talked about it over the last couple of quarters. We talked about the sales force hiring, the sales force productivity and it's a very specific selling process here in devices and if you're a new rep, it takes some time to kind of understand it. So that's been going -- that's been progressing well, we've had some stabilization in the sales force and some of the monthly KPIs that we track them on their improving. But we've also seen as you pointed out a little bit of a market decline, especially in the first half of this year and it follows a couple of years of double-digit growth rate. So lot of our focus here has got to be on sales force execution and productivity. The approval of Proclaim XR this quarter I think really provides a nice addition to the portfolio and provide the sales force with the new technology to promote. And early signs of the launch, it's only been a couple of weeks. But early signs are positive. We tend to look at our trials and our trials across the U.S. in spinal as our leading indicator. And I'd say early signs are positive, but there is more monitoring there for us to be aware of. On the market side, there's really no third-party data source here like we have in stents or pacemakers, et cetera. So it's difficult to peg the growth rate here. We usually have to wait until everybody reports and we can kind of look at and added up and kind of see where it's at. So yeah, I would anticipate here Q3 to be similar in terms of market growth rate as the first half of this year, which is in that low-to-mid single digit decline here. Robbie Marcus -- JP Morgan -- Analyst Appreciate it. Operator Thank you. Our next question comes from Rick Wise from Stifel. Your line is open. Rick Wise -- Stifel -- Analyst Good morning, everybody. Miles, I'm always embrace to ask questions about the EPD business because, I would feel like I don't really understand it, but, and you said enough to see that you actually ex-currency had another solid quarter in many of the emerging markets that you're targeting. Maybe just help us understand some of your high level thoughts there the outlook is it going as you would have expected growth has slowed a little bit relative to the last few years. But again, it seems like on track and sustainably on track. Is that the right way to think about it? Miles D. White -- Chairman and Chief Executive Officer Yeah, I -- we can't say, I'm never quite as satisfied as it like to be, that's for sure. What we've learned a couple of things I think -- of the seven or eight years, we've now been fundamentally focused on emerging markets and they're growing economies and so forth. I'd say, if anything was underestimated, it was the degree of volatility of currency, which is also heavily driven by the strength of the U.S. dollar, while we can't predict those things. So this business is 100% in emerging markets that's always a bit of a challenge. Now that said, the underlying growth in those markets has been steadily strong and it's interesting one indicator of the attractiveness of those markets is -- let's just say the multiples and prices and so forth that anybody who owns a pharmaceutical business in those markets. Thanks to the company is worth. And it was a track was for a long time. Probably some of the highest multiples in the world in any business -- you now I'd say for businesses that make money. They are other attractive, the markets are attractive and the attractive parts of branded generic pharmaceutical worldwide, they are the most profitable -- they're are very profitable markets for good branded products as compared to Europe or the U.S. or something like that, if you're in that business. So we targeted this business for a reason there is underlying real growth brands matter, quality matters, breadth matters and it's got all the fundamentals that we think are stable, durable, attractive, et cetera. And frankly all those kind of economies have progressed. As we would like, maybe not as stable and maybe not as strongly in some cases, but the growth there is still strong. Our own challenge is the R&D investments to continue to expand product lines and product depth into the markets we keep our R&D somewhat decentralized by region, India has its own, Latin America has its own, et cetera. We're always looking for greater and greater productivity and greater and greater launch activity out of our teams. Every now and then we're going to run into an Argentina, a Venezuela or a tax issue in a Country like we did in India, a couple of years ago, et cetera, that are going to put a dent in the growth rate for a given year, and we've seen that. But the underlying fundamentals are quite strong, quite good and we keep plugging away at all the fundamentals that we know how to manage. And as you can tell this last year, we've had steady sequential improvement in our performance excluding exchange and they are up at 8%, I think that's pretty good. That means that we -- know how to take the corrective actions to get stronger, to get better, to drive the business better and I think the fact that the managers of pharmaceutical business are up to an 8% [Phonetic] growth rate and looking forward to even improvement. And that -- I think that's pretty strong. So yeah, we like the business. Rick Wise -- Stifel -- Analyst Great. And if I could follow up just on two quick things. At TCT, we saw some very solid Portico data. I assume we're still on track for a mid 2020 U.S. launch any updates there would be great on Portico. And last, just -- the U.S. Vascular business still seems pressured, not really improving. What are the issues? What are you doing? I know you're still focused on execution is a competition, is it -- it's how do you turn that portion of the business around? Thank you. Robert B. Ford -- President and Chief Operating Officer Yeah Rick, this is our Robert here. So on your Portico question. Yeah, we submitted end of Q3, so we expect a kind of a mid-year approval here and launch and we're getting ready for that. On your question on vascular as we previously mentioned, there are a couple -- what I would call non-commercial items that impact the growth rate here, these are third-party royalties, third-party manufacturing agreements that we put in place is part of the St. Jude divestiture -- some of the assets. So those -- as those ramp down as those manufacturing agreements ramped down as those royalties ramped down, they obviously impact the growth rate and we've allocated those agreements into the U.S. line even though their global -- their global agreement. So here if you, if you remove those items that are naturally going down as we transition to manufacture over to the new -- to the new owners of those businesses and as the royalties ramped down you remove that out our vascular business was flat and the dynamic there was really a little bit of pricing that we've seen on the stent side we've continue to grow share in the U.S. actually and maintain our leadership position in the international markets. And that price pressure was then offset by double-digit growth in our Endo and in peripheral business and in our imaging and diagnostic business and that's part of our strategy, which is, we know that there will be some pricing pressure on the DS side, and we know we need to make our investments to maintain our competitive position there, but we also know that we over investing in our Endo and our imaging strategy. So that, those businesses can get large enough and that those double digits when can really return Vascular to a healthy growth rate. Rick Wise -- Stifel -- Analyst Thanks, Robert. Scott Leinenweber -- Vice President-Investor Relations, Licensing, and Acquisitions Operator, we'll take one more question. Operator Thank you. And our last question comes from Matt Taylor from UBS. Your line is open. Matt Taylor -- UBS -- Analyst Hi, good morning. Thanks for taking the question. I was hoping that you might just expand a little bit on the Libre in dynamics given the continued strength that you've seen outside the U.S. Could you comment on anything like installed base mix of Type 1 versus Type 2 our payers -- are getting involved they see value there. Anything like that, that could help us understand the sustainability of the growth especially outside the U.S., where you continue to have a larger and larger base? Miles D. White -- Chairman and Chief Executive Officer Yeah. So let's talk about that base. I mean the one way to describe it here, that it's a very large and it's growing. We focus a lot on the sales side. But if you look at the user base, where we're at the 1.5 million close to 1.6 million users at the end of this quarter. As we talked a little bit -- there was a little bit of constraint on that user base given our manufacturing capacity. So as we've now unleashed it, I think we've got the potential here to kind of grow that user base even faster. One of the things that is important here that we've seen as payers and contract start to look at this is that they're very convinced on the outcomes of using sensor-based technology, there's a lot of clinical data that proves that. We actually have RCT trials that show that Libre reduces hypo, reduces time out of range, reduces the time that patients are in hypoglycemia. And we backed that up with some fairly large real world evidence trials showing that and competitors also have that too. So, the value proposition here is how do you get that outcome at a cost that makes sense for the payer, where they can actually expand the use of the product in the technology into a much larger user base versus kind of niche it to kind of very small segments and that's been the value proposition that we've adopted and as I said in the beginning of the call that value proposition is not only very impact, but it is growing and we see that we see that in the negotiations we've had with Canadian reimbursement authorities. We see that expansion of the technology beyond just Type 1 or insulin users in other markets, we start seeing it expand into Type 2. So we think the value proposition here is very strong and it's a real an opportunity to provide the benefits of the outcomes that are proven at a cost profile that makes sense for the payer. So and it's ultimately about having the impact on outcomes for patients and we're seeing that through our trials and through our real world evidence. If you think about the composition of the patients we're looking at 50-50 what we're getting a lot of Type 1s and insulin users, but we're also getting a lot of Type 2s, Type 2s that are on single injections or Type 2s are on oral medication. There are different utilization rates, but we're getting all those patients. Matt Taylor -- UBS -- Analyst One quick follow up. Are you now completely unconstrained on manufacturing? Miles D. White -- Chairman and Chief Executive Officer Yes. Matt Taylor -- UBS -- Analyst Okay. Great. Thanks a lot. Thanks for the color. Miles D. White -- Chairman and Chief Executive Officer Okay. I'm going to wrap up, where we started. We had a strong quarter, exceptionally strong quarter. Our momentum continues, we've got some great growth drivers in Libre, MitraClip, the Alinity platforms other businesses, they're all growing, many of them double digits and across the board. So the balance of that performance across all businesses and across all geographies is heartening. It is sustainable. We -- our top line growth rate was 7.6% this quarter. We think it will be close to 8% in the fourth quarter and as we look into 2020. I see no reason to change any expectations about the strength of our top line sales growth rate, which is I think all of you know for a fairly large company unusual to find the other people that are able to do this for tech companies. And so we got some great strength here, owing to the strength of our pipeline, our new product launches. The improvements to access and/or reimbursement and further capabilities of those products. So we've got a good sustainable road ahead of us, obviously there are surprises or things that don't meet our expectations from time-to-time or the speed with which we want to accomplish things. But overall, I think this is good evidence to you all -- a good performance super performance really and sustainably, so. So we look at 2020 with great optimism and great expectations in spite of a lot of the uncertainties in the world and in the economies around the world. We're feeling pretty strong and pretty bullish about where we sit. So with that, we'll see in 90 days. Scott Leinenweber -- Vice President-Investor Relations, Licensing, and Acquisitions Thank you, operator, and thank you for all of your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11:00 a.m. Central time today on Abbott Investor Relations website at abbottinvestor.com. Thank you for joining us today. Operator [Operator Closing Remarks] Duration: 50 minutes Call participants: Scott Leinenweber -- Vice President-Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer David Lewis -- Morgan Stanley -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Bob Hopkins -- Bank of America -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Robbie Marcus -- JP Morgan -- Analyst Rick Wise -- Stifel -- Analyst Matt Taylor -- UBS -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of June 1, 2019 This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Abbott Laboratories (NYSE: ABT) Q3 2019 Earnings Call Oct 16, 2019, 9:00 a.m. Operator [Operator Closing Remarks] Duration: 50 minutes Call participants: Scott Leinenweber -- Vice President-Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer David Lewis -- Morgan Stanley -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Bob Hopkins -- Bank of America -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Robbie Marcus -- JP Morgan -- Analyst Rick Wise -- Stifel -- Analyst Matt Taylor -- UBS -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. During the quarter we received U.S. FDA approval for our next generation MitraClip device and we initiated the first ever U.S. pivotal trial for the minimally invasive treatment of tricuspid regurgitation, which will evaluate the safety and efficacy of our TriClip repair system.
Operator [Operator Closing Remarks] Duration: 50 minutes Call participants: Scott Leinenweber -- Vice President-Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer David Lewis -- Morgan Stanley -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Bob Hopkins -- Bank of America -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Robbie Marcus -- JP Morgan -- Analyst Rick Wise -- Stifel -- Analyst Matt Taylor -- UBS -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abbott Laboratories (NYSE: ABT) Q3 2019 Earnings Call Oct 16, 2019, 9:00 a.m. With me today are Miles White, Chairman of the Board and Chief Executive Officer; Robert Ford, President and Chief Operating Officer; and Brian Yoor, Executive Vice President, Finance and Chief Financial Officer.
Operator [Operator Closing Remarks] Duration: 50 minutes Call participants: Scott Leinenweber -- Vice President-Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer David Lewis -- Morgan Stanley -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Bob Hopkins -- Bank of America -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Robbie Marcus -- JP Morgan -- Analyst Rick Wise -- Stifel -- Analyst Matt Taylor -- UBS -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abbott Laboratories (NYSE: ABT) Q3 2019 Earnings Call Oct 16, 2019, 9:00 a.m. With me today are Miles White, Chairman of the Board and Chief Executive Officer; Robert Ford, President and Chief Operating Officer; and Brian Yoor, Executive Vice President, Finance and Chief Financial Officer.
Operator [Operator Closing Remarks] Duration: 50 minutes Call participants: Scott Leinenweber -- Vice President-Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer David Lewis -- Morgan Stanley -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Bob Hopkins -- Bank of America -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Robbie Marcus -- JP Morgan -- Analyst Rick Wise -- Stifel -- Analyst Matt Taylor -- UBS -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abbott Laboratories (NYSE: ABT) Q3 2019 Earnings Call Oct 16, 2019, 9:00 a.m. Before we open the call for questions.
32895.0
2019-10-16 00:00:00 UTC
Health Care Sector Update for 10/16/2019: CRMD,ABT,NTRA
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-10-16-2019%3A-crmdabtntra-2019-10-16
nan
nan
Top Health Care Stocks JNJ +2.47% PFE +0.02% ABT -0.26% MRK -0.39% AMGN -0.77% Health care stocks were little changed in recent trade, with the NYSE Health Care Index falling less than 0.1% while the shares of health care companies in the S&P 500 were down almost 0.1% as a group. The Nasdaq Biotechnology index was climbing fractionally. Among health care stocks moving on news: (+) CorMedix (CRMD) raced 13% higher on Wednesday after the specialty drugmaker said it has successfully completed talks with the US Food and Drug Administration over the chemistry, manufacturing and controls for its Neutrolin drug candidate ahead of the company submitting the new drug application for the prospective medication to prevent infections in adult patients during hemodialysis. The agency and CorMedix have now scheduled a pre-NDA meeting to expedite review of the application, including a potential priority review designation. In other sector news: (-) Abbott Laboratories (ABT) was fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean.
In other sector news: (-) Abbott Laboratories (ABT) was fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean. Among health care stocks moving on news: (+) CorMedix (CRMD) raced 13% higher on Wednesday after the specialty drugmaker said it has successfully completed talks with the US Food and Drug Administration over the chemistry, manufacturing and controls for its Neutrolin drug candidate ahead of the company submitting the new drug application for the prospective medication to prevent infections in adult patients during hemodialysis. The agency and CorMedix have now scheduled a pre-NDA meeting to expedite review of the application, including a potential priority review designation.
In other sector news: (-) Abbott Laboratories (ABT) was fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean. Top Health Care Stocks Health care stocks were little changed in recent trade, with the NYSE Health Care Index falling less than 0.1% while the shares of health care companies in the S&P 500 were down almost 0.1% as a group.
In other sector news: (-) Abbott Laboratories (ABT) was fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean. Health care stocks were little changed in recent trade, with the NYSE Health Care Index falling less than 0.1% while the shares of health care companies in the S&P 500 were down almost 0.1% as a group. Among health care stocks moving on news: (+) CorMedix (CRMD) raced 13% higher on Wednesday after the specialty drugmaker said it has successfully completed talks with the US Food and Drug Administration over the chemistry, manufacturing and controls for its Neutrolin drug candidate ahead of the company submitting the new drug application for the prospective medication to prevent infections in adult patients during hemodialysis.
In other sector news: (-) Abbott Laboratories (ABT) was fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean. Top Health Care Stocks Health care stocks were little changed in recent trade, with the NYSE Health Care Index falling less than 0.1% while the shares of health care companies in the S&P 500 were down almost 0.1% as a group.
32896.0
2019-10-16 00:00:00 UTC
Health Care Sector Update for 10/16/2019: TEVA, JNJ, PFE, ABT, MRK, AMGN, JNJ, MNK, ENDP, RYTM
ABT
https://www.nasdaq.com/articles/health-care-sector-update-for-10-16-2019%3A-teva-jnj-pfe-abt-mrk-amgn-jnj-mnk-endp-rytm-2019
nan
nan
Top Health Care Stocks: JNJ: +1.32% PFE: -0.03% ABT: -2.62% MRK: Flat AMGN: Flat Leading health care stocks were mixed pre-market Tuesday. Stocks moving on news include: (+) Opioid-associated players were advancing pre-bell, with Teva Pharmaceutical Industries (TEVA) up 3%, Endo International (ENDP) gaining 2%, Mallinckrodt (MNK) surging 8%, Johnson & Johnson (JNJ) up more than 1%, as media reports said late Tuesday that drug distributors are engaging in discussions to reach an opioid settlement for $18 billion. (-) Rhythm Pharmaceuticals (RYTM), a developer of treatments for rare genetic disorders, was down almost 7% after pricing an offering 8.11 million shares of common stock at $18.50 per share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
MRK: Flat AMGN: Flat Leading health care stocks were mixed pre-market Tuesday. Stocks moving on news include: (+) Opioid-associated players were advancing pre-bell, with Teva Pharmaceutical Industries (TEVA) up 3%, Endo International (ENDP) gaining 2%, Mallinckrodt (MNK) surging 8%, Johnson & Johnson (JNJ) up more than 1%, as media reports said late Tuesday that drug distributors are engaging in discussions to reach an opioid settlement for $18 billion. (-) Rhythm Pharmaceuticals (RYTM), a developer of treatments for rare genetic disorders, was down almost 7% after pricing an offering 8.11 million shares of common stock at $18.50 per share.
Top Health Care Stocks: MRK: Flat AMGN: Flat Leading health care stocks were mixed pre-market Tuesday. Stocks moving on news include: (+) Opioid-associated players were advancing pre-bell, with Teva Pharmaceutical Industries (TEVA) up 3%, Endo International (ENDP) gaining 2%, Mallinckrodt (MNK) surging 8%, Johnson & Johnson (JNJ) up more than 1%, as media reports said late Tuesday that drug distributors are engaging in discussions to reach an opioid settlement for $18 billion.
MRK: Flat AMGN: Flat Leading health care stocks were mixed pre-market Tuesday. Stocks moving on news include: (+) Opioid-associated players were advancing pre-bell, with Teva Pharmaceutical Industries (TEVA) up 3%, Endo International (ENDP) gaining 2%, Mallinckrodt (MNK) surging 8%, Johnson & Johnson (JNJ) up more than 1%, as media reports said late Tuesday that drug distributors are engaging in discussions to reach an opioid settlement for $18 billion. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Top Health Care Stocks: MRK: Flat AMGN: Flat Leading health care stocks were mixed pre-market Tuesday. Stocks moving on news include: (+) Opioid-associated players were advancing pre-bell, with Teva Pharmaceutical Industries (TEVA) up 3%, Endo International (ENDP) gaining 2%, Mallinckrodt (MNK) surging 8%, Johnson & Johnson (JNJ) up more than 1%, as media reports said late Tuesday that drug distributors are engaging in discussions to reach an opioid settlement for $18 billion.
32897.0
2019-10-16 00:00:00 UTC
Abbott Laboratories Q3 19 Earnings Conference Call At 9:00 AM ET
ABT
https://www.nasdaq.com/articles/abbott-laboratories-q3-19-earnings-conference-call-at-9%3A00-am-et-2019-10-16
nan
nan
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 16, 2019, to discuss Q3 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 16, 2019, to discuss Q3 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 16, 2019, to discuss Q3 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 16, 2019, to discuss Q3 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 16, 2019, to discuss Q3 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
32898.0
2019-10-16 00:00:00 UTC
Abbott Sees Q4 Profit In Line With View; Narrows FY Profit View
ABT
https://www.nasdaq.com/articles/abbott-sees-q4-profit-in-line-with-view-narrows-fy-profit-view-2019-10-16
nan
nan
(RTTNews) - Abbott Laboratories (ABT) said it expects earnings per share from continuing operations to be in the range of $0.59 to $0.61, and adjusted earnings per share from continuing operations of $0.94 to $0.96 for the fourth quarter. Analysts polled by Thomson Reuters expect the company to report earnings of $0.95 per share for the fourth-quarter. Analysts' estimates typically exclude special items. Abbott narrowed its guidance for 2019 earnings per share from continuing operations to $2.06 to $2.08. Excluding specified items, adjusted earnings per share from continuing operations would be $3.23 to $3.25 for the full year 2019. The company said in July that it expected earnings per share from continuing operations to be in the range of $2.06 to $2.12, adjusted earnings per share from continuing operations of $3.21 to $3.27. Analysts project annual earnings of $3.24 per share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) said it expects earnings per share from continuing operations to be in the range of $0.59 to $0.61, and adjusted earnings per share from continuing operations of $0.94 to $0.96 for the fourth quarter. Analysts polled by Thomson Reuters expect the company to report earnings of $0.95 per share for the fourth-quarter. Excluding specified items, adjusted earnings per share from continuing operations would be $3.23 to $3.25 for the full year 2019.
(RTTNews) - Abbott Laboratories (ABT) said it expects earnings per share from continuing operations to be in the range of $0.59 to $0.61, and adjusted earnings per share from continuing operations of $0.94 to $0.96 for the fourth quarter. Excluding specified items, adjusted earnings per share from continuing operations would be $3.23 to $3.25 for the full year 2019. The company said in July that it expected earnings per share from continuing operations to be in the range of $2.06 to $2.12, adjusted earnings per share from continuing operations of $3.21 to $3.27.
(RTTNews) - Abbott Laboratories (ABT) said it expects earnings per share from continuing operations to be in the range of $0.59 to $0.61, and adjusted earnings per share from continuing operations of $0.94 to $0.96 for the fourth quarter. Excluding specified items, adjusted earnings per share from continuing operations would be $3.23 to $3.25 for the full year 2019. The company said in July that it expected earnings per share from continuing operations to be in the range of $2.06 to $2.12, adjusted earnings per share from continuing operations of $3.21 to $3.27.
(RTTNews) - Abbott Laboratories (ABT) said it expects earnings per share from continuing operations to be in the range of $0.59 to $0.61, and adjusted earnings per share from continuing operations of $0.94 to $0.96 for the fourth quarter. Excluding specified items, adjusted earnings per share from continuing operations would be $3.23 to $3.25 for the full year 2019. The company said in July that it expected earnings per share from continuing operations to be in the range of $2.06 to $2.12, adjusted earnings per share from continuing operations of $3.21 to $3.27.
32899.0
2019-10-16 00:00:00 UTC
Abbott Laboratories Q3 adjusted earnings Inline With Estimates
ABT
https://www.nasdaq.com/articles/abbott-laboratories-q3-adjusted-earnings-inline-with-estimates-2019-10-16
nan
nan
(RTTNews) - Abbott Laboratories (ABT) revealed earnings for its third quarter that advanced from last year. The company's earnings came in at $960 million, or $0.53 per share. This compares with $563 million, or $0.32 per share, in last year's third quarter. Excluding items, Abbott Laboratories reported adjusted earnings of $1.51 billion or $0.84 per share for the period. Analysts had expected the company to earn $0.84 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items. The company's revenue for the quarter rose 5.5% to $8.08 billion from $7.66 billion last year. Abbott Laboratories earnings at a glance: -Earnings (Q3): $1.51 Bln. vs. $1.34 Bln. last year. -EPS (Q3): $0.84 vs. $0.75 last year. -Analysts Estimate: $0.84 -Revenue (Q3): $8.08 Bln vs. $7.66 Bln last year. -Guidance: Next quarter EPS guidance: $0.94 to $0.96 Full year EPS guidance: $3.23 to $3.25 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) revealed earnings for its third quarter that advanced from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $1.51 billion or $0.84 per share for the period. Analysts had expected the company to earn $0.84 per share, according to figures compiled by Thomson Reuters.
(RTTNews) - Abbott Laboratories (ABT) revealed earnings for its third quarter that advanced from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $1.51 billion or $0.84 per share for the period. -Analysts Estimate: $0.84 -Revenue (Q3): $8.08 Bln vs. $7.66 Bln last year.
(RTTNews) - Abbott Laboratories (ABT) revealed earnings for its third quarter that advanced from last year. -Analysts Estimate: $0.84 -Revenue (Q3): $8.08 Bln vs. $7.66 Bln last year. -Guidance: Next quarter EPS guidance: $0.94 to $0.96 Full year EPS guidance: $3.23 to $3.25 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Abbott Laboratories (ABT) revealed earnings for its third quarter that advanced from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $1.51 billion or $0.84 per share for the period. last year.